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ABSTRACT
Regeneration of injured CNS tracts poses a significant clinical challenge due to 
the multi factorial nature o f the degenerative processes that ensues and technically 
complex delivery of therapeutic molecules. To circumvent these problems, highly 
disabled Herpes Simplex 1 (HSV1) based vectors were used to deliver NT3, 
BDNF and CNTF to the injured rat CNS. The ability of these vectors to promote 
the regeneration o f corticospinal (CST), rubrospinal (RST) and optic nerve tracts 
was evaluated. Transgene expressing constructs were based on the backbone 
HSVl.pR19CMV that carries a combination of essential and non-essential gene 
deletions. These render it replication incompetent in vivo whilst allowing it to 
maintain transgene expression in the long term via expression cassettes that 
employ HSV1 latency associated transcript promoters.
Via retrograde transport, a single spinal cord inoculation results in widespread, 
stable transgene expression in neurons throughout the CNS, from spinal cord to 
hypothalamus. In spinal cord regeneration experiments, NT3-expressing vector 
alone failed to promote regeneration in the chronically injured CST. In 
combination with transplanted embryonic day-14 spinal cord segments however, 
it led to enhanced CST sprouting and axon elongation up to 600pm within the 
lesion site. In the chronically injured RST, BDNF and CNTF-expressing vectors 
produced no significant regeneration. In the optic nerve crush model however, 
both robust transduction and substantial axonal regeneration resulted from 
inoculation o f retinal ganglion cell (RGC) targets. A combination of CNTF, 
BDNF, bFGF and Neurturin-expressing vectors induced regeneration of injured 
RGC axons in optic nerve, up to 1000 pm distal to the crush site. Further vector 
development led to less-disabled vectors that supported strong transgene 
expression and targeted spinal cord, RGCs and even CST neurons, with high 
efficiency. By counteracting the host's immune response, minimally disabled 
IL 10-expressing vectors supported long-term expression of transgenes in DRG 
neurons following footpad inoculation. HSV1-based vectors are therefore 
powerful and versatile gene therapy tools for CNS regeneration.
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GLOSSARY
AAV Adeno-Associated Virus LV Lent i-virus
ABC Avidin Biotin peroxidase Complex MAG Myelin Associated Protein
ATF3 Activating Transcription Factor 3 MOl Multiplicity of Infection
BDA Biotinylated Dextran Amine MOSP Myelin Oligodendrocyte Specific Protein
BDNF Brain-Derived Neurotrophic Factor mRNA Messenger RNA
BM Basal Membrane NaCI Sodium Chloride
BSA Bovine Serum Albumin NaOH Sodium Hydroxide
CAM Cell Adhesion Molecule NCAM Natural Cell Adhesion Molecule
CMC Carboxy-Methyl Cellulose NGF Nerve Growth Factor
CMV Cytomegalovirus NgR Nogo Receptor
CSF Cerebrospinal Fluid NO Nitric Oxide
CSPGs Chondroitin Sulphate Proteoglycans nNOs Neuronal Nitric Oxide Synthase
CST Corticospinal Tract NT-3 Neurotrophin 3
CNS Central Nervous System NT-4/5 Neurotrophin 4/S
CNTF Cilliary Neurotrophic Factor NTN Neurturin
DAB 3,3’Diaminodenzidine tetrahydrochloride OC Optic Chiasm
DMEM Dulbecco’s Modified Eagle’s Medium OD Optical Density
DMSO Di-methyl Sulfoxide OEG Olfactory Ensheathing Glia
DNA Deoxyribonucleic Acid OMgp Oligodendrocyte myelin glycoprotein
DREZ Dorsal Root Entry Zone PBS Phosphate Buffer Saline
Egene Early gene PFA Paraformaldehyde
ECM Extracellular Matrix Pfu Plaque-forming Unit
EDTA Ethylenediaminetetraacctic Acid rAAV Recombinant AAV
EFla Elongation factor la rAAV2 rAAV serotype 2
eGFP Enhanced Green Fluorescent Protein rAAV2/5 rAAV pseudotyped 2/5
ELISA Enzyme-Linked Immunosorbent Assay rh Recombinant Human
FCS Foetal Calf Serum PNS Peripheral Nervous System
FGF Fibroblast Growth Factor RGC Retinal Ganglion Cells
FGM Full Growth Medium RN Red Nucleus
Gal-1 Galectin -1 RNA Ribonucleic Acid
GAP Growth Associated Protein RNAi RNA interference
GDNF Glial-derived Neurotrophic Factor RST Rubrospinal tract
GFAP Glial Fibrin-Associated Protein SC Schwann cell
HBSS Hank's Buffered Salt Solution SCG10 Superior cervical ganglion-10
HCF Human Cellular Factor SD Standard Deviation
HCI Hydrochloric Acid SEM Standard Error of the Mean
HEPES 4-(2-hydroxyethy 1)-1 -piperazineethanesulfonate shRNA short hairpin RNA
HMBA Hexamethylammonium bisacetamide siRNA small interfering RNA
HRP Horseradish peroxidase SNpc Substantia Nigra Pars Compacts
1L Interleukin
IR Immunoreactivity TBS Tween 20® Buffered Saline
IRES Internal Ribosome Entry Site TMB Tetra-Methyl Benzidine
ITR Inverted terminal repeats TNF Tumour Necrosis Factor
JNK Jun N-terminal Kinase Trk Tyrosine Kinase
LPR Lipopolysaccharide WHV Woodchuck Hepatitis Virus
LRR Leucine-rich repeats WPRE Post-transcriptional regulatory element
LTR Long-terminal repeats X-GAL P galactosidase
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C h a p t e r  1.0
INTRODUCTION
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1.1 Introduction
Acute injuries o f the spinal cord are among the most common causes of severe 
disability and death following trauma. Until recently, it was thought that repair 
o f lesioned neurons of the central nervous system (CNS) was impossible while 
the resulting clinical impairment was considered irreversible. The neuroscientist 
Ramon Y Cajal was the first to report that “...the failure o f  regeneration is not 
an irresistible law, but a secondary outcome o f  a physical or chemical 
environment unfavourable fo r  the growth o f  the sprouts” (Ramon Y Cajal, 1928). 
Nearly a century later a number of studies have provided more convincing 
evidence that adult CNS mammalian neurons do retain their embryonic ability to 
mount a regenerative response but their axons are unable to cross the site o f an 
injury, a step that is necessary in order to form synapses (Schwab and Bartholdi,
1996). Numerous studies have put forward potential hypotheses that seek to 
explain the mechanism behind this abortive regenerative response: firstly, the 
induction of axonal elongation in sprouting CNS neurons may require a 
significant amounts o f different neurotrophic factors not readily available in the 
adult CNS (Berry et al., 1996; Zhang et al., 1998; Bradbury et al., 1999; Logan 
and Berry, 2002); secondly, the innate ability of adult CNS axons may not be 
strong enough to sustain axonal elongation in the long term (Richardson and 
Verge, 1986; Chong et al., 1996; Anderson and Lieberman, 1999); thirdly, the 
process o f neuronal damage is in itself complex and unique to the CNS 
environment. Identification o f key factors involved in the CNS response to injury 
has demonstrated that it is an inhospitable milieu for regeneration as it contains 
significantly potent inhibitory molecules that are either present in normal myelin 
(Schwab, 1996) or are upregulated following a mechanical injury (Fawcett and 
Asher, 1999; Pasterkamp et al., 1999; GrandPre and Strittmatter, 2001; Schwab, 
2002; Fournier et al., 2002; Hunt et al., 2002b; Sandvig et al., 2004; Schwab, 
2004).
In this thesis emphasis is placed on whether enabling injured CNS neurons to 
endogenously produce neurotrophic factors via gene delivery has a beneficial 
effect on axonal regeneration. A plethora of different techniques are currently 
under investigation for their ability to deliver therapeutic genes to the lesioned
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CNS and tracts of the spinal cord in particular. One gene delivery technique, 
under investigation in this study, was based on the use of disabled Herpes 
Simplex Virus 1 (HSV1) vectors. The construction of neurotrophic expressing 
HSV 1 based vectors and their potential as gene therapy tools for amelioration of 
the neurodegenerative effects of injury in the corticospinal, rubrospinal tracts in 
the spinal cord as well as the optic nerve, was investigated.
1.2 Spinal cord injury
Spinal cord injury can be defined as “ ... a lesion to the spinal cord that results in 
partial or complete paralysis” (Johnson and Griffin, 1997). It can be the result of 
acute trauma, caused by a direct insult to the spine or disease such as vertebral 
tumours, polio and motor-neuron disease. This study focused on the factors 
involved in traumatic spinal cord injury and will attempt to examine the manner 
in which these contribute to the disabling neurological impairment that follows. 
Overall, the type and severity o f the neurological deficit depends on the way that 
spinal elements respond to the force o f the injury (Hardy, 1975).
1.2.1 Incidence and prevalence of spinal cord injury
Spinal cord injury is one of the leading causes of mortality following acute 
trauma but there are significant variations in incidence and prevalence between 
western and developing countries (Ackery et a l , 2004). There is a lack of 
countrywide statistics taking into account all the different spinal cord injury 
rehabilitation centres in the UK. The last peer-reviewed statistical report specific 
to the UK was published in 2005 (Amin et a l , 2005). The authors report a four- 
year retrospective review between March 1988 and March 2003 on all new 
spinal cord injury admissions to the Royal National Orthopaedic Hospital in 
Stanmore. According to this survey, spinal cord injury primarily affects adults 
with an average age o f 38.6 years for men and 41.8 for women. Out of the total 
number o f patients affected, 82% were male and 18% were female while the 
leading causes o f traumatic spinal cord injury were predominantly: motor vehicle 
accidents (35.9%), falls (58.6%), sports injuries and gunshot wounds (5.5%).
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The most common cause of death amongst spinal cord injury patients is 
respiratory failure while advances in acute trauma management have enhanced 
prevention of renal failure (Bums, 2007). An increasing number of spinal cord 
injury patients are dying due to other causes such as cancer or cardiovascular 
disease, similar to that o f the general population. Overall, 85% of patients who 
survive the first 24 hours after trauma are still alive 10 years later. However, 
mortality rates are significantly higher during the first year after injury than in 
subsequent years. In 2004 the National Spinal Cord Injury Statistical Centre 
(NSCISC, University of Alabama, http://www.spinalcord.uab.edu, PMID: 
16396388) reported an annual incidence of 40 cases per million population in the 
USA, with a prevalence o f 250,000 cases. In this study the most common causes 
of spinal cord injury were industrial injuries (34.5%) and road traffic accidents 
(33.1%) (Jackson et al., 2004).
1.2.2 Summary of Clinical Manifestation of Spinal Cord Injury
To accurately evaluate the extent of neurological impairment as a result of spinal 
cord injury, assessment of lesions in motor and sensory pathways is required. 
Loss o f function in myotomes and/or dermatomes can give an indication of the 
spinal nerves involved and an anatomical reference to the level o f the spinal cord 
injury. Due to the complexity in the distribution of the sensory and motor 
pathways along the spinal cord, more than one tract can be involved in a single 
injury. Hence, consideration o f reflex actions, functions controlled by spinal 
nerves in the viscera and the distribution of the neurological impairment should 
always be considered in conjunction. A summary of the clinical manifestation of 
spinal cord injury with relation to the segment of the spinal cord affected is given 
in Table 1.2.2-a. However, certain features of neurological function after an 
acute injury provide significant assistance in pin-pointing the tracts affected 
(Hardy, 1975; Guthkelch, 1996; Rolak, 2004; Snell, 2004).
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Spinal
Cord
Sensation
Affected
Motor Function 
Affected
Summary of 
Clinical Features
( 1 ( 3
( 4
C5-C6
C7-C8
T1-T10
T1I-T12
LI-L2
L3-L5
SI-S4
Face,
Scalp
Neck
Shoulder cape
Thumb, index and 
middle finger
Middle & Small 
Finger
Trunk, progressively 
down to the navel
Head, Neck
Inguinal Ligament
Anterior Thigh 
Medial Thigh
Medial calf 
Dorsum of Foot
Lateral aspects of Foot 
Posterior Thigh 
Perianal region
Diaphragmatic control
Deltoid
Biceps
Triceps, 
Wrist Flexors, 
Finger Extensors 
Finger Flexors
Intercostals 
Spine Extensors
Rectus
Abdominis
Iliopsoas 
Sartorius & 
Adductors
Quadriceps
Toe flexors 
Extensors 
Bowel & Bladder 
Sphincters
Changes in Voluntary Power
Muscle control is impaired. Clinical examination 
can give an indication of the cervical spinal cord 
segment affected. However, muscle innervation is 
derived from at least two or three segments. In 
addition, the majority of spinal cord lesions usually 
involve more than one segment. Hence, the upper 
level of motor paralysis is difficult to define.
Decrease in Sensibility (sensory neurons) 
Cutaneous areas supplied by adjacent spinal nerves 
overlap to a certain degree. Thus, there is little 
sensory loss following the disruption of a single 
spinal nerve root. However, spinal cord injury 
rarely involves damage of only a single spinal 
nerve.
Changes in Reflex activity (Spinal Shock)
Reflex activity is altered above and below the 
injury site. In cases of complete loss of reflex 
activity (Spinal shock), all somatic & visceral 
activity is lost.
Difficulty in Respiration
Lesions of the third and fourth cervical segments 
affect control of respiration. A complete lesion is 
not compatible with unsupported life.
Dominant or transient Pain 
Pain is associated primarily with fractures and its 
intensity varies considerably. Absence of pain has 
been observed in cases of traumatic paraplegia.
Impaired Respiration
Difficulties in respiration are primarily caused by 
paralysis of die intercostal muscles although 
associated soft tissue injuries, such as rib fractures, 
can result in hemothorax and lung function 
impairment.
Impairment of the Abdominal Viscera 
Loss of rectal sensation and inability to pass urine.
Dominant or transient pain
Changes in Reflex activity
Tendon reflexes can be lost but on the sensory side
sensation in the perianal are may be retained.
Paralysis of the buttock & foot muscles
Paralysis of urethral & anal sphincters
Changes in sensation of the genitalia 
Patients with sacral fractures suffer impairment or 
loss of sexual ability.
Table 1.2.2-a: Clinical Manifestation of spinal cord injury.
(Adapted from Rolak 2004).
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1.3 Neuronal responses to axotomy
Mechanical trauma, compression or ischemic conditions can result in axotomy, 
which involves a cascade of morphological and cellular changes. The extent of 
axotomy is a combination of the immediate disruption caused by the insult itself 
(primary axotomy) as well as the impact of the delayed cellular reactions that 
take place around the lesion site (secondary axotomy) (Blesch and Tuszynski, 
2002). This does not lead just to the breakdown of a communicating link 
between the immediately affected neurons. The degenerative reaction initiated 
results in retrograde changes that can lead to variable degrees of deficit, ranging 
from transient alterations in axonal physiology to permanent atrophy and cell 
death (Ramon Y Cajal, 1928; Lieberman, 1971; Brodal, 1981; Kreutzberg et al., 
1989; Berry et al., 1999). Generally, groups of neurons that are similar in 
function and physiology tend to respond to axotomy in a similar manner. This 
feature is thought to be a reflection of the intrinsic properties of the same group 
of neurons as well as similarities in the extracellular matrix (ECM) 
characteristics that these neurons have to adapt to (Sofroniew, 1999). Unlike the 
Peripheral Nervous system (PNS), the CNS does not exhibit the same ability to 
regenerate after axotomy. The molecular mechanisms behind this difference are 
slowly becoming clear but the prevailing theory suggests that the CNS 
regenerative failure is thought to be due to both intrinsic and extrinsic factors 
(Grill and Tuszynski, 1999). Intrinsic, referring to the innate ability of CNS 
neurons to mount a regenerative response and reinitiate axonal growth (Bregman 
and Kunkel-Bagden, 1988; Anderson and Lieberman, 1999; Homer and Gage, 
2000; Hunt et al., 2002a) and extrinsic referring to features of the extracellular 
environment that render any such attempt abortive (Logan et al., 1994; Fawcett 
and Asher, 1999; Logan and Berry, 2002; Sandvig et al., 2004; Raisman, 2004). 
In the sections that follow, differences between PNS and CNS neurons and the 
intrinsic and extrinsic factors that govern their responses will be examined1. 
Emphasis is, placed on studies that focus on the lack of regeneration following a 
spinal cord axotomising lesion.
1 The exact responses o f  the corticospinal, rubrospinal and optic nerve tracts are examined in great detail in 
Chapters 4, 5 and 6 o f  this thesis respectively.
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1.3.1 PNS neurons -  cellular responses to axotomy
PNS neurons o f adult mammals are capable of a higher degree of regeneration 
than their CNS counterparts. Despite the fact that these regenerative responses 
do eventually lead to some recovery of function, this is achieved via a slow and 
error-prone process that can lead to aberrant synapse formation clinically 
manifested as non-specific neuropathic pain (for a review: Grill and Tuszynski 
1999).
Following axotomy o f adult DRGs and motor neurons, a degenerative process 
termed Wallerian degeneration occurs (Waller, 1850). This is an apoptosis-like 
process intrinsic to the axon itself (Glass et al., 1993; Stoll et al., 2002) that 
describes the degeneration of the distal axonal stump. This degenerative process 
is a rapid, wave-like process (Lubinska, 1982) that occurs at different intervals 
for the axons comprising a mixed peripheral nerve (Beirowski et a l ,  2005). 
Within hours following transection, the myelin sheath begins to swell and 
degenerate with myelin breaking down into fatty material which by the end of 
the first 10 days following axotomy becomes oily droplets surrounding the axons 
(Lassmann et al., 1978). This debris is removed by phagocytosing Schwann cells 
and macrophages, which surround the disintegrating axons (Stoll et al., 1989; 
Liu et al., 1995; Fernandez-Valle et a l , 1995). Macrophages and other 
leukocytes start to invade the distal axon between 3 and 5 days after the lesion, 
reaching a peak between two and three weeks later (Perry and Brown, 1992; Liu 
et a l , 1995; Avellino et a l , 1995). The axon becomes granular and the 
cytoskeleton starts to disintegrate as the microtubule and neurofilament proteins 
disengage. It is thought that it is this disruption in the microtubule system and the 
severe compromise it causes in the anterograde axonal transport mechanism of 
the neuron that exacerbates axonal degeneration (Bignami et a l , 1981). This is 
based on findings that Wallerian degeneration can be initiated with the use of 
microtubule disrupting agents such as colchicine (Singer and Steinberg, 1972). 
Within 24 hours following injury, axons of the proximal stump become swollen 
due to the arrival o f newly synthesised cytoskeletal components and organelles 
that are transported down to the site o f growth cone formation (Meller, 1987; 
Fournier and McKerracher, 1995).
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Soon after the lesion Schwann cells undergo hypertrophy and start to invade the 
vacant areas previously occupied by the now disintegrating myelin and axons 
(Liu et al., 1995). In the distal axon segment, Schwann cells divide and align 
themselves along pre-existing basal lamina forming columns termed Bands of 
BUngner (Ide, 1996) which act as growth pathways for the growth cones arising 
from regenerating axons in the proximal stump (Grill and Tuszynski, 1999). 
Schwann cells comprising the Bands o f Btlngner produce a number of factors 
that aid the process of axonal elongation. Firstly they produce adhesion 
molecules such as LI and neural cell adhesion molecule (NCAM) (Nieke and 
Schachner, 1985; Tacke and Martini, 1990) to which growth cones can attach. 
Secondly, they synthesise ECM protein components such as laminin, fibronectin 
(Salonen et al., 1987; Wang et al., 1992a; Wang et al., 1992b; Fawcett and 
Asher, 1999) and tenascin-C (Martini et al., 1990) which stimulate axonal 
attachment and elongation. Thirdly, in response to cytokines such as interleukin 
(IL) 1 (Lindholm et al., 1987; Heumann et al., 1987), they secrete trophic factors 
such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
basic fibroblast growth factor (bFGF) and glial cell line-derived neurotrophic 
factor (GDNF) (Tacke and Martini, 1990; Acheson et al., 1991; Meyer et al., 
1992; Funakoshi et al., 1993; Liu et al., 1995; Hammarberg et al., 1996).
13.2 CNS neurons - cellular responses to injury
The environment of CNS axons is structurally different from that o f PNS 
neurons. A schematic representation o f the organisation of neuronal and non­
neuronal cells o f the CNS is shown in Figure 1.3.2-b (page 31). Firstly, CNS 
axons are not physically separated like peripheral nerves but are instead 
organised into anatomically distinct tracts of similar function e.g.: dorsal 
columns. Secondly, oligodendrocytes (the CNS myelinating cells) differ from 
Schwann cells in that a single cell can myelinate a number of axons at the same 
time (Grill and Tuszynski, 1999). A mechanical injury alters the 
electrophysiological properties o f the neuronal cell membrane. Such changes, 
result in a sudden influx of Ca2+ and Na+ ions that can reach the cell body 
(Emery et al., 1991; George et al., 1995; Ziv and Spira, 1997). This increase in
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intracellular calcium levels activates intracellular proteases such as calpain, 
which by digesting cytoskeletal components causes the degradation of axons at 
the lesion site (Newcomb et a l , 1997; Posmantur et al., 1997; Kampfl et a l,
1997). The initial sudden influx of Ca ions following the mechanical damage 
has also been shown to induce the dedifferentiation of axonal segments into 
growth cones (Ziv and Spira, 1998). As is the case in the PNS, damage to CNS 
intrinsic neurons causes the distal axon to undergo Wallerian degeneration. Even 
though the proximal stump and associated cell body usually survives, left 
unaided fails to initiate a regenerative response. The cellular events initiated after 
a traumatic spinal cord (focal) lesion, result in the progressive degeneration of 
neuronal cells and can be divided into an immediate, an intermediate and a late 
phase (Summarised in Figure 1.3.2-a).
There is a substantial difference in the cellular responses that occur in the PNS 
and CNS following axotomy (reviewed in Grill and Tuszynski, 1999). Unlike the 
case in the PNS, there are no structures with a function equivalent to the Bands 
o f Bdngner that could support the elongation of growth cones. Responses in the 
CNS are slow and not as efficient as those seen in the case of a PNS injury. 
Following an acute injury in the PNS, the majority of the myelin and axonal 
debris is removed by 30 days after the lesion, in the CNS the debris is still 
present in large amounts by the end of 90 days after spinal cord injury (George 
and Griffin, 1994) and at least 42 days after an optic nerve lesion (Ludwin and 
Bisby, 1992). This delay could be a reflection of the properties of glial cells, that 
support neuronal function. Unlike Schwann cells, oligodendrocytes do not have 
the ability to phagocytose fragmented myelin debris (Bignami and Ralston, 
1969). Oligodendrocytes do not align themselves into linear structures such as 
the Bands of Btingner as Schwann cells do following a PNS lesion. In addition, 
due to the presence of the blood-brain barrier, peripheral macrophages are not so 
easily recruited in the CNS. Therefore, the main phagocytic activity is carried 
out by the activation o f CNS-resident microglia (Figure 1.3.2-c, page 32) (Stence 
et al., 2001). Activated microglia have number of significant functions including 
antigen presentation via their MHC class II and complement-mediated 
phagocytosis (George and Griffin, 1994; Aloisi, 2001).
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Axons are transected 
Astrocytes & oligodendrocytes destroyed 
Local blood supply interrupted 
Inward leakage of serum components
Degeneration of cut axons 
Accumulation of myelin debris 
Astrocytes produce laminin and proteoglycans 
Astrocytes produce truncated neurotrophin receptors 
Infiltrating macrophages & microglia 
Production of inflammatory cytokines (IL-1, IL-6) 
Leakage due to compromised blood-brain barrier
Formation of necrotic tissue
Formation of acellular cavity
Cavity extends outwards from the site of lesion
Inflammatory cells persist in low numbers
Failure of axon regeneration -  acellular cavity
Dystrophic present in fluid cavity
Outward leakage of serum 
components from the lesioned 
area into surrounding tissues
Tissue damage area expands
Death of neurons
Astrocytes begin to wall-off the 
injury site
Inflammatory response spreads 
to surrounding tissue
Astrocytic response scar 
surrounding the lesion
Failure of axon regeneration at 
the glial scar
Cavity is walled off from 
surrounding viable tissue
Figure 13.2-a: Summary of cellular changes following spinal cord injury.
Yellow segments and blue lines represent myelin and axons respectively. Adapted from Fitch and 
Silver (1999).
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In addition they are capable of expressing neurotrophins at least in vitro 
(Nakajima et al., 2001) and they reduce glutamate toxicity by scavenging 
glutamate (Nakajima and Kohsaka, 2001). Microglial activation is prominent by 
three days following an axotomising lesion after which it declines. Three weeks 
later, macrophage activity reaches its peak (George and Griffin, 1994). This two 
week delay in the onset of any significant phagocytic activity further prolongs 
the accumulation o f debris (George and Griffin, 1994). Some reports though 
point out that this delay in activation varies between different rodent strains 
(Shaked et al., 2004). Astrocytes are also instrumental in maintaining the correct 
environment around normal CNS neurons. These cells reside throughout the 
CNS and are responsible for maintaining an ionic balance in the neural 
microenvironment by removal of excess potassium ions (Risau and Wolburg, 
1990; Wolburg et al., 1994; Grange-Messent et a l , 1996). They also prevent 
excitotoxicity by metabolising extracellular glutamate, high levels of which can 
lead to neural death, and by releasing glutathione which may have a function in 
protecting neurons against free radical damage (Lee et al., 1992; Schousboe et 
al., 1993; Sonnewald et al., 1997). In addition, they mediate an
inflammatory/immune response by release and concomitant response to immune 
mediators such as IL1, major histocompatibility complex (MHC) class II or 
transforming growth factor (TGF) p (Frank et al., 1986; Stoll et al., 1989; Morris 
and Esiri, 1991; Aranguez et al., 1995; Farina et al., 2007). Cytokines around the 
lesion site can contribute to the overall inhospitable nature of the injured CNS. 
They have been shown to modulate the ability of cultured astrocytes to provide a 
supportive environment to regenerating CNS axons. For example, in vitro the 
combination o f IL1 and bFGF promotes the migration and differentiation of 
oligodendrocyte progenitors and therefore promotes CNS re-myelination while 
interferon gamma and TGFP have the opposite effect (Fok-Seang et al., 1998). It 
is therefore not surprising that these cells are thought to play a significant role in 
the overall response to injury and it was initially thought that they are the main 
contributors to the inhospitable for axonal regeneration nature of the CNS 
environment by creating a physical barrier to any regenerating neurons in the 
form of a glial scar (Reier and Houle, 1988). A large number of studies have 
attempted to establish the mechanism behind their involvement in the failure of
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CNS neurons to regenerate. One of the experimental models that have been used 
for this type o f study is based on the use of dorsal root injury (rhizotomy). This 
model focuses on the events that occur at the dorsal root entry zone (DREZ), the 
interface between PNS and CNS. Injured DRG neurons are not capable of 
crossing the DREZ in order to re-establish connections with their target CNS 
neurons (Liuzzi and Lasek, 1987; Chong et a l , 1999) even when their 
regenerative potential is increased by a preconditioning lesion (Chong et al., 
1996). Upon contact with the CNS astrocytic processes, regenerating DRG axons 
either stop regenerating (Liuzzi and Lasek, 1987) or are induced to turn back on 
themselves and redirect their growth towards the cell body (Zhang et al., 2001). 
This could be due to either the astrocytes and the potentially inhibitory 
molecules they secrete in the DREZ (Pindzola et al., 1993; Zhang et a l,  2001; 
Beggah et a l ,  2005; Zhang et a l, 2006) or due to the lack of trophic signals 
present on these cells (Zhang et a l, 2000).
Very quickly following an axotomising injury, astrocytes hypertrophy and 
increase in volume via a process termed cytotoxic oedema. The astrocytic 
hypertrophy is associated with an increased production of intermediate filaments, 
which manifests as an increase in glial fibrillary acidic protein (GFAP) 
immunoreactivity (Barrett et a l, 1981; Eng, 1985; Berry et a l ,  1996; Zhang et 
a l ,  1997). The cause of this is not fully known but astrocyte swelling is 
attributed to elevated levels of potassium, glutamate, fatty acids and free radicals 
at the site o f injury (Eng et a l, 2000). There is a notable increase in their 
proliferating state termed reactive gliosis in an attempt to “wall o ff’ the lesion 
site (Figure 1.3.2-a, page 27) (Silver and Miller, 2004). Unlike in a peripheral 
nerve injury where Schwann cells can be found within the lesion site, GFAP 
immunoreactivity patterns indicate that astrocytes surround the borders o f the 
lesion but do not enter the core of the lesion site (Farooque et a l ,  1995). In 
addition to reactive gliosis and cytotoxic oedema, astrocytes also participate in 
the initiation o f a local inflammatory response. This involves the production of 
inflammatory cytokines (Figure 1.3.2-b, page 31), which in turn leads to the 
activation o f resting microglia. In the case of lesions that leave the dura intact, 
the glial scar formed is primarily composed of astrocytes. In contrast, when the
29
lesion is severe enough to compromise the blood-brain barrier the glial scar is 
formed by astrocytes as well as a significant number of connective tissue 
elements such as fibroblasts (Silver and Miller, 2004). This creates fluid-filled 
cysts that quickly become acellular by an unclear process involving both 
apoptosis and necrosis (Beattie et al., 2000). There is evidence to suggest that 
there are some differences between different species with regards to the cellular 
consistency o f the cysts that follow an injury in the spinal cord. For example, the 
cysts formed in the rat contusion injury model are largely acellular compared to 
the cysts forming in a similar injury model in the mouse which are filled 
primarily with connective tissue (Inman and Steward, 2003). Cysts are formed at 
the site o f lesion, by infiltrating peripheral macrophages, activated microglia and 
serum components leaking into the primary lesion area from the compromised 
blood-brain barrier. It has been demonstrated that the blood-brain barrier remains 
“leaky” to blood and other serum components for up to two weeks following a 
CNS lesion (Preston et al., 2001).
As time progresses, necrosis occurs in the fluid filled cavity and degeneration 
extends both in a lateral and rostro-caudal manner. Such cavitations make the 
regenerative process completely impossible, as axons are unable to grow in an 
acellular environment (Fitch et a l, 1999; Silver and Miller, 2004). It has been 
suggested that the purpose of the astrogliosis is actually protective for the animal 
as a whole. It is thought that the accumulating astrocytes can repair the blood- 
brain barrier and limit the infiltration of peripheral macrophages in this highly 
sensitive immune privileged site. This would limit further degeneration by 
preventing the development of an overwhelming inflammatory response (Bush et 
al., 1999; Silver and Miller, 2004; Faulkner et al., 2004). It has been proposed 
that reactivating astrocytes, found distally to the lesion site, may support 
regenerating axons prior to the development of the physically impeding scar 
(Tom et al., 2004; Okada et al., 2006). The formation of the scar may be 
important to the survival o f the animal but comes at the expense of long-distance 
regenerative capacity (Silver and Miller, 2004). When CNS axons encounter the 
glial scar their morphology changes (Ramon Y Cajal, 1928), axonal growth 
cones collapse and develop into dystrophic end-bulbs.
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________________________________ Effect___________________________________
GM-CSF, IL-3, CSF-1, trigger the activation and proliferation of microglia.
IL-3 expression by astrocytes acts as a chemotactic agent for microglia.
GM-CSF & CSF-1 cause the inhibition of class II MHC expression from microglia.
Enhances the permeability o f endothelial cells and facilitates migration of 
neutrophils, monocytes and lymphocytes at the site o f injury.
Increases the production of class 1 and class II MHC molecules.
Stimulates microglia to produce: IL-1, IL-6, CSF & TNF-a
IFN-y
IL-1
IL -6
TGF-P
Enhances the expression of class I and class II MHC.
Enhances the activation of microglia to a phagocytic state.
Induces the production of secondary inflammatory metabolites
Induces the production of other cytokines: TNF-a, IL-6, TGF-P, CSF, IL-1 itself.
IL-6 produced by astrocytes induces their proliferation.
TGF-P is a chemotactic agent for astrocytes and microglia.
F ig u re  1 .3 .2-b : I n te ra c tio n  betw een  C N S n eu ro n s & glia in the  in ju re d  sp in a l co rd .
In terac tion  o f  sp inal cord  neurons, astrocytes, oligodendrocytes and C N S m icroglia. The table 
above sum m arises  the cy tokines that are produced by CNS astrocytes in response to an 
ax o to m isin g  lesion.
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F ig u re  1 .3 .2-c: M ic ro g lia l cell ac tiva tion .
R esting  m ic ro g lia  a re  h igh ly  ram ified cells with -5 0  pm long branches (R -stage). Follow ing the 
arrival o f  an  a c tiv a tin g  signal, the ram ified branches begin to w ithdraw  at a rate o f  0.5-1.5 
g m /m in  (W -stag e). A t the transition stage (T-stage) the old processes are still being w ithdraw n 
w hile  new  p ro tru s io n s  begin to emerge. In the motility stage (M -stage) the new ly form ed 
p ro tru s io n s rep ea ted ly  pro trude and retract at a rate o f  4 gm /m in. It is at this stage that m icroglia 
begin  to  co n tac t ad jacen t cells. During the locomotor stage, they continue to com e into contact 
w ith  n e ig h b o u rin g  ce lls  as they translocate through the tissue at a rate o f  118 gm /m in. (A dapted 
from  S tence , 2 0 01 ).
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Growth cone collapse takes place when regenerating CNS axons come into 
contact with myelin components and oligodendrocytes present in the glial scar 
(Bandtlow et al., 1990; Burden-Gulley et al., 1995). For many years it was 
thought that once axons develop end-bulbs, it is impossible to reinitiate any 
regeneration. However, this was later disproved when it was shown that 
chronically injured rubrospinal axons which had developed dystrophic end-bulbs 
retain their ability to regenerate into a peripheral nerve graft placed within the 
lesion site (Houle, 1991). Further research into the structure of neuronal end- 
bulbs has confirmed at the molecular level that despite the fact they are termed 
dystrophic and appear incapable of any motility, these structures remain highly 
active, constantly altering their cytoskeleton (Silver and Miller, 2004).
1.4 Characteristics of the non-regenerative nature of CNS neurons
Unlike the vigorous response mounted from injured PNS neurons, the response 
seen by intrinsic CNS neurons following a lesion of similar severity and nature is 
characteristically abortive. It has been suggested that this feature may be a 
reflection o f the importance of maintaining the integrity of the highly specialised 
neuronal circuits o f the CNS (Lamer, 1995). Specifically for spinal cord intrinsic 
neurons, axons are capable of collateral sprouting proximal to the lesion. 
However, left unaided, these growth cones quickly become atrophic, sprouting 
ceases and elongation arrests prematurely. From early on, researchers attempted 
to shed some light on whether this was due to the intrinsic inability of CNS 
neurons to mount a regenerative response or whether it was down to the 
properties o f the CNS milieu that did not permit for such a response to be 
sustained.
A series o f experiments hinted to the fact that the main limitation to successful 
CNS regeneration was the presence of inhibitory factors in the extracellular 
environment. Firstly, Ramon Y Cajal and his student Tello (Ramon Y Cajal, 
1928) demonstrated nearly 100 years ago that it is possible for lesioned CNS 
neurons to regenerate when placed in an environment that favours regeneration 
like that o f the PNS. In their experiment they placed a segment of a peripheral
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nerve into the cortex of adult rabbits. Four weeks later they noted that bundles of 
injured putative cerebral axons had extended into the transplant. Due to 
limitations o f the technique at the time (silver staining) it was not possible to 
prove beyond doubt that the regenerating axons seen entering the graft were 
those o f regenerating CNS fibres and this experiment was treated with scepticism 
until the early eighties. Then, the experiment was repeated by others but this time 
the graft was placed either in the brain (Benfey and Aguayo, 1982; Benfey et al., 
1985) or in the thoracic spinal cord (David and Aguayo, 1981; Richardson et a l , 
1982) and more accurate retrograde labelling techniques were used to identify 
regenerating axons as those of CNS neurons. These experiments supported the 
earlier claims made by Ramon Y Cajal and demonstrated that regenerating CNS 
axons could extend for several mm into the autologous graft. Despite the obvious 
regeneration, only very few regenerating fibres grew through the lesion site and 
into the distal spinal cord where they quickly arrested (David and Aguayo, 
1981).
In a later set o f experiments Berry and colleagues tested the ability of a similar 
peripheral nerve to stimulate the regeneration of axotomised adult retinal 
ganglion cells (RGCs) of the rat optic nerve (Berry et al., 1986). They showed 
that in the optic nerve paradigm the key factor that led to RGC axonal 
regeneration was the Schwann cells which through the Bands of Biingner were 
providing the same support to CNS growth cones as they did for the axotomised 
peripheral axons (Berry et al., 1988; Hall and Berry, 1989). However, having a 
Schwann cell enriched microenvironment does not promote the same 
regenerative outcome in all subgroups of CNS neurons. For example, a 
peripheral nerve graft fails to promote the regeneration of either corticospinal or 
Purkinje axons, indicating that the presence of Schwann cells is not always 
sufficient to enable axonal regeneration (Richardson et al., 1982; Anderson et 
a l 1998; Chaisuksunt et al., 2000; Chaisuksunt et al., 2003). This further 
suggests that there are inherent differences between different classes of CNS 
neurons that affect their ability to respond to axotomy.
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1.4.1 Cell body responses of axotomised CNS neurons
The response to axotomy is not universal to all CNS neurons but depends on the 
group of neurons affected. However, the manner in which a single group of 
neurons respond reflects their inherent regenerative potential. One such factor is 
the age o f the injured animal. For example, corticospinal tract neurons, perish 
when axotomised in the early postnatal stage but survive when axotomy is 
carried out in two-week old animals hinting that these neurons die if axotomy 
occurs prior to them innervating their targets (Lieberman, 1971; Merline and 
Kalil, 1990; Rossiter et al., 1996). Age related responses to axotomy could 
reflect changes in either the availability or the requirements for growth factors 
that change as CNS neurons mature.
Another factor that has been proposed to play a part in the ability of CNS 
neurons to regenerate is the distance of the lesion site from the neuronal cell 
body. When an axotomising lesion in the spinal cord leads to the degeneration of 
the damaged axon back to a point of significant collateral branching, then the 
neuron is able to survive this injury (Ramon Y Cajal, 1928; Lieberman, 1971). In 
addition, the CNS neurons that were found to be regenerating into a transplanted 
peripheral nerve graft were found to have their somata very close to the lesion 
site (Richardson et al., 1982). However, studies into the regenerative ability of 
axotomised RGC and Purkinje neurons revealed that they still survived axotomy 
even though the distance of the site of injury from the cell body was not 
interrupted with any collateral branching, thus suggesting that the presence of 
collaterals was not a determining factor in CNS neuronal survival and 
subsequent axonal regeneration (Sofroniew, 1999). It has also been suggested 
that the longer the distance of the site of injury from the cell body, the more 
difficult it is to retrogradely transmit injury-related signals such as cytokines and 
growth factors produced in the vicinity of the lesion. This hypothesis was 
postulated by a number of studies examining the effects of axonal injury on the 
dynamics of neuronal transport. It was noted that rubrospinal neurons 
axotomised at the C3 level retrogradely transported tracer dyes faster than when 
the axotomy was carried out at the T10 level (Tseng et al., 1995). This pattern 
appears to correlate with the expression of growth associated genes in this tract.
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Specifically, it was found that the expression of growth associated protein 43 
(GAP43), laminin, tubulin and neurofilament-M is increased when axotomy 
occurs at the cervical but not thoracic level (Fernandes et al., 1999). Similarly, 
corticospinal neurons are able to upregulate the expression of GAP43 when 
axotomy is performed in the sub-cortical white matter but this does not occur 
when the lesion is inflicted at the more distant level of the pyramidal decussation 
(Kalil and Skene, 1986; Bisby and Tetzlaff, 1992). Finally, in the case of the 
optic nerve, GAP43 was only found to be upregulated when RGCs were 
axotomised at just 3 mm from the retinal layer (Doster et al., 1991).
In addition to the importance of the retrograde axonal transport, the rate of 
anterograde transport of cytoskeletal components is of equal significance for the 
repair o f the severed axon. Transport of cytoskeletal components such as actin, 
tubulin and neurofilament, occurs via the slow component b (Scb) system in the 
CNS and via the slow component a (Sea) system in the PNS (Fournier and 
McKerracher, 1995). Following axotomy in the PNS, the rate of Sea transport 
increases to match the rate of axonal elongation (McKerracher and Hirscheimer,
1992). In contrast, in axotomised RGCs, the rate of Scb transport decreases from 
0.5 mm/day to 0.06 mm/day (McKerracher et a l , 1990b). However, when RGCs 
are placed next to a peripheral nerve graft, they extend new processes into the 
graft at a rate o f 1 mm/day following injury suggesting that when aided, 
regenerating CNS neurons can also increase the activity of Scb system in order 
to support the demands of axonal elongation (McKerracher et al., 1990a).
1.4.2 Gene expression in axotomised CNS neurons
For CNS axonal regeneration to translate into functional restoration, neurons 
must be able to firstly survive the initial mechanical disruption, secondly sprout 
and thirdly elongate their axons in order to reach their targets. Several molecules 
have been implicated in stimulating axonal growth pathways, including GAP43, 
c-Jun and activating transcription factor 3 (ATF3), which will be briefly 
discussed below. Note that the patterns of expression of these molecules with 
regards to the corticospinal, rubrospinal and optic nerve tracts are discussed in 
more detail in the relevant chapters of this thesis.
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GAP43 expression
GAP43 is a 43 kDa, phosphorylated protein that is highly upregulated during 
development (Strittmatter et al., 1995; Benowitz and Routtenberg, 1997; Zhu 
and Julien, 1999). Its expression is re-initiated in regenerating PNS neurons and 
sprouting CNS neurons (Oestreicher et al., 1994; Benowitz and Routtenberg, 
1997; Grill and Tuszynski, 1999). GAP43 is a substrate for Protein Kinase C 
(PKC) and it localises to axonal growth cones where it is involved in the 
reorganisation o f the neuronal cytoskeleton (Akers and Routtenberg, 1985; 
Benowitz and Routtenberg, 1997). The importance of GAP43 in axonal growth 
has been examined in a variety of in vitro and in vivo experiments. For example, 
the addition o f NGF to phaeochromocytoma (PC 12) cells, results in the 
upregulation o f GAP43 expression and neurite extension (Federoff et al., 1988). 
Overexpression of GAP43 in PC 12 cells increases the number of neurites 
produced (Yankner et al., 1990) whilst the use of antisense oligonucleotides to 
GAP43 mRNA reduces the number of neurites produced (Jap Tjoen et al., 1992). 
When GAP43 antisense oligonucleotides were used on primary cultures of chick 
DRGs, there was a reduced number of neurites produced. The neurites produced 
had smaller and more unstable growth cones present and they were far more 
susceptible to inhibition when exposed to the inhibitory effects of CNS myelin- 
derived liposomes compared to neurons that expressed GAP43 as normal 
(Aigner and Caroni, 1993; Aigner and Caroni, 1995). However, there are some 
reports that tend to doubt the direct association of GAP43 expression with axonal 
elongation post injury. For example it has been shown that GAP43 deficient 
PC 12 cells were capable of differentiation and axonal extension in response to 
NGF (Baetge and Hammang, 1991). The difference between these in vitro 
experiments could be due to the fact that GAP43 may not be an essential 
prerequisite for the initiation of neurite outgrowth but its presence is required in 
order for this response to be sustained (Baetge and Hammang, 1991; Aigner and 
Caroni, 1995). Further evidence that support this notion comes from a series of 
experiments on two different strains of transgenic mice that lack the ability to 
produce GAP43 (Strittmatter et al., 1995; Zhu and Julien, 1999). Both strains 
appear to have significant developmental defects, especially in the synaptic 
architecture o f the visual system. These experiments reinforce the fact that even
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in the total absence of GAP43, it is possible for most CNS neurons to form 
synapses. There are, however, some classes of neurons that rely on its effects for 
normal axonal development and elongation (Strittmatter et al., 1995; Zhu and 
Julien, 1999).
A number of in vivo experiments have shown that the upregulation of GAP43 
does not necessarily translate into successful regeneration of all adult CNS 
neurons. It is important to mention that the GAP43 gene promoter contains a 
binding site that is responsive to the AP-1 transcription factor, which as 
discussed bellow, is formed by the association of c-Jun and ATF3 (Weber and 
Skene, 1998). This means that the apparent upregulation of GAP43 could 
actually by the result of c-Jun upregulation (Hunt et al., 2004). Placing a 
peripheral nerve graft into the thalamus of adult rats does lead to the 
upregulation o f GAP43, followed by sprouting of thalamic neurons and 
regeneration o f their axons into the graft (Vaudano et a l , 1995). This however 
does not occur in the case of cerebellar Purkinje neurons that do not upregulate 
GAP43 and fail to elongate their axons even in the presence of a peripheral nerve 
graft (Anderson et al., 1998). When GAP43 is artificially overexpressed in 
Purkinje neurons, axonal sprouting does increase but this is still not sufficient to 
lead to regeneration into a peripheral nerve graft placed within the lesion site 
(Buffo et al., 1997). Overall, these data suggest that the upregulation of GAP43 
alone may not be a strong enough molecular stimulus to induce neurons that are 
intrinsically refractory to regeneration to elongate their axons even in the 
presence o f a growth permissive environment like a peripheral nerve graft (Buffo 
et al., 1997; Mason et al., 2000).
c-Jun expression
c-Jun is a transcription factor which is primarily active during the embryonic 
stages o f neuronal development (Herdegen et al., 1993a; Herdegen et al., 1993b; 
Herdegen et al., 1997). Amongst its many functions, it has been shown to 
participate in the cell-cycle regulation, cellular differentiation and apoptosis in a 
variety o f cell types (Angel and Karin, 1991; Jochum et al., 2001). c-Jun forms 
heterodimers with proteins such as c-Fos or with ATF (Hai et al., 1999). These
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complexes comprise the AP-1 complex that goes on to initiate transcription from 
conserved TGACTCA sequences (Lee et a l , 1987; Angel et al.y 1988a) in 
response to stress signals such as cytokines and growth factors. The mechanism 
by which these factors go on to initiate the activation of AP-1 involve the N- 
terminal phosphorylation of c-Jun by the c-Jun N-terminal Kinases (JNKs) 
(Davis, 2000) which takes place at serine residues 62 and 73 and threonine 
residues 91 and 93. These residues are located within the c-Jun transactivating 
domain and their phosphorylation increases the transcription of a variety of 
genes including c-Jun itself (Angel et al.y 1988b). c-Jun is still expressed at low 
levels in the adult PNS as well as brain and spinal cord neurons (Herdegen et al.y
1997). Its expression is upregulated soon after an axotomising PNS lesion and 
high levels of expression are observed throughout the period necessary for target 
innervation to occur (Jenkins and Hunt, 1991). In vitro experiments have shown 
that this upregulation coincides with the onset of Wallerian degeneration and it is 
thought to be mediated by myelinating Schwann cells of the distal stump in 
response to losing contact with the degenerating axons. Moreover, c-Jun 
expression declines once re-myelination of regenerated axons occurs (Shy et al.y 
1996). The involvement of c-Jun in neuronal regeneration has also been 
confirmed in vivo using conditional, c-Jun null mutant mice. After facial nerve 
axotomy these mice do not upregulate GAP43 while axonal sprouting and 
regeneration is significantly impaired compared to wild type mice (Raivich et al.y 
2004). This elucidates that c-Jun plays an important role in the events following 
neuronal injury and axonal regeneration. Overall, the expression of c-Jun tends 
to be directly related to the ability of CNS neurons to initiate a regenerative 
response and extend their axons into a permissive environment such as a 
peripheral nerve graft. However, as was the case with GAP43, there appear to be 
some exceptions, which correlate with the intrinsic characteristics of particular 
groups of CNS neurons. For example, placing a peripheral nerve graft into the 
thalamus of adult rats can promote the regeneration of thalamic reticular nucleus 
neurons into the graft (Vaudano et al.y 1998; Chaisuksunt et al.y 2000). These 
neurons are able to express high levels of c-Jun after injury. In contrast, neurons 
of the substantia nigra are capable of regenerating their axons into a peripheral 
nerve graft but fail to upregulate c-Jun (Chaisuksunt et al.y 2003).
39
ATF3
ATF3 is a member of the ATF/CREB family of transcription factors. These have 
a highly conserved basic region leucine zipper (bZip) element that enables them 
to associate with other members of the same family of transcription factors 
(ATF/CREB) and form homodimers that suppresses expression from DNA 
containing the sequence TGACGTCA. Alternatively, ATF3 can form 
heterodimers by associating with c-Jun. These heterodimers form the AP-1 
complex that by binding to the TGACTCA DNA sequence, it activates 
transcription (Hai et al., 1999; Hai and Hartman, 2001). Following peripheral 
nerve axotomy, ATF3 is upregulated in both sensory and motor neurons of the 
spinal cord, in a similar manner to that seen in the case of c-Jun (Hai et al., 
1999). CNS intrinsic neurons that can successfully regenerate their axons into a 
peripheral nerve graft placed within the lesion site also appear to be able to 
upregulate the expression of ATF3. However, this appears to vary depending on 
the type o f neuron and the distance of the neuronal cell body from the site of the 
injury. For example, corticospinal tract neurons are capable of upregulating 
ATF3 if the axotomy is carried out intracortically but fail to do so when the 
lesion is performed at the level of the spinal cord (Mason et al., 2003).
Like the case o f c-Jun, the expression of ATF3 is upregulated by Schwann cells 
in the distal stump o f axotomised peripheral nerves. This increase in expression 
is initiated within 24 hours following injury, probably due to the fact that 
Schwann cells lose contact with the axons they used to myelinate (Hunt et al., 
2004). Expression o f ATF3 declines once the axons have regenerated, but it can 
be switched on again if the regenerating axons are re-injured (Hunt et al., 2004). 
In the same study it was shown that CNS glia present in the DREZ and in the 
dorsal columns do not upregulate the expression of ATF3 during Wallerian 
degeneration. This was different in the case of the optic nerve where ATF3 
immunoreactivity was more evident within the lesion site but was comparatively 
weak in the distal or proximal stumps (Hunt et al., 2004). Hunt and colleagues 
(2004) proposed that this may have been a reflection of the fact that CNS glia 
upregulate ATF3 in response to direct injury and not in response to Wallerian 
degeneration.
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1.5 Neurotrophic factors and spinal cord regeneration
Neurotrophic factors are molecules whose biological activities involve cell 
survival, synaptogenesis and axonal plasticity. The term “neurotrophic factors” is 
used to describe the different families of molecules that share the ability to carry 
out these functions. These families include: the neurotrophin family, the 
neurokine family including the ciliary neurotrophic factor (CNTF), the TGF- 
related family including the glial-derived neurotrophic factor (GDNF) and the 
insulin-like growth factor family (IGF). Exogenous administration of 
neurotrophic factors has been proposed as a potentially therapeutic approach for 
inducing regeneration after spinal cord injury. The potential o f this approach has 
been evaluated using various growth factors including BDNF (Houweling et al., 
1998; McTigue et al., 1998; Jakeman et al., 1998; Shumsky et al., 2003; Tobias 
et al., 2003; Zhou and Shine, 2003; Tobias et a l , 2005), bFGF (Lee et al., 1999), 
NT3 (McTigue et al., 1998; Shumsky et a l , 2003; Tobias et a l , 2003; Tuszynski 
et a l , 2003) and GDNF (Blesch and Tuszynski, 2003; Zhou and Shine, 2003). 
The following section focuses on the main characteristics of neurotrophic factors 
and their receptors with emphasis on the neurotrophin family. A more detailed 
account o f their effectiveness in various CNS injury models is given in the 
relevant chapters o f this thesis.
Neurotrophins were the first family of neurotrophic factors to be identified and 
its members include: NGF, BDNF, neurotrophin 3 (NT3), neurotrophin 4 (NT4) 
as well as the non mammalian neurotrophin 6 (NT6) and neurotrophin 7 (NT7) 
(Barde et a l , 1982; Leibrock et a l , 1989; Maisonpierre et a l, 1990a; 
Maisonpierre et a l ,  1990b; Hallbook et a l,  1991; Ip et a l, 1992; Lai et a l, 
1998). The neurotrophic factor NGF, was the first member of the neurotrophic 
family identified over 50 years ago (Levi-Montalcini, 1987). Its importance was 
revealed when sympathetic sensory ganglia of developing chicks treated with 
NGF in vitro, resulted in a characteristic halo of axonal outgrowth. During 
development, NT3, BDNF and NGF exhibit parallel as well as reciprocal 
patterns o f expression (Maisonpierre et a l, 1990a). They are all upregulated 
between the 11th and 12th day of embryogenesis, which coincides with the onset 
o f neurogenesis. However, the levels of expression for each neurotrophin vary
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significantly, indicating that their roles are different. NT3 is predominantly 
expressed in spinal cord neurons and is associated with proliferation, migration 
and differentiation and its expression decreases as neurons reach maturation. In 
contrast, BDNF expression increases as CNS maturation progresses 
(Maisonpierre et al., 1990a). NGF is expressed at relatively low levels in early 
spinal cord development during a period associated with naturally occurring 
death of newly formed motor neurons (Emfors et al., 1989). These differences 
correlate to a requirement for a separate physiological activity exerted by each 
neurotrophic factor at different stages of neuronal development. NT3 appears to 
be required for the early stages of development (Maisonpierre et al., 1990b) and 
establishment o f target innervation (Korsching and Thoenen, 1983), whereas 
BDNF acts as a maturation maintenance factor (Maisonpierre et al., 1990a).
Apart from the NGF related neurotrophic factors there are two more classes of 
growth factors that have a neurotrophic function. Survival of motor and sensory 
neurons is supported by CNTF in vivo (Apfel et al., 1993) while in vitro it 
increases survival and neurite outgrowth of purified embryonic motor neuron 
cultures (Arakawa et al., 1990). GDNF deficient mice completely lack the 
enteric nervous system, including urethras and kidneys pointing to the potential 
role o f this neurotrophin in organ development (Moore and Thanos, 1996). 
Neurotrophic factors have been the focus of extensive research in a variety of in 
vivo and in vitro CNS injury models [reviewed in detail for the corticospinal 
(Chapter 4), rubrospinal (Chapter 5) and optic nerve (Chapter 6) tracts]. The 
intracellular signalling events initiated by neurotrophic factors and their 
receptors are examined in the following section.
1.5.1 Neurotrophic factor receptors
Neurotrophic factors exert their effects by binding to their corresponding 
transmembrane receptors (Figure 1.5.1-a, page 45). Neurotrophic receptors can 
be divided in two classes: p75 , a low affinity receptor that can bind every
neurotrophin (Chao, 1994) and the Tyrosine Kinase (Trk) family of receptors, 
which display subspecies specificity for each neurotrophin (Barbacid, 1994).
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Trk receptors
There are three distinct Trk receptors which have been characterised as 
transmembrane glycoproteins with a tyrosine kinase intracellular functional 
domain (Segal and Greenberg, 1996). NGF binds to TrkA (Kaplan et al., 1991; 
Klein et al., 1991a), BDNF to TrkB receptor (Klein et al., 1991b) and NT3 to 
TrkC or TrkB (Lamballe et al., 1991; Squinto et al., 1991; Klein et al., 1991b). 
Mutations in the TrkA gene have shown that it plays an important role in the 
development o f nociceptive and thermoregulatory neuronal pathways (Smeyne et 
al., 1994). In addition, studies utilising conditional knock-out TrkB mutants have 
revealed that this receptor is essential for synaptic plasticity and hippocampus 
mediated learning (Minichiello et a l , 1999; Tolwani et al., 2002). Interestingly, 
BDNF and NT3 appear to have opposite effects in the myelination of the 
peripheral nervous system during development. NT3 inhibits myelination acting 
via its TrkC receptor while BDNF enhances myelination acting via the weak 
p75NTR receptor (Cosgaya et al., 2002). NT3-mediated TrkC activation has been 
shown to enhance Schwann cell migration in the peripheral nervous system. This 
signalling pathway is mediated by the JNK cascade, regulated by the Rho 
GTPases Racl and Cdc42 (Yamauchi et al., 2005). Upon binding a neurotrophic 
factor, the Trk receptor dimerises leading to the activation of the tyrosine kinase 
domain and consequent auto-phosphorylation of tyrosine residues. These are in 
turn recognised by specific signalling proteins, which share a Src homology 
domain, such as Phospholipase-C (PLC) and Phosphatidyl Inositol-3 Kinase (PI- 
3K) (Figure 1.5.1-a, page 45). Subsequently, second messenger proteins become 
activated, leading to multiple biological responses within the cell (Segal and 
Greenberg, 1996; Kaplan and Miller, 1997).
p75NTR receptor
p75NTR is a glycosylated transmembrane protein that belongs to the TNFa 
superfamily (Rao et al., 1995) and exists in two isoforms: a full-length and a 
short-length form (Johnson et al., 1986). Out of these, it is only the full-length 
version that is capable of neurotrophin binding, as the short form has only three 
o f the four extracellular domains responsible for this function. p75NTR can 
modulate the response of a Trk receptor to its ligand. For example, p75NTR can
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increase the affinity of TrkA for NGF so that the neuron concerned becomes 
responsive to lower concentrations of NGF (Hempstead et al., 1991; Davies et 
al., 1993). Interestingly, the precursor to the active form of NGF (pro-NGF) 
appears to bind to p75NTR with higher affinity than to TrkA. The reverse is true 
for the biologically active, mature NGF. It is thought that in the presence of pro- 
NGF, p75NIR acts as an apoptosis-inducing receptor, especially during neuronal 
development (Rabizadeh et al., 1993). It does so via its own signalling pathway 
via the activation of the transcription factor nuclear factor (NF) Kp (Carter et al.,
1996). It is now thought that for this to occur, p75NTR has to interact with its co­
receptor, Sortilin (Nykjaer et a l , 2004). This function can be silenced when the 
TrkA receptor is activated (Dobrowsky et al., 1995). This p75NTR-mediated 
apoptosis is thought to be behind the death o f oligodendrocytes which occurs 
after a CNS axotomising lesion (Beattie et al., 2002).
In addition to the above neurotrophin related functions, p75NTR can bind 
numerous other ligands, including the Nogo receptor (Wong et al., 2002; Wang 
et al., 2002b) and LINGO (Mi et a l , 2004). p75NTF signalling has been shown to 
increase Rho activation (Yamashita et a l , 1999) by interacting with the Rho 
GDP dissociation inhibitor (Rho-GDI). This leads to the subsequent activation of 
Rho GTPase and results in the inhibition of axonal growth (Yamashita and 
Tohyama, 2003). More importantly, there is evidence to suggest that this 
interaction between p75NTR and Rho-GDI is strengthened by the presence of 
Nogo or MAG (Yamashita et a l , 2002; Yamashita and Tohyama, 2003) which 
would fit in with their role as inhibitors to axonal elongation (discussed in later 
sections o f this chapter).
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1.6 Glial scar inhibitory molecules -  Extrinsic factors
It has been hypothesised that reactive astrocytes may produce the required 
supportive molecules for axonal elongation but the corresponding receptors may 
be unresponsive at the site of injury. In contrast to the secretion of regeneration- 
supportive agents, reactive astrocytes also secrete molecules such as chondroitin 
sulphate proteoglycans (CSPG) such as aggrecan, brevican, neurocan, versican, 
phosphacan and NG2 (McKeon et al., 1991). Structurally, these proteins have a 
large protein core, which has attached large and poly-sulphated 
glycosaminoglycan (GAG) (Morgenstem et al., 2002). It is thought that it is this 
large GAG that is responsible for the inhibitory characteristics of CSPGs. 
Treatment with the enzyme chondroitinase ABC stops this inhibitory effect 
(Carulli et al., 2005). However, the core proteins also contribute to this 
inhibitory function (Ughrin et al., 2003). The manner in which CSPGs exert their 
inhibition is thought to involve the activation of a number of signalling 
pathways. This notion is based on the fact that neurons that come into contact 
with CSPGs appear to show enhanced activation of Rho-ROCK signalling 
pathway. In addition, blocking this pathway abolishes the CSPGs inhibitory 
effect (Monnier et al., 2003). In experimental animals, blocking of Rho with 
protein kinase C inhibitors, promotes dorsal column regeneration after spinal 
cord injury (Sivasankaran et a l , 2004). In addition to CSPGs, there are several 
other molecules deposited at the lesion site that also hinder regeneration. For 
example, Semaphorin 3A (Sema3A) expression is upregulated by meningeal 
cells. Sema3A binds to neuropilin 1 which is also upregulated in injured CNS 
neurons. The interaction of Sema3A with neuropilin results in growth cone 
collapse (Sandvig et a l , 2004). Certain structural domains on semaphorins 
(thrombospondin repeats), physically interact with the long GAG chains on the 
abundant CSPGs and regulate their impact on CNS injured axons (Kantor et a l , 
2004).
Tenascin-R is another cell adhesion protein that is upregulated following a CNS 
axotomising lesion and is also thought to exert a negative influence in the CNS 
axonal regeneration process (Gates et a l , 1996). Even though most of the cells 
around the lesion area that express tenascin also express GFAP, those located
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within the lesion site are GFAP negative. This may suggest that tenascin 
expression was not only due to reactive astrocytes but also due to other cells 
attracted at the lesion site in response to injury: e.g. macrophages (Zhang et a l ,
1997). Tenascin-R has been shown to inhibit axonal elongation (Probstmeier et 
al., 2000). Tenascin-R knockout mice show increased recovery of function after 
spinal cord axotomy but this is thought to be due to the re-arrangement of spared 
fibres rather than due to frank regeneration of the injured neurons (Apostolova et 
a l 2006).
Following axotomy, there is some unassisted sprouting of spinal cord neurons. 
This however ceases after a short period of time. Astrocytes have been shown to 
express a truncated form of neurotrophic receptor specific to neurotrophic factor 
BDNF (TrkB) which lacks its tyrosine kinase catalytic domain (Frisen et al., 
1993). In vitro experiments demonstrated that cells expressing this truncated 
form o f the BDNF receptor were unable to support neurite outgrowth in the 
presence o f exogenous BDNF. From those findings, Fryer (1997) hypothesised 
that neurotrophic factors may be available at the lesion site following injury but 
they are taken up by a truncated neurotrophin receptor on reactivated astrocytes 
o f the glial scar, thus becoming quickly unavailable (Fryer et al., 1997).
The role o f the inflammatory response following an injury is controversial. Some 
studies suggest that the delayed recruitment of macrophages from the peripheral 
blood stream and the activation of resident microglia leads to the accumulation 
o f debris such as myelin and axonal fragments (Perry et a l , 1993; George and 
Griffin, 1994). In addition, the ability of activated microglia to release cytotoxic 
factors at the site of injury has been suggested to have further side effects to the 
viability o f neurons and their connections (Giulian et a l, 1994). However, when 
PNS neurons were transplanted in the CNS, regeneration was accompanied by 
mild inflammation at the PNS-CNS junction. This led to the hypothesis that low 
levels o f  inflammation may have positive effects in neuronal regeneration (Kliot 
et a l ,  1990; Siegal et al, 1990). The implication of axonal injury on the growth 
capacity o f the affected neurons has also been considered as a causal agent in the 
regenerative failure. Neumann et a l (1999) have reported successful
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regeneration of dorsal column fibres into and beyond the lesion site following 
adult spinal cord injury. In this experiment, the sciatic nerve of adult rats was 
transected one week before cutting the afferent sensory fibres of the ipsilateral 
dorsal root ganglion (Neumann and Woolf, 1999). It was hypothesised that the 
increased capacity of sensory neurons to regenerate is in part due to an increase 
in their growth state. Moreover, Filbin M. (1999) suggested that this 
regeneration, observed when a pre-conditioning lesions are inflicted, could be 
due to modified responses of the inhibitory molecules found in myelin and glial 
scar (Filbin, 1999). Her theory is based on the fact that the neuron's endogenous 
levels of cAMP dictate its response to inhibitors. It is thus likely that transection 
of dorsal root ganglia causes an increase in the intracellular levels of cAMP that 
resembles those found during developmental stages and leads to the 
neutralisation of inhibitory molecules (Chong et al., 1996).
1.7 Myelin-derived inhibitors to CNS regeneration
CNS axons cannot regenerate following a mechanical lesion but can mount some 
regenerative response if the axotomising injury does not disturb any of the 
adjacent myelinated fibres (Berry, 1982). This observation led Berry and 
colleagues to propose that CNS myelin-contained elements were inhibitory to 
regeneration (For a review see: He and Koprivica, 2004).
Nogo
Confirmation that CNS myelin could directly inhibit neurite extension came later 
from a number of experiments that demonstrated that CNS but not PNS myelin 
was inhibitory to neurite extension (Savio and Schwab, 1989; Khan et al., 1990). 
In addition, in co-cultures of adult neurons and dissociated oligodendrocytes, 
neurites were strongly repelled by these glial cells (Caroni et al., 1988; Bandtlow 
et al., 1990; Moorman, 1996). Size fiactionation experiments of rat myelin 
constituents, revealed the presence of two protein: NI-35 and NI-250 which were 
also shown to be potent inhibitors of growing neurites in vitro (Caroni and 
Schwab, 1988). The monoclonal antibody IN-1, was shown to react with both 
these fractions, leading to increased neurite outgrowth both in vitro and in vivo 
(Caroni and Schwab, 1988; Schnell and Schwab, 1990; Schnell and Schwab,
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1993; Bregman et al., 1995). A partial sequence was eventually obtained for the 
N 1-250 molecule which led to the cloning of the gene encoding Nogo (GrandPre 
et al., 2000; Prinjha et al., 2000). Blocking Nogo using IN-1 enhances sprouting 
o f  corticospinal axons, modestly improving their regeneration and reportedly 
enhancing functional recovery following spinal cord injury (Schnell and Schwab, 
1990). In addition, it produces a modest increase in regeneration following an 
intracranial optic nerve injury (Weibel et al., 1994). Nogo is a member of the 
reticulon family of transmembrane proteins and exists in three isoforms: A, B 
and C, thought to be produced via alternative splicing. Nogo A has been shown to 
be highly expressed on the surface of oligodendrocytes (Huber et a l ,  2002).
Myelin-associated glycoprotein (MAG)
MAG is an inhibitory molecule for the majority of adult CNS neurons 
(Mukhopadhyay et al., 1994; DeBellard et al., 1996) and is thought to be the 
main inhibitory component of myelin (McKerracher et al., 1994). It is a 
transmembrane protein whose extracellular domain is expressed in the PNS and 
CNS (Lai et al., 1987; Salzer et al., 1987). Interestingly, MAG has two opposing 
functions depending on the age of the animal. For example, it was shown that 
MAG acts as a growth-promoting factor for axons during embryonic 
development and as an inhibitor after postnatal day 3 (Mukhopadhyay et al., 
1994; DeBellard et al., 1996). Despite the fact that MAG is present in both the 
PNS and CNS myelin, it is only inhibitory in the CNS. It has been suggested 
that this may be due to the fact that PNS macrophages are able to remove the 
myelin debris very quickly after the mechanical damage (He and Koprivica,
2004). This is not the case following a CNS lesion (David et al., 1990). 
Moreover, if  MAG function is eliminated in chick E l5 retina and optic nerve 
explants, then large numbers of RGC axons are able to regenerate across a crush 
site in the early myelinated optic nerve (Wong et al., 2003).
Oligodendrocyte-myelin glycoprotein (OMgp)
OMgp is another putative inhibitor of neurite growth (Wang et al., 2002a). It is a 
GPI-anchored protein that contains a leucine rich repeat (Mikol et a l,  1990). It 
has been shown to contribute to growth cone collapse in vitro (Kottis et a l,
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2002) but its role in inhibiting CNS axonal elongation in vivo is still unclear. 
OMgp is expressed on oligodendrocytes and on the myelin sheaths that are in the 
immediate vicinity of CNS axons. The onset of its expression appears to coincide 
with the initiation of myelination (Mikol and Stefansson, 1988; Mikol et a l, 
1993; Habib et al., 1998). In particular, it was recently shown that it is 
prominently expressed near the nodes of Ranvier and may have a role in 
preventing collateral sprouting (Huang et a l,  2005). Recombinant OMgp, was 
shown to induce growth cone collapse in cultured neurons (Wang et al., 2002a; 
Barton et al., 2003).
Down-stream effectors
All o f  these molecules have recently been shown to exert the majority of their 
inhibitory influence by binding to the Nogo receptor (NgR) (Fournier et a l, 
2001; Fournier et al., 2002; Hunt et al., 2002b; McGee and Strittmatter, 2003). 
MAG and OMgp have also been shown to act through the cAMP/pKA/Arginase 
pathway, independently from NgR (Cai et al., 2002). All these molecules have a 
common characteristic: they all signal via the small Rho GTPase signalling 
pathway. RhoA belongs to a family of GTPases that regulate cytoskeletal 
dynamics o f growth cones and neurite extension. It has been shown that a 
dominant negative RhoA can enhance RGC axonal regeneration in vitro. This 
effect is also evident in vivo as treatment with C3, a RhoA inactivator, was 
shown to induce regeneration in the crushed optic nerve (Lehmann et al., 1999).
1.8 Strategies for inducing regeneration in the injured CNS
Spinal cord injury poses a multifactorial problem and as such it requires a 
combination o f different treatments. Over the last decade research has focused 
on combining different treatments for promoting neuronal survival and 
regeneration in a variety of different paradigms. Such reports are reviewed and 
discussed in relation to the corticospinal (Chapter 4), rubrospinal (Chapter 5) and 
optic nerve (Chapter 6) tracts and they are briefly summarised here.
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1.8.1 Cellular interventions
This technique aims to provide a “bridge” that links the proximal and distal 
stumps, normally separated by an acellular cyst, whose presence hinders any 
regenerative attempt. This can be achieved by placing a growth-promoting 
substrate into the lesion site. Such substrates can be peripheral nerve grafts, 
Schwann cells or olfactory ensheathing glial (OEG) cells (for a review see 
Thuret et a l , 2006).
Peripheral Nerve Grafts
The rationale behind the use of peripheral nerve grafts has been discussed in 
previous sections, while the application of this technique in rodent models of 
spinal cord and optic nerve injury is further discussed in detail in the relevant 
Chapters (4-6). Peripheral nerve grafts have been used either alone or in 
combinations with modulators of the inflammatory response or neurotrophic 
factors such as acidic FGF and fibrin glue (Lee et a l , 2002; Cheng et a l, 2004; 
Lee et a l , 2004). The combination of acidic FGF and a peripheral nerve graft has 
been used in a human case of a chronic paraplegia (Cheng et a l , 2004). In this 
isolated case the authors report some recovery of function but this was not 
replicated in a case of complete spinal cord transection (Amador and Guest,
2005).
Schwann Cell Grafts
A considerable number of studies document that these cells have the ability to 
induce axotomised CNS neurons to regenerate. When these cells were placed as 
a suspension into the lesion site of a transected spinal cord, they induced sensory 
and motor neurons to extend their axons into the graft (Takami et a l , 2002). In 
addition, the authors report that this is accompanied by some recovery of 
function (Takami et a l , 2002). In another experiment, Schwann cells embedded 
within channels containing extracellular matrix, were transplanted into the site of 
a lateral cord hemisection. These animals also received a combination of BDNF 
and NT3 (Xu et a l , 1995; Bamber et a l , 2001). Injured axons could again be 
seen entering the graft but as in the previous experiment by Takami et a l (2002), 
they failed to enter the distal stump (Xu et a l , 1995; Pinzon et a l , 2001).
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Olfactory Ensheathing Glial Cells
OEGCs have been the focus of considerable research in CNS regeneration 
paradigms and the injured spinal cord in particular. This type of glial cell is 
responsible for ensheathing the axons of olfactory receptors which are also of 
neuronal origin. These neurons are unique in that they can regenerate their axons 
through the adult CNS environment. The potential of these cells to influence 
axonal regeneration was elucidated when purified cultures where transplanted 
into the dorsal hom of a spinal cord that had previously received a rhizotomy 
(Ramon-Cueto et a l , 1993). The authors found that the lesioned DRG axons 
were able to regenerate into the ipsilateral dorsal hom. Despite their original 
promise, OEGCs have not been conclusively shown to promote regeneration in 
the injured spinal cord with often contradicting reports regarding their 
effectiveness. Some groups report significant regeneration through the CNS 
environment (Raisman, 2001). Recovery of function and axonal regeneration has 
been reported in paradigms where OEGCs were transplanted into the lesion site, 
either immediately or within 2 months following spinal cord axotomy (Lu et a l , 
2001; Keyvan-Fouladi et a l , 2003; Li et a l,  2004; Li et a l ,  2005; Collazos- 
Castro et a l ,  2005). Other groups report that OEGCs fail to promote any 
regeneration in similar spinal cord injury models (Gomez et a l,  2003; Riddell et 
a l ,  2004). In addition, another group has found that OEGCs are not as efficient 
at promoting regeneration as Schwann cells in the injured rat spinal cord 
(Takami et a l ,  2002). Surprisingly, and despite the uncertainty, transplants of 
cells derived from foetal or adult olfactory bulbs have been grafted into humans 
in clinical research centres in China, Portugal and Colombia (Huang et a l, 2003; 
Dobkin et a l ,  2006) (also reviewed in Thuret et a l ,  2006).
Counteracting myelin inhibitors
Numerous strategies have been employed in order to counteract the effects of 
myelin-derived inhibitors to axonal regeneration. Their effect on axotomised 
CNS neurons has been assessed in a variety of experimental paradigms (Sandvig 
et a l ,  2004; Yiu and He, 2006). These studies and their main findings are further 
discussed in the relevant chapters of this thesis.
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1.8.2 Gene Therapy for inducing CNS regeneration
A plethora o f in vivo and ex-vivo genetic engineering techniques have been 
developed with the aim of inducing and supporting the generation of injured 
CNS neurons. As previously discussed, the CNS response to injury is a complex 
mechanism involving neurons themselves and their extracellular environment. It 
therefore follows that for a regenerative approach to be successful it must 
augment all stages of CNS regeneration. Potentially therapeutic genes and 
factors that can counteract inhibitory cues must be provided over three time 
windows: As soon as injury is inflicted (i.e. emergency damage control) aiming 
to rescue injured neurons and prevent inhibition from the forming glial scar. It 
must be able to sustain transgene expression for a significantly long period of 
time in order to support and direct neurite outgrowth from sprouting axons. It 
must also be able to supply factors that can aid in the recognition of target tissue 
and facilitate the formation of synapses (Breakefield et al., 1999).
The appeal o f utilising gene therapy vectors for promoting regeneration is based 
on the fact that they enable the cell bodies of injured CNS neurons themselves to 
synthesise the growth promoting factors they need in order to enhance their 
limited regenerative potential. This means that the factors produced are not 
subject to the usual limitations of accessing CNS neurons, imposed by the 
protective blood-brain barrier. In addition, molecules such as neurotrophins have 
an extremely short half-life and quickly become degraded. This is an important 
impediment as for regeneration to occur such growth promoting factors must be 
present for a considerable length of time. Alternative methods, such as osmotic 
min-pumps also aim to ensure prolonged presence of trophic molecules but have 
the added disadvantage that they further compromise local tissue integrity. 
Furthermore, neurotrophic factors have a number of functions in addition to their 
role in axonal growth. They are anterogradely transported and released to post- 
synaptic targets. By limiting their production to the small number of neurons 
affected by the lesion helps to ensure that the effects they exert remain local thus 
minimising their potential for non-specific, side effects. Finally, in contrast to the 
use o f ex vivo approaches, gene therapy techniques such as viral vectors can be 
delivered via minimally invasive, stereotactic procedures that do not exacerbate a
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pre-existing injury. Considerable research has led to the production of a number 
o f vector systems that can be used in the injured CNS. These range from non- 
viral systems such as liposomes, to viral vector systems based on the use of 
Adenovirus (AV), Adeno-associated virus (AAV), lentivirus and retrovirus 
backbones (Breakefield et a i91999; Abdellatif et al., 2006). A number of studies 
have emerged that report variable degrees of success with these systems within 
the context o f inducing regeneration of injured spinal cord neurons. These are 
reviewed and discussed in the relevant Chapters o f this thesis.
1.8.2.1 Herpes simplex virus
The innate characteristics of HSV1 have long been exploited in order to produce 
a gene delivery tool for a variety of applications. In particular, the innate 
characteristics o f this virus have pointed towards its potential as a powerful tool 
for gene delivery applications to the nervous system (reviewed in Lilley and 
Coffin 2003). Firstly, it has a natural propensity to infect neuronal cells where it 
can establish life-long latency. Secondly, it does not integrate into the host 
genome but elements o f its latency can be exploited to confer long-term foreign 
gene expression. Thirdly, the genome of HSV1 is capable of accepting large 
inserts such as foreign genes but also other DNA based elements such as 
expression cassettes that can maximise gene expression. The features 
summarised above are the basis of utilising this virus for delivering regeneration 
promoting genes to the injured spinal cord, under consideration in this study.
1.9 Biology of HSV1
HSV is a member of the alpha herpesviridae family of double stranded DNA 
(dsDNA) viruses and exists in two subtypes: HSV1 and HSV2 (Roizman et al., 
1981). These two viruses have different clinical manifestations. HSV2 causes 
genital warts while HSV1 causes recurrent mucocutaneous lesions (cold sores) in 
only one third of the population (Roizman and Sears, 1996) despite it being 
seroprevelent in >80% in some populations (Sharp, 2002). Very rarely and 
primarily in immunocompromised hosts, wild type virus can enter the CNS and 
cause viral encephalitis. In order to understand the steps taken for the production
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of non-toxic HSV1 based vectors suitable for delivery to the CNS (described in 
Chapter 3) it is important to have an understanding of the life cycle o f the wild 
type virus. The salient features of the physiology of HSV1 and gene expression 
patterns noted in the lytic and latent phases of its life cycle are reviewed in the 
sections that follow.
1.9.1 Structure of the virion
The mature HSV1 virion can be divided into four morphologically distinct 
structural layers: the double stranded viral DNA core, the protein capsid, the 
proteinaceous tegument and finally the glycoprotein containing viral envelope 
(Steven and Spear, 1997). A schematic representation of an HSV1 virion is given 
in Figure 1.9.2-a (panel A, page 58). The 152kb double stranded viral DNA 
genome encodes 84 viral proteins and is encased in the protein capsid. The 
capsid has an icosahedral morphology, consisting of 161 capsomers (Steven and 
Spear, 1997; Kasamatsu and Nakanishi, 1998). The proteins involved in the 
formation of this icosahedron are: VP5, VP 19, VP23 and VP26 (Zhou et al., 
1995; Bowman et al., 2003). The nucleocapsid, measures 125nm in diameter 
(-1250A) and is surrounded by the amorphous tegument (Zhou et a l,  1994; 
Zhou et al., 2000; Baker et a l, 2003). The tegument constitutes -65%  of the 
total virion mass, even though it only contains 14 different viral proteins. These 
include proteins such as VP 16 (also known as a-TIF, ICP25, vmw65 and UL48), 
involved in viral gene transcription (Stem et a l,  1989; Wysocka and Herr, 
2003), the virion host shut-off protein (vhs or UL41) responsible for the 
suppression of host cell protein synthesis (Kwong and Frenkel, 1989) and a 
number o f glycoproteins (g) involved in viral egress from the infected cell 
(Granzow et a l ,  2001; Foster et a l, 2003). The bi-layered external envelope, 
bearing short protein spikes, surrounds the tegument and nucleocapsid giving the 
enveloped virion a mean diameter of 200 -  300 nm (-2000A) (Whitley, 1996; 
Steven and Spear, 1997). Overall the envelope contains 12 proteins, which 
correspond to the protein spikes protruding from the lipid envelope. Ten of these 
proteins correspond to viral glycoproteins that play a role in virus host immune 
evasion (Lubinski et al., 2002; Friedman, 2003), attachment, host cell entry 
(Spear, 2004) and cell-to-cell propagation (Dingwell et al., 1994).
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1.9.2 Virion attachment and host cell entry
HSV1 enters host cells via a pH-independent mechanism that occurs in two 
stages: virion attachment to the host cell and subsequent fusion of the viral 
envelope with the plasma membrane (reviewed in Spear 2004 and Frampton et 
al. 2005). These two processes involve a series of poorly understood interactions 
between virion glycoproteins and various host cell receptors. Only four envelope 
glycoproteins have been shown to be essential for HSV1 infection, at least in 
vitro: gB, gD, gH and gL (Desai et al., 1988; Cai et a l , 1988; Shieh et al., 1992; 
Hutchinson et al., 1992; Fuller and Lee, 1992). Deletion mutants for one or more 
of these glycoproteins results in the production of enveloped virions that are still 
able to attach to the host cell membrane but cannot penetrate the cell membrane 
as they fail to initiate the entry cascade (Cai et al., 1988; Ligas and Johnson, 
1988; Fuller et al., 1989; Forrester et al., 1992; Roop et al., 1993). On the 
contrary, gC and gC/gB deletion mutants can penetrate the cell membrane but 
the efficiency o f initial virion attachment to the target cell plasma membrane is 
reduced 10-fold (Svennerholm et al., 1991; Laquerre et al., 1998). These 
experiments point to the fact that attachment and entry are two separate 
mechanisms that rely on separate glycoproteins. Attachment is thought to 
involve interactions between the positively charged sequences on virion 
glycoproteins gC (Tal-Singer et al., 1995) and gB (Herold et al., 1995) with the 
negatively charged elements of heparan sulphate moieties found on cell surface 
proteoglycans (WuDunn and Spear, 1989; Shieh et al., 1992; Laquerre et al.,
1998). This is supported by the findings that heparin can inhibit virion 
attachment (Herold et al., 1995) while cell lines that are deficient in the synthesis 
o f heparan sulphate are 85% resistant to HSV1 infection (Shieh et al., 1992). In 
addition, the simultaneous deletion of gC and the heparan sulphate binding 
domain o f gB results in a reduction in the efficiency with which the virion binds 
to the target cell membrane. This reduction in efficiency is similar to that seen in 
the previously mentioned heparan sulphate deficient cell lines (Gruenheid et al.,
1993). It becomes evident therefore that gC and gB are the key glycoproteins 
involved in this first stage of virus infection. Interestingly, gC is also thought to 
block the complement-mediated neutralisation of the virus by binding to the C3b 
element o f the complement cascade (Fries et al., 1986; McNeamey et a l, 1987).
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Following attachment, the virus becomes internalised into the host cell. The 
attachment o f the virion facilitates the subsequent binding of gD to specific 
receptors on the target cell surface. The instrumental role gD has in the ability of 
the virus to enter the host cell is shown by the fact that pre-incubating host cells 
with soluble gD prior to infection, prevent infection by wild type HSV1 (Dean et 
al., 1994). Overall, three receptors have been identified as targets for gD (Figure 
1.9.2-a, panel B, page 58): Firstly, the herpes virus entry mediator (HVEM or 
HveA), a member o f the TNFa/NGF receptor family. HVEM was identified by 
screening o f a cDNA expression library for clones that enabled virus infections 
in a CHO cell line that was resistant to HSV1 infection (Montgomery et al., 
1996). HVEM is expressed in a variety of cell types including lymphocytes, 
fibroblasts and epithelial cells and it is thought that HVEM signalling may be 
involved in the regulation of the host immune response (Kwon et al., 2003). 
Secondly, Nectin-1 (HveC) (Geraghty et al., 1998), a member of the Nectin 
group of adhesion molecules belonging to the immunoglobulin superfamily. 
Nectin-1 is involved in cell-cell adhesion (Takahashi et a l , 1999; Sakisaka et al.,
2001) and synapse formation (Mizoguchi et al., 2002) and is thought to be the 
main receptor for HSV1 entry in peripheral sensory neurons (Richart et a l ,
2003). Nectin-1 mRNA is found in abundance in the human CNS (Cocchi et a l ,
1998), in neuronal cell lines (Geraghty et a l,  1998), peripheral sensory neurons, 
sympathetic and parasympathetic ganglia (Haarr et a l ,  2001). Thirdly, 3-0- 
sulphated heparan sulphate, an alternative version of the heparan sulphate 
moiety, generated by 3-0-sulfotransferases (Shukla et a l,  1999). It is generally 
believed that the binding of gD to its cellular receptors serves two functions. 
Firstly it stabilises the virion-host cell attachment initiated via the gC/gB binding 
on cell surface heparan sulphate and secondly it serves to initiate the fusion of 
the viral envelope and the host cell plasma membrane. The exact sequence of 
events that lead to fusion and virion entry is not fully understood. One 
hypothesis is that the binding of gD to one of its receptors results in a 
conformational change in this glycoprotein that enables it to interact with gB 
and/or gH/gL (Fuller and Lee, 1992). Alternatively, the binding of gD enables 
gB and gH/gL to bind to their own receptors, that can initiate their fusogenic 
activity without the direct participation of gD (Spear and Longnecker, 2003).
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Figure 1.9 .2-a: S tru c tu r e  o f  the HSV1 virion a n d  viral en try .
A. T he v irion  structure is based on the theoretical m athem atical param eters o f  an icosahedral 
struc tu re2. T he capsid  is com posed o f  12 vertices and 20 facets, each o f  w hich is an 
equ ila tera l triangle and displays an overall 5:3:2 sym m etry. This results from: six 5-fold axes 
o f  sym m etry  passing  through the vertices, ten 3 -fold axes passing through each face and 
fifteen  2-fo ld  axes passing through each o f  the sides o f  the icosahedron (C aspar and K lug, 
1962).
B. A ttachm en t o f  the virion involves the binding o f  gC and gB to heparan sulphate m oieties on 
p ro teog lycan  chains (depicted in red). This interaction facilitates the binding o f  gD  to: 
/ .H V E M , a m em ber o f  the TNF/NGF receptor fam ily (gray), 2. the Nectin-1 receptor a 
m em ber o f  the im m unoglobulin superfam ily (N ectin-1/H veC , green) and 3. 3-O -sulphated 
H eparan  S ulphate proteoglycan (pink with sulphate groups shown in blue). B inding o f  gD  
w ith  the  involvem ent o f  gB and gH/L, triggers the fusion o f  the envelope and subsequent 
release o f  the nucleocapsid  into the host.
2 BUchen-Osmond, C. (Ed) (2004). 00.031.1. Alphaherpesvirinae. In: ICTVdB - The Universal Virus 
Database, V3. ICTVdB Management, Columbia University, New York, USA
http://www.ncbi.nlm.nih.gov/lCTVdb
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1.9.3 Trafficking of HSV1 in the nervous system following infection
Upon coming into contact with a potential animal host, HSV1 initially infects 
epithelial cells of the skin and mucosal surfaces. The virus then undergoes a lytic 
cycle and replicates at the site of primary infection, destroying the host cells in 
the process. Clinically this manifests as herpes labial is, a blistering 
mucocutaneous lesion (cold sore) which serves the purpose of disseminating the 
virus and aid transmission to another host (Roizman and Sears, 1996; Flint et a l ,
2004). As the local number of particles increases, the virus enters the underlying 
sensory nerve terminals and is retrogradely transported to the nuclei of peripheral 
sensory neurons in dorsal root or trigeminal ganglia (Cook and Stevens, 1973; 
Topp et al., 1994; Bearer et a l, 2000). For the next few days, the virus is capable 
of replicating within these neurons (Knotts et a l ,  1974; Kramer et a l, 1998). 
However, within ~7 days, the virus enters latency and viral gene expression and 
replication is quickly suppressed. No free viral particles can be detected within 
neurons after that time (Stevens and Cook, 1971; Walz et a l, 1974; Cabrera et 
a l,  1980; Fraser et a l, 1981). A summary of events following a primary HSV1 
infection is shown in Figure 1.9.4-a (page 63). During latency, lytic gene 
expression is silenced as the double stranded viral DNA becomes quiescent. It 
adopts a circular, episomal structure that becomes associated with nucleosomes 
(Deshmane and Fraser, 1989). The viral genome is capable of persisting in this 
state for the lifetime of the cell (Nesbum et a l ,  1972; Stevens et a l, 1972; Rock 
and Fraser, 1983; Efstathiou et a l, 1986; Mellerick and Fraser, 1987). Upon 
appropriate stimuli such as stress, trauma or drug induced immuno-suppression 
(Latchman, 1990), the virus may periodically reactivate and re-enter the lytic 
cycle. Latent virus reactivation occurs in only a small proportion of latently 
infected neurons (Baringer and Swoveland, 1973) and is the mechanism 
responsible for the recurrent nature of HSV1 infections (Baringer and 
Swoveland, 1973; Knotts et a l, 1974). After reactivation, the resulting viral 
progeny can follow two routes: either be transported anterogradely back to the 
primary site o f infection where secondary lesions develop (Roizman and Sears, 
1996) or be retrogradely transported to the CNS where if lytic expression is 
established, it will result in either aseptic meningitis or encephalitis (Knotts et 
a l, 1974; Enquist et a l, 1998; Roizman and Whitley, 2001).
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HSV1 encephalitis is a rare complication, with an incidence of 1:250,000 
population/year in the USA and 2.5 per 1 million of population in Sweden 
(Skoldenberg et a l ,  1984; Whitley and Roizman, 2001). Even though rare, if left 
untreated herpes encephalitis has a mortality of >70% (Tyler, 2004). The exact 
pathway via which the virus reaches the CNS in human hosts in order to cause 
encephalitis is unclear. One hypothesis is that latent virus reactivating in 
trigeminal or sensory ganglia, instead of spreading via its usual anterograde route 
to cause secondary epidermal infections may spread via tentorial nerves to the 
anterior and medial cranial fossa (Davis and Johnson, 1979). Alternatively, and 
to explain the occurrence of HSV1 encephalitis following a primary infection, 
virus could be retrogradely transported via olfactory nerve pathways to the 
orbitofrontal and medial temporal lobes (Tyler, 2004).
1.9.4 Intra-axonal transport mechanisms
The use of the terms anterograde and retrograde can be confusing as they are 
used in the literature to describe both the movement of the virus between first 
and second order neurons and intra-axonal transport. So, when describing 
aspects o f the HSV1 life cycle, such as lytic events or reactivation, the terms are 
used to describe the directional crossing of synapses (Enquist et a l , 1998). The 
same terms are also used to describe the mechanisms involved in the transport of 
the virion within a single neuron. In this case, retrograde transport describes the 
movement o f the virion from axonal terminals to the cell nucleus and 
anterograde the reverse. It has been estimated that it would take an average of 
231 years for a herpes virus capsid to diffuse 10mm in the axonal cytoplasm 
(Sodeik, 2000). In reality, this is an active process which is reflected in the fact 
that actual rate o f transport for HSV1 nucleocapsids in vivo is 0.3-3.5 pm/s 
retrogradely (Smith et a l, 2001) and 0.6 pm/s anterogradely (Penfold et a l,
1994). Microtubule-inhibiting drugs such as colchicine, nocodazole and 
vinblastine inhibit HSV1 axonal transport, demonstrating that the virus utilises 
this intra-axonal microtubule system (Topp et a l, 1994; Sodeik et a l,  1997). The 
interactions between the nucleocapsid and tegument components and elements of 
the microtubule mechanism are the focus of this section (schematically 
represented in Figure 1.9.4-b, page 63 and reviewed in Frampton et a l 2005).
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The microtubule system is capable of bidirectional movement of intracellular 
materials due to its plus and minus polarity, with the plus ends pointing towards 
the axon terminals and the minus ends pointing towards the nucleus. Retrograde 
transport occurs in a plus to minus orientation and takes place following primary 
infection of sensory neurons as the nucleocapsid and tegument are transported 
from neuronal terminals, along the axon to the cell body and finally the nucleus 
(Frampton, Jr. et al., 2005).
Cytoplasmic dynein is the only motor protein responsible for retrograde transport 
in non-dividing cells such as neurons (Paschal and Vallee, 1987). It is a large 
protein complex (1.2MDa) composed of heavy and light chains. Heavy chains 
carry out the motor function, while the intermediate and light chains interact with 
the loading cargo (King, 2000). Immunolabelling studies have shown that HSV1 
capsids colocalise with cellular dynein (Dohner et al., 2002). The HSV1 
tegument protein UL34, has been shown to specifically interact with the 
neuronal isoform o f the dynein intermediate chain la  (IC-la) (Ye et al., 2000). It 
is however possible that the UL34 protein may not be the sole component of this 
virion-dynein interaction as it is absent from mature virions and it is therefore 
doubtful if it would be present during infection (Reynolds et al., 2002; Douglas 
et al., 2004). Douglas et al. (2004) recently suggested that virion protein 26 
(VP26), a capsid component, also interacts with the light chains o f dynein during 
infection. These authors suggest that VP26 may be more suited to this role than 
UL34 because unlike UL34, VP26 is a component of the capsid and not the 
tegument, which is quickly lost after cell entry (Wingfield et al., 1997). Other 
tegument or virion proteins that have been suggested to play a perhaps less 
important role are VP1/2 and UL25 (Tomishima et al., 2001; Dohner et al.,
2002). However, further research is needed into their role, as currently the extent 
and nature o f their involvement is unclear. During reactivation from latency, 
virion progeny is transported in a minus to plus orientation (Frampton, Jr. et al.,
2005). Virions are propelled anterogradely down the axon towards neuronal 
terminals in a process mediated by kinesins, a family o f microtubule-associated 
motor proteins. Kinesins exist in two isoforms: ubiquitous and neuronal 
(Hirokawa et al., 1991; Niclas et al., 1994; Goldstein and Yang, 2000).
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Figure 1.9.4-a: Neuronal trafficking of HSVI i/i vivo.
Following infection and replication within the epithelial cells o f mucosal surfaces, virions are 
taken up by sensory neuron terminals and are retrogradely transported into the nuclei of 
peripheral DRG or trigeminal neurons where they can establish latency. The dsDNA genome 
can remain in this quiescent state for the lifetime o f  the host. When conditions are favourable 
the latent genome can reactivate and enter a lytic cycle. Progeny virions are then anterogradely 
transported to the neuronal terminals where they manifest as herpes labialis (cold sores). 
Alternatively, virions can enter the CNS where they can again either enter latency or cause 
lethal encephalitis.
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Figure 1.9.4-b: Anterograde and retrograde mechanisms of HSVI axonal transport.
M icro tubu les are hollow  tubulin cylinders w ith a negative and a positive end attached to the 
cen tro som e (N oga les, 2000). Incoming nucleocapsids are actively transported from  neuronal 
te rm inals to w ard s  the host nucleus (retrogradely) in a mechanism that m akes use o f  the + /- 
po larity  o f  th e  axon  m icrotubule system. Infecting  H SV I capsids attach to dynein via the viral 
pro tein  V P 2 6  (U L 35) and is retrogradely transported  to the nucleus in a plus to m inus direction 
(D ohner et al., 2002; Douglas et al., 2004). P rogeny procapsids are transported from the cell 
body to w ard s  neuronal terminals (anterograde). The viral tegum ent protein US 11 directly  
in teracts w ith  K inesins (Diefenbach et al., 2002), a group o f  m icrotubule associated m otor 
p ro teins th a t ca rry  pro-capsids in a minus to plus d irection  (Flint et al., 2004).
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Interestingly, a number of reports suggest that nucleocapsids and tegument travel 
separately from envelope components such as virion glycoproteins (Miranda- 
Saksena et al., 2002; Frampton, Jr. et al., 2005). The HSVI tegument component 
US11, a viral RNA-binding protein (Roller and Roizman, 1992), has been shown 
to associate directly with the ubiquitous heavy chain of kinesin (Diefenbach et 
al., 2002). In a recent study, the amyloid precursor protein (APP), itself a 
putative kinesin receptor (Kamal et al., 2000; Kamal et al., 2001), has been 
found to be an abundant component of the herpes virion (Satpute-Krishnan et al.,
2003). The authors of the later study suggest that in the presence of HSVI, the 
normal transport o f APP is disrupted and it is this disruption that may precipitate 
the pathology associated with Alzheimer’s disease.
1.9.5 Structure of the HSVI genome
The HSVI genome is a linear, 152Kb (Kieff et al., 1971), double stranded DNA 
molecule (reviewed in Roizman and Sears 1996). Viral genes are arranged in 
segments (Figure 1.9.5-a, page 65): a unique short (Us) and a unique long (U l) 
region, each o f which is flanked by a pair o f inverted repeats: a terminal (TRl or 
TRs) and an internal repeat (IRl or IRs). There are approximately 84 
polypeptides expressed from the HSVI genome (Roizman, 1996). Five of those 
have open reading frames (ORFs) in the inverted repeats, and are therefore 
present in two copies per genome. In addition, ORFs located in the TRl region 
are responsible for a mixed population of RNA transcripts produced during 
latency, termed latency associated transcripts (LATs), which will be discussed in 
section 1.9.7 (page 75). These ORFs lead to the production of a variety of viral 
proteins some of which are essential for viral replication in vitro (termed 
essential) and proteins whose function is not a prerequisite for viral propagation 
in vitro (termed non-essential). Viral genes fit into three categories, based on the 
timing o f their expression during replication. Thus, the first viral proteins to be 
transcribed are the Immediate Early (designated IE or a) proteins, followed by 
the Early (E or (3) group of proteins and finally the Late (L or yl/y2) genes. Their 
expression is tightly regulated and occurs in a cascade manner. A schematic 
representation o f the sequential nature o f IE, E and L gene transcription is shown 
in Figure 1.9.6-a (page 70, panel B).
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Figure 1.9.5-a: Structure of the HSVI genome & map of the LAT transcriptional unit.
T he H S V 1 genom e is organised in two unique segm ents o f  different sizes: a long region (UL, 
g reen ) an d  a  unique short region (Us, blue). Each segm ent is flanked by a term inal and an 
in ternal seq u en ce  repeat (TR and IR respectively). The regions designated a ’ (dark blue) contains 
seq u en ces  than  are necessary for packaging o f  progeny virions. (Adapted from  Roizm an 1996).
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The IE gene products are the first viral proteins to be produced following the 
arrival o f the viral DNA in the host cell nucleus. These IE proteins are necessary 
for initiating the expression of the E proteins from the p genes. The products of 
the p genes are responsible for viral DNA synthesis and further regulate the 
expression o f y proteins (yl “leaky” and y2 true late genes). Both a  and p gene 
products are required for the final expression of the y genes which are structural 
proteins used in the virion progeny construction. Important late proteins include: 
VP 16, the virion host shut-off protein (Vhs) responsible for the non-specific 
degradation o f host m-RNA and blocking of host protein synthesis and ICP34.5, 
the viral neurovirulence factor responsible for establishment of infection in 
sensory neurons (Roizman, 1996).
1.9.6 Lytic life cycle of HSV1
As discussed in previous sections the nucleocapsid, surrounded by its tegument, 
arrives at the neuronal nucleus via retrograde transport. Once at the nucleus, the 
parental capsid attaches to a Nuclear Pore Complex (NPC) (Tognon et al., 1981; 
McClain and Fuller, 1994; Spear, 2004). Electron microscope studies have 
shown that the viral DNA is quickly ejected from the NPC-bound parental 
capsid, through the nuclear pore and into the nucleoplasm, leaving behind the 
empty parental capsid that is eventually released in the cytoplasm (Tognon et al., 
1981; Ojala et a l , 2000). Once inside the nucleus, the viral DNA localises to 
sub-nuclear structures termed Nuclear Domain 10 (ND10, otherwise known as k- 
bodies or Pro-myelocytic leukaemia protein) (Burkham et a l , 1998). ND10 are 
discrete structures that are involved in a variety of cellular functions such as 
transcription, apoptosis or DNA repair (Borden, 2002; Bemardi and Pandolfi, 
2003; Xu et a l , 2003) and are disrupted by a variety of other DNA viruses 
including adenovirus and papovavirus (Maul, 1998; Everett, 2001). In the case of 
HSVI, ND10 disruption occurs within 2 hours following infection (Maul et a l , 
1993). The practical implication of the virally mediated disruption of the ND10 
structures is complex. On the one hand, it is thought that this may serve to 
prevent the activation of antiviral genes by circulating interferon which is 
produced in response to the viral infection (Chee et al., 2003). Alternatively,
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ND10 may act either as nuclear depots for proteins kept in an inactive state until 
needed or as nuclear dumps for excess proteins awaiting degradation (Maul, 
1998). The fact that HSVI gene transcription occurs exclusively at ND10 
following infection suggests that ND10 may provide the factors necessary for 
viral gene transcription to occur (Ishov et al., 1997). ND10 have been likened to 
repositories for transactivating factors (Negorev and Maul, 2001). Thus, by 
disrupting the ND10 structures, HSVI is in effect hijacking the machinery that is 
already in place in the host cell nucleus in order to transcribe its own genes 
(Maul, 1998; Roizman et al., 2005). This would fit in with the ability of some 
viral proteins, such as the infected cell protein 0 (ICPO), to facilitate the 
expression o f the remaining immediate early genes. Indeed, genetic analysis has 
revealed that ICPO can directly modify the structure of the proteins comprising 
the ND10 structure and cause it to disperse (Maul et al., 1993; Hagglund and 
Roizman, 2004).
The cascade o f events leading to viral gene expression during the establishment 
of the lytic life cycle, are summarised in Figure 1.9.6-a (page 70). Overall, the 
cascade o f expression starts with the production of IE proteins whose 
transcription is initiated by VP 16 acting as a transactivator of IE gene promoters. 
VP 16 cannot carry out this function alone as at it cannot directly bind to the viral 
DNA (Hughes et al., 1999). It is therefore necessary for it to interact with host 
cell factors such as Octl, a POU domain containing protein, and host cell factor 
(HCF) (Figure 1.9.6-a, panel C). The role o f HCF is to import VP 16 into the host 
cell nucleus (La Boissiere et a l, 1999) while Octl confers the ability to interact 
with the viral DNA. Via Octl, the VP16/Octl/HCF complex binds to a specific 
sequence on the viral DNA. This sequence has the motif TAATGARAT (where 
R is a purine) and it is present just upstream of the TATA box element of all the 
IE genes promoters (Gaffney et al., 1985). Octl interacts with the TAAT part of 
the m otif (Gerster and Roeder, 1988) while the VP 16 itself binds on the GARAT 
part (O'Hare and Goding, 1988). After binding of the VP16/Octl/HCF complex, 
the C ’-terminal transactivating domain of VP 16 (Sadowski et al., 1988) interacts 
with the host cell transcription factor IID (TFIID) and initiates the transcription 
o f the IE genes (Klemm et al., 1995).
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The initiation of IE gene transcription heralds the beginning of the lytic life cycle 
o f the virus. There are five IE proteins: ICPO, ICP4, ICP22, ICP27 and ICP47. 
ICPO and ICP4 are responsible for the transcription of the p group of genes while 
ICP22 and ICP27 are required for the optimum expression of the y genes 
(Roizman and Sears, 1996). The salient functions of the five IE genes are 
summarised below.
Gene Protein Alternative 
Name (kDa)
Function
a0 ICPO VmwllO Promiscuous transactivator. Optimal activity requires the presence of ICP4
a4 ICP4 Vmwl75
Positively regulates the (3 and y gene expression. 
Negatively regulates its own expression and the 
expression of ICPO. Also blocks apoptosis in 
infected cells
a22 ICP22 Vmw68 Regulatory protein, required for optimal expression of ICPO and y proteins
a ll ICP27 Vmw63 Negative regulator of a  and positive regulator of y genes expression
a47 ICP47 Vmwl2 Stops antigen presentation to CD8+ T cells
VmwllO, the gene encoding ICPO, maps to the short region repeats and 
therefore exists in two copies. Each copy of the gene is present in an antisense 
orientation to the latency associated transcripts (LAT) (Pereira et a l , 1977; Zhu 
et al., 1991) (Figure 1.9.5-a, page 65) which is important in the role o f ICPO in 
the establishment and reactivation from latency (Wilcox et al., 1997). ICPO is 
not essential for the growth of the virus in vivo but disabling it negatively 
impacts on the efficiency with which it can propagate (Sacks and Schaffer, 1987; 
Everett, 1989; Chen and Silverstein, 1992; Cai and Schaffer, 1992). In cell lines 
infected with ICPO deletion mutants (AICPO), especially at low multiplicities of 
infection (MOI), viral yields are 10 to 100-fold lower that those cell lines 
infected with wild type virus (Sacks and Schaffer, 1987; Everett, 1989). 
Transient transfection studies in which an ICPO plasmid was co-transfected with 
different exogenous promoters, demonstrated that this protein is actually a 
promiscuous transactivator, capable of activating the transcription of non-viral 
genes (Everett and Dunlop, 1984; Everett, 1987). This transactivator property of 
ICPO is enhanced in the presence of another IE protein: ICP4 (Everett, 1984; 
Gelman and Silverstein, 1985). Newly synthesized ICPO accumulates at ND10
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structures and as the levels of the protein increase they eventually occupy the 
whole o f the nucleus. With further increases, ICPO is displaced into the 
cytoplasm (Kawaguchi et al., 1997; Lopez et al., 2001) via a mechanism 
involving cyclin-D (Van Sant et al., 2001). Since ICPO cannot directly bind onto 
the viral DNA (Everett et al., 1991), it is necessary for it to associate with 
selected cellular factors to carry out its effects. One of the proposed models for 
the way ICPO promotes the expression of IE genes, attempts to identify this 
mechanism. It recently emerged that ICPO contains an amino acid sequence that 
resembles the amino acid sequence present in the CoREST cellular protein (Gu 
et al., 2005). CoREST is a cellular protein that by binding to another cellular 
protein termed REST, it can repress the expression of neuronal genes in non­
neuronal cells (Andres et al., 1999). The CoREST/REST complex exists in tight 
complexes with another protein HDAC, in both neuronal and non-neuronal cells. 
It is thought that this complex can lead to the complete silencing of target genes 
(Lunyak et al., 2002; Balias et al., 2005). Importantly, CoREST/REST and 
HDACs are found in complexes in uninfected neurons. However, when those 
neurons become infected with wild type HSVI, which of course expresses high 
levels o f ICPO, a different picture emerges. In these cells, 50% of the 
CoREST/REST/HDAC complexes are dissociated (Gu et al., 2005). It is possible 
that this effect of ICPO could lead to the reversal in the repression of viral gene 
expression within the host cell (Figure 1.9.6-a, panel C, page 70). This 
hypothesis provides a plausible explanation for the mechanism by which ICPO 
initiates the expression of the a genes (Roizman et al., 2005). The ICP4 gene 
(Vmwl75) is located in the terminal repeats of the Us region of the viral 
genome. ICP4 is another essential protein of HSVI and an important 
transcriptional regulator (DeLuca et al., 1985). ICP4 binds as a homodimer 
(Metzler and Wilcox, 1985) onto viral DNA sequences with the conserved motif: 
RTCGTCNNYNYSG, where R is a purine, Y is a pyrimidine while S represents 
either a C or G nucleotide (N is any nucleotide) (DiDonato et al., 1991). The C -  
terminal region of ICP4 then recruits the TATA binding transcription activation 
factor TFIID (Carrozza and DeLuca, 1996). The binding of TFIID facilitates the 
subsequent recruitment of TFIIB and polymerase-I and transcription is then 
initiated (Grondin and DeLuca, 2000).
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Figure 1.9.6-a: Viral gene expression during the HSVI lytic cycle & latency.
A. Stages of the HSVI life cycle. Following the arrival o f vUNA into the cell nucleus the 
virus will either enter the quiescent state o f latency or initiate a lytic life cycle. During 
latency, the dsVDNA circularizes and there is no expression o f any viral proteins. Only 
the LAT mRNA transcripts are produced. During the lytic cycle, IE, E and L gene 
expression ensues. Concatameric, dsVDNA is cleaved and packaged into new virions 
(Glorioso et al., 1995).
B. IE gene expression occurs in a well-controlled cascade manner. The tegument 
component VP 16 transactivates the expression o f the IE proteins ICPO and ICP4. ICPO 
and ICP4 are necessary for the expression o f  the E and L genes as they act as 
transactivators for their promoters. The ICP22 and ICP27 IE genes are required for the 
efficient production o f the L genes (Roizman, 1996; Roizman et al., 2005).
C. Proposed model for the control of IE gene expression. Upon entry o f  the viral DNA 
into the host cell nucleus, the tegument component VP 16 associates with cellular factors 
such as Octl and HCF and initiates the transcription (A, green arrow) o f the IE genes: 
ICPO, ICP4, ICP22, ICP27 and ICP47 (Roizman and Sears, 1996). ICPO causes the 
dissociation o f  HDAC1 from the CoREST-REST complex (red arrow) while the 
subsequently produced E and L viral proteins cause the translocation o f  the HDAC1 and 
CoREST into the cytoplasm (dotted arrow), thus alleviating the transcriptional repression 
these molecules exert on the viral genome (Roizman et al., 2005).
Diagrams: A adapted from Glorioso et al. (1995), B & C adapted from Roizman et al. (2005).
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Being a transcriptional activator ICP4 is responsible for the transactivation of the 
remaining E and L genes during the lytic cycle. In addition, ICP4 represses the 
activity of latency promoter and down-regulates its own expression and that of 
ICPO (Dixon and Schaffer, 1980; DeLuca and Schaffer, 1985; Roberts et a l , 
1988).
ICP27 (Vmw63) is another essential viral protein with a number of different 
regulatory functions (Sacks et a l , 1985). ICP27 can directly bind RNA through 
its RGG-box (Mears and Rice, 1996), while its N’-terminus contains nuclear 
export and localisation signals that allow for its shuttling between the host cell 
nucleus and cytoplasm (Sandri-Goldin, 1998; Sokolowski et a l , 2003). Studies 
utilising ICP27 mutants have demonstrated that ICP27 is necessary for efficient 
DNA replication (Sekulovich et a l , 1988; Estridge et a l , 1989; McCarthy et a l, 
1989; Larralde et a l, 2006). In the initial stages of infection ICP27 favours the 
expression of E proteins but in the later stages it switches the emphasis of 
transcription towards the production of L proteins by suppressing the a and p 
gene promoters (Rice and Knipe, 1990; Uprichard and Knipe, 1996). ICP27 
directly interacts with ICP4 and ICPO. This interaction on the one hand leads to 
the repression of E gene expression and on the other hand leads to the activation 
of L gene transcription (Sekulovich et a l, 1988; Hardwicke et a l, 1989; 
McMahan and Schaffer, 1990). In addition, ICP27 can exert some regulatory 
effects at the level of post-transcriptional regulation (Jean et a l, 2001; Smith et 
a l, 2005). The protein has been demonstrated to stimulate 3’RNA processing at 
some viral polyadenylation sites while at the same time inhibiting the splicing of 
cellular mRNAs and susceptible viral pre-mRNAs. This favours the production 
of viral proteins as the majority of the viral genes, unlike the host, do not contain 
introns and do not interact with the splicing machinery (Sandri-Goldin, 1994). 
ICP27 can also inhibit splicing of the few viral pre-mRNAs that contain introns 
(e.g.: ICP34.5, ICP22, and ICPO) but only in the absence of other viral factors 
(Lindberg and Kreivi, 2002). The mechanism of this is still unclear but ICP27 
appears to be capable of differentiating intron-containing from intronless viral 
pre-RNAs. ICP27 facilitates the quick nuclear export of intronless viral mRNAs 
(Smith et a l , 2005).
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ICP22 (Vmw68) is a non-essential viral protein and has been shown to be 
dispensable for viral growth in some cell lines (PofFenberger et al., 1993; Rice et 
al., 1995). The function of this protein is not totally understood (Roizman and 
Sears, 1996) but its presence has been shown to boost the efficiency of L gene 
expression (Poffenberger et al., 1994; Orlando et al., 2006). It has been 
suggested that ICP22 has two separate functions, one linked to a unique N’- 
terminal amino acid sequence (Ogle and Roizman, 1999; Cun et al., 2006). On 
the one hand, it has been reported that ICP22 is involved in the production of an 
aberrantly phosphorylated form of RNA polymerase II that is capable of both 
repressing host cell transcription (Rice et al., 1995; Spencer et al., 1997; Long et 
al., 1999) and increasing the stability of ICPO mRNA (Carter and Roizman, 
1996). In addition, it has been suggested that ICP22 may be directly involved in 
viral replication as it has been repeatedly shown to localise in ND10 structures 
(Leopardi et al., 1997; Stelz et al., 2002).
The final IE gene, ICP47 (Vmwl2) is not essential for viral growth in cell lines 
and does not have a regulatory function (Mavromara-Nazos et al., 1986). Its 
main function is to inhibit antigen presentation to CD8+ T lymphocytes, therefore 
enabling the virus to escape immune surveillance mechanisms (Goldsmith et al., 
1998). ICP47 achieves this by binding to the transporter of antigen processing 
(TAP) (Hill et al., 1995) complex thus preventing it being loaded with viral 
proteins onto MHC Class I molecules (Bauer and Tampe, 2002). The role of 
ICP47 in immune evasion, as well as the involvement of the immune system in 
the longevity of the virally mediated foreign gene expression, is further 
examined in Chapter 7. Following the expression of IE genes the lytic cycle 
progresses with the E and L genes. The E genes are responsible for viral DNA 
replication and encode proteins such as ICP8, a major DNA binding protein, 
thymidine kinase (TK), a ribonucleotide reductase (RR) and various viral 
polymerases (Roizman and Sears, 1996; Devi-Rao et al., 1997; Wagner and 
Bloom, 1997). Viral replication occurs in the ND10 structures (Ishov and Maul, 
1996) and, despite earlier reports, it has recently been demonstrated that the viral 
DNA does not circularise in order for replication to occur in the lytic cycle 
(Jackson and DeLuca, 2003).
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The last genes to be transcribed are the L genes (Figure 1.9.6-a, panel A, page 
70). These encode structural components of the capsid, tegument and envelope 
including Vhs, VP 16, envelope glycoproteins and ICP34.5, the neurovirulence 
factor. The transactivators ICPO and ICP4 activate the L promoters. However, 
completion of viral DNA replication is a prerequisite for the initiation of L gene 
transcription (Roizman and Sears, 1996). Unlike earlier reports, it is now clear 
that the viral DNA does not circularise during the lytic cycle (Jackson and 
DeLuca, 2003). Following replication, the newly synthesised viral DNA is 
cleaved into functional units based on the presence of the a’ sequences located in 
the repeat regions of the genome (Figure 1.9.5-a, page 65) and is subsequently 
packaged into new capsids. Once assembly is completed the nucleocapsids 
acquire their tegument proteins including vhs and VP 16. The tegument proteins 
aid the exit of the nucleocapsid from the nucleus and its subsequent envelopment 
(Smibert et al., 1994; Mossman et al., 2000). As tegument surrounded 
nucleocapsids bud through the inner nuclear membrane and into the cytoplasm, 
they acquire their glycoprotein-studded envelope.
The route that progeny virions follow in order to exit the cell has been the 
subject of considerable research and two alternative pathways have been 
proposed. Firstly, the re-envelopment pathway (Granzow et al., 2001) suggests 
that the enveloped virions exiting the inner nuclear membrane loose their 
envelope as they fuse with the outer nuclear membrane and therefore non­
enveloped virions are released into the cytoplasm. The naked capsids pass 
through the Golgi apparatus, are packaged into secretory vesicles and are finally 
released into the extracellular space. Secondly, the luminal pathway (Enquist et 
al., 1998) suggests that virions exit the nucleus with their envelope and pass 
through the ER and cytoplasm where the envelope glycoproteins are further 
processed and adopt their mature form. Mature enveloped virions are finally 
released in the extracellular space via the secretory route (Roizman and Sears, 
1996).
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1.9.7 The Latent life cycle
Normally, once the viral DNA arrives at the nucleus of sensory neurons, it does 
not follow the lytic life cycle. Instead, it enters into a latent life cycle. During 
latency, the viral DNA circularises and becomes an episomal, quiescent structure 
(Honess et a l , 1989). During latency, transcription of viral genes is silenced and 
no viral gene proteins or new virions are produced. Unlike the beta and gamma 
herpes viruses, HSV1 viral DNA does not use methylation as a means of 
silencing viral gene expression (Dressier et a l , 1987; Kubat et a l, 2004). There 
is however a small region of the viral DNA that remains transcriptionally active. 
This region, termed the latency associated transcript (LAT) region is located in 
the repeats of the Ul segment of the viral genome. The LAT region produces a 
group of RNA transcripts named latency associated transcripts (LATs). Their 
presence has been confirmed by in situ hybridisation studies in animal models 
and human trigeminal ganglia (Deatly et a l, 1987; Croen et a l, 1987). 
Interestingly, LATs are transcribed in an antisense orientation to that of ICPO 
(Stevens et a l,  1987; Croen et a l, 1987). This led to the suggestion that the 
production of LATs inhibits the expression of ICPO, which as discussed favours 
viral gene expression and the lytic life cycle (Stevens et a l, 1987; Farrell et a l, 
1991; Ahmed and Fraser, 2001).
LATs exist as a mixed population of a large 8.3kb long and the highly abundant 
2 kb and 1.5kb stable introns, resulting from the splicing of the larger LAT 
(Figure 1.9.5-a, page 65) (Wagner et a l, 1988; Dobson et a l, 1989; Zwaagstra et 
a l, 1990; Mitchell et a l, 1990). The largest 8.3kb LAT is termed primary LAT 
and appears to be polyadenylated and is highly unstable. However the most 
abundant LAT species are the smaller 2 kb and 1.5kb LATs, which remain non- 
polyadenylated and uncapped within neuronal cells (Stevens et a l, 1987; 
Wagner et a l, 1988; Devi-Rao et a l, 1991). Within the vicinity of the 2 kb LAT 
there are approximately three ORFs that encode a 273 aa sequence which is 
highly conserved between different HSV1 strains (Coffin et a l, 1998). The fact 
that this 2 kb LAT has been found to associate with splicing factors in the host 
cell may suggest that either the 2 kb LAT may have some regulatory function or 
that ORF encodes a protein that may have some regulatory properties (Nicosia et
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al., 1994; Goldenberg et al., 1997; Ahmed and Fraser, 2001). This however still 
remains only a hypothesis as deletion of the 2 kb LAT ORF has no effect on 
virus physiology (Fareed and Spivack, 1994). A study conducted in our 
laboratory demonstrated that artificially over-expressing the 2 kb LAT-ORF, 
results in improved viral growth, even in cell lines that are normally non- 
permissive. An increased ability to overcome any deficiencies in the ICPO 
expression was also demonstrated (Thomas et a l , 1999). Interestingly, when 
frame shift mutations were introduced in the LAT-ORF and over-expression 
experiments were repeated, there was no evidence of improved growth while the 
ability to compensate for ICPO deficiencies was lost. Finally, when in vitro 
transcription/translation reactions were performed, a 30 kDa protein was 
detected that was absent when frame shift mutations were introduced in the 
LAT-ORF. Thomas et al. (1999) went on to propose that the localisation of the 
LAT ORF-encoding RNA is modified during reactivation, so that its translation 
is possible. This LAT-ORF protein could then compensate for the antisense 
effect exerted on ICPO during latency and thus contribute to the reactivation 
process (Thomas et a l, 1999). During latency, there are two promoters that 
remain active: latency active promoter-1 (LAP1) and latency active promoter-2 
(LAP2). In this part of the introduction, the features of these two promoters are 
examined. The various attempts at exploiting those features in order to drive the 
expression of exogenous genes will be further explored in Chapter 3.
Each of the LAP promoters is capable of functioning independently from one 
another (Dobson et a l, 1989; Goins et a l, 1994; Jones, 2003). LAP1 is located 
approximately 700bp upstream from the 5' end of the 2 kb LAT. Transcription is 
initiated 28bp downstream of the TATA element and it has been demonstrated 
that it is the principal latency promoter (Dobson et a l, 1989; Zwaagstra et a l, 
1990). LAP1 is active in both neuronal and non-neuronal cells but its activity is 
somewhat lower in the non-neuronal cell lines, a feature that has been attributed 
to the inhibition of sequences upstream of the TATA element (Batchelor and 
O'Hare, 1990; Zwaagstra et a l, 1990). The LAP1 is thought to contain a variety 
of control elements including a sequence element that resembles an ICP4 binding 
site, located upstream of the primary LAT cap site. These control elements in the
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LAP1 could interact with both negative and positive regulatory signals. Nicosia 
et a l (1993) were the first to propose the existence of a second LAT promoter 
since they reported that the 2 kb LAT could still be produced even when the 
TATA element of LAP1 was absent (Nicosia et al., 1993). LAP2 is mapped 
downstream of LAP1 and 58bp upstream of the 5’ end of the 2 kb LAT (Goins et 
al., 1994). LAP2 is a TATA-less promoter and although it is classified as a 
latency-associated promoter, it is primarily active during productive infections 
(Chen et al., 1995). In addition, it contains neuronally active elements such as 
E2F sites (Goins et al., 1994) which have been suggested to increase the activity 
of this promoter. Interestingly, LAP2 shares a sequence homology with 
eukaryotic housekeeping and oncogene promoters, which are also TATA-less 
and contain elements such as CT rich motifs or poly-T elements that can 
potentially alter chromatin structure (Reynolds et al., 1984; Valerio et al., 1985). 
It has been proposed that alteration of the chromatin structure is the mechanism 
by which LAP2 influences the activity of LAP 1. Deletion mutants where LAP1 
or LAP2 were abolished during latency, showed that there was a 500 fold 
decrease in the levels of the 2 kb LAT when the LAP1 was not functioning as 
opposed to a 3 fold decrease when the deletion affected LAP2 alone. It therefore 
follows that even though LAP1 is the primary latency promoter, responsible for 
enhanced activity in neurons, the weaker LAP2 promoter is also required for the 
optimum production of LATs (Goins et al., 1994; Chen et al., 1995). In addition 
it was shown that LAP1 can not support the long term expression during latency 
in DRG neurons without the presence of LAP2 (Lokensgard et al., 1997). This 
was taken to suggest that there was a long-term expression element in the LAP2 
region. Lokensgard and colleagues (1997) proposed that this element overlaps 
LAP2 and part of the 2kb LAT intron. Furthermore, it was reported that this 
element could act in a bi-directional manner to confer long-term activity on 
LAP1 from the gC locus of the viral genome (Berthomme et al., 2000). In our 
laboratory we have shown that it is possible to exploit these sequences present in 
LAP2 to confer long term activity on non-LAT promoters such as the CMV 
promoter (Palmer et al., 2000; Lilley et al., 2001b).
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1.9.8 HSV1 and gene therapy for the nervous system
Wild type virus is highly pathogenic and cannot therefore be administered to the 
CNS by direct inoculation. Hence, in order for a potentially useful gene delivery 
vector system to be of use, this potentially lethal cytotoxicity should be 
eliminated. In addition, the particular requirements for any potentially 
therapeutic gene to have any meaningful benefit in the injured CNS it is 
necessary to utilise suitable promoters that will be able to sustain its expression 
in the long term (Lilley et al., 2001a).
There are two types of HSV vectors, which have been used as gene therapy 
vectors. The first approach is based on the construction of disabled HSV1 
vectors where the transgene is recombined into the viral genome, which has 
previously been deleted for any potentially cytotoxic viral genes. The second 
approach relies on the use of defective vectors termed amplicons (Frenkel, 2006; 
Tyler et al., 2006). Amplicon vectors are created from plasmids that contain the 
transgene, an HSV1 packaging signal and an HSV1 origin of replication (Spaete 
and Frenkel, 1982). The plasmid is co-transfected with a defective HSV1 helper 
virus into a cell line that complements the disability of the helper virus. The 
plasmid then replicates in fragments of up to a full viral genome length relying 
on the machinery from the helper virus acting on the HSV1 origin of replication 
in the amplicon plasmid. These newly formed concatamers are packaged into the 
progeny capsids but this can only be successful in the presence of the helper 
virus. The progeny harvested will be a mixture of virion containing the original 
helper virus genome and amplicon virions, which will have packaged 
concatameric plasmid sequences. A variety of defective helper viruses have been 
used in this system. These included virus constructs with temperature sensitive 
mutations or deletions in essential genes such as ICP4 (Geller and Breakefield, 
1988). Although amplicons could be used to deliver genes to neuronal cells, their 
wide spread use has been hindered by the fact that high titre stock production is 
hard to achieve and stocks were often contaminated with the cytotoxic helper 
virus (Kwong and Frenkel, 1985; Lowenstein et al., 1994). The few applications 
of these vectors in the nervous system that have been reported are focused on 
transducing cerebral neurons (Tyler et al., 2006).
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This thesis and the attempts at inducing regeneration in the injured CNS milieu 
are based on the use of highly disabled HSV1 vectors. The vectors utilised here 
lack a combination of essential and non-essential genes, which significantly 
impairs the innate cytotoxicity of the virus. In addition, this vector system makes 
use of especially designed cassettes that fully exploit the ability of HS V1 for low 
level transcription during latency (Lilley et a l, 2001a).
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MATERIALS &  METHODS
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2.1 Materials
2.1.1 Suppliers
Amersham International Pic. (Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, 
UK). Rainbow™ coloured protein molecular weight markers, a-32P-dCTP (3000Ci/mM), 
Hybond™-C+ & Hybond™-N nitrocellulose membranes, N,N’-methylene-bis-acrylamide, ECL™ 
western blotting detection system.
BD Biosciences. (The Danby Building, Edmund Hailey Rd, Oxford science Park, 0X4 4DQ, 
UK). Yeast extract, Bacto®-agar, Bacto®-tryptone.
Berkley Antibody Company (BAbCo) Ltd. (1223 south 47th Street, Richmond, CA, 94804, 
USA). Anti-TUJl specific antibody (section 2.1.6).
Cay la (Toulouse, France) Zeocin™, Phleomycin derivative.
COHESION Technologies Inc. (2500 Faber Place, Palo Alto, California 94303, USA). 
Vitrogen™ Collagen.
Dako Ltd. (Cambridge House, St Thomas Place, CB7 4EX, UK). Rhodamine and HRP 
conjugated antibodies.
Gelman/Pall Life Sciences Inc. (Wagner Road, Ann Arbor, MI, Washtenaw County, USA). 
0.45pm and 0.20pm disposable filters.
Gibco-BRL Life Technologies Ltd. (Invitrogen: 3 Fountain Drive, Inchinnan Business Park, 
Paisley, PA4 9RF, UK). Tissue culture media, solutions and supplements for fibroblast and 
primary neuronal cultures, G418 (Neomycin), 1Kb DNA ladder.
Greiner Ltd. (Brackmills Business Park, Caswell Rd, Northampton, NN4 7EZ, UK). General 
disposable plasticware.
Insight Biotechnology Ltd. (P.O. BOX 520, Wembley, Middlesex, HA9 7YN, UK). 4-chloro, 5- 
bromo, 3-indolyl-p-galactosidase (X-Gal).
Invitrogen - Life Technologies UK. (3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 
9RF, UK). Murine Nerve Growth Factor (NGF), 2.5S Subunit.
MERCK Chemicals Ltd. (Padge Road, Nottingham, NG9 2JR, UK). Analytical grade laboratory 
chemicals.
NEN - Life Science Products (549 Albany Str., Boston, Massachusetts, 02118-2512, USA). 
NEN™ Kit - Tyramide Signal Amplification
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Nalge Nunc Inc. (75 Panorama, Creek Drive, Rochester, NY, 14625-2385, USA). Plastic-ware 
for tissue culture purposes.
Pfizer Inc. (Walton Oaks, Dorking Rd., Tadworth, Surrey, KT20 7NS, UK). Ready-beads for 
radioactivity labelling of plasmid DNA probes.
Promega Inc. (Delta House, Southampton Science Park, Southampton, SO 16 7NS, UK). 
Restriction and DNA modifying enzymes and respective buffer solutions. Recombinant CNTF.
Qiagen Ltd. (Fleming Way, Crawley, West Sussex, RH10 9NQ, UK). Qiagen™ Midi-prep 
plasmid DNA kits.
Quadratech Ltd. (P.O. BOX 167, Epsom, Surrey, KT18 7YL, UK). Cholera -  toxin Subunit B -  
HRP Conjugate.
R&D Systems Eyrope Ltd. (19 Barton Lane, Abington Science Park, 0X14 3NB, UK). 
Recombinant human NT3.
Santa - Cruz Biotechnology Inc. (Insight Biotechnology Ltd, P.O. BOX 520, Wembley, HA9 
7YN, UK). Antibodies to rat NT3, rat CNTF, mouse IL10 and rat BDNF.
Sera -  Tech Biologicals Inc. (900 Bugg Ln Suite 101, San Marcos, TX 78666)
Normal goat serum and normal horse serum, Streptavidin-HRP antibodies.
Serotec Ltd. (Oxford Science Park, UK). Anti-rat 0X42.
Sigma-Aldrich Company Ltd. (The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT). 
Analytical grade laboratory chemicals, recombinant rat Cilliary Neurotrophic Factor (CNTF), 
BS3 Bis(sulfosuccinimidyl)suberate protein cross - linking agent.
Sterilin Ltd. (Pengam Road, Aberbargoed, Pontypridd, CF81 9FW, UK). General disposable 
plasticware.
Stratagene Europe Ltd. (Gebouw Texas, Hogehilweg 19, 1101 CB Amsterdam Zuidoost, 
Netherlands). E.Coli XL 1-Blue bacterial strain.
VECTOR Laboratories Ltd. (3 Accent Park, Bakewell Road, Orton Southgate, Peterborough, 
PE2 6XS, UK). Biotinylated antibodies and Vectastain™ ELITE ABC (avidin -  biotin) Kit
Whatman International Ltd. (Whatman House, St. Leonard's Road, Maidstone, Kent, ME 16 
OLS, UK). 3MM chromatography paper, Plydisc™ HD disposable 5pm filters.
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2.1.2 Animals
All the animals used in this study (rats: LEWIS and Fischer 344, mice: Balb/c 
and SCID) were obtained either from breeding colonies within the Department of 
Biological services, UCL or from Harlan Laboratories, Oxon, UK. Animal
Surgery was carried out according to approved protocols (Home Office project
licence No: PPL70/4293).
2.1.3 Primers
Oligonucleotide primers were constructed by Genosys (Pampsiford, UK).
Primer Sequence (5’-»3’)
Rat NT3 Forward GGTGCTGTCACTCAGCAGGACCCGGGG
Rat NT3 Reverse CCCCGGGTCCTGCTGAGTGACAGCACC
2.1.4 Bacterial strains
The bacterial strain used for the molecular biology aspect in this thesis was 
E.Coli XL 1-Blue, Genotype: RecAl endAl gyrA96 thi-1 hsdR17 supE44 relAl 
lac [F’proAB LacF ZAM15, TnlO (Tetf] (Stratagene Ltd).
2.1.5 Cell lines
ATCC®* is the trademark of the American Type Culture Collection
Cell Line Origin Culture Media Source
BHK21 
Clone 13
Baby Hamster 
Kidney cells
lxDMEM 
lOOU/ml Penicillin 
lOOpg/ml Streptomycin 
10 %(v/v) FCS 
5%(v/v) TPB
Macpherson et al. 1962 
ATCC®* CCL 10
27/12/M:4
BHK-based 
complementing 
vm65, ICP4 and 
ICP27 deletions
As for BHK but further 
supplemented with: 
800pg/ml G418 
750pg/ml Zeocin
Thomas etal. 1999
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1° Antibody Dilution 2° Antibody Source
Mouse TUJ1 anti-neuronal specific tubulin 
(Cat. No: MMS-435P, Stock: 1 mg/ml) 1:5000
Rhodamine conjugated anti­
mouse Ig, 1:100 BabCo, USA
Mouse anti-rat OX-42, clone CD11 IgG 
(Cat. No: MCA275B, Stock: 0.1 mg/ml) 1:200
Biotinylated horse anti mouse 
IgG, rat absorbed Serotec, UK
Monoclonal anti-GFAP clone GA5 
(Cat. No: G3893, ascitic fluid) 1:600
Biotinylated horse anti mouse 
IgG, rat absorbed Sigma - Aldrich Company, UK
Rabbit polyclonal anti-rat NT3 (N-20) 
(Cat. No: SC-547, Stock: 200 pg/ml)
Goat polyclonal anti-mouse IL-10 (Ml8) 
(Cat. No: SC-1783, Stock: 200 pg/ml)
1:200
1:200
HRP - conjugated anti-rabbit 
1:1000
HRP -  conjugated anti-goat 
1:1000
Santa Cruz Biotechnology, USA
Polyclonal, rabbit anti-SCGlO 1:3000 Biotinylated goat anti rabbit IgG, rat absorbed
Dr G. Grenningloh (University of 
Lausanne Switzerland)
Rabbit polyclonal anti-rat BDNF (N-20) 
(Cat. No: SC-546, Stock: 200 pg/ml)
Goat polyclonal anti-rat CNTF (R-20) 
(Cat. No: SC-1912, Stock: 200 pg/ml)
1:200
1:200
HRP - conjugated anti-rabbit 
1:1000
HRP -  conjugated anti-goat 
1:1000
Santa Cruz Biotechnology, USA
00■fa*
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2.1.7 Standard buffers 
TE Buffer:
lOmM Tris-HCl pH 8.0 
ImM EDTA pH 8.0
TAE Buffer:
400mM Tris Base 
200mM Sodium Acetate 
20mM EDTA pH 8.3
0.4M PBS Buffer:
10.44g NaH2P 04(H20)
46g Na2HP0 4 (anhydrous) 
up to lltr and 36g Sodium Chloride
0.1M TBS Buffer:
13.22g Tris-HCl 
1.94g Tris Base 
9g Sodium Chloride up to lltr
SSC:
150mM NaCl 
15mM Sodium Citrate
Luria Bertani (LB) media:
1% (w/v) Bacto®-tryptone 
1% (w/v) NaCl
0.5% (w/v) Bacto®-yeast extract 
LB media was autoclaved prior to use at 120°C for 20 min at lOlb/square 
inch (psi).
Chloroform/IAA:
96%(v/v) Chloroform 
96%(v/v) Isoamyl Alcohol
Equilibrated Phenol:
Liquefied phenol was equilibrated with an equal volume of 0.1M Tris-HCl 
pH8.0. An average of two extractions were required for a 500ml batch. 
Equilibrated phenol was stored at 4°C in a dark room and was discarded one 
month after equilibration.
TNT Buffer:
lOmM Tris-HCl pH 7.5 
15mM NaCl 
0.05% Tween 20
SSC:
150mM NaCl 
15mM Sodium Citrate
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2.2 Methods
2.2.1 Propagation of bacterial strains
Bacteria were grown either on solid agar plates containing 2% Bacto®-agar or 
liquid Luria -  Broth (LB). Both were supplemented with 100 pg/ml Ampicillin 
when selection was required. Agar plates were incubated overnight at 37°C in a 
standard incubator. Liquid cultures were incubated overnight at 37°C in an orbital 
shaker at 200rpm.
2.2.2 Transformation of bacteria
A single colony of E. Coli XL 1-Blue was inoculated in 15ml of LB containing no 
antibiotic and incubated at 37°C in an orbital shaker at 200rpm, overnight. lOOpl 
of the overnight culture were used to inoculate 100ml of LB containing no 
antibiotic and returned to the orbital shaker until bacterial growth reached an 
OD580 of approximately 0.5 indicating that growth was in a log phase. A standard 
calcium chloride technique was used to prepare competent cells. Bacteria were 
then pelleted by centrifugation at 3000rpm for 10 minutes. The supernatant was 
then discarded and the bacteria were re-suspended in 10ml of ice cold lOOmM 
CaCb, pelleted as before and finally re-suspended in 4ml of ice cold CaCL. 
Competent cells were stored on ice until required and used no more than 72 hours 
after preparation. Competent cells were transformed by addition of DNA and 
subsequent incubation on ice for 30 minutes. The cells were then heat-shocked 
for 90 seconds at 42°C and returned on ice for a further two minutes. 800pl of LB 
was added and after a brief, one-hour incubation at 37°C/200rpm, bacteria were 
pelleted, re-suspended in 100pl of LB and plated onto selective agar medium 
containing ampicillin at lOOpg/ml. If detection of p-galactosidase activity was 
required, bacteria were plated onto agar plates containing 50pl of a 20mg/ml 
stock of X-GAL made up in dimethyl formamide(DMF). Plates were incubated at 
37°C, overnight in a standard incubator.
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2.2.3 Small scale plasmid DNA extraction
Single colonies of E. Coli XL 1-Blue, transformed successfully with the plasmid 
of interest, were inoculated in 3ml of Luria Broth (LB) containing ampicillin at 
1 OOpg/ml and incubated overnight at 37°C in an orbital shaker at 200rpm. 1.5ml 
of the overnight culture was spun down for one minute and lOOpl of solution I 
(50mM Tris-HCl pH7.5, lOmM EDTA, lOOpg/ml RnaseA), 200pl of solution II 
(200mM NaOH, 1%(V/V) Triton xlOO) and 150pl of solution III (3M KOAc 
pH4.8) were sequentially added and thoroughly mixed by vortexing. The 
resulting protein pellet was discarded and the DNA was precipitated with 500pl 
of isopropanol. It was then washed twice with 70% ethanol, dried and re­
suspended in 50j l i 1 of dH20 containing 20pg/ml RnaseA. The DNA was stored at 
-20°C.
2.2.4 Large scale plasmid DNA extraction
Midi-Preps were carried out using the QIAGEN -Tip 100 columns, according to 
the manufacturer's protocol. A single bacterial colony, picked from an agar plate, 
was inoculated into 500ml of LB supplemented with the appropriate antibiotic 
and incubated overnight at 37°C in an orbital shaker at 150rpm. 100ml of the 
resulting culture were centrifuged at 3500 rpm for 10 minutes. The average yield 
from a 100ml overnight culture was 1 pg/pl of DNA (about 100 jug in total).
2.2.5 Agarose gel electrophoresis
Low melting point (LMP) Agarose gels l%(w/v) and normal agarose 0.08%(w/v) 
gels containing 0.5pg/ml of Ethidium Bromide were run in lx TAE buffer at 50 
and 100 Volts respectively. Approximately 0.1 volume of lOx loading buffer was 
added to the samples prior to loading. The bands were visualised using a UV 
trans-illuminator and photographed using a Polaroid camera and film. A 1 
kilobase (kb) ladder was used as a marker to identify band sizes on the gel.
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2.2.6 Quantification of DNA
Quantification of plasmid DNA was performed following DNA extraction. 5pl of
purified DNA were diluted 200 fold into a total volume of 1ml ddfhO and the
absorbance was read at A260 using a calibrated spectrophotometer. The DNA
content was then calculated using the formula below, which is based on the fact
that an A260 of 1 corresponds to 50pg/ml.
[DNA] = (A260 x 200 x 50) ng ml'1 
1000
2.2.7 DNA sequencing
Plasmid DNA was purified using phenol/chloroform. DNA at a concentration of 
50ng/jnl was sequenced by the Dept, of Biochemistry (sequencing facility), 
University of Cambridge, UK. The primers for each case were used at a 
concentration of lOpmol/pl.
2.2.8 Purification of plasmid DNA by phenol extraction
The total volume of the DNA digest was adjusted to 400pl with dthO. An equal 
volume of phenol:chloroform:isoamyl alcohol(IAA) (24:24:1) was added. The 
mixture was thoroughly vortexed and then centrifuged at 14,000 rpm for 2 
minutes. The top layer consisting of the aqueous phase was removed and the 
above step was repeated until the interface appeared clear. Once this was 
achieved, the aqueous phase was mixed with an equal volume of chloroform:IAA 
and pulse spun. After spinning at 14,000 rpm for 2 minutes, the aqueous layer 
was again removed and mixed with 40pl of 3M Sodium Acetate (pH 5.5) and 
880pl of ice cold 100% Ethanol. DNA was allowed to precipitate by an one-hour 
incubation at -70°C. The DNA was pelleted by a 15 min centrifugation step at
14,000 rpm. The supernatant was then discarded and the pellet was washed twice 
with 70%(v/v) Ethanol. The DNA was allowed to dry and it was finally re­
suspended in lOpl of dH2 0 .
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2.2.9 Restriction enzyme digestion of plasmid DNA
Restriction digests were carried out either in small scale for investigative 
purposes or in large scale for the linearization of plasmids intended for 
transfections, preparation of probes for southern blotting or for cloning purposes. 
In both cases, the total volume of enzyme used did not exceed 0.1 volumes, the 
corresponding buffer was always used at lx and incubations were carried out at 
the temperature recommended by the manufacturer. For small-scale digests, the 
total volume did not exceed 20pl with 1 - 5 pi DNA. Large-scale digests were 
carried out in a total volume of lOOpl with approximately 10~20pl of DNA. 
Purification was carried out by running the digest in an LMP l%(w/v) agarose 
gel, excising the band of interest and purifying the DNA fragment from the 
melted gel. The digest was analysed using a normal 0.8%(w/v) agarose gel and 
purifying the fragment by Gene-Clean (Strata-tech Scientific, Luton, UK) after 
excision of the band. Gene-Clean purification was carried out according to the 
manufacturer's instructions.
2.2.10 Blunt -  ending of plasmid DNA overhangs
3' overhangs were blunt ended by a 1-hour incubation at 37°C of the DNA 
fragment of interest with 15 units of T4 DNA polymerase (Promega, 
Southampton, UK) and 1 pi of 25mM dNTP stock. If further enzyme processing 
was required, the T4 Polymerase was heat inactivated at 80°C for 30 minutes and 
subsequently cooled on ice for 20 minutes. Finally, the DNA was purified by 
phenol/chloroform, precipitated using ethanol and re-suspended in lOpl of H2O.
2.2.11 Ligation of plasmid DNA
Ligations were carried out in a total volume of 25pi, with lx T4 Ligase buffer 
and 3 units of T4 DNA Ligase. The volumes of insert and vector used were 8 and 
2pl respectively. Reactions were carried out in a cycle of 2-minute incubation at 
16°C followed by another 2-minute incubation at 36°C. The total number of 
cycles used per ligation was 21. After ligation was complete the mixture was 
transformed in E. Coli XL 1-Blue competent cells.
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2.2.12 Small scale viral DNA extraction
A single well of a six well plate infected with the virus in question was harvested 
and the cells were spun at 3,000 rpm for 10 minutes. The pellet was re-suspended 
in 200pl of 50mM TES. 200pl of 10%(w/v) SDS and 200pl of lOOmM. 0- 
mercaptoethanol were then added. The mixture was chilled on ice for 30 minutes 
and incubated overnight at 55°C with lOpl of 20pg/ml Proteinase K/lOmM CaCk 
solution. DNA was extracted using phenol/chloroform/IAA (24:1), precipitated 
with ethanol/0.5 M ammonium acetate, re-suspended in 50pl of ddthO.
2.2.13 Large scale viral DNA extraction
The volume of virally infected cultures required for sufficient viral DNA 
extraction depends on how disabled the virus in question is. In the case of 
1764/2774' viruses, twelve 175cm plates were required for obtaining a moderate 
amount of viral DNA. Once the cells are harvested, they were transferred in 
250ml Beckman centrifuge tubes and spun at 12,000 rpm for two hours at 5°C. 
The pellet was re-suspended in lOmls of Proteinase K Buffer/Proteinase K 
(lOmM Tris pH 8.0, 5mM EDTA, 0.5%(w/v) SDS, 50pg/ml Proteinase K). Cell 
lysis was carried out in an orbital shaker, at 37°C overnight. The next day, lOmls 
of dH20  were added to the clear lysate followed by an equal volume of 
Phenol/Chloroform/IAA (25:24:1). The lysate was mixed by gentle inversion for 
ten minutes, divided into Beckman polyallomer centrifuge tubes and spun at
15,000 rpm for 30 minutes. The top layer from each tube was removed, without 
disturbing the white interface appearing between the two layers and pooled in a 
50ml falcon tube. An equal volume of phenol/chloroform/IAA was added again 
and the spinning steps were repeated until no interface appeared between the two 
layers. When the layers were pooled for the last time, an equal volume of 
chloroform/IAA was added and the lysate was spun at 2,000 rpm for ten minutes. 
The top layer was transferred to a new falcon tube, precipitated with ethanol and 
air-dried overnight at room temperature. The DNA was finally re-suspended in 
lOOpl of dH2<D and stored at -20°C.
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2.2.14 Southern blot analysis of viral genomes
Southern blots were performed on digested viral DNA of recombinant and 
control viruses in order to confirm that homologous recombination has produced 
the right genetic outcome. lOpl of purified viral DNA was digested overnight 
with the required enzymes, in a total volume of 50pl. Usually, a plasmid control 
digest was also included for correct insert size identification. 0.1 pg of plasmid 
DNA was digested in a total volume of 20pl. Viral and plasmid DNA samples 
were analysed in a 1.0% TAE agarose gel.
2.2.15 Transfer of DNA onto a nitrocellulose membrane
After the bands of interest were well separated, the gel was placed on a UV trans­
illuminator for 2 minutes and then denatured by soaking the gel in a large volume 
of Denaturing Solution (1.5M NaCl, 0.5M NaOH) for 45 minutes, rinsed in dlUO 
and transferred in Neutralising Solution (2M NaCl, 1M Tris pH 5.5) for 45 
minutes. After a wash with 2x SSC, the DNA was placed upside down on a 
plastic support covered with two layers of 3MM Whatman filter paper. This was 
used as a wick placed in a reservoir of 20x SSC. A piece of Hybond-N+ 
membrane, was carefully placed on the gel. Any trapped bubbles were removed 
and 10 pieces of 3MM Whatman paper, pre-soaked in 20x SSC, were placed on 
top of the nitrocellulose membrane. Strips of paraffin film were used to separate 
the wick from the filter paper. A stack of paper towels and a weight of 
approximately 250g were placed on top of the filter paper. The DNA was 
transferred onto the nitrocellulose by capillary action, overnight, with 20x SSC as 
the carrier. The following day, the nitrocellulose membrane was rinsed in 6x SSC 
and air-dried at room temperature for 20 minutes. Finally, the DNA was the 
cross-linked to the membrane using a UV Stratalinker 2400.
2.2.16 Radiolabelling of plasmid DNA probes
1 pg of the plasmid DNA, containing the probe sequence, was digested overnight. 
Radio labelling was carried out using the Ready-To-Go™ DNA labelling Beads 
(-dCTP) kit. Probes were excised from a normal agarose gel and purified using 
the Gene Clean Kit in a total volume of 20pl. 1 pi of purified probe DNA was
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analysed on a gel to determine the amount required for the radio labelling 
reaction. The DNA was denatured by a 2-minute incubation at 90°C and 
immediately cooled on ice for 2 minutes. In one microcentrifuge tube containing 
the Reaction Mix Beads, the following were added: ljig of denatured DNA 
(probe), 50pCi [a-32P]dCTP (3000Ci/nmol) and dF^O to a total volume of 50pl. 
The content were thoroughly mixed to ensure that the beads were fully dissolved 
and the mixture was incubated at 37°C for 1 hour. Unincorporated nucleotides 
were removed by filtering the reaction mixture through a Sephadex column (G25 
to G50) using a 2cm x 1cm bed (height x diameter). The radioactive probe was 
again denatured as previously and added to the hybridisation solution.
2.2.17 Hybridisation
Cross-linked nitrocellulose membranes were incubated at 65°C for 4 hours with 
30ml of Pre-hybridisation Solution (6x SSC, 5x Denhardt’s reagent, 0.5%(w/v) 
SDS and lOOpg/ml of denatured hearing sperm DNA in dH2o). The pre­
hybridisation solution was replenished but only to a reduced volume of 5ml. The 
denatured probe was added and hybridisation was carried out overnight at 65°C. 
The membrane was then washed twice for 15 minutes in 2x SSC/0.1%(w/v) SDS 
and once in 0.5x SSC/0.1%(w/v) SDS. The membrane was then wrapped in cling 
film and exposed to X-ray film at -70°C.
2.3 Cell Culture
2.3.1 Storage and recovery of cell stocks
Cells from a 175cm flask were trypsinised and re-suspended in serum free 
media, pelleted by centrifugation at 1,500 rpm for 10 minutes and then re­
suspended in 10ml of freezing solution (8%(v/v) DMSO, 30%(v/v) FCS, 
68%(v/v) DMEM). Cells were stored overnight at -70°C at 1.5ml aliquots which 
were then transferred to liquid nitrogen for permanent storage. Each aliquot was 
quickly defrosted and re-suspended in 10ml of FGM. Cells were pelleted by 
centrifugation at 1,500 rpm for 10 minutes. The supernatant was discarded and 
the cells were transferred into a 25cm flask containing 5mls of the appropriate, 
pre-warmed media.
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2.3.2 Counting of cells
Counting of suspended cells was performed using the haemocytometer. A 
haemocytometer contains two chambers. When filled and coverslipped, each 
chamber contains a total volume of 9x10' ml. Each chamber is ruled into nine 
major squares. Thus, when coverslipped, the volume of each square is 0.1mm or 
lxlO'4 ml. Two samples of the same volume were removed from the same 
preparation. Cell suspensions were well shaken before the removal of samples in 
order to ensure accurate sampling. Using a pipette, each sample was delivered to 
each chamber of the haemocytometer by capillary action. It was ensured that the 
samples did not overfill the chamber. The total number of cells present in five of 
the nine squares in each of the two chambers of the haemocytometer were 
counted for a total of ten squares. Cells that overlapped the border on two sides of 
the square were included in the cell count and not counted on the other two sides. 
The number of cells in a total of ten chambers was counted to give the number of 
cells in lxlO'3 ml (l.OxlO-4 ml per square x 10 squares = 10*3 ml). The total 
number of cells was then multiplied by 1000 to give the number of cells per 
millimetre in the sample counted. After use the haemocytometer was cleaned 
with 70% Ethanol and dried with lens paper. Each well of suspended cells was 
counted four times to ensure accuracy.
2.3.3 Routine cell passage
Cells were grown on a variety of tissue culture plastics: 25cm2, 80cm2 and 
175cm flasks and 500cm plates. For passaging purposes, cells were trypsinised 
when they reached a 80-90% confluence. After removal of the growth media, the 
cell monolayer was briefly rinsed with Hank’s balanced salt Solution (HBSS). 
Cells were detached with trypsin/versene solution (1:10). Cells were re­
suspended in fresh media and new flasks were seeded at a ratio of 1:6 for 
MAM49 and 1.10 for BHK cells.
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2.3.4 Transient transfection of plasmid DNA
Transient transfections were carried out on BHK or BHK-based cell lines. Cells, 
grown on 6-well plates, were transfected after reaching a 70 -  80% confluence. 
The procedure followed was based on the standard calcium phosphate 
transfection method. 5-10pg of super coiled plasmid DNA was used per 
transfection. The following solutions were required:
HEBES
Transfection
Buffer
Tube A
Tube B
140mM NaCl 
5mM KC1 
0.7mM Na2HP04 
5.5mM D-glucose 
20mM Hepes
pH was adjusted to 7.05 with NaOH 
The buffer was filter-sterilised with a 0.2pm filter and 
stored at 4°C.
31 pi 2M CaCl2 
lOpg plasmid DNA
20pg Herring sperm DNA (phenol extracted)
400ml HEBES Transfection buffer
Shocking Solution 25% (v/v) DMSO in HEBES transfection buffer
The contents of tube A were thoroughly mixed and added to tube B in a slow and 
steady flow with simultaneous gentle vortexing. The DNA was allowed to 
precipitate at room temperature for 20-40 minutes. The media was removed from 
the cells and the mixture containing the precipitated DNA was added in a drop 
wise manner. Following 20-40 minute incubation at 37°C, 1ml of full growth 
media was added. Cells were returned to 37°C for another 4-6 hours. The media 
was then removed and the monolayer was washed twice with 2mls of growth 
media. 1ml of shocking solution in HEBES transfection buffer was added to the 
cells, which were then left without shaking at room temperature, for exactly 150 
seconds. The shocking solution was quickly removed and the cell monolayer was 
immediately washed twice with 2mls of growth media. Finally, 2mls of full 
growth media, without antibiotic selection, were added and the cells were 
incubated for a further 24 - 48 hours at 37°C under a 5% C 02, humidified 
atmosphere.
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2.3.5 Detection of GFP expression
Cells expressing GFP could be directly visualised using an inverted fluorescent 
microscope at a wavelength of 520nm.
2.3.6 Detection of p-gal expression
Full growth media from the monolayer in a well of a 6-well plate was removed 
and cells were washed twice with 2mls of 0.1 M PBS. They were then fixed by a 
10-minute incubation with 0.1M PBS/0.05% (v/v) glutaraldehyde. Cells were 
again washed twice with 2mls of 0.1 M PBS and incubated at 37°C for 1-16 hours 
with 3mis of X-Gal stain (5mM K3Fe(CN)6, 5mM K4Fe(CN)6.6H20, ImM 
MgCl2, 150pg/ml X-Gal in DMSO made up in 0.1M PBS). If storage was 
required then the stain was removed and the cell monolayer was overlaid with 
2mls of 70% glycerol in dF^O. If the staining was carried out for the purposes of 
plaque picking, the cells were not fixed prior to staining.
2.4 Viral vector construction and propagation
2.4.1 Homologous recombination into the HSV1 genome
Insertion of expression cassettes in the HSV1 genome by homologous 
recombination was achieved by transfections on the appropriate cell line. 10-20 
pg of purified viral DNA was added in tube A. The following mixing and 
vortexing steps were carried out in a more cautious manner. The transfection mix 
was left for 7 hours prior to DMSO shocking. Transfections were left for 4-6 days 
until complete cytopathic effect (CPE) had occurred. As the viruses used and 
produced in this study had a deactivated VP 16 gene, the growth media had to be 
supplemented with 3mM hexamethylene bisacetamide (HMBA), which can 
induce immediate early gene transcription (McFarlane et al 1992). Once complete 
CPE had occurred the transfections were harvested and freeze-thawed once. A 
lOOpl aliquot of the transfection was serially diluted and the efficiency of the 
recombination was assessed by the presence of viral plaques that had the new 
phenotype encoded by the inserted gene.
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2.4.2 Purification of recombinant virus by plaque selection
After titration of the transfections, cells were not fixed. Instead they were stained 
for the presence of P-galactosidase (P-gal). The presence of P-gal was monitored 
carefully and blue viral plaques were picked as soon as the colour started to 
develop. This was due to toxicity of the staining procedure. Recombinant plaques 
were picked from the monolayer at a volume of 3 pi, using a P20 Gilson 
micropipette. Each plaque was thoroughly re-suspended in lOOpl of SFM, freeze- 
thawed and plated out in two wells of a 6-well plate at 40 and 60pl. The cells, 
70% confluent, were overlaid with 500pl of SFM prior to infection and once the 
virus was added they were incubated at 37°C for two days. In the case of a highly 
disabled virus, incubation was allowed to proceed for four days. This procedure 
of picking and infecting was carried out until all plaques had the recombinant 
phenotype. When pure, each plaque was used to infect a single well of a six well 
plate. When CPE was observed, the virally infected cells were harvested, stored 
at -80°C and one aliquot was used to titre the stock on both complementing and 
non-complementing cells. This was done in order to make sure that there were no 
reversion mutants. In addition to titration, viral DNA from recombinant plaques 
was also extracted in a small-scale preparation and analysed by southern blotting 
for the presence of the gene inserted.
2.4.3 Production of high titre HSV-1 stocks
Minimally disabled viruses, such as 1764, were grown in Coming 850cm2 roller 
bottles. BHK cells were seeded in 100 ml of full growth media. Roller bottles 
were gassed with 5%CC>2 through a filtered gas line and incubated at 32°C in a 
rotated platform at 0.5rpm. When cells reached 90% confluence they were 
infected at an MOI of 0.01 (lx  106 pfu/ml of vims per roller bottle), in a total 
volume of 100ml FGM supplemented with 3mM HMBA. Roller bottles were 
then incubated at 32°C/5% CO2 for a further two to three days, until full CPE had 
occurred. Cells were detached from the walls of the roller bottles by vigorous 
shaking. The cell suspension was the frozen at -80°C. Ten roller bottles were 
infected for each batch preparation.
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Disabled viruses that had essential and immediate early genes deleted or 
inactivated were grown in large 500cm2 tissue culture plates. Ten large plates 
were used for each high titre viral stock. Complementing cells 27/12/M:4 
(Thomas et a l , 1999) were seeded in ten large plates in a total volume of 50mls 
of FGM per plate. Cells were incubated at 37°C/5% CO2 until they reached 90% 
confluence. They were then infected at an MOI of 0.05 (3x 106 pfu/ml of virus 
per 500cm2 plate). The virus was used in a total volume of 50ml FGM 
supplemented with 3mM HMBA. Plates were returned to 37°C/5% CO2 until 
complete CPE had occurred. They were then frozen at -80°C.
The cell suspension was then thawed and centrifuged at 3500rpm for 45 minutes 
at 4°C in order to remove any cell debris. The supernatant was then separated 
from the cell pellet and sequentially filtered through a 5pm and 0.45pm filter. 
The virus was then pelleted by a 2-hour, 12000rpm centrifugation at 4°C. The 
supernatant was then discarded and the viral pellet was re-suspended in fresh, ice 
cold DMEM. The final volume of the viral stock depended on the level of 
disablement as well as the quality of each preparation. Generally, minimally 
disabled viruses were re-suspended in l-3mls per 10 roller bottle stock. Highly 
disabled viruses were re-suspended in 300-500ml per 10 500cm plates. In each 
case, the viral pellet was sonicated five times in 10-second bursts. The stock was 
chilled on ice for 20 seconds in between sonication steps. Once the suspension 
was homogeneous, the virus was stored in liquid nitrogen in 20-5Opl aliquots. 
One aliquot was freeze-thawed and used to determine the viral titre.
2.4.4 Establishing the viral titre of HSV-1 stocks
Six-well plates were seeded with the appropriate cells and incubated at 37°C until 
confluence had reached 80-90%. The FGM was then removed and 500pl of 
DMEM, also referred to as Serum Free Medium (SFM), were aliquoted in each 
well. The virus was then added to the monolayer of each well in a 1:10 serial 
dilution in SFM, progressing from 10'1 down to 10-6. Following a one hour 
incubation at 37°C, each well was overlaid with 1.5ml of FGM/3mM HMBA 
containing 1.6% carboxymethyl cellulose (CMC) in 1:2 ratio. Plates were then
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incubated at 37°C for a further two days. In order to calculate the viral titre, as 
plaque forming units per ml of stock (pfu/ml), cells were either fixed and stained 
for lacZ expression, or examined under fluorescence for the expression of Green 
Fluorescent Protein (GFP).
2.5 Protein isolation and analysis
2.5.1 Concentration of secreted proteins from cultured cells
lxlO6 cells in a 36mm well were washed twice with 0.1M PB. 500ml of DMEM 
were aliquoted in each well and the cells were returned to a 37°C/5%C02 
incubator. At the desired time point, the DMEM was collected and centrifuged at 
2,000rpm for 5 minutes to remove any cells present. The supernatant was then 
transferred to a 500pl microcon column (G-10000, Green) and spun at ll,500g 
for 25 minutes at room temperature. The microcon columns used for the 
experiments described in this study had a molecular weight cut-off of lOKda as 
the proteins of interest were in the region of 12-14Kda. The total volume of the 
concentrated sample was lOjul. An equal volume of protein sample buffer [5% 
(v/v) b-mercaptoethanol, 50mM Tris-HCl pH 8.0, 2% (w/v) SDS, 6% (v/v) 
glycerol and 0.005% (w/v) bromophenol blue] was added. Samples were placed 
on ice immediately and then denatured by heating to 95°C for 4 minutes. They 
were then cooled on ice for 2 minutes and either loaded onto a SDS- 
polyacrylamide gel or stored at -20°C.
2.5.2 Extraction of intracellular proteins from cultured cells
lxlO6 cells in a 36mm plate were washed twice with 0.1M PB and harvested in 
1 OOpl of protein sample buffer. Harvested cells were placed on ice immediately 
and then denatured by heating to 95°C for 4 minutes. Samples were then cooled 
on ice for 2 minutes and either loaded onto a SDS-polyacrylamide gel or stored at 
-20°C.
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2.5.3 SDS -  polyacrylamide gel electrophoresis
Protein samples were heated to 95°C for 4 minutes and then immediately cooled 
on ice for 2 minutes. In a SDS-PAGE gel 20pl of each sample and 5pi of 
coloured molecular weight protein standards (rainbow markers) were loaded in 
appropriate spaced lanes. Gels were prepared and run in a vertical electrophoresis 
system. The consistency of the stacking and resolving SDS-PAGE gels is shown 
below.
5% Stacking gel • 1*Bis-Acrylamide (30:1.5)
• 4x Stacking gel buffer
• 10% (w/v) APS
• **TEMED
• ddH20  to a final volume of
• Bis-Acrylamide (30:1.5)
15% Resolving Gel • 4x Stacking gel buffer
• 10% (w/v) APS
• TEMED
• ddH20  to a final volume of
• 4x Stacking gel buffer: 0.5M Tris base and 0.01M SDS, pH 6.8
• 4x Resolving gel buffer: 1.5M Tris base and 0.01M SDS, pH 8.8
Protein separation was achieved by applying a constant current of 30-40mA/gel 
with variable voltage, in lx running buffer (25mM Tris, 250mM glycine and 
0.1% (w/v) SDS, pH 8.3). Gels were run until the bands of interest were fully 
separated, as judged by the migration pattern of the coloured molecular weight 
markers.
2.5.4 Equalisation of protein loading
Duplicate protein samples were analysed on a separate SDS-PAGE gel. This gel 
was placed in Coomassie stain solution [2% (w/v) Coomassie Brilliant blue 
R250, 50% (v/v) Methanol, 50% (v/v) glacial acetic acid] for 1 hour at room 
temperature with continual agitation. The gel was then transferred to de-staining 
solution [10% (v/v) glacial acetic acid, 30% (v/v) Methanol] for the removal of 
any non-protein bound stain. The de-staining solution was replaced twice until no 
background staining was visible.
1 *Bis: N ,N’-Methylene-bis-acrylamide, **TEMED: NNNN-tetraethylethalinediamine.
1.6ml 
2.6ml 
lOOpl 
5 pi 
10.55ml
15.75ml
7.9ml
150pl
9pl
32.5ml
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2.5.5 Western blotting
Separated protein bands on an SDS-PAGE gel were transferred onto a 
nitrocellulose membrane (Hybond-C) using a wet-transfer method based on the 
technique outlined in (Towbin, et al., 1979). Briefly, the SDS-PAGE gel, the 
nitrocellulose membrane and four sheets of 3MM Whatman paper were pre­
soaked in transfer buffer (50mM Tris, 380mM glycine, 0.1% (w/v) SDS and 20% 
(v/v) methanol). The gel and the nitrocellulose membrane were then sandwiched 
between the filter paper in a Trans-Blot™ Cell (BioRad) according to the 
manufacturer’s instructions. Protein band transfer onto the nitrocellulose 
membrane was carried out overnight at 4°C at 200mA. Protein bands were 
visualised by staining the membrane with 0.5% (w/v) Ponceau S in 1% (v/v) 
acetic acid for 30 minutes. Excess stain was removed by washing the membrane 
in several changes of 0.1 M PB.
2.5.6 Immunodetection of proteins on nitrocellulose membranes
Following transfer, membranes were washed in 0.1M PB and then blocked by 
incubating them in 5% (w/v) skimmed milk made up in 0.1 M PBS for 1 hour, at 
room temperature, with shaking. The membrane was then incubated with the 
primary antibody, diluted in 3% (w/v) skimmed milk, for 1-2 hours at room 
temperature, with vigorous shaking. All the antibodies used in this thesis, as well 
as their working dilutions are listed in section 2.1.6 (page 84). Any unbound 
antibody was removed from the membrane by three washes for 10 minutes each 
with PBST [0.1M PBS, 0.1% (v/v) Tween-20] at room temperature with constant 
shaking. Washed membranes were then incubated in the appropriate anti-IgG 
horseradish peroxidase (HRP) conjugated secondary antibody, diluted in 3% 
(w/v) skimmed milk made up in 0.1 M PBS for 1 hour, at room temperature, with 
vigorous shaking. Any unbound antibody was removed from the membrane by 
three washes, for 10 minutes each with PBST, at room temperature with shaking. 
The bound HRP was visualised using the Enhanced Chemiluminescence system 
(ECL™) according to the manufacturer’s instructions. The membrane was then 
exposed to X-ray film to capture the resulting light emissions. Exposure times 
varied between 10 seconds and 15 minutes, according to the strength of the 
signal.
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2.5.7 Enzyme linked immunosorbent assay for NT3 detection
Each well of a 96-well Nunc-MaxiSorp plate was incubated overnight at 4°C with 
lOOpl of anti-Human NT-3 polyclonal antibody in Coating Buffer pH 9.7 
(0.025M Sodium Carbonate, 0.025M Sodium Bicarbonate). After washing the 
wells 5 times with TBST buffer (20mM Tris-HCl pH 7.6, 150mM NaCl, 
0.05%(v/v) Tween-20), using a plate washer, non-specific sites were blocked with 
lx Blocking buffer for 1 hour. The TBST washing step was repeated after every 
incubation step. A standard curve was prepared by serially diluting the NT-3 
standard from 4.7 to 300pg/ml in lx sample buffer. The samples, i.e. the 
transfection supernatants, were added undiluted. The plate was then incubated for 
6 hours at 4°C at 500 rpm. Once the incubation was complete, the anti-NT-3 Ab 
was added and the plate was incubated overnight at 4°C, without shaking. The 
next day the samples were incubated at room temperature with anti-mouse IgG 
HRP conjugate for one hour at 500rpm. Colour reaction was initiated with the 
addition of TMB substrate and it was stopped after 15 minutes with the addition 
of lOOpl/well of 1M Phosphoric Acid. The sample and standard UV absorbance 
values were measured at 450nm and a standard curve was generated. The 
experimental values obtained were considered accurate if the standard curve 
generated had an r2 value greater than 0.98.
2.6 Primary cultures
2.6.1 Isolation of E14 rat embryonic dorsal root ganglia (DRG)
An E14 pregnant Lewis rat was terminated via CO2 administration. The rat was 
transported to a laminar flow hood and subsequent steps were carried out in 
sterile conditions. The abdominal area was sprayed with 70%(v/v) Ethanol and an 
incision was made along the lower abdomen. The chain of pods containing the 
embryos was removed and placed in a Petri dish containing sterile 0.1M PBS. 
Each embryo was removed from the amniotic sack and placed in a new Petri dish 
also containing sterile 0.1M PBS. The tail and head were removed and an 
incision was made along the length of the spinal column. The spinal cord was 
then removed with the dorsal root ganglia still attached. Each DRG was then
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snipped off and cleaned of any membrane surrounding it. The cleaned DRGs 
were pooled in ice-cold Leibovitch medium (L-15; Sigma) and kept on ice under 
sterile conditions. DRGs were plated out in supplemented media as quickly as 
possible.
2.6.2 Setting of DRGs in collagen matrices
All the steps listed in this procedure were carried out under sterile conditions. In a 
15 ml falcon tube, 8mls of chilled Vitrogen Collagen were thoroughly mixed with 
lml of lOx PBS. 1ml of 0.1 M NaOH was then added and the contents we again 
mixed. The pH was then adjusted to 7.4 ± 0.2 by the addition of either 0.1M HC1 
or 0.1 M NaOH accordingly. The now neutralised and isotonic Vitrogen Collagen 
solution was stored at 4°C for a maximum of 3 hours. A 50jnl drop was placed in 
a tissue culture dish and a DRG explant was gently embedded in it. 
Fibrillogenesis was initiated by a 1-hour incubation at 37°C in the absence of 
CO2. Once the collagen had fully set, explants were flooded with chemically 
defined medium (DMEM/F12 (3:1) supplemented with 200pg/ml transferrin, 
200pM putrescine, 40nM progesterone, 60nM selenium, lOpg/ml insulin and 
0.01% (w/v) albumin).
2.7 In vivo gene delivery - Animal surgery
2.7.1 Anaesthesia
Female LEWIS Rats, as close to 200g as possible, were initially anaesthetised by 
a mixture of 1.5% Oxygen, 3% Nitrous oxide and 4% Halothane (Fluothane, ICI) 
administered within an anaesthetic chamber. Once deep anaesthesia was 
established, animals were transferred into the operating theatre and placed on an 
electrically heated pad. The anaesthetic mixture was adjusted to 1.5 -  2% 
Halothane and was administered by means of a scavenging face/nose mask. Post- 
operatively, the animals were kept in a clean cage and monitored every hour for 
the first 6 hours and twice a day after the first day, until stable.
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2.7.2 Animal Preparation
Prior to any procedure, animal fur was shaved using veterinary clippers. The 
exposed areas were then thoroughly cleaned by means of a 70% Ethanol solution. 
The animal was then covered with a sterile surgical cloth, exposing only the area 
of interest.
2.7.3 Injections into the spinal cord
A 25pi Hamilton syringe fitted with a fine needle (outer 0  300 pm) was used to 
administer the vector at a 1.5 mm depth into the uninjured spinal cord or within 
the lesion site in CST lesioned animals. A World Precision Instruments 
microinjection controller (Micro4 Smart Controller, WPI, Europe) in combination 
with a type II ultra-micropump (Ultra-Micropump II), in order to administer the 
vector at a steady rate. Delivery of the vector in these experiments was done by 
convection. Convection relies upon creating a pressure gradient that forces the 
viral particles into the solid neural tissue. The delivered particles then diffuse into 
the tissue surrounding the injection site (Chen et al., 2005). Viral suspensions 
were injected at a rate of 0.5 pl/min using a micro-pump. For the purposes on this 
thesis, spinal cord delivery was carried out either at the lumbar level (L3-4) or at 
the cervical level for (C6-7). The needle was slowly removed, the dura, spine 
muscles and the overlaying skin was then repaired with Michel clips.
2.7.4 Injections in the cerebellum
The co-ordinates for injecting the motor cortex were: Rostral-Caudal 11.5 mm, 
Medial-Lateral 1.5 mm, Dorsal-Ventral 3.0 mm.
2.7.5 Foot -  pad injections
Three-week-old female BALB/c or SCID mice were inoculated via right footpad 
injection using an insulin needle. Virus of approximately lx l0 8 pfu/ml was 
inoculated at a volume of 20-25pi. BALB/c mice remained sedated under 5% 
Halothane. In the case of SCID mice this was not possible and injections had to 
be carried out in a sterile hood without anaesthesia.
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2.7.6 Mouse DRG extraction
At the appropriate time point, mice were sacrificed. DRGs from the lumbar spine 
(LI to L6) and ipsilateral to the inoculated side were dissected and fixed for 1 
hour at 4°C with 2% Paraformaldehyde (PFA) in 0.2M Phosphate Buffer pH7.4. 
After incubation they were washed twice with 0.1M PBS and examined for the 
expression GFP. They were then stained with X-gal stain and incubated at 37°C 
overnight for assessing (3-gal activity.
2.7.7 Perfusion of animals
The animals were terminally anaesthetised with CO2. The heart was exposed, and 
after an incision of the pericardium a blunt needle was inserted in the left 
ventricle. 4% PFA (in 0.2M Phosphate Buffer pH 7.4) was pumped through the 
heart using a peristaltic pump at a rate of approximately 30 rpm. In the cases were 
tetramethylbenzidine processing of tissue was required, animals were fixed with a 
solution of 1% (w/v) PFA/1.25% (v/v) Glutaraldehyde. Once perfusion was 
completed, the animals were dissected and the tissue of interest was collected. 
Tissue was post-fixed in 4% PFA for 1 hour on ice and washed twice with 0.1M 
PBS.
2.7.8 Processing of brain and spinal cords
Extracted tissue (spinal cords and brains), were cryo-protected by overnight 
incubation in 30%(w/v) Sucrose at 4°C. The next day they were sectioned to the 
desired thickness, usually 40pm for spinal cords and 70pm for brains. Free- 
floating sections were further processed and they were then mounted onto slides 
and coverslipped for permanent keeping.
2.7.9 Processing of optic nerves
Extracted optic nerves were kept in fixative overnight at 4°C before being 
dehydrated and embedded in low melting point polyester wax (Aldrich). 
Longitudinal sections were cut at 10pm on cryostat, washed in PBS, incubated 
for 15 min with 0.3% (v/v) H2O2 in PBS to remove endogenous peroxidase
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activity, washed in PBS, exposed to blocking serum, (5% normal rabbit serum) 
and 0.3% TritonX-100 in PBS and then incubated with goat anti-CTB (List 
Biological, Campbell, California) 1:80,000 in blocking serum for 2 days at 4°C. 
They were then washed in PBS, incubated for 2hr with rabbit anti-goat IgG 1:200 
in PBS, washed in PBS and treated for 2hrs with the avidin-biotin peroxidase 
complex (ELITE Kit, Vector, USA, 1:200 in PBS).
2.8 Immunological and histological techniques
2.8.1 Immunostaining on tissue sections
This method was used for SCG10 and GFAP immunolabelling (Chapter 5). 
Cryostat sections were dried overnight and their boundaries marked with a grease 
pen. The following day they were rinsed three times with 0.1M TBS for 10 
minutes each time. They were then incubated in 0.1% (v/v) Hydrogen Peroxide in 
0.1M TBS for 15 minutes to quench endogenous peroxidases. After washing 
twice for 5 minutes in 0.1M TBS, sections were incubated in Blocking Buffer 
(10% (v/v) Goat Serum, 5% (w/v) Bovine Serum Albumin in 0.1 M TBS) for 30 
minutes at room temperature. The blocking buffer was removed and sections 
were incubated with the primary antibody, diluted in 0.1M TBS, at 4°C, 
overnight. Sections were washed three times for 10 minutes with washing buffer 
(0.1M TBS/0.3% (v/v) Triton xlOO) and incubated in the biotinylated secondary 
antibody, diluted also in washing buffer, for 2 hours at room temperature. 
Sections were then washed twice for 10 minutes in washing buffer and twice for 
10 minutes in 0.1 M TBS. They were then incubated in ABC complex/0.1M TBS 
at a 1:200 dilution, for 1 hour at room temperature. After washing twice for 5 
minutes in 0.1 M TBS, sections were incubated in 0.005% (w/v) DAB with 0.01% 
(v/v) Hydrogen Peroxide in 0.05M TB for 5 minutes at room temperature. Once 
the reaction was completed, sections were washed 3 times with 0.05M TB, rinsed 
with dH20  and left to dry overnight.
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2.8.2 Immunofluorescence on tissue sections
Immunofluorescence was carried out primarily on free-floating sections as this 
allowed better penetration of the antibodies used. Freezing microtome sections 
were washed three times for 10 minutes with washing buffer (2% (w/v) Skimmed 
milk, 0.05% (v/v) Tween-20 in 0.1 M TBS). Non-specific sites were blocked by a 
one hour incubation with Blocking Buffer (1% (w/v) BSA, 10% Goat serum, 
0.25% (v/v) Triton xlOO in 0.1M TBS), at room temperature on a rocking 
platform. Sections were incubated in primary antibody diluted in blocking buffer, 
at 4°C overnight. After washing three times for 10 minutes with washing buffer, 
sections were incubated with the secondary antibody for 2 hours at room 
temperature with gentle rocking. The streptavidine fluophore secondary antibody 
was diluted in blocking buffer at a 1:200 dilution. The New England Nuclear 
(NEN) Tyramide Signal Amplification (TSA™) Kit was used to enhance the 
fluorescent signal. Sections were washed three times for 10 minutes in TNT 
washing buffer and incubated for 1 hour at room temperature in streptavidin-HRP 
diluted in blocking buffer (1:100). Again, sections were washed three times for 
10 minutes at room temperature with TNT washing buffer. They were then 
incubated in Fluorophore Tyramide, diluted 1:50 in amplification diluent for a 
maximum of 10 minutes at room temperature. Sections were washed again in 
TNT washing buffer, three times for 10 minutes. Finally, sections were mounted 
onto gelatinised slides and coverslipped using PBS/glycerol 1:9 with 2.5% (v/v) 
1,4-diazabicyclo[2.2.2]octane (DABCO).
2.8.3 Immunofluorescence E14 rat DRG explants
DRG explants were washed twice with 0.1M PBS. They were then fixed with 4% 
(w/v) Paraformaldehyde in 0.1 M PB for 15 minutes at room temperature without 
shaking then washed three times with 0.1M PBS and permeabilised by a 5 minute 
incubation in 0.1M PBS/0.1% (v/v) Triton xlOO. After a brief wash with 0.1M 
PBS they were incubated in 0.1 M PBS/30% (v/v) Goat serum for 30 minutes to 
block any non-specific sites and then incubated for 1 hour at room temperature 
with the mouse TUJ1 anti neuronal -  specific tubulin, in a final dilution of 
1:5000. TUJ1 was diluted in 0.1M PBS/10% (v/v) Goat serum. The primary 
antibody was removed and explants were washed three times with 0.1M PBS.
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Then, they were incubated for 2 hours in a light protected container with anti 
mouse IgG2A rhodamine conjugated antibody. The secondary antibody was used 
at a 1:1000 dilution in 0.1M PBS/10% (v/v) Goat serum. Explants were then 
washed in 0.1 M PBS and photographed the same day.
2.8.4 Tracing of neurons by biotin dextran (BDA) processing
BDA is an anterograde tracer and it was injected in motor cortex or the red 
nucleus for labelling of corticospinal or rubrospinal tract neurons respectively 
(Chapter 4 and 5 respectively). Processing was carried out on free-floating 
sections based on a well known method (Herzog and Brosamle, 1997). Sections 
were washed three times for 10 minutes in 0.05M TBST (0.05M TBS /0.5% (v/v) 
Triton xlOO). They were then incubated in 0.3% (v/v) Hydrogen Peroxide to 
quench endogenous peroxidases. After washing them twice for 10 minutes in 
0.05M TBST and incubated overnight at 4°C in ABC solution. The ABC solution 
was used in a final dilution of 1:200 and consisted of reagents A and B (50:50). 
The following day sections were washed twice in 0.05M TBST and twice in 
0.05M TB, for 10 minutes each time. They were then rinsed in 0.4% (w/v) 
ammonium nickel sulphate for 10 minutes. They were then incubated in 0.0015% 
(w/v) DAB made up in 0.15M TB, pH 7.4. To this, hydrogen peroxide was added 
to a final volume of 0.01%. The reaction was allowed to proceed until the desired 
colour intensity was achieved. Finally, sections were washed twice in 0.05M TB 
for 10 minutes, mounted onto gelatinised slides and processed as in section 2.8.9.
2.8.5 Tracing of neurons by cholera toxin - b (CTB)
Sections were rinsed in dH20 and placed in reaction solution (3.4mM Sodium 
Nitroferricyanide, 23.4mM Sodium Acetate pH 3.3, 0.2mM
Tetramethylbenzidine) for 20 minutes. Hydrogen peroxide was added at a final 
volume of 0.01% (v/v) and the reaction was allowed to proceed for 5 minutes on 
ice. The solutions were then discarded and the above step was repeated until the 
reaction solution had been replaced six times. Sections were then rinsed twice in 
lOOmM Sodium Acetate buffer pH 3.3 for 5 minutes each time. Finally, they 
were mounted onto gelatinised slides and further processed as in section 2.8.10.
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2.8.6 Detection of p-Galactosidase (p-Gal) in DRG
Extracted DRG were placed in ice cold 0.1M PBS. These were then fixed with 
4%(w/v) Paraformaldehyde in 0.1M phosphate buffer pH 7.6. After a 1 hour 
incubation on ice, DRGs were washed twice in 0.1M PBS for 15 minutes each 
wash. The DRGs were then incubated in lOOpl of DRG X-Gal stain made up in 
0.1M PBS (5mM K3Fe(CN)6, 5mM K4Fe(CN)6.6H20 , ImM MgCl2, 0.02% 
Sodium Deoxycholate, 0.02% NP-40 and 40mg/ml X-Gal in DMSO) overnight at 
37°C. The X-Gal solution was the removed and DRGs were placed in a 70%(v/v) 
glycerol solution and stored at 4°C prior to photography.
2.8.7 Detection of p-Gal in Retinas
Retinas were placed in ice cold 0.1M PBS and later fixed with 4%(w/v) Para 
formaldehyde in 0.1M phosphate buffer pH 7.6 for 1 hour on ice. During that 
time retinas were kept attached on a silicone bed with fine steel needles. Retinas 
were washed twice in 0.1M PBS for 15 minutes each wash and incubated 
overnight at 37°C in X-gal stain. Once processing was complete, retinas were 
mounted onto slides and covered with a drop of glycerol. The coverslip was 
sealed using nail varnish and the slides were stored at 4°C prior to photography.
2.8.8 Detection of p-Gal in free-floating spinal cord & brain sections
After sectioning, slices were washed twice in 0.1M PBS and examined under 
fluorescent light for the expression of GFP. The presence of LacZ was examined 
by staining the slices with X-gal stain at 37°C. The X-gal stain used was not the 
same as the one used for DRG staining as the presence of detergents could 
damage the integrity of the slices. Instead tissue culture stain was used as 
described previously for viral plaque selection. P-Galactosidase presence was 
monitored to avoid the development of background. After blue colour 
development, the slices were washed with 0.1M PBS and counter-stained with 
Neutral red.
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2.8.9 Detection of GFP expression in DRGs and tissue sections
DRGs and free-floating tissue sections were transferred onto a glass slide using a 
pipette tip and artists fine brush respectively. They were then coverslipped and 
GFP expression was visualised under UV light (520 nm) and photographed. GFP 
fluorescence was always recorded prior to any further processing, as it is 
susceptible to bleaching by detergents used in other techniques such as X-Gal 
staining.
2.8.10 Counter staining of sectioned tissue
Tissue sections were mounted onto gelatinised microscopic slides by immersing 
them into 0.2M Phosphate Buffer pH 7.4 and slowly guiding each one onto the 
slide using a fine tipped artist's brush. They were allowed to dry overnight at 
room temperature and the following day they were fully immersed into Neutral 
Red stain. (4mM Sodium Acetate pH 8.5, 24mM Acetic Acid pH 2.4 and 
0.02%(w/v) Neutral Red) until they were stained a dark red colour. Sections were 
dehydrated by sequentially soaking them in 70%, 90% and 100% Ethanol for 10 
minutes each time. Finally, tissue fats were removed by incubating in Histoclear 
for 30 min. Once counter-staining was complete, cover slips were fixed on the 
slides using DPX mounting solution (BDH, Poole, UK).
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C h a pt e r  3.0
DISABLED HSVl VECTOR BACKBONES FOR 
TRANSGENE DELIVERY TO THE CNS
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3.1 Introduction
As reviewed in Chapter 1, its natural propensity to infect terminally 
differentiated cells, its neurotropism as well as its ability to be retrogradely 
transported to the nucleus and enter latency which can be maintained for the 
lifetime of the host, are the key characteristic that make HSV-1 an attractive 
vector for gene delivery in the injured CNS (Lilley et al., 2001a; Lilley and 
Coffin, 2003). The vectors employed in this thesis, carry mutations that allow 
them to be minimally cytotoxic and expression cassettes that utilise endogenous 
elements from the LAT region thus maximising their ability to achieve transgene 
expression in the long term. These are based on constructs that were produced in 
our laboratory, but whose potential as a gene delivery tool to the CNS had not 
yet been assessed in vivo until the initiation of the study described here. Out of a 
panel of vectors with different levels of disablement that became available as the 
study progressed, two vectors were particularly selected. Firstly, a fully disabled 
vector: 1764/ICP277P27ICP47pR20.5v/w (HSVl/P2'.pR20.5vfo) and a slightly 
less disabled vector: 1764/ICP27/ICP47pR19CMV (HSVl.pR19CMV). The 
construction and genetic make up of these two vectors has been published 
(Palmer et al., 2000; Lilley et al., 2001b) and is briefly reviewed in section 3.2.1 
(page 126). These vectors were selected because they presented the best practical 
compromise between the necessary ability to transduce neuronal cell 
populations, while ensuring minimal levels of cytotoxicity to the host. The 
expression patterns achieved with these vectors are characterised in the 
following sections. The focus is the transduction patterns achieved following a 
single inoculation of these vectors in various areas of the CNS such as the spinal 
cord, cortex and cerebellum. This approach aimed to establish the strengths and 
limitations of these two vectors that may define their utility. These were 
established along with differences in their ability to support the expression of a 
transgene such as p-galactosidase or GFP, which directly relates to their potential 
as gene delivery tools for the injured spinal cord and the CNS in general. This is 
particularly important, as CNS regeneration is a complex and slow process that 
can last from months to years. It is therefore likely that for a gene delivery 
system to be successful in aiding such a process, it has to be able to sustain 
transgene expression in the long term.
i l l
Ultimately, the main target of the studies described in this thesis was to utilise 
these vectors as a platform from which to screen various factors that could have 
a positive impact on injured neurons of the spinal cord as well as other tracts 
such as the optic nerve. HSVl/P2\pR20.5v/z.s and HSVl.pR19CMV vector 
backbones, used in this thesis, were constructed by Dr C.E. Lilley following 
previous work in our laboratory. These two disabled vectors were chosen for the 
production of the neurotrophin expressing constructs described in the following 
chapters. The rationale behind their use is discussed in the sections below.
3.1.1 Reducing vector cytotoxicity
Wild type HSV1 is highly pathogenic. When HSV1 was first under investigation 
for its potential as a gene delivery tool, a variety of researchers attempted to 
establish the origin of the toxic effect that follows the inoculation of the virus 
into the CNS. Extensive work in our laboratory led us to conclude that the main 
cause of cytotoxicity is due to the production of the a proteins which takes place 
during the establishment of the lytic cycle. It was not due to a particular feature 
of the virion itself or due to the processes occurring during viral entry into the 
host (Johnson et a l , 1992).
As discussed in Chapter 1, ICP4 is the primary transactivator responsible for 
regulating the expression of the downstream P and y viral genes (DeLuca et al., 
1985) and has been shown to be cytotoxic in many cell lines, including neuronal 
cells (Johnson et al., 1992). It was therefore logical to suggest that deletion of 
ICP4 would reduce the level of expression of the remaining HSV1 genes and 
prevent the virus from entering a lytic life cycle (DeLuca et al., 1985). Indeed, 
forcing the virus into latency forms the basis of the vectors utilised in our 
experiments. However, initial studies utilising temperature sensitive mutants 
suggested that the sole deletion of ICP4 aggravated rather than reduced 
cytotoxicity (DeLuca et al., 1985). In these experiments it was shown that when 
ICP4 expression was blocked, the expression of the rest of the a genes was not 
abolished. IE genes encoding ICPO, ICP22, ICP27, ICP47 as well as ICP6, a 
viral protein that does not rely on ICP4 for its induction, were still produced 
(DeLuca et al., 1985). It is therefore not surprising that fibroblasts infected with
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an ICP4 deleted mutant displayed evidence of cytotoxicity, such as 
fragmentation of host genomic DNA and formation of cytoplasmic vesicles 
(Johnson et al., 1992). This feature of the ICP4 deleted mutants is easily 
explained by the fact that ICP4 negatively regulates its own expression and that 
of ICPO. Consequently, deleting ICP4 alone would result in the continued 
expression of the remaining IE proteins which, with the exception of ICP47, are 
also toxic (Johnson et al., 1992).
From the reported studies up to this point, a consensus was starting to emerge 
that deleting just ICP4 was not enough of a disablement to produce a vector that 
could be considered non-cytotoxic, and that it was necessary for other IE genes 
to be deleted as well. Evidence that support this notion came from both in vivo 
and in vitro experiments that employ vectors that are disabled for a combination 
of IE genes instead of just ICP4 mutants. Cortical or DRG neurons infected with 
a virus that has been deleted for the ICP4, ICP22 and ICP27 IE genes survived 
significantly longer (21 days p.i) than those neurons that were infected with 
HSV1 mutants that were individually mutated for each of these genes (4 days 
p.i) (Krisky et al., 1998). When these vectors were injected into areas of the 
adult rat brain, including the frontal cortex, there was a reduced area of necrosis 
surrounding the injection site compared to wild-type virus injected animals 
(Chiocca et al., 1990). Therefore, deleting a combination of IE genes has a 
beneficial effect in terms of reducing cytotoxicity, that can be manifested in both 
in vitro and in vivo paradigms.
Further experiments set out to explore which of the remaining a genes were 
primarily responsible for this toxic effect and determine whether there were 
some combinations of deletions that were more effective than others at reducing 
cytotoxicity. Firstly, transient transfections with plasmids encoding each of the 
IE genes ICPO, ICP22 or ICP27 were conducted in fibroblasts infected with an 
ICP4 deleted mutant virus (Johnson et al., 1994). The authors realised that each 
of the IE genes tested (i.e. ICPO, ICP22 and ICP27), were implicated in the 
cytopathic effect of ICP4 deleted vectors. ICP47 and ICP6 proteins were not 
included in these experiments as they were not expected to be cytotoxic based on 
their known properties at the time (Johnson et al., 1994). This finding was
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confirmed when another research group demonstrated that a virus that carried a 
combination of ICP4, ICP22 and ICP27 deletions was markedly lacking in 
cytotoxicity when compared to other mutants that had these genes deleted either 
singly or in double combinations (ICP4 and ICP27 or ICP4 and ICP22) (Wu et 
a l , 1996; Krisky et al., 1998). This combination of three deletions was unique 
because it allowed Vero or human embryonic lung cells (HEL) to survive for 
three days when infected at high MOI (MOI=10), compared to just 24 hours 
when infected with viruses mutated for double combinations of IE genes (Wu et 
al., 1996). Interestingly, further examination of cellular protein expression 
profiles demonstrated that viruses that were deleted for ICP4 alone or ICP22 in 
combination with ICP27 did not cause impairment in the cell’s transcriptional 
activity whereas there was a marked reduction in transcription when the cell was 
infected with a mutant that was only deleted for ICP4 (Wu et a l , 1996). These 
findings pointed to the fact that in order to produce a vector that is non-toxic for 
the purpose of delivering genes to the CNS, it would be necessary to silence the 
expression of all the remaining a genes. Whether this approach would indeed 
have an effect was put to the test in the work of Samaniego et a l who were the 
first to produce a mutant virus that had been deleted for all five IE genes: ICPO, 
ICP4, ICP22, ICP27 and ICP47. In vitro, Vero or HEL cells transduced by these 
very disabled vectors displayed the same viral protein expression patterns as 
cells that had not been infected with virus (mock infected) (Samaniego et a l , 
1998). Significantly, these experiments demonstrated that highly disabled virus 
constructs such as the ones used by these researchers displayed such low level 
toxicity (if any) to host cells that they enabled the viral genome to persist in a 
functional state for a minimum of 28 days (Samaniego et a l, 1998). This finding 
demonstrated the significant reductions in cytotoxicity which a combined 
approach to deleting the IE genes can achieve.
Even though deletions in the immediate early genes themselves do achieve 
significant reductions in cytotoxicity, deleting each one individually is not a 
significantly effective strategy. Another means of causing a blanket reduction in 
IE genes is to delete the portion of the gene which encodes the VP 16 
transactivator protein (Ace et a l, 1988). As discussed in Chapter 1, VP 16, a
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structural component of the virion, is the product of the essential y gene (Vmw65 
or UL48), that enters the host cell nucleus along with the viral DNA and 
transactivates the HSV1 IE genes (Batterson and Roizman, 1983; Campbell et 
al., 1984). As an essential structural component of the viral capsid, it is not 
possible to outright delete this gene as this approach would produce a non-viable 
virus. Also, it would make propagation in culture impossible as VP 16 is required 
for viral egress (Mossman et al., 2000). Instead, Ace and colleagues (1989) 
inserted a 12bp fragment into the transactivating domain of the C-terminus of the 
protein. The disruption caused by the insertion of this fragment was sufficient to 
disrupt the domain of VP 16 that interacts with the Oct-1 or HCF (O'Hare, 1993), 
while maintaining the ability of the protein to be incorporated into the virion 
during assembly. This virus was termed m l814 (Ace et a l , 1989). It should be 
emphasised that the insertion of the fragment does not abolish the transactivating 
function of VP 16 but rather leads to a marked impairment (Mossman and 
Smiley, 1999) with a four to five fold reduction in the levels of ICPO mRNA 
expressed in infected BHK cells (Ace et al., 1989). Interestingly, the ICP4 RNA 
transcript levels remain unaltered (Ace et al., 1989). In principle, the use of the 
m l814 mutation would complement the reduction in cytotoxicity achieved by 
deletions in IE genes. Indeed, it has been demonstrated in cell survival assays 
that it can reduce the deleterious effects of ICP4' mutants (Johnson et al., 1994). 
The authors of this study proposed that the reason the ml 814 mutation had such 
an effect in the cytotoxicity of the ICP4 deleted mutant was because the 
remaining transactivating activity of VP 16 was insufficient to successfully 
initiate the production of transcripts from the ICPO, ICP22 and ICP27 promoters 
(Johnson et al., 1994). Nearly a decade later, another research group produced a 
mutant with the whole of the VP 16 transactivating domain deleted (Smiley and 
Duncan, 1997). This mutation, termed V422 (deleted from codon 422, C- 
terminal domain), displayed significantly reduced levels of the genes encoding 
ICPO and ICP4 even in the presence of hexamethylene bisacetamide (HMBA), a 
synthetic IE gene transactivator (McFarlane et al., 1992). In terms of the effects 
of this mutation on transcript levels, there is an apparent 20 fold reduction in the 
levels of ICPO and ICP4 in Vero cells (Smiley and Duncan, 1997). A later study 
confirmed that a VP 16 mutation combined with a reduction in ICPO and ICP4
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levels does indeed lead to lower levels of cytotoxicity to Vero cells (Preston et 
al., 1997). The viruses used for these studies did not have any deletions in the IE 
genes. Instead a temperature-sensitive mutation in ICPO was used. This mutation 
also utilised an ICPO promoter that was less active that the wild type one. 
Culturing at limiting temperatures, these studies demonstrated that these vectors 
did not produce any IE genes and were thus able to persist in Vero cells 
following infection at a high MOI (5) (Preston et al., 1997). Overall, the main 
dissimilarity between the two mutants is that the m l814 mutation has no effect 
on the levels of ICP4 transcripts while the V422 mutation results in a significant 
reduction. These differences could explain the cytotoxicity patterns observed 
with these vectors as emerged in comparative studies of ICP0/V422 and 
ICP0/ml814 double mutants where the ICP0/ml814 mutant appeared to be 
consistently more cytotoxic than the ICP0/V422 mutant even at low MOI (1) 
(Mossman and Smiley, 1999). The vector constructs used throughout this study 
carry the m l814 and not the V422 mutation. Since the cytotoxicity differences 
between these two mutants are likely to be due to the marked difference in the 
levels of ICP4, the inclusion of the m l814 mutation on a backbone that is 
already deleted for the presence of ICP4 would result in a vector that was no 
more cytotoxic than a vector carrying the V422 mutation (Lilley et al., 2001b). 
The impaired ability of a VP 16 inactivated virus in inducing IE gene expression 
has the added advantage that in vivo, the virus is forced to enter a latency-like 
state with low cytopathic effects, even though viral replication does occur at very 
high MOI (Ace et al., 1989). This is an added advantage in terms of our aim of 
delivering genes to the CNS, as inducing latency would allow for our constructs 
to persist in the host cell and favour transgene delivery.
The deletion of essential IE genes such as ICP4 and ICP27 (DeLuca et al., 1985; 
Sacks et al., 1985), means that the virus is unable to enter a lytic life cycle. 
However in terms of delivering foreign genes to the injured CNS, more 
safeguards have to be put in place to ensure that the natural neurovirulence of 
HSV1 is abolished. This means that in addition to the deletion or inactivation of 
immediate early genes, it is necessary to disable the non-essential genes that 
come into play when establishing an infection in non-dividing cells such as
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neurons. For example, ICP36 and ICP6 genes, encoding a thymidine kinase (tk) 
(MacLean et a l, 1991) and a ribonucleotide reductase respectively (Cameron et 
al., 1988), as well as the y34.5 gene, encoding the ICP34.5 neurovirulence factor 
(Chou et al., 1990) are proteins that are mainly useful for the replication of 
HSV1 in neuronal cells. It therefore follows that preventing their expression 
could be beneficial. However, deletions in the above-mentioned genes alone are 
not equally efficient at reducing neurovirulence. Deletions in the tk gene result in 
some reduction in neurovirulence but only if the mutant virus is inoculated at a 
low titre (Palella et al., 1988; Palella et al., 1989). ICP34.5 deleted viruses have 
been shown to significantly impair the neurovirulent nature of HSV1. Deleting 
the ICP34.5 gene allows for a lxlO6 increase in LD50 compared to wild type 
HSV1 following direct inoculation in the brain of mice (Chou et al., 1990). Even 
though, ICP34.5' (Coffin et al., 1996) and ICP34.5/VP16 deletion mutants 
(McMenamin et al., 1998) are avirulent when administered in either the 
peripheral or central nervous system, they are able to grow at near wild type 
titers in vitro using non-neuronal cell lines (Coffin et al., 1996).
Other non-essential genes that have been studied for their contribution to 
cytotoxicity include: the IE genes ICPO, ICP22 and ICP47 and structural proteins 
of the virion such as Vhs (UL41 gene) (Coffin and Latchman, 1996). ICPO 
deleted mutants are still able to grow in culture but at a much slower rate, 
especially when used at a low MOI (MOI=0.01) (Chen and Silverstein, 1992). In 
addition, in vivo experiments demonstrate that an ICPO mutant largely retains the 
innate ability of HSV1 to be retrogradely transported to regions projecting to the 
inoculation site as opposed to an ICP4 deleted vector which did not produce a 
similarly widespread expression (Chiocca et al., 1990). Thus, deleting the non- 
essential gene encoding ICPO, reduces the ability of the virus to replicate but, 
unlike the deletion in the ICP4 transactivator, it does not totally abolish this 
ability (Chiocca et al., 1990). Another IE protein shown to be cytotoxic is ICP22 
(Johnson et a l, 1994). The additional deletion of ICP22 in a virus already 
mutated for ICP4 and ICP27 can further reduce cytotoxicity as tested in neuronal 
and non neuronal cell lines (Wu et a l, 1996; Krisky et al., 1998). As discussed 
in Chapter 1, the functions of Vhs include the non-specific degradation of host
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mRNA and thus the inhibition of host protein synthesis (Read et al., 1993). Even 
though such a function implies the creation of deleterious effects for the host, 
cells infected with an ICP4 and Vhs deleted or ICP4 and Vhs and VP 16 mutant 
viruses do not appear to have any dramatic differences in cytotoxicity compared 
with ICP4 or ICP4 deleted and VP16-inactivated mutant viruses (Becker et al.,
1993). Since ICP4 (DeLuca et a l , 1985) and ICP27 (Sacks et al., 1985) are 
essential viral genes, their removal renders the virus incapable of initiating a lytic 
cycle unless they are provided in trans by growing the mutant virus on a 
ICP4/ICP27 complementing cell line (DeLuca et al., 1985; Chiocca et al., 1990; 
Dobson et al., 1990). Further consideration needs to be given to mutants also 
carrying the />? 1814 mutation. When the m 1814 mutation has been combined 
with a deletion in an essential IE gene such as ICP4 then HMBA is inadequate at 
complementing the residual VP 16 activity even if ICP4 is provided by the cell 
line in trans (Thomas et al., 1999). In our laboratory, this problem was overcome 
following the creation of a cell line that can not only complement the deletions in 
ICP4 andICP27 genes but also complement the VP 16 inactivating mutation as 
well. It is not possible to provide the HSV1 VP 16 protein via a complementing 
cell line as this would allow the protein to be packaged into the new virions 
produced. This would cause the virus to be cytotoxic following a CNS injection, 
as the protein would lead to the transcription of IE genes.
Thomas et al. (1999) overcame this problem by constructing a cell line that 
expressed an analogue of the HSV1 VP 16 protein that could not be packaged 
into the progeny virions but could still transactivate the IE gene promoters. This 
was the EHVI gene 12 which encodes for the equivalent of VP 16 in the equine 
HSV1 virus and had previously been shown to be able to transactivate HSV1 IE 
genes (Purewal et al., 1994). Importantly, as there is very little DNA sequence 
homology between the two genes there is no risk of a homologous recombination 
of the EHVl-gene 12 into the VP 16 locus in the disabled HSV1 genome. The 
resulting cell line was termed 27/12/M:4 and it was used for the production of 
high titre stocks of the highly disabled vectors used throughout this thesis 
(Thomas et al., 1999).
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3.1.2 Achieving long term transgene expression
As already mentioned in Chapter 1, in addition to combating cytotoxicity it is 
necessary to ensure that the vector can support the expression of the transgene 
for as long as possible following the successful transduction of the host cell. The 
long-term expression achieved with the expression cassettes incorporated in 
these vectors exploit the innate ability of HSV to remain transcriptionally active 
during latency by making use of specific elements from the LAT promoters 
(Palmer et a l, 2000; Lilley et a l, 2001b). The highly efficient expression 
cassettes employed here are the product of a substantial body of research from 
ours as well as other laboratories. The rationale that governed the production of 
the current cassettes is briefly reviewed in the paragraphs that follow (Lilley et 
a l, 2001a).
Early attempts at achieving transgene expression with disabled HSV1 viral 
vectors demonstrated that the location of insertion of the transgene in the viral 
genome as well as the choice of promoter, are key parameters that directly affect 
the expression pattern of the foreign gene. First attempts utilised viral promoters 
that were active during the lytic cycle of the virus. The preliminary expression 
cassettes that were constructed employed promoters such as ICPO, ICP4, ICP6, 
ICP8, gC and tk that were active during the lytic phase of the virus life cycle (Ho 
and Mocarski, 1988; Palella et a l, 1988; Chiocca et a l, 1990). These promoters 
were linked to the marker gene LacZ. These expression cassettes were all 
inserted via homologous recombination into the loci of genes also active during 
the lytic cycle. What all these early experiments had in common was that 
insertion of marker transgenes in place of viral genes under the control of 
promoters not normally active during latency did not result in long term 
expression of the transgene. Expression stops very quickly as soon as latency is 
established. For example, inserting lacZ into the ICP4 locus under the control of 
the ICP6 promoter, not active during latency, gives only short-term expression 
when delivered in the mouse CNS or PNS (Chiocca et a l, 1990). This was not 
necessarily a problem relating to the fact that the promoters used were of HSV1 
origin as the same pattern emerged in other experiments where exogenous 
promoters such as CMV (Fink et a l, 1992) or the moloney murine leukaemia
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virus (MMLV) long terminal repeat (LTR) (Lokensgard et al., 1994) were placed 
into the US3 or gC loci respectively. Interestingly, when an MMLV LTR-lacZ 
construct was placed in an anti-sense orientation to ICP4 (thus inactivating it), 
expression in the mouse DRG continued for a period of 24 weeks following 
sciatic nerve inoculation (Dobson et al., 1990), i.e.: long after the virus had 
entered latency. There must have been something relevant to the orientation and 
location of the insertion that allowed it to be active during latency, something 
that was not possible in any of the other locations this cassette had been inserted 
in previously. What these researchers did not know at the time was that by 
inserting the construct in an anti-sense orientation they placed the promoter in 
close proximity to the endogenous LAT region and in the same orientation as the 
LAT promoters. This impressive result therefore suggested that there might have 
been elements in the MMLV LTR promoter that together with the location of its 
insertion in relation to the latency promoters facilitated the long-term expression 
observed.
As already explained in Chapter 1 the production of LAT transcripts is under the 
control of two promoters LAP1 and LAP2. To recap, LAP1 is a TATA sequence 
promoter that is located 700 to 1300bp upstream from the of the actual LAT 
(8.3kb) (Batchelor and O'Hare, 1990; Zwaagstra et al., 1990). LAP2 does not 
contain a TATA element and is located downstream of LAP1 and ~750bp 
upstream of the 2kb LAT intron (Goins et al., 1994). These promoters have long 
been the target of attempts to exploit the fact that they remain active throughout 
latency. Initial studies into exploring their potential concentrated around the role 
of LAP1 as LAP2 was then unrecognised. What these initial experiments 
demonstrated was that in order for the LAP1 promoter to influence the longevity 
of transgene expression from an exogenous promoter, that promoter must be 
placed within the LAT region and at a specific distance from LAP1 itself. The 
evidence that led researchers to this realisation comes from several experiments. 
For example, when lacZ or NGF were inserted just downstream of the TATA 
element of the LAP1 promoter, transgenes expression was only supported for 21 
days post inoculation (Margolis et al., 1993). When the insertion site was placed 
-800 bp further downstream from the TATA element from the LAP1 promoter
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and within the endogenous LAT region then transgene expression could be 
supported for 56 days in mouse DRGs (Ho and Mocarski, 1989). In these 
experiments, the histological appearance of the resulting LacZ staining appeared 
unusual and punctate which the authors hypothesised may relate to physiological 
changes in the latently infected neuron relating to the transition from the acute to 
the latent stage of infection (Ho and Mocarski, 1989). Placing the LAP1 
promoter at sites other than the endogenous LAT region abolishes any beneficial 
effect it may have in supporting long-term expression of transgenes. This was the 
case when Dobson and colleagues placed a LAPl-lacZ construct into the gC 
locus (Dobson et al., 1995). No transgene expression was observed in this case. 
These findings further support the suggestion made by a number of different 
research groups that LAP1 on its own cannot support transgene expression in the 
long term.
The realisation that the region downstream of LAP1 (now known LAP2) was 
important for long-term expression, resulted from a number of additional 
experiments. When the lacZ gene was placed just downstream of the LAP2 
either in the ectopic gC locus or in its native position in LAT, expression was 
maintained for more than 300 days in mouse trigeminal ganglia (Goins et al.,
1994). In reality however, the LacZ expression in this study was so weak that it 
could only be detected by PCR. In another study, the two promoters were 
combined. In this study, lacZ was fused with the encephalomyocarditis virus 
(EMCV) internal ribosome entry site (IRES), and inserted 1.5Kb downstream 
from the TATA box in LAP1 thus leaving LAP1 and LAP2 undisturbed. The 
authors reported that LacZ could be detected in cervical ganglia and cervical 
spinal cord sections at approximately three months and ten months respectively 
(Lachmann and Efstathiou, 1997). Again however, the transgene was present at 
very low levels and in only a handful of cells. The presence of LAP2 could also 
enable the LAP1 promoter to support the expression of foreign genes at HSV1 
genome sites other than the endogenous LAT region. This was something that 
did not occur when LAP1 alone was placed at the gC locus (Dobson et al.,
1995). It was shown that it was possible for the LAP1 promoter to support the 
production of lacZ mRNA transcripts from the same gC locus but only when it
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was placed upstream from the LAP2, and in the reverse orientation (Lokensgard 
et al., 1997). In these experiments transgene transcript production could be 
detected in mouse DRGs at 28 days post footpad inoculation. This experiment 
demonstrated that in principle, the enhancer element in LAP2 could act at sites 
other than the endogenous LAT region. Lokensgard and colleagues (1997) 
conducted a series of experiments into the properties of LAP2. They concluded 
that LAP2 was most effective when it was placed downstream of LAP 1 and in its 
natural orientation (Lokensgard et al., 1997).
As mentioned previously the MMLV LTR promoter was unique in its ability to 
confer long term transgene expression during latency but only when placed in 
close proximity to the LAT region in the ICP4 locus (Dobson et al., 1990; 
Lokensgard et al., 1994). Further experiments were carried out aiming at finding 
out what was the mechanism behind this. In these experiments, the LAP1 
promoter, without its TATA box, was fused with the MMLV LTR-lacZ (MMLV 
LTR-lacZ/LAPlTATA‘) cassette and inserted into the gC locus (Lokensgard et al., 
1994). Lokensgard et al. (1994) demonstrated that this chimeric promoter could 
support the expression of LacZ in murine DRGs for around 42 days post footpad 
inoculation. Therefore it appears that the MMLV LTR promoter can substitute 
for the LAP2 contribution in the long-term activity of LAP1. It has been 
suggested that the reason MMLV LTR and LAP2 appear to be capable of similar 
function may be a reflection of their ability to keep this region of DNA 
accessible to transcription factors (Lilley et al., 2001a) such as the high mobility 
group (HMG) of proteins. These can directly bind and disrupt LAP2 (French et 
al., 1996). Also, the local region has a dinucleotide content that is proportionally 
different to the rest of the HSV1 genome and could therefore reflect some 
structural characteristics that enable the LAP2 region to escape transcriptional 
silencing during latency (Coffin et al., 1995).
This ability of LAP2 to maintain adjacent promoters in an active state would be 
useful in constructing vectors aimed at gene delivery to the injured CNS. This 
was exploited in our laboratory when cassettes were constructed carrying 
elements of the LAP2 and LAP1 regions that allowed exogenous promoters such
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as CMV, RSV, NSE and MMLV LTR to sustain the expression of marker genes 
both in the PNS (Palmer et a l , 2000) and CNS (Lilley et a l , 2001b). In 
particular, in the expression cassettes constructed the exogenous promoter was 
placed at 700bp upstream of the 3’ end of the LAP2 region and after a 1.4kb 
DNA fragment that has been named as LAT P2 in our laboratory (Palmer et a l , 
2000). This location corresponds to 1.5kb downstream of the transcription 
initiation site for the primary LAT transcript. These expression cassettes were 
initially characterised following delivery to the CNS via sciatic nerve or footpad 
inoculations and were shown to be able to support the long term expression of 
transgenes (Palmer et a l , 2000). In later studies they were shown to be able to 
transduce spinal cord motor neurons retrogradely following a sciatic nerve 
inoculation (Perez et a l , 2004). These expression cassettes can be placed 
anywhere in the viral genome and not just into the LAT region. This is because 
they can act autonomously due to the presence of the LAT P2 region next to two 
exogenous promoters driving the expression of two (e.g. the pR20.5 expression 
cassette shown Figure 3.3.1-a, page 135) or one transgene (e.g. the pR19 
expression cassette, Figure 3.3.2-a, page 138) (Palmer et a l , 2000). Indeed these 
vectors have been shown to support the expression of transgenes from ectopic 
sites of the viral genome for at least two months in murine DRGs following 
sciatic nerve inoculation (Palmer et a l , 2000).
3.1.3 Characteristics of the highly-disabled vectors used
The injured CNS environment is a very delicate tissue in terms of regeneration 
and places high demands on any tool designed for inducing regeneration. On the 
one hand the viral vector must be devoid of cytotoxicity while at the same time 
be able to support the long term expression of any potentially therapeutic 
transgene. Despite the difficulties posed, the current viral vector technology 
appears to combine both characteristics and can therefore be considered as a very 
powerful tool available for exploitation in terms of regeneration studies targeting 
the injured CNS. Deletions designed to reduce cytotoxicity, negatively impact 
the ability of the virus to support the long-term expression of transgenes. This is 
because when IE genes such as the ICP4 and VP 16 transactivators are absent, the
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viral genome is actively repressed very quickly following host infection (Preston 
and Nicholl, 1997). It has therefore been proposed that the task of developing a 
suitable viral vector system based on HSV1 is essentially a balance with each 
deletion in essential genes potentially resulting in a compromise in the efficiency 
of transgene delivery. Some researchers have even suggested that it might not be 
possible to produce a non toxic vector that is capable of sustaining a meaningful 
level of transgene expression (Samaniego et al., 1998). A potential solution to 
this problem is to exploit the natural propensity of the virus to produce LATs by 
forcing the virus into latency.
As discussed in previous sections, effective reduction in cytotoxicity requires a 
combination of deletions in both essential and non-essential genes. Deletion of 
viral genes also enhances the capacity of HSV vectors to accommodate 
transgenes greater that 30Kb (Coffin and Latchman, 1996). The highly disabled 
HSV1 viral vectors utilised as the basis for the production of neurotrophin 
expressing vectors in this thesis, make use of the m l814 inactivating mutation 
and are deleted for ICP34.5, including ORF P. This double mutant is known by 
the term 1764. They also carry full deletions in the IE genes encoding ICP4 and 
ICP27 (Lilley et al., 2001b). The initial characterisation of this backbone showed 
that it does not produce detectable levels of ICPO on non-complementing cell 
lines, as shown by Western blotting (Lilley et al., 2001b). The vectors used here 
are disabled to such an extent that they cannot replicate in vivo as they lack 
essential genes. Due to this they have to be supplemented in culture by especially 
designed cell lines in order to be propagated in high titre stocks (Thomas et al., 
1999; Lilley et al., 2001b). Despite their multiple disabling deletions these 
viruses can support the expression of transgenes in transduced neuronal cells in 
vivo and in vitro in both the CNS (Lilley et al., 2001b) and PNS (Palmer et al., 
2000). This is accomplished through the use of unique expression cassettes that 
make use of the LAT P2 region of the HSV 1 genome, which is placed next to 
exogenous promoters. Out of a panel of expression cassettes produced in our 
laboratory, two were selected for the studies described in this thesis. Firstly, 
vector cassette pR20.5v/zs, which allows the simultaneous delivery of two 
separate transgenes under the control of the RSV and CMV exogenous
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promoters. One copy of this expression cassette was present for each copy of the 
viral genome as it was inserted into the locus of the vhs gene in the Ul region of 
the genome. The second cassette employed was the pR19CMV cassette, which 
can deliver a single gene under the control of the CMV promoter. This 
expression cassette however is inserted in the LAT region and is thus present 
twice per viral genome.
3.1.4 Rationale
The experiments employed in this chapter set out to examine whether there is a 
correlation between the location of the expression cassette employed in vector 
constructs and the pattern of transgene expression achieved following a single 
inoculation in the spinal cord. Specifically, it was hypothesised that placing the 
expression cassette in the endogenous LAT region would allow for more 
efficient transcription as the virus establishes latency. To test this hypothesis two 
vector constructs were compared for their ability to firstly achieve widespread 
transgene expression and secondly for their ability to support that expression in 
the long term. The first construct contained the ectopically placed pR20.5 
cassette while the second construct contained the pR19 cassette, which is present 
in two copies within the endogenous LAT region.
It was also hypothesised that if expression in cortical pyramidal neurons is 
related to the level of deletion of viral endogenous genes, then by utilising a less 
disabled construct, such as HSVl.RLl+/pR19CMV or 
HSVl.ICP27+/RLl+/pR19CMV, it would be possible to transduce cortical 
neurons. This could in turn translate in longer and more widespread transgene 
expression in cortical neurons compared to the more disabled HSVl.pR19CMV 
construct. The experiments that follow aim to measure differences between two 
vector constructs that bear different levels of disablement. The vectors were 
assessed their ability firstly to achieve long term expression and secondly for 
differences in their ability to target different neuronal populations following a 
single spinal cord inoculation. Based on the work presented here suitable HSV1 
vectors were selected in order to construct new, neurotrophin expressing viral 
constructs that could potentially be used in various injured CNS paradigms.
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3.2 Methods
The initial part of this study concentrated on the identification of optimally 
disabled HSV1 based vectors for use as a gene delivery tool for the CNS, in 
general and the spinal cord in particular. Vector mediated transduction of retinal 
ganglion neurons is examined in Chapter 6. As part of this study a series of 
different vectors were evaluated for their ability to efficiently transduce spinal 
cord neurons and support the expression of transgenes for a period of time 
thought sufficient to encourage regeneration, while at the same time having 
minimal cytotoxic effects.
3.2.1 Vectors utilised in Chapter 3
The following vectors were used in this study:
Table 3.2.1-a: Vectors used in the vector backbone screening studies.
As discussed in the introduction to this Chapter the vector backbones that 
displayed the best practical compromise between vector toxicity and ability to 
efficiently transduce CNS neurons were those based on the 1764 backbone with 
the additional deletion of the ICP4 and ICP27 genes. This backbone, designated 
1764/ICP277ICP4", as well as the marker gene expressing vectors HSV1/P2' 
.pR20.5v/w and HSVl.pR19CMV were all constructed by Dr C. Lilley in our 
laboratory and were available at the time when this study was initiated. Their 
construction has been previously published (Thomas et a t , 1999; Lilley et a t, 
2001b) and is briefly summarised here. Vectors 1764/ICP277ICP4' 
/RLl+/pR19CMVLacZ and 1764/ICP27+/ICP47RL1 +/pR 19CMVLacZ were 
produced towards the end of this study by Dr J. Palmer in our laboratory and 
their construction is briefly reviewed here (unpublished work).
Virus Abbreviation
1764/ICP277P27ICP47pR20.5v/w 
1764/ICP277ICP47 pR 19CMVLacZ 
1764/ICP27/ICP47RL17pR 19CM VLacZ 
1764/ICP27VICP47RL17pR 19CM VLacZ
HSVl/P2'.pR20.5v/w 
HSVl.pR19CM VLacZ 
HSV1 .RL1 +/pR 19CM VLacZ 
HS V1 .ICP27VRL1 VpR 19CM VLacZ
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3.2.1.1 1764/ICP27 /ICP4 & 1764/ICP277P2 /ICP4' (HSV1) backbones
All viruses were derived from the HSV1 strain \7syn+. The term 1764 is used to 
designate a vector that contains the m l814 mutation in the VP 16 gene and has 
the gene encoding ICP34.5 and ORF P completely deleted between HSV1 
n t\24,945 to n t\25,723 (GenBank file HE1CG). The term ICP27* refers to the 
deletion of nucleotides HSV1 nt\ 13,273 to nt\ 16,869 (Mlul - Mlul). This means 
that the backbone also has genes UL54, UL55 and UL56 completely deleted. 
UL54 encodes the IE protein ICP27 which is essential while UL55 and UL56 are 
both non-essential genes (Howard et al., 1998; Lilley et al., 2001b). This 
backbone was designated 1764/ICP277ICP4' (HSV1) and is often referred to as 
“fully disabled” for the purposes of this thesis. In addition, the 1764/ICP277P2' 
/ICP4‘ designated backbone (HSV1/P2') was deleted for the endogenous LAT P2 
region [HSV1 nt\ 18,768 (DdeI) -  nt\20,470 (HpaY)] in order to avoid any 
recombination events with the pR20.5 expression cassettes that also contains a 
LATP2 element (Palmer et al., 2000).
3.2.1.2 Vector 1764/ICP277P27ICP4 /pR20.5vhs (HSV1/P2\pR20.5vhs)
The pR20.5vhs expression cassette was available at the time of initiation of this 
study and details of its construction have already been published (Palmer et al., 
2000; Lilley et al., 2001b). Briefly, the pR20.5 cassette contains a central LATP2 
region (HSV nt\ 18866 to nt\20219; GenBank file HE ICG) flanked by two 
promoters in a back-to-back orientation. Firstly, the CMV promoter (Invitrogen) 
driving the expression of eGFP (Clontech) and secondly the RSV promoter 
(pRcRSV-Invitrogen) driving the expression of lacZ (Hindlll-BamHI; 
Pharmacia). The pR20.5 expression cassette was flanked by vhs gene sequences 
[HSV1 w/90313 (Kpnl) - «/91854 (Nrul) and w/91854 (Nrul)- «/93660 (Hpal)\ 
and this construct was termed pR20.5vhs. Vector 1764/ICP277P27ICP4’ 
/pR20.5vhs (designated HSVl.pR20.5vhs for the purpose of this thesis and 
depicted in Figure 3.3.1-a, page 135) was constructed by homologous 
recombination of the pR20.5vhs cassette into the UL41 gene in the HSV1 
genome. The cassette was recombined into the unique Nrul site (HSV1 h/91854) 
resulting in the insertional inactivation of the UL41 gene (Thomas et a l , 1999; 
Palmer et al., 2000; Lilley et al., 2001b).
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3.2.1.3 Vector 1764/ICP277ICP47pR19CMV(HSVl.pR19CMV)
The construction of the pR19CMV cassette has been previously described 
(Palmer et al., 2000). Briefly, lacZ was cloned from pCHllO (Hindlll-BamHI; 
Pharmacia) and the full length CMV promoter from pcDNA3 (654bp; 
Invitrogen). In the GFP versions of the pR19 cassette the gene was the eGFP 
(Clontech) version. The cassette was cloned into the HSV1 LAT region using a 
3.5kb Notl fragment (HSV1 nt\ 18,443 to 122,029) inserted into pGem5 plasmid 
(Promega). The pR19CMV cassette, with either GFP or lacZ, was cloned 
between the BstXI sites (HSV1 h/120,219 to h/120,413). For the construction of 
the recombinant vectors the pR19CMV cassette, expressing either LacZ or 
eGFP, was recombined into the two endogenous LAT regions between the two 
BstX I sites (HSV1 n t\20,220 - nt\20,408) of the fully disabled backbone 
(1764/ICP277ICP4"; Figure 3.3.2-a, page 138). The pR19CMV cassette was 
inserted in both endogenous LAT regions and therefore exists in two copies in 
each recombinant genome.
3.2.1.4 Vectors 1764/ICP277ICP47RL1+ & 1764/ICP27+/ICP47RL1+
As discussed in section 3.2.1, both these vectors were produced by Dr J. Palmer 
and their details have not yet been published. Both ICP34.5 and ICP27 genes 
were sequentially reinserted into their original locations into the viral genome. 
Both genes were inserted via homologous recombination with appropriate 
plasmid constructs.
3.2.2 Cell culture and high titre viral stock production
Production of high titre viral stocks, suitable for in vivo inoculation was carried 
out as outlined in the methods section and was based on the use of the 27/12/M:4 
cell line. This was a BHK-derived cell line designed to complement the high 
level of deletions in essential genes in the 1764/ICP277ICP4' deletions (Thomas 
et al., 1999). The 27/12/M:4 cell line is specifically designed to propagate 
vectors that carry mutations in the vmw65 and ICP4 genes. Firstly, it encodes a 
non-HSVl homologue of the vmw65 gene derived from the EHV1 gene 12. 
Secondly, complementation for the ICP4 deletion is achieved via the inclusion of
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plasmid pMAMZeo/ICP4 that allows for the expression if ICP4 [HSV1 
«/127,167-«/131,187 (MseI - Rs/EII)] under the control of the MMLV promoter. 
The complementing capacity of this cell line was maintained by ensuring that 
passaged cells were maintained in 800pg/ml of neomycin (G418) and 750 pg/ml 
of phleomycin D1 (Zeocin; Cayla, Toulouse, France). 3mM HMBA was 
included in the growth media of viruses as they contained the ml 814 mutation. 
Details of stock production, concentration and purification are detailed in 
Chapter 2.
3.2.3 In vivo transgene delivery via disabled viral vectors
The experiments described in this Chapter aim to explore the ability of the 
variably disabled vectors described in section 3.2.1 (page 126) to achieve 
maximal transgene delivery to the CNS and the spinal cord in particular. Even 
though there are subtle technical differences between them, the experiments 
described here were carried out primarily in uninjured animals with the
exception of vector HSVl.pR19CMV that formed the basis of future,
neurotrophin expressing vector construction and is therefore examined for its 
ability to deliver genes to the acutely and chronically injured spinal cord 
(sections 3.3.2, page 137 and 3.3.3 page 151).
3.2.3.1 Spinal cord lesions prior to vector delivery
All experiments were carried out on deeply anaesthetised adult Lewis rats 
(~200g). Before proceeding further, all animals were given a subcutaneous dose 
of the analgesic Finadyne (2.2 mg/kg, Schering-Plough). A longitudinal incision 
was made along the spine at either the cervical or lumbar level. This was 
followed by a deeper incision, separating the superficial muscle layers and 
further dissecting the deeper muscle layers by blunt dissection. The vertebrae 
were exposed and a bilateral laminectomy was performed using malleus scissors. 
The dura matter was then cut with micro-scissors. In cases where no injury was 
required, the procedure continued as outlined in the following section (3.2.3.2, 
page 130), and the virus under consideration was delivered. Alternatively, a 
lesion of the corticospinal tract (CST) was performed prior to virus delivery.
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Using irridectomy scissors, an incision severing both the ascending dorsal 
columns and the dorsal corticospinal tracts and extending to the central canal 
was performed. The dura and overlying muscle tissue was repaired using silk 
sutures prior to closing the skin with Michel clips.
3.2.3.2 Spinal cord Microinjection of disabled HSV1 vectors
Injections were carried out as described in the general methods Chapter (Chapter 
2, section 2.7.3). Briefly, a 25pi Hamilton syringe fitted with a fine needle (outer 
0  300 pm) was used to administer the vector at a 1.5 mm depth into the 
uninjured spinal cord or within the lesion site in CST lesioned animals. Viral 
suspensions were injected at a rate of 0.5 pl/min using a micro-pump. The spinal 
cord lesions described in this Chapter vary depending on which vector was being 
compared and their deletions. Therefore, each of the results sections briefly 
outlines the nature of the experiment conducted and the relevant lesion that was 
performed. In the spinal cord injection experiments described here the majority 
of animals had not received a lesion prior to being inoculated with the vector 
under consideration. In section 3.3.3, the transgene delivery achieved with vector 
HSVl.pR19CMVLacZ was evaluated in the setting of a CST lesion which was 
performed either immediately prior or one month following the lesion.
3.2.3.3 Vector microinjection into the cerebellum of adult rats
Injections were carried out as described in the general methods Chapter (Chapter 
2) and in the previous section. Briefly, a 25pi syringe fitted with a fine needle 
(outer 0  300pm) was used to administer the vector at a 4 mm depth into the 
cerebellum. Again, viral suspensions were injected at a rate of 0.5pl/min using a 
micro-pump. The coordinates used for the injection were: Rostral-Caudal: 
11.5mm using bregma as zero, Medial-Lateral: 1.5mm, Dorsal-Ventral: 3 - 5mm.
3.2.4 Detection of viral mediated marker gene transduction
Vector mediated neuronal transduction following an in vivo delivery was 
assessed based on the expression of either LacZ or GFP. Detection of the marker 
genes was carried out as outlined in the methods section (Chapter 2). Briefly,
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GFP was visualized under fluorescence as soon as tissue was sectioned while 
LacZ expression was based on the detection of p-gal detection. Sections were 
incubated at 37°C with the 0.1% solution of X-gal in a solution containing 5mM 
potassium ferrocyanide, 5mM potassium ferricyanide and 2mM MgCfy It is 
worth pointing out that vector HSVl.pR20.5vhs is capable of expressing both 
LacZ and GFP.
3.2.5 Mapping of LacZ gene expression in virally transduced neurons
Both spinal cords and brains from injected animals were extracted three weeks 
post inoculation. Spinal cords were sectioned transversely at 40pm thickness 
while brains were again cut into coronal sections of 100pm thickness. After they 
were reacted for the presence of LacZ, as outlined in the previous section, all 
sections were mounted onto slides maintaining their correct sequence. Each 
section was then inspected for the presence of LacZ positive neuronal somata. 
All sections, spinal cord or brain that contained LacZ positive neuronal somata 
were drawn onto tracing paper using a camera Lucida attached to a microscope. 
Each of the neuronal groups were then identified using a reference atlas 
(Paxinos, 1994). These results are collectively presented in section 3.3.3, page 
151.
3.2.6 GFAP and 0X42 Immunostaining of spinal cord sections
As shown in section 3.3.2 (page 137) 40 pm thick spinal cord sections, 
previously reacted for the presence of LacZ, were subsequently immunolabelled 
for GFAP and 0X42. For GFAP staining a monoclonal, anti-GFAP (clone GA5) 
antibody was used at a 1:600 dilution (Sigma Chemical Company, Ltd, Poole, 
Dorset, UK). Similarly, for identifying activated microglia a mouse anti-rat 
0X42 (clone CD11) antibody was used at a dilution of 1:200 (Sera-Tech 
Biologicals Inc.). The preparation of spinal cord sections, as well as the steps 
taken for each of the above immunolabelling procedures is described in the 
methods section (Chapter 2). One type of negative control was employed in each 
of the immuno-histochemistry techniques described in this Chapter. For either 
GFAP or 0X42 staining, three LacZ-stained sections for each procedure were
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isolated and processed as normal but the primary antibody incubation step was 
omitted. On processing, neither of the secondary antibodies at the dilutions 
detailed above led to any non-specific staining (results not shown).
3.2.7 Histological characteristics of CNS resident cells
The discrimination between neuronal and non-neuronal cell populations in this 
thesis was based mainly on morphological appearance. Findings were referenced 
against well-documented histological features (Young and Heath, 2003).
N e u r o n s  display great morphological variation depending on which part of the 
nervous system they reside in. Despite this, all cells share the same basic 
structure with a large soma (30-50pm wide), a relatively large and eccentrically 
placed nucleus and a prominent nucleolus. Neuron somas give rise to a slender, 
straight axon and characteristic highly branched dendritic trees.
A s t r o c y t e s  have small round to oval cell bodies that are <10pm wide with 
evenly dispersed, pale chromatin and they are present in both grey and white 
matter. They have a star-shaped appearance, imparted by the multipolar, 
branching cytoplasmic processes that emanate from the cell body containing the 
characteristic cytoplasmic protein, GFAP. Overall, they have a pale cytoplasm 
that is rich in Golgi complexes and GFAP. The GFAP filaments are either 
aggregated in fascicles {protoplasmic) or diffusely dispersed throughout the 
cytoplasm (fibrous astrocytes).
O l i g o d e n d r o c y t e s  have a denser, more homogeneous chromatin, found 
within a small, characteristically round, lymphocyte-like nucleus. They are small 
cells (~8pm wide) and their cytoplasm contains a large number of mitochondria, 
microtubules and lysosomes. They vary in morphology from large euchromatic 
nuclei and pale cytoplasm to heterochromatic nuclei and dense cytoplasm. In 
sections where oligodendrocytes have been transduced by a LacZ expressing 
vector, these cells can be distinguished by their nuclei and their processes which 
wrap around numerous adjacent axons.
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M i c r o g l i a  are small cells (5-8pm wide) with very little cytoplasm, which 
forms fine, short and highly branched processes. They have an elongated, 
irregular shaped nucleus with clumped chromatin. In response to injury, 
microglia lose their ramifications and transform into large amoeboid phagocytes 
(Figure 1.3.2-c) (Stence et a l, 2001).
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3.3 Results
3.3.1 Characterization of the fully disabled HSVl/P2\pR20.5v&s
The only available construct thought to be suitable for gene delivery to the 
injured spinal cord at the time when this study was initiated was vector 
1764/ICP277P2TCP47pR20.5v/w (HSVl/P2\pR20.5v/*.s). As depicted in Figure
3.3.1-a, this construct is based on the use of the pR20.5 expression cassette that 
allows for the simultaneous expression of two separate transgenes (Palmer et a l , 
2000). In theory, this would make monitoring of transgene expression in vivo 
easier compared with other options such as “tagging” the neurotrophin. 
Additionally, as discussed in the introduction, the fully disabled backbone 
seemed suitable for delivery to the spinal cord in particular due to its minimal 
cytotoxic effects to cultured DRG or hippocampal neurons (Palmer et al., 2000; 
Lilley et al., 2001b). The ability and efficiency of HSVl/P2\pR20.5v/zs to 
transduce spinal cord neurons to express both LacZ and GFP in adult rats was 
evaluated. Adult rat spinal cords (n=6) were inoculated with 2.5x104 pfu of 
HSVl/P2\pR20.5v/zs at the L4-L5 level. Transduced cells were identified based 
on the criteria listed in section 3.2.7.
As it can be seen in Figure 3.3.1-b (adjacent sections shown) infected cells can 
express both GFP (Ai) and LacZ (Aii) transgenes at the one-week time point. 
Interestingly, this vector does not appear to preferentially transduce neurons 
despite the innate neurotropism of HSV1. As shown in the enlarged panels in 
Figure 3.3.1-b, HSVl/P2\pR20.5v/is can transduce neurons (Bi & ii) as well as 
glial cells (Biii) around the injection site. This is not surprising since HSV1 is 
innately able to infect glial cells as they too express heparan sulphate 
proteoglycan which allows viral particle attachment (Vahlne et al., 1980; Marsh 
et a l , 2000). Even though microscopically there appeared to be both astrocytes 
and oligodendrocytes transduced these were not differentiated with cell specific 
markers such as GFAP or Myelin Oligodendrocyte Specific Protein (MOSP). 
Some neuronal cells display a distinct peri-nuclear and punctate LacZ staining 
pattern (Figure 3.3.1-b, panel Bii, !) indicative of low level LacZ expression or 
localisation in defined cytoplasmic structures (Ho and Mocarski, 1989).
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A. HSV1/P2\pR20.5v/w
*
ii
B. HSV1/P2 .pR20.5v/is high power
F igure 3.3.1-b: H SV l/P2 '.pR 20.5v/ts m ediated expression o f  G F P  and  LacZ  in sp inal cord .
M icrographs o f  spinal cord sagittal sections, showing GFP (Ai, Bi) and LacZ (Aii, Bii and iii) 
expressing transduced cells at the one-week tim e point, located close to the injection site o f  
H SV l/P2-.pR 20.5vhs (2.5x104 pfu). H igher magnification o f  cells in other sections reveals that 
there was transduction o f  both neurons (Bi, ii) and glia (Biii). Arrow  indicates punctate staining 
in spinal cord neurons (Injection site *).
Scale bars: A ii=50pm , applies to Ai; Bii=40pm, applies to Bi, Biii=15pm.
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3.3.2 Characterisation of the highly disabled HSVl.pR19CMV vector
Unlike HSVl/P2'.pR20.5v/w, HSVl.pR19CMV (1764/ICP277ICP4' 
/pR19CMVLacZ) contains two copies of the pR19CMV cassette with a single 
transgene under the control of the CMV promoter. Each pR19CMV expression 
cassette is inserted into each of the two endogenous regions of the viral genome 
(Figure 3.3.2-a, page 138). The properties of HSVl.pR19CMVLacZ in terms of 
transgene delivery were examined following a single injection of 2.5x105 pfu at 
the C6-C7 level of the adult rat spinal cord (n=6). At the three-week time point, 
transgene expression in the spinal cord was evaluated.
Prior to proceeding, it is important to point out that, as Figure 3.3.2-b (page 139) 
demonstrates, incubating spinal cord sections with X-Gal stain does not result in 
non-specific LacZ staining. This is true when animals have been injected with 
2.5xl04 pfu of vector HSVl.pR19CMVGFP (n=l) (Figure 3.3.2-b, panel i), or 
DMEM (n=l) (Figure 3.3.2-b, panel ii), which is used in viral stock formulation. 
The only area that develops some pale blue discolouration is the choroid plexus 
but that is very rare and occurs mostly following direct inoculation into the brain 
parenchyma (personal observation, results not shown). However, this is only 
observed following incubations in X-Gal buffer that are allowed to proceed for 
longer than 8 hours and can be exacerbated in the presence of 5% CO2. It could 
be argued that since the injection process in itself does cause some tissue damage 
in the animals examined, it would be reasonable to suggest that injuring the 
neural tissue does not lead to any non-specific LacZ staining.
Preliminary experiments using a GFP expressing construct of the 
HSVl.pR19CMV backbone demonstrate that a single 2.5x104 pfu inoculation 
(n=2) is sufficient to maintain GFP expression for at least one month following 
inoculation (Figure 3.3.2-c, panel i). On the contrary, a single 2.5x104 pfu 
inoculation with HSVl/P2\pR20.5v/zs vector (n=2) does not lead to any 
transduction at the same time point (Figure 3.3.2-c, panel ii). The fact that GFP 
expression is under the control of the same promoter between the two vectors 
demonstrates that the differences in expression patterns at the one-month time 
point are due to differences between the two backbones rather than the 
expression cassettes themselves.
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i. HSVl.pR19CMVGFP ii. DMEM
(stained for LacZ)
Figure 3.3.2-b: LacZ staining on HSVl.pR19CMVGFP & DMEM injected animals.
This control experim ent aimed to dem onstrate the lack o f  LacZ staining in X-Gal processed 
sections from H SV l.pR19C M V G FP (2 .5 x l0 4 pfu) & DMEM injected animals. Longitudinal 
spinal cord sections reacted with X-Gal stain show no LacZ reaction product. 
H SV l.pR 19C M V G FP (i) and DMEM (ii) were injected at the C6-C7 level o f  the spinal cord. 
Scale Bar: 250pm , injection site *.
i. HSVl.pR19CMVGFP ii. HSV1/P2 .pR20.5vAs
Figure 3.3.2-c: HSVl.pR19CMVGFP & HSV1/P2 .pR20.5v/is expression, 1-month p.i.
Sagittal sections o f  C6-C7 spinal cord previously injected with either vector 
H SV 1 .pR 19CM VGFP (i: 2.5x104 pfu, n=2) or vector H SV l/P2\pR 20.5v/w  (ii: 2.5x104 pfu, n=2) 
dem onstrating that only H SV l.pR19C M V G FP transduced cells express the GFP marker gene at 
one-month post injection. Bright axonal processes and cell somata are present (i). Scale Bar: 
250pm, injection site *.
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It was therefore decided that assessment of the expression patterns achieved with 
either of these vectors could be further characterised using the LacZ rather than 
GFP marker gene as this would provide a more permanent record at the longer 
time point of one month. Figure 3.3.2-b (page 139) shows that despite the fact 
that HSVl.pR19CMV vector carries the same deletions in the IE genes ICP4 and 
ICP27 as vector HSVl/P2\pR20.5v/w, it displays a different pattern of transgene 
expression. A three cm, longitudinal spinal cord section (displayed in panel A) 
clearly demonstrates that this vector retains the innate ability of HSV1 to be 
retrogradely transported from the injection site, along axonal processes to reach 
the neuronal somata. The neurons transduced are not only spinal cord neurons 
within the injection site (panel D) but also sensory neurons in ipsilateral DRGs 
(panel C) as well as neurons located at the medulla, pons and midbrain level that 
also project in the vicinity of the inoculum (panel B). The exact nature of these 
neurons is examined in section 3.3.3 (page 151). HSVl.pR19CMVLacZ 
appeared to confer significantly better expression than that observed with vector 
HSVl/P2\pR20.5v/is. It was therefore decided to examine the transgene 
expression achieved with each of these two vectors in parallel. Again the same 
parameters were used and each vector was delivered at the C6-C7 level of adult 
rats via a single 2.5x104 pfu inoculation. It is important to clarify here that the 
number of virus particles utilised for the comparison of the two vectors was 
adjusted so that an equal amount of virus was delivered in each group of animals. 
This was necessary, as the HSVl/P2\pR20.5v/wv vector could not be grown at as 
high a titre as the HSVl.pR19CMVLacZ vector. Neuronal transduction was 
evaluated at 3 days, 2 weeks and 1 month (n=4 per vector, per time point). 
Figure 3.3.2-e (page 143) demonstrates that the two vectors vary in their ability 
to support transgene expression at one-month post inoculation. The compilation 
in Figure 3.3.2-e represents the best examples of each batch of animals, per time 
point. Even though there were some differences between animals in each group, 
these were not extensive enough to suggest that there were big variations in the 
amount of virus delivered via the current protocol. Vector 
HSVl.pR19CMVLacZ (panels B) appear to not only transduce more spinal cord 
neurons around the lesion site but also to support the expression of LacZ for at
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Figure 3.3.2-d: HSVl.pR19CMVLacZmediated neuron transduction in the spinal cord.
A. Very low magnification micrograph of a longitudinal (80pm) section through the C6-C7 
level spinal cord of a rat that had received an injection of HSVl.pR19CM VLacZ (2.5x105 pfu). 
LacZ expression is strong in both somata and axons (dark blue/black) in both grey matter (red) 
and white matter (pale central region) with evidence of retrograde transport to neurons 
projecting to the injection site (*). The inset shows a serial section of the injection site and the 
adjacent region, which is revealed at higher magnification in panel D  where neurons and axons 
display strong LacZ transduction. B. Transduced neurons in the pons, medulla and midbrain 
levels below the dark red granule cell layer of the cerebellum of the same rat. C. Strongly 
transduced neurons and axons (1) within the ipsilateral DRG project to the injection site
Scale bars: A=400pm, inset 300pm; B=lmm; C= 150pm; D =  100pm.
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Figure 3.3.2-e: HSVl/P2-.pR20.5/vhs versus HSVl.pR19CMVLacZ transduction.
HSVl/P2'.pR20.5v/w (2.5xl04 pfu) (A) or HSVl.pR19CMVLacZ (2.5xl04 pfu) (B) were 
inoculated at the C6-7 level. LacZ expression was examined on longitudinal (40pm) sections at 
3 days (i), 2 weeks (ii) and 1 month (iii) later. LacZ expression achieved with 
HSVl.pR19CMVLacZ is more widespread, stronger at the one month post-administration and 
selective to neurons compared with HSVl/P2‘.pR20.5v/w, which mediated weaker transduction 
in neurons and glia. The insert panels in each photograph depict examples of transduced 
neurons at higher magnification (Injection site *).
Scale bars: Ai=250pm, applies to Aii & Aiii; Bi=250pm, applies to Bii & Biii; all insets, 
200pm.
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least one-month, the longest time point examined (panel Biii). Between the 
three-day (panel Bi) and two-week (panel Bii) time points there was a gradual 
and subtle decline in LacZ expression that was continued in the later time point 
of one month. In contrast to the HSVl.pR19CMVLacZ vector, the HSV1/P2' 
.pR20.5v/w construct was not able to support the expression of LacZ in the long 
term. LacZ levels declined sharply between the three-day (Ai) and two-week 
time point (panel Aii) but was absent by the end of the one-month time point 
(panel Aiii).
The initial promise that vector HSVl.pR19CMVLacZ demonstrated as a CNS 
gene therapy tool was reinforced when its performance was tested in animals that 
had previously received a dorsal column lesion in L4-L5 (n=4, Figure 3.3.2-f, 
panel Aii, t)- Two weeks following the lesion, all animals were inoculated with 
2.5x105 pfu of HSVl.pR19CMVLacZ vector and the expression of LacZ was 
examined three weeks later. A whole mounted spinal cord (panel Ai) emphasises 
the strong levels of transgene expression surrounding the injection site (panel Ai, 
insert). In addition, LacZ stained neuronal processes can be seen leaving the 
spinal cord and entering either the dorsal or ventral root (panel Ai, V). The 
extent to which DRG neurons were transduced varies depending on the location 
of the injection site. For example in another animal, transduced DRG neurons 
can be seen next to a very strongly stained ventral root (both ipsilateral), 
indicating a very efficient transduction of ventral spinal cord motor neurons 
(panel Aiii, ▼). This is easier to see in a coronal section from the same animal. 
Here, ventral spinal cord motor neurons can be seen next to their axons (panel 
Aii, V). Unfortunately, despite repeated attempts at trying to transduce CST 
neuronal somata by modifying the delivery parameters to the spinal cord, such as 
altering the injection depth or delivering the same viral load in multiple aliquots, 
it proved an unattainable target. This inability to transduce neurons was 
somewhat unexpected at the time. However further investigations from projects 
carried out in parallel to this study did throw some light into the reasons behind 
this expression feature (further discussed in section 3.4). Importantly, the pre- 
lesioning of the spinal cord does not seem to affect the retrograde virally 
mediated transduction of brain stem neurons projecting to the injection site
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(panel Aiv). Looking closely at the tissue surrounding the 
HSVl.pR19CMVLacZ injection site (Figure 3.3.2-d, panel D, page 141 & 
Figure 3.3.2-e, panel Bi, page 143), there appears to be a distinct lack of 
transduced glial cells. This is in direct contrast to the pattern observed with the 
HSVl/P2\pR20.5v/w vector (Figure 3.3.1-b, page 136, panel Biii & Figure
3.3.2-e, panel Ai, page 143). It is possible that the HSVl.pR19CMVLacZ vector 
also displays a predilection for glial cells. However this may be difficult to detect 
due to the strong LacZ staining seen within cells around the injection site.
It was also decided to investigate whether the expression of high level of LacZ 
would cause inflammation in the in vivo CNS environment. In order to take a 
closer view at the transduced neurons, non-lesioned animals were injected with 
2.5x105 pfu of HSVl.pR19CMVLacZ vector (n=4) and 21 days later were 
stained with LacZ and examined for the presence of astrocytes and microglia at 
the lesion site. Coronal sections from the same HSVl.pR19CMV transduced 
animal shown in Figure 3.3.2-f, was stained with GFAP for astrocytes (panel Bi- 
iii) and 0X42 for the presence of microglia (panel Biv-vi). At low magnification 
it is evident that the motor neurons of the left hand side ventral horn are strongly 
expressing the transgene (panels Bi). Note that the transduction pattern was 
unlike that seen in the lesioned animal depicted in the coronal section in panel 
Aii, which displays bilateral ventral horn staining. This is because in the case of 
the animal in panel Aii the injection took place closer to the midline thus 
reaching bilateral groups of ventral horn motor neurons. The animal sections 
shown in panel B however received the injection deep into the left hand side 
ventral horn. The injection site, which can be seen at low (panels Bi & iv) and 
high magnification (panels Bii, iii, v & vi), has caused a significant local 
disruption (panel Bii & v) but its cause is thought to be mechanical and 
attributed to the flexible needle used to carry out the stereotactic injection, 
further discussed in section 3.4 (page 166).
Close inspection of the GFAP staining pattern demonstrates that even adjacently 
to a cluster of LacZ expressing neurons, there is a lack of transduced astrocytes
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(panel Biii). None of the GFAP stained astrocytes were found to be expressing 
LacZ (panel Biii, j ). Admittedly, the pattern observed in this particular section 
may not be a true representation of the whole of the transduced spinal cord. 
However, it is fairly obvious that this vector displays a strong neuronal 
preference.
In terms of the astrocyte morphology, there appeared to be a somewhat stronger 
labelling at the edges of the immediate injection site where most of the tissue 
damage has occurred (panel Bii). These astrocytic processes appeared to be 
denser and more elongated while their cytoplasm is more strongly stained for 
GFAP compared to areas distal to the area of mechanical damage. Thick 
astrocytic processes were present in the area of maximum tissue damage (panel 
Bii, <—) amongst the LacZ stained axons of ventral motor neurons seen within 
the injection site (panel Bii, T).  The astrocytes surrounding the virally 
transduced neuronal somata appear to be less densely stained for the presence of 
GFAP, with finer processes and a paler cytoplasm (panel Biii, I  ’ ’ ). Overall, 
there does not seem to be gross evidence of reactive astrogliosis around the 
neuronal somata that would be indicative of viral or transgene toxicity.
In addition to the LacZ and GFAP staining, the same sections were stained for 
the presence of the microglia/macrophages using the 0X42 marker (Figure
3.3.2-f, panels Biv-vi). It should be emphasised here that 0X42 does not 
distinguish between microglia and infiltrating macrophages and although the 
intensity of 0X42 staining is greater on activating microglia, resting cells are 
also OX42-positive. Nevertheless, 0X42 staining was maximal at the site of 
injection where tissue damage was severe (panel Biv) and appears to correlate 
with the boundaries of the necrotic region. Given the fact that there is such a 
strong LacZ expression in neurons of the left ventral horn it was somewhat 
surprising not to see a high level of 0X42 immunofluorescence around the 
neuronal somata due to the levels of the P gal protein produced. It should be 
acknowledged that this crude technique does not rule out the possibility that 
there is at least some peri-neuronal inflammation that could be seen using a more
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sensitive detection method. It is however plausible to suggest that with such high 
levels of transduction, both in terms of the number of neurons transduced but 
also in terms of the levels of the foreign gene expressed from transduced 
neurons, there was no significant microglia/macrophage presence around the 
neurons themselves. This indicates that there is little cytotoxicity with this 
vector.
Perhaps it would have been more appropriate to examine more closely the 
morphology of microglia in the grey matter and especially the areas surrounding 
the transduced neurons for evidence of activation such as loss of ramification or 
expression of activation specific markers such as EDI. There is, however, a high 
number of microglia/macrophages in the area of the injection site. It is most 
likely that these are infiltrating macrophages responding to the mechanical 
damage (panel Bv & vi). On higher magnification (panel Bvi) the majority of the 
cells within the injection site displayed a rounded morphology typical of 
infiltrating macrophages (panel Bvi, f 1“).
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Figure 3.3.2-f: 0X42 & GFAP staining of HSVl.pR19CMVLacZ transduced SC neurons.
A. Vector HSVl.pR19CMVLacZ (2.5xl04 pfu) was injected at the L4-L5 level of a pre- 
lesioned spinal cord. LacZ expression in transduced neurons is strong as it is observed in a 
whole mounted spinal cord (Ai inset shows higher magnification of the transduced spinal cord 
region). Ventral, spinal cord motor neurons are transduced and can express the transgene for at 
least 21 days (Aii). DRG (Aii) and brainstem (Aiv) neurons projecting to the lesion site are also 
retrogradely transduced.
B. The same spinal cord section was processed sequentially for LacZ, GFAP (light brown, Bi- 
iii) and 0X42 (green, Biv-vi). Around the LacZ expressing neurons (dark blue) the GFAP 
positive astrocytes (Biii) appear to have a normal morphology while there is a lack of 0X42 
upregulation (Bvi). 0X42 (Biv-vi) immunoreactivity is however enhanced at the site of tissue 
destruction and is suggestive of the presence of activated microglia or infiltrating macrophages 
(Axonal processes ▼, astrocytes I, infiltrating macrophages J,°, Injection site *, lesion site t ).
Scale bars: Ai=800pm, inset=250pm; Aii=350pm; Aiii=200|im; Aiv=400|im; Bi=800|im, 
applies to iv; Bii=50pm, applies to v; Biii=50pm, applies to vi.
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3.3.3 Examination of HSVl.pR19CMV mediated transduction
As shown in the previous sections the HSVl.pR19CMV vector retains the innate 
ability of HSV1 to be retrogradely transported from axonal terminals to the 
corresponding neuronal somata. Prior to initiating any regeneration experiments 
utilising this vector it was thought necessary to explore exactly what types of 
neuronal populations could be transduced following a single injection in the 
spinal cord at the lumbar level. This series of experiments presented the 
opportunity to also explore whether the virus behaved differently in terms of 
which populations are transduced when it was injected into an acutely or 
chronically lesioned spinal cord.
Animals were split into three groups. Each group was assigned three animals and 
each animal within each group received a single injection of 2.5x105 pfu of 
HSVl.pR19CMV vector into the L4-5 level. Group A (n=4) only received the 
vector inoculation. Groups B and C (n=4 each) first received a dorsal column 
hemisection lesion at the L4-5 level. Group B was injected with the same amount 
of vector two weeks following this lesion while Group C received the vector 
immediately after the lesion was performed. All animals were sacrificed three 
weeks following vector inoculation and the expression of the transgene was 
mapped from spinal cord through to the brain.
The figures in the following pages are compiled by selecting representative 
drawings from the animal that demonstrated the best transduction in each of the 
treatment groups. On the whole, vector HSVl.pR19CMVLacZ transduces a 
variety of different neuronal types in nuclei including: ventral and dorsal horn, 
reticular formation, vestibular nucleus, locus coeruleus, inferior olivary nucleus, 
inferior colliculus, trigeminal nuclei, Edinger-Westphal and hypothalamic nuclei. 
Overall, there were no obvious differences between the types of neurons that 
were transduced by the HSVl.pR19CMVLacZ vector in the non-injured (Figure
3.3.3-a), acutely injured (Figure 3.3.3-b) and chronically injured lumbar spinal 
cord setting (Figure 3.3.3-c). It must be emphasised that this study was designed 
with the aim of evaluating any major qualitative rather than quantitative 
differences in transduced neuronal populations. In order to confirm that the
151
nature of the neuronal groups transduced in non-lesioned (Group A) and 
chronically lesioned (Group B) spinal cords were similar, one animal from each 
group was selected (Rat A and Rat B respectively). Each of the two selected 
animals demonstrated the strongest and most widespread LacZ transduction 
within its group. Approximately 180 sections per animal were analysed and 
neuronal cell numbers for each neuronal group were counted. The collated data 
for Rat A (representative rat in Group A) and Rat B (representative rat in Group 
B) were tabulated.
Tract Rat A Rat B
Nucleus Tractus Solitarius 2 3
Vestibular Nucleus 11 54
Reticular Formation 82 580
Raphae Nucleus 99 62
Inferior Olivary Nucleus 26 3
Central Gray 36 17
Locus Coeruleus 186 364
Edinger-Westphal 31 5
Trigeminal Nucleus 30 3
Inferior Colliculus 1 10
Medial Geniculate Nucleus 2 5
Ventro-basal Thalamic Nuclei 1 2
Hypothalamic Nuclei 32 4
Table 333-a: HSVl.pR19CMVLacZ mediated transduction of neuronal groups
Number of transduced neuronal cell bodies for each representative rat from the non-lesioned 
(Group A) or injected with vector 2 weeks after a dorsal column hemisection (Group B). Only 
LacZ expressing neuronal somata were counted while LacZ positive axons were not included in 
this table. Note the similar distribution of transduced neurons in disparate brain locations e.g. 
nucleus tractus solitarius in caudal brainstem to hypothalamic nuclei more rostrally.
As it can be seen in Table 3.3.3-a, there are some differences in the numbers of 
transduced neurons even though the same classes of neurons were transduced in 
either of the two representative animals. However, it is more plausible that the 
variation in the numbers noted could reflect normal variations in the method of 
delivering the inoculum rather than variations in the efficiency of transduction 
between the two groups.
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Figure 3.3.3-a: Mapping of HSVl.pR19CMVLacZ expression in the non-injured SC. (Group 
A) N eurons transduced via a single injection in the lumbar spinal cord o f  adult, non-pre-lesioned, 
lum bar spinal cord. T ransduced neurons (show n in red) include: 1: Ventral and dorsal spinal cord 
neurons, 2: V estibular nucleus, raphae nucleus and reticular formation neurons, 3: Reticular 
form ation and olivary nucleus neurons, 4: Trigeminal nucleus and reticular form ation nuclei, 5: 
V estibular and reticular form ation nuclei, 6: Locus coeruleus, reticular formation and olivary 
nucleus neurons, 7: Raphae and trigem inal nuclei, 8: O culom otor and red nucleus neurons, 9: 
H ypothalam ic nuclei. M any o f  these transduced neurons are shown in photom icrographs on the 
adjacent page. Note the sim ilarity o f  location o f  the retrogradely transduced neurons to  that in 
Group B, chronically injured SC Figure 3.3.3-b and in Group C, acutely injured SC Figure 3.3.3-c. 
Scale bars: Spinal cord=500pm ; Locus coeruleus=500pm , inset= 150pm; Raph6=450pm ; 
Reticular form ation=500pm , inset= 150pm; Red nucleus=700pm , inset= 150pm.
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1Figure 3.3.3-b: Mapping of HSVl.pR19CMVLacZ expression in the chronically injured SC.
(G roup  B ) N eurons tran sd u c ed  v ia  a  sing le  in jection  in the  ch ron ically  lesioned  C S T  in the  lum ber 
sp ina l cord . T ran sd u ced  neu rons (show n  in red ) include: 1: V entra l and  dorsal horn  neurons, 2: 
R eticu lar fo rm ation  neu rons, 3: R eticu lar fo rm ation  an d  ves tib u la r nucleus neurons, 4: Locus 
coeru leus, re ticu la r fo rm ation  and  o liva ry  nucleus neurons 5: In fe rio r co llicu lus, locus coeruleus, 
trigem inal and  re ticu la r fo rm ation  nucle i, 6 : E d inger-W estpha l and cen tral g rey  neurons, 7: 
H ypo thalam ic nuclei. M any o f  these  tran sd u ced  neurons are show n in pho tom icrographs on the 
ad jacen t page. N o te  the  sim ila rity  o f  location  o f  the re tro g rad ely  transduced  neurons to  that in 
G roup  A , n o n -in ju red  SC (F igu re  3 .3 .3 -a ) and  in G roup  C , acu te ly  in jured  SC (F igure  3.3.3-c). 
Scale bars: R e ticu la r form ation : low  p o w er= 5 0 0 p m , h igh  p o w e rs  100pm ; Raph6: low  
po w er= 2 0 0 p m , h igh  p ow er=  100pm ; O livary  nucleus: low  p o w er= 2 0 0 p m , h igh  pow er= 50pm ; 
O cu lo m o to r nucleus: low  p o w er= 5 0 0 p m , in se t= 50pm .
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Figure 3.3.3-c: Mapping of HSVl.pR19CMVLacZ expression in the acutely injured SC.
(Group C) Neurons transduced via a single injection in the chronically lesioned CST in the 
lumber spinal cord. Transduced neuronal cell bodies (represented in red) include: 1: Ventral and 
dorsal horn neurons, 2: Reticular formation neurons 3: Locus coeruleus, reticular formation and 
olivary nucleus neurons 4: Locus coeruleus, trigeminal nucleus and reticular formation neurons 
5: Reticular formation neurons 6: Central grey and Edinger-W estphal nucleus neurons 7:
Hypothalamic nuclei. Note the similarity o f  location o f  the retrogradely transduced neurons to 
that in Group A, non-injured SC (Figure 3.3.3-a) and in Group B, chronically injured SC Figure 
3.3.3-b.
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It is important to point out that none of the animals injected with the 
HSVl.pR19CMVLacZ vector, be it non-lesioned, acutely or chronically lesioned 
displayed any cerebral cortical neuron transduction. This was an unfortunate 
discovery in terms of the then envisaged attempts to promote regeneration of the 
CST (discussed in Chapter 4). Even the direct injection of 2xl05 pfu of 
HSVl.pR19CMVLacZ in the cortex itself resulted in the transduction of only 
three cortical neurons (shown in Figure 3.3.4-d, panel A, page 165). However, 
this development was not totally unexpected and the potential reasons for this are 
discussed in sections 3.3.4 and 3.4. At the time that this study was carried out 
there were no other alternatives that could potentially bypass this problem and 
the production of neurotrophin expressing constructs was initiated based on this 
backbone. However attempts at improving the vector backbones continued. As 
this study drew to a close a new generation of vectors became available. Some of 
the preliminary experiments that were carried out showed some promise in terms 
of their ability to target cortical neurons. Some of those results are outlined in the 
following section.
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3.3.4 Minimally disabled pR19CMV based vectors
As detailed in the previous section, the highly disabled vector backbone 
HSVl.pR19CMV was unable to transduce cortical neurons. On the one hand this 
feature is a testament to the non-toxic nature of this construct (Lilley et al., 
2001b) but was also a hindrance in terms of any CST regenerative attempts. 
However, further vector development carried out in our laboratory opened the 
possibility of using less disabled vectors to directly transduce those neurons. As 
this development occurred at the later stages of this study only a few preliminary 
experiments were carried out. These focused on primarily trying to establish 
whether they present a more attractive option for the future. Two vectors were 
considered here: HSVl.RLl+/pR19CMVLacZ and
HS V 1 .ICP27+/RL1 +/pR 19CMVLacZ (Figure 3.3.1-a, panels A & B 
respectively). The two vectors were compared firstly in terms of their ability to 
sustain the long-term transgene expression in the non-injured spinal cord and 
secondly on their ability to directly transduce neurons of the motor cortex.
These vectors displayed a growth advantage and could therefore be produced at
• Q • otitres in the order of 2x10 pfu/ml, which is higher than the 5x10 pfu/ml 
achieved with vector HSVl.pR19CMV. In order to ensure that any differences 
observed with the two new vectors were not attributed to simply injecting more 
viral particles, all spinal cords were inoculated with 2xl06 pfu, which is higher 
than the number of particles injected in the HSVl.pR19CMV characterisation 
experiments. However, it must be emphasised that by the time these injections 
were carried out the purification of viral stocks and also the experimental 
parameters had been perfected to improve reproducibility (not presented here), 
which is likely to have affected overall vector performance. Injections were 
carried out in non-lesioned animals and at the C6-C7 level (n=3 per time point 
per vector). LacZ expression was evaluated at two weeks, one and two months 
post inoculation. The animal with the best transduction selected from each time 
point is presented in Figure 3.3.4-b for vector HSVl.RLl+/pR19CMVLacZ and 
Figure 3.3.4-c for vector HSV1. ICP27+/RLl+/pR19CMVLacZ.
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Figure 3.3.4-a: Schematic representation of RL1+ & ICP27+, HSVl.pR19CMV vectors.
The two vectors depicted above are based on the H SVl.pR19CM V backbone and they have the 
genes ICP27 and ICP34.5 reinserted in the viral backbone (further described in 3.2.1, page 126).
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Figure 3.3.4-b: Effect of R L1+ reinsertion  in H SV lpR 19C M V  m ediated  LacZ  expression. Longitudinal sections o f dorsal (i) and ventral (ii) spinal cord demonstrate virus 
mediated transgene expression with ventral motor neurons strongly expressing LacZ. (Injection site *). H SV l.RLl7pR 19CM V LacZ-m ediated expression was assessed at the 
two-week (Ai & ii), one month (Bi & ii) and two month (Ci & ii) time points following a single injection to the cervical spinal cord (C6-C7). High magnification micrographs of 
transduced neurons are shown in inserts at the lower edge o f  each photograph. Scale bars: Ai=500pm, applies to Aii, Bi, Bii, Ci, Cii; inset= 100pm also applies to all insets.
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Figure 3.3.4-c: Effect o f ICP27 reinsertion  in H S V l.R L l+/pR 19CM V  LacZ expression. Longitudinal sections o f dorsal (i) and ventral (ii) cervical (C6-C7) spinal 
cord showing vector-mediated expression in motor neurons as assessed at 2-week (Ai & ii), one month (Bi & ii) and two-month (Ci & ii) time points. The addition of 
ICP27 in the vector enhanced transgene expression in ventral spinal cord at all time points as compared to the same vector without ICP27 as shown in Figure 3.3.4-b. 
(Injection site *). Scale bars: Ai=500|im, applies to Aii, Bi, Bii, Ci, Cii; inset= 100pm, applies to all insets.
HSVl ,ICP27+/RL 1 +/pR 
19CM 
V
LacZ
For each injection, both ventral and dorsal aspects of the injection site are shown 
to account for differences in the depth of inoculation that could confound the 
number of motor neurons transduced. Interestingly, there appears to be little 
difference between the ability of these two vectors to maintain transgene 
expression in the long term. As it can be seen by comparing Figure 3.3.4-b and 
Figure 3.3.4-c, motor neurons transduced with either vector are capable of 
expressing the transgene for at least two months, which is the longest time point 
examined. In the case of vector HSVl.RLl+/pR19CMVLacZ there does not 
seem to be a significant reduction in the number of motor neurons expressing the 
transgene between the three time points (Figure 3.3.4-b, panels A, B & C). 
However, in the case of vector HSVl.ICP27+/RLl+/pR19CMVLacZ, there is a 
more apparent, yet subtle and gradual reduction in the LacZ positive neurons 
between the three time points (Figure 3.3.4-c, panels A, B & C).
Overall, inoculation of vector HSVl.RLl+/pR19CMVLacZ appears to lead to the 
transduction of fewer motor neurons than its less disabled counterpart 
HSVl.ICP27+/RLl+/pR19CMVLacZ. The number of motor neurons transduced 
at the two-week time point is significantly higher with the 
HSV1 .ICP27+/RLl+/pRl9CMVLacZ vector (Figure 3.3.4-c, panels Ai & ii) 
compared to those transduced at the same time point with vector 
HSVl.RLl+/pR19CMVLacZ (Figure 3.3.4-b, panels Ai & ii). Also, the inserts in 
each illustration demonstrate that despite the disablement, the transduced 
neurons appear to have a healthy morphology. Based on the fact that vector 
HSV 1 .ICP27+/RL1 +/pRl 9CMVLacZ appeared better than vector
HSV 1 .pRl9CMVLacZ and even HSVl.RLl+/pR19CMVLacZ at transducing 
ventral spinal cord motor neurons, it was decided to examine whether it also 
performs better in mediating foreign gene expression in cortical neurons. For this 
experiment, 2.5x105 pfu of vector HSVl.ICP27+/RLl+/pR19CMVLacZ (Figure
3.3.4-d, panel Bi) or vector HSVl.pR19CMVLacZ (Figure 3.3.4-d, panel Ai) 
were injected directly into the motor cortex of adult rats (n=3 per vector). One- 
month post injection, the vector mediated transduction of cortical neurons 
achieved with vector HSVl.ICP27+/RLl+/pR19CMVLacZ is more extensive 
than that achieved with vector HSVl.pR19CMVLacZ. Even though the actual
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number of neurons transduced was not counted accurately, it is evident from the 
images shown that the difference in the numbers transduced is significant. 
Ideally, in terms of spinal cord regeneration experiments targeting the CST tract, 
it would have been more relevant to examine whether CST neurons can be 
retrogradely transduced following a single spinal cord inoculation with vector 
HSV 1 .ICP27+/RL1 VpRl 9CMVLacZ because it obviously presents a powerful 
tool for regeneration experiments. As this important development in vector 
technology came at the closing stages of this study only a few such preliminary 
experiments were carried out. These produced some very promising results that 
are discussed briefly in Chapter 6 of this thesis and are relevant not only to the 
injured spinal cord but also to other tracts of the CNS such as the lesioned optic 
nerve.
As the vectors assessed here are less disabled they are potentially more toxic 
than the fully disabled vectors already discussed. It was therefore decided to 
examine whether either of these vectors were still capable of transducing and 
maintaining marker gene expression for any length of time in cerebellar purkinje 
neurons. These particular neurons were selected due to the fact that they are 
notoriously sensitive to toxic insults. Here they were briefly used to explore 
whether they are receptive to infection by these vectors and whether expression 
of the transgene can be supported for any length of time. 2.5x106 pfu of each 
vector (i.e.: HSVl.RLl+/pR19CMVLacZ or
HSVl.ICP27+/RLl+/pR19CMVLacZ) were injected directly into the cerebellum 
of adult rats (n=3 per vector). LacZ expression was evaluated at the one-month 
time point and the animals with the best transduction are shown in Figure
3.3.4-d. Even though the number of animals used in this brief experiment was 
too small to draw any definitive conclusions about their comparative efficacy, it 
is evident that both vectors have the ability to transduce cerebellar neurons. Both 
HSV 1 .RL1 +/pRl 9CMVLacZ (panel C) and vector
HSVl.ICP27+/RLl+/pR19CMVLacZ appear to successfully transduce purkinje 
neurons as well as processes of the spinocerebellar tract.
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A. HSVl.pR19CMVLacZ
B. HSV 1 .ICP27+/RL1 +/pRl9CMVLacZ
C. HSV l.RLl /pR19CMVLacZ D. HSV1.ICP27+/ R L l+DR19CMVLacZ
Figure 3.3.4-d: C o rtical and  ce rebella r neuron tran sd u c tio n  via pR 19C M V  backbones.
A, B: C e re b ra l cortex, low magnification sagittal sections o f  transduced cortical projection 
neurons close to the injection site (*) o f  vector. Note the limited LacZ expression with vector 
H SV l.pR19C M V LacZ (A) but widespread LacZ expression with vector HSV1.ICP27+/ 
R L l+/pR19CM VLacZ (B). Some o f  the transduced projection neurons are shown at high 
magnification in the separate images at right. Scale bars: A: Left=500pm, Right= 100pm; B: 
Left=500pm, Right= 100pm.
C, D: C erebellum , low magnification sagittal sections o f  cerebellum dem onstrating that both 
HSV 1 .R L 1 +/pR 19CM VLacZ (C) and HSV 1 .ICP27+/R L 1 +/pR  19CM VLacZ (D) constructs appear 
to transduce purkinje neurons ( t )  as well as spinocerebellar tract processes ({) following a single 
2.5x105 pfu inoculation into the cerebellum. Scale bars: C = 1000pm, applies to D.
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3.4 Discussion
The HSV 1 constructs described here were designed with the view of creating a 
platform that could be used to evaluate the potentially therapeutic effect of 
regeneration-promoting molecules and specifically to evaluate their ability to 
promote the survival and regeneration of injured CNS neurons. In this Chapter, 
experiments were designed with the view to screen the available vector 
constructs for their ability to sustain the long-term transgene expression in 
neurons while at the same time demonstrating minimal toxic effects in the CNS 
environment. This is a particularly difficult balance to reach with regards to a 
sensitive but at the same time demanding tissue in terms of regeneration.
The first construct characterised was the HSVl/P2\pR20.5v/zs vector. This 
vector appeared to be capable of transducing neuronal as well as glial cells 
following a single inoculation in the spinal cord which is a natural property of 
the virus (Huang et al., 1992). It could be argued that in this case this noticeable 
preference for glial cell transduction may be artifactual. It could be a reflection 
of an injection that accidentally delivered the majority of the virus in white rather 
than grey spinal cord matter. This is possible as these experiments were carried 
out in the initial stages of this study when the injection technique and related 
experimental parameters where still being perfected. The needle used in all the 
HSVl/P2\pR20.5v/w and only the initial HSVl.pR19CMVLacZ vector 
experiments, was a flexible silicone needle (SilFlex, World Precision 
Instruments, Europe) that was thought at the time to induce less neuronal tissue 
damage. Due to its flexible nature however, stereotactic injections were not 
accurate enough for this type of experiment. Indeed, the use of this model of 
injection needle was at a later date abandoned. It quickly became clear that due 
to its blunt nature, the needle tip induced a compression injury to the spinal cord 
that could confound the regeneration experiments that followed. Still, as 
plausible as this explanation may sound, it is unlikely to be the cause of this glial 
cell preference, as this was not an isolated case. The same expression pattern was 
observed when HSVl/P2\pR20.5v/w vector was compared to the less disabled 
vector HSVl.pR19CMVLacZ (Figure 3.3.2-e, page 143). These experiments 
were the first to be carried out with a standard, rigid stereotactic needle (as
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outlined in the methods section). Even though there were now more neuronal 
cells transduced by the HSVl/P2\pR20.5v/w vector, the majority were still glia. 
The HSVl.pR19CMVLacZ vector displayed a comparatively stringent 
preference for neuronal cells and clearly maintained the innate HSV1 ability for 
retrograde transport to neuronal cell bodies distal to the injection site, not seen 
with the HSVl/P2'.pR20.5W*s vector.
This pattern of cell transduction has been reported by other researchers working 
with HSV1 vectors bearing a similar level of disablement (Marsh et a l , 2000). In 
their case, spinal cord organotypic cultures were transduced to express LacZ 
with a vector that was not as highly disabled as the one used here. Their vector 
was deleted for ICP4 and carried the same m l814 inactivating mutation in VP 16 
(Ace et al., 1989; Johnson et al., 1994; Holmes et al., 2000). This group 
microinjected their construct at a high MOI and also found that despite the 
neurotropism of HSV1, glial cells were also highly transduced to express the 
transgene, which was under the control of a CMV promoter. Marsh and 
colleagues (2000) suggested that the lack of neuronal transduction may have 
been due to the lack of axonal processes in the organotypic cultures. Similar to 
the vector employed by Marsh et al. (2000), vector HSVl/P2\pR20.5v/zs 
described here was capable of transducing mainly neuronal cells in addition to a 
number of supporting cells when tested in organotypic hippocampal cultures 
(Lilley et al., 2001b). Their explanation is therefore plausible for their 
organotypic spinal cord culture system and is in line with the expression seen in 
organotypic hippocampal cultures transduced with the HSVl/P2'.pR20.5v/w 
vector (Lilley et al., 2001b). It does not however address the pattern observed in 
our in vivo spinal cord delivery of the HSVl/P2\pR20.5v/?„v vector, where 
neuronal processes are easily accessible.
A more logical explanation behind this difference may have to do with the levels 
of ICP0, which this virus potentially expresses (Lilley et al., 2001b). It has been 
postulated that this may be the reason behind the fact that the HSV1/P2' 
.pR20.5v/w vector appears to infect different neuronal cell populations in vitro 
and in vivo compared to a less disabled vector such as HSVl.pR19CMV (Palmer
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et al., 2000; Lilley et al., 2001b). As already discussed, vectors such as 
HSVl/P2\pR20.5v/w have some residual levels of ICPO, as they are not deleted 
for this gene. In this case, the levels of ICPO may be too low to detect by 
Western blotting or to cause a microscopically evident toxic effect but the 
protein may be present in sufficient levels to transactivate the exogenous 
promoters (RSV and CMV) present in the pR20.5 expression cassette (Lilley et 
al., 2001b). It is plausible that glial cells have a lower requirement for ICPO in 
order for this to occur compared to neuronal cells. This would explain why the 
less disabled HSVl.pR19CMV vector is seemingly better at transducing neurons 
in vivo. It could also to some extent explain the punctate, peri-nuclear staining 
observed in neurons transduced by the HSVl/P2\pR20.5v/w vector. This 
staining pattern was observed only in neuronal somata and not glia and it may be 
indicative of low level transgene expression (Ho and Mocarski, 1989). This 
could be explained if ICPO levels were sufficient to transactivate the CMV 
promoter in glial but not in neuronal cells. It is very difficult to say with any 
certainty that it is the small changes in the levels of ICPO that make such a 
difference in terms of the vector’s ability to transduce glia rather than neuronal 
cells. Previous researchers in this laboratory have tried to look at the differences 
in ICPO expression between the disabled vectors HSVl/P2'.pR20.5v/w and 
HSVl.pR19CMV. This was done using Western blotting techniques, which are 
perhaps not sensitive enough to detect subtle differences. Nevertheless, there 
appears to be very little difference in the levels of ICPO expressed by either 
vector (Lilley et al., 2001b). However, this pattern of transgene expression and 
the involvement of ICPO were perhaps not investigated accurately enough in the 
in vitro comparison experiments to make this claim. This can be said not only 
because the comparison was made using Western blotting, but also because these 
experiments were based on the principle that by using equal titres for each 
vector, it is possible to compare the ICPO expression patterns for each of these 
vectors. Both vectors were normalised prior to infection of an equal number of 
non-complementing, BHK cells. However, in this case this may not have been 
true. As described previously, the HSVl.pR19CMV vector that contained the 
exogenous cassette in each of the endogenous LAT regions displayed a growth 
advantage and could therefore be propagated at higher titres in culture. To put it
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simply this means that in the case of the HSVl.pR19CMV vector one viral 
particle may have corresponded to one plaque forming unit but in the case of the 
more disabled HSVl/P2\pR20.5v/zs vector more than one particle may equate to 
one plaque forming unit (Lilley, 2000). However, «150 molecules of ICPO are 
packaged into the tegument region of each purified viral particle (Yao and 
Courtney, 1992). It is therefore possible that there was more ICPO protein 
delivered to the infected cells in the case of vector HSVl/P2\pR20.5v/w as more 
particles would be needed to achieve an equal titre to that of HSVl.pR19CMV 
vector. This would mean that there could potentially be some confounding in the 
results obtained, as some ICPO would be delivered rather than produced de novo 
from the vector itself. Overall, the experiments designed by Dr C.E. Lilley to 
detect small differences in IE gene expression were relatively too crude 
considering the subtle differences in ICPO that they set out to detect. Since no 
further investigation has been carried out into the levels of ICPO, it is not 
possible to draw any definite conclusions with regards to the role of ICPO. It 
would be interesting to see whether normalising the two viruses for the number 
of viral particles actually makes a detectable difference in the levels of ICPO.
Another point that becomes apparent from the comparison of the HSV1/P2' 
.pR20.5v/z5 and HSVl.pR19CMV vector backbones is that there is a noticeable 
amount of inflammation around the lesion site. Injections with HSV1/P2' 
.pR20.5vhs almost invariably result in the presence of a central area of necrosis 
just surrounding the injection tract. This is easy to see, both in the case of the 
GFP (Figure 3.3.1-b, panel Ai) and LacZ (panel Bii) stained section. The area of 
inflammation can be identified by the presence of a collection of cellular debris. 
These appeared to be mononuclear infiltrate cells, which would indicate the 
presence of an inflammatory reaction. Interestingly, the same pattern was noted 
in the early experiments carried out with vector HSVl.pR19CMVLacZ as 
demonstrated in Figure 3.3.2-e (panel Bii, page 143). In the later case, the area of 
necrosis was not diffuse but it appears to be prominent. However, later 
experiments with this vector demonstrated a less prominent reaction around the 
lesion site. Both these vectors had previously been reported to be non-toxic to 
embryonic DRG or adult hippocampal cultures, even at high MOIs (Lilley et al.,
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\2001b). Moreover, they have been shown to express minimal amounts of IE 
genes such as ICP22 and ICP47 which if present, can cause host toxicity (Lilley 
et a l , 2001b). It is therefore logical to suggest that the reaction observed in the 
early experiments described here may have been due to the mechanical damage 
inflicted to the spinal cord during the injection procedure, rather than a process 
directed against the vector itself. As discussed already, the injection technique 
employed in the early experiments did cause more tissue trauma than that 
observed in later experiments. Alternatively, the then viral stock production 
procedure was less refined than that employed in the regeneration experiments 
reported in later chapters. For example, the initial stock production of the 
HSVl/P2\pR20.5v/w and later HSVl.pR19CMVLacZ vectors did not include a 
filtration step. Of course, both these vectors were propagated in specially 
designed complementing cell lines (such as the 27/12/M:4 described in the 
methods section in Chapter 2). Western blots have demonstrated that 
complementing cell lines produce large amounts of ICPO, ICP22 and ICP47 
(Thomas et a l , 1999; Lilley et a l, 2001b). Even though cell line products and 
debris were in theory removed from the virus stock during stock concentration 
and purification step (Chapter 2), the method employed at the time was not as 
stringent and contamination with such products could not be excluded. This 
would allow for the possibility that the high titre stocks used here may have been 
causing a local inflammatory reaction. This appears even more plausible when 
one considers the alternative way that these vectors have been used to transduce 
spinal cord motor neurons. Specifically, when the HSVl.pR19CMVLacZ vector 
was delivered to spinal cord motor neurons via a sciatic nerve injection, there 
was minimal presence of cell infiltration around the transduced ventral horn 
spinal motor neurons, hinting to the possibility that these backbones may not be 
immunogenic (Palmer et a l, 2000). This point becomes more evident when one 
considers the sections displaying the injection sites of either 
HSV 1 .RL1 +/pRl9CMVLacZ or HSVl.ICP27+/RLl+/pR19CMVLacZ (Figure
3.3.4-b and Figure 3.3.4-c respectively), which would be expected to have a 
higher level of toxicity since they still retain the ICP34.5 or/and ICP27 genes. 
However, the injection site of these two vectors does not appear to be that much 
different in terms of an inflammatory response compared to the more disabled
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HSVl.pR19CMVLacZ vector. This would point more towards the potential 
implication of stock purity in terms of local tissue necrosis around the 
inoculation site. Finally, given the fact that p-Gal is a large, bacterial protein it 
too in theory has the potential to cause an immune reaction. Throughout the 
experiments carried out by this operator as well as others in this lab, no 
differences were observed in terms of morphology at the lesion site when a GFP 
expressing vector was used. However, this is something that could have been 
examined in greater detail using suitable immunological markers. This had not 
been previously performed and was not formally performed in this study.
Based on the fact that the vectors described here are disabled for different gene 
combinations, it is logical to examine the ways in which the nature of these 
deletions impact on their expression pattern as well as their ability to induce an 
immune reaction from the host. Thinking along these lines, it is possible to put 
forward another reason as to why there appears to be a prominent local reaction 
around the injection site and also why the expression achieved with the 
HSVl/P2\pR20.5v/tt' vector appears to be so short lived. Essentially, the major 
difference between the HSVl.pR19CMV vector and HSVl/P2‘.pR20.5v/M' is the 
location of the cassette. As discussed previously, the ectopic location of the 
pR20.5 cassette (disrupting the vhs gene) appeared to be play a role in the ability 
of the vector to sustain the expression of transgenes in the long term (Palmer et 
al., 2000; Lilley et al., 2001b). The function of the vhs gene is to shut down host 
protein synthesis of molecules that can promote an immune response such as 
interleukin 1 (Suzutani et al., 2000), interferon (Lin et a l , 2004) and MHC Class 
I and II (Hill et al., 1994; Trgovcich et al., 2002) in neuronal cells (Barzilai et 
al., 2006). Therefore the host’s immune system could react more readily to the 
infected cells resulting in the local reaction as well as the loss of a number of 
transduced cells. This could confound the overall expression picture of the 
transgene. The above possibility could also explain the lack of any 
morphologically significant tissue reaction to the inoculum in the case of the less 
disabled vectors. This could be due to the fact that the ICP34.5 protein 
contributes to the immune evasion of vector infected cells by suppressing INFp 
(Pasieka et al., 2006) and MHC Class I and II production (Trgovcich et al.,
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2002) from infected cells. These less disabled vectors do have the ICP34.5 
protein and can essentially suppress the ability of the cell to initiate a local 
reaction. Furthermore, this could explain why these vectors appear to be able to 
sustain transgene expression for at least two months post-inoculation. It is 
possible that the transduced cells are not cleared from the host. That is not to say 
that the HSVl.RLl+/pR19CMVLacZ or HSVl.ICP27+/RLl+/pR19CMVLacZ 
vectors do not display any toxicity to the cells they transduce. As these vectors 
were never used in any regeneration experiments they were not further 
characterised neither by this author nor by the operator that produced them as 
part of a separate project. As a consequence, there are no data that detail their IE 
gene expression patterns or their behaviour in vitro or in vivo. This is something 
that should undoubtedly be addressed prior to the application of these vectors in 
any future CNS regeneration experiments.
Preliminary results illustrated that the HSVl.pR19CMV vector, is overall a more 
promising tool for gene delivery to the CNS and spinal cord neurons in 
particular. A single vector inoculation at the C6-C7 level results in a stable and 
efficient transduction of motor neurons in the ventral horn and sensory neurons 
in ipsilateral DRGs that project to the immediate vicinity of the injection site 
(Figure 3.3.2-d, page 141). Transduced neurons strongly express the marker gene 
for at least 21 days, which was the longest time point tested here. The fact that 
vector HSVl.pR19CMV was unable to transduce cortical neurons at a 
potentially significant level, either by direct cortical injection (Figure 3.3.4-d, 
panel A) or by retrograde transport, was a hindrance in the then envisaged 
regenerative studies, especially as one of the main pathways considered for 
regenerative attempts was the CST. In earlier experiments of other research 
groups it was suggested that the difference in the expression patterns of LacZ 
following intracranial inoculation vary depending on whether the vector is 
replication-attenuated, as in the case of an ICPO deleted vector, or replication- 
incompetent, like the vectors utilised here (Chiocca et a l , 1990). Interestingly, 
this feature appears to be a reflection of the non-toxic nature of the 
HSVl.pR19CMV vector, a notion that is supported in the later experiments 
conducted in this laboratory. Comparing the expression patterns of vectors
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carrying different levels of disablement after a single striatum inoculation it 
becomes evident that the more severe the disablement, the less able the vector is 
to transduce cortical neurons (Chiocca et al., 1990). Analytically, a single 
striatum injection of a 17+/ICP27' virus led to the transduction of both striatum 
and cortical neurons that persisted for 1 month post injection (Lilley et al., 
2001b). This pattern resembles the pattern of LacZ expression achieved with a 
virus that has been deleted for the endogenous ICPO gene (Chiocca et a l , 1990). 
On the contrary, the striatum injection of HSVl.pR19CMV resulted in the strong 
transduction of striatal and substantia nigra neurons but transgene expression in 
transduced cortical neurons appeared to decline sharply after the three day time 
point (Lilley et a l , 2001b). The expression pattern noted in this case resembled 
that achieved with ICP4 deleted vectors (Chiocca et a l, 1990; Maidment et a l, 
1996). It could therefore be suggested that due to their higher toxicity, less 
disabled vectors can perhaps overcome the strong inhibition to viral gene 
transcription which may be present in cortical neurons (Lilley et a l, 2001b). This 
could explain why the less disabled vectors examined here appear to lead to a 
more efficient transduction of cortical neurons.
However plausible the above explanations may seem, they are unlikely to be the 
sole reason for the loss of transgene expression, especially in the case of cortical 
neurons where this occurs so quickly after infection. Early experiments designed 
to examine the toxicity of mutants carrying different mutations in IE genes were 
able to shed some light in their ability to establish a latent infection in host cells. 
Even though the immune system does play a role in terms of the longevity of 
transgene expression (also reviewed in detail in Chapter 7), the apparently quick 
loss of transgene expression in transduced cortical neurons is more likely to be 
due to the repression of promoters rather that the clearance of virally infected 
cells. This statement emanates from the culmination of evidence from research 
carried out by this as well as other laboratories. The experiments exploring any 
potential silencing occurring with our fully disabled vectors in cortical neurons, 
are based on the early experiments by Samaniego et al (1998). Briefly, it was 
demonstrated that the silencing of exogenous promoters in a highly disabled 
virus is attributable to the lack of expression of ICPO. Providing ICPO can re-
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Disabled HSU vector backbones for transgene delivery to the CNS
stimulate the expression of the transgene that is controlled by the exogenous 
promoter (Samaniego et al., 1998). Further experiments carried out in our 
laboratory (non- published data), confirm that indeed the loss of expression from 
cortical neurons so quickly after injection is most likely to be due to the 
repression of transgene expression rather than the immune mediated clearance of 
the vector infected cells.
Firstly, it was demonstrated that two weeks following a striatum injection of 
5xl05 pfu of vector HSVl.pR19CM VLacZ, there may be no LacZ staining but a 
large number of cortical neurons can be found to harbour copies of LAT mRNA 
(performed by Dr J. Palmer and included here as reference, non-published 
material).
Cortex  (t) & S ubstan tia  N igra (J)
The hybridised, sagittal sections shown above, demonstrate the presence of LAT 
mRNA (black staining) in cortical neurons two weeks after 
HSVl.pR19CMVLacZ vector inoculation. Their presence signifies that the viral 
genome is present in cortical neurons but the CMV promoter governing the 
expression of the LacZ marker gene is silenced (Dr C.E. Lilley -  personal 
communication). A different study carried out in parallel to the one described 
here, attempted to replicate the Samaniego et al. (1998) experiments in order to 
prove that it is the exogenous promoter controlling the transgene that is silenced 
and transgene expression can be re-initiated using a vector that is not as highly 
disabled. The striatum of adult rats was injected with the fully disabled vector 
HSVl/P2\pR20.5v/zs and as expected, the LacZ and GFP expression ceased 
within three days. Two weeks later, the same animals were re-infected with 
vector 17+/ICP27', which carried no marker gene. The cortical neurons were now
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able to re-express the LacZ marker gene. Of course this could only have been 
produced if the initial construct was still present within the transduced cells. The 
above experiment supports the notion that the Samaniego principle applies to our 
vectors in vivo and can potentially explain the lack of transgene production in 
these neurons (this work was carried out by Dr C.E. Lilley as part of a separate 
research project and is included here as a reference). This is a suitable point to 
bring up another important issue that was considered at the time these 
experiments were carried out. The marker gene used for most of the experiments 
designed to evaluate the length of transgene expression was PGal. One of the 
criticisms that this work has received in the past is that the choice of this 
transgene may have, to some extent, confounded the outcome of these studies. 
This is based on the fact that the pGal protein is a very stable protein with a long 
half-life of «43 hours, at least in human fibroblasts (Ko et al., 1983). Due to this 
long half-life the LacZ staining can be detected for a very long time and indeed 
some reports suggest that the use of histological staining techniques, such as 
those used here, can not be used reliably to evaluate the activity of the exogenous 
promoter driving its expression at the early stages of latency establishment (i.e.: 
the first twenty one days post transduction) due to the persistence of the existing 
protein rather than the production of new molecules (Margolis et al., 1993; 
Lokensgard et ah, 1994). The normalising factor would be that there are obvious 
differences in between the vectors examined here which would be lost if this was 
the case. It therefore follows that even if there is an element of confounding, then 
this is uniform enough to allow differences between vector constructs to be 
manifested. More importantly, it should be emphasised that the transgene 
expression obtained by the least disabled vectors, was assessed at the two month 
time point by which any LacZ staining present should represent a new and de 
novo synthesis of p-galactosidase (Lokensgard et ah, 1994).
Despite the lack of significant neuronal transduction observed with vector 
HSVl/P2'.pR20.5vfe (Figure 3.3.1-b, page 136) as well as its inability to support 
long-term transgene expression, at the time, it presented the best practical 
compromise between cytotoxicity and in vivo transduction. Given the lack of 
alternatives it was decided to proceed with the production of neurotrophin
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expressing vectors based on this backbone. A panel of vectors expressing NT3, 
BDNF or CNTF in combination with each other or with the marker gene for p 
Gal were constructed and characterised (not presented here). However, due to the 
inability to produce high titre stocks consistently, as well as the lack of long-term 
transduction, it was impossible to draw any firm conclusions with regards to the 
ability of HSVl/P2'.pR20.5v//5 vector-mediated transduction to influence axonal 
regeneration. With hindsight, it might have been more prudent to accept the fact 
that the HSVl/P2\pR20.5v/w backbone was not suitable as a tool for 
regeneration studies targeting the spinal cord and not proceed to the construction 
of neurotrophin expressing versions at that point. Admittedly, as the production 
of the better-suited HSVl.pR19CMV backbone was the subject of another 
research project there were not many alternatives available at the time. It would 
perhaps have been more productive to instead concentrate efforts on first 
perfecting other parameters that could affect the outcome of regeneration studies 
such as improvements in stock purification protocol and addressing the lack of 
reproducibility in the in vivo spinal cord lesioning model or vector delivery 
method. This was instead done in parallel with vector construction but 
admittedly not in a methodical manner.
Su m m ary
The experiments performed in this chapter demonstrate two points. Firstly, 
widespread and more prominent transgene expression is achieved by placing the 
expression cassette within the endogenous LAT region, as is the case with the 
pR19CMV cassette. Secondly, it was shown that a maximally deleted vector 
backbone is less efficient at transducing neuronal cell populations compared to 
other minimally disabled constructs, thus demonstrating that some viral genes 
are involved in mechanisms that favour longer transgene expression
The production of the HSVl.pR19CMV backbone was the first of the highly 
disabled HSV1 constructs that retained the innate ability of HSV1 for retrograde 
intra-axonal transport (Bak et al., 1977) while maintaining a high level of 
transgene expression (Lilley et a l, 2001b), as shown here. The creation of this 
construct presented the first realistic and exciting opportunity to modify the
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injured CNS milieu. The transduction achieved with this vector, even in 
considerably distant sites projecting around and into the lesion site, is strong and 
more importantly, can be maintained for a length of time that could potentially 
affect regeneration studies (Figure 3.3.3-a, b and c). In addition, transduction of 
different neuronal subtypes achieved with this vector is not affected by the 
presence of a lesion in the spinal cord. These features offered a major advantage 
in terms of future regeneration experiments and presented a formidable tool that 
could potentially allow us to explore the function of regeneration related 
molecules targeting tracts such as the CST (Chapter 4), RST (Chapter 5) and 
optic nerve tract (Chapter 6) in axotomising injury paradigms. The chapters that 
follow describe the steps taken to construct neurotrophin expressing vectors 
based on the HSVl.pR19CMV backbone with the view to explore the potential 
of these molecules to influence regeneration in each of these systems.
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C h a pter  4.0
VECTOR-MEDIATED DELIVERY OF NEUROTROPHIN-3 
IN THE INJURED CORTICOSPINAL TRACT
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4.1 Introduction
Damage to the long descending tracts of the spinal cord such as the corticospinal 
tract (CST), is not followed by any meaningful regeneration, in contrast to the 
response exhibited by injured PNS axons. The CST shows very limited sprouting 
following transection (Bregman et al., 1989; Schnell et al., 1994) and a number 
of technically varied attempts have managed to induce only a limited degree of 
regeneration. Unlike some other tracts of the CNS which can regenerate into 
segments of peripheral nerve grafts (Richardson et al., 1980; David and Aguayo, 
1981; Berry et al., 1986; Morrow et al., 1993), CST axons, are notoriously 
resistant to even this regenerative paradigm (Richardson et al., 1982; Ye and 
Houle, 1997; Blits et al., 2000). The particular reasons governing this reluctance 
of CST fibres to regenerate, along with a review of the different attempts made at 
instigating their regeneration and maximising their potential are further examined 
in the introductory segments of this chapter.
Amongst the different approaches applied, neurotrophic factor delivery has been 
extensively studied for its ability to promote regeneration of axotomised CST 
fibres (Lacroix and Tuszynski, 2000; Jones et al., 2001; Sayer et al., 2002; Blesch 
et a l, 2002). Neurotrophin 3 (HDNTF3 or NT3) in particular has been shown to 
be a promising growth-augmenting molecule (Schnell and Schwab, 1993; Schnell 
et al., 1994; Tetzlaff et al., 1994; Grill et al., 1997a; Bradbury et al., 1998; Sayer 
et al., 2002; Zhou et al., 2003; Hagg et a l, 2005). As it was demonstrated in 
Chapter 3, highly disabled HSV1 vectors and vector HSVl.pR19CMV in 
particular (Lilley et al., 2001b), can efficiently support the expression of 
transgenes in both the lesioned and chronically lesioned CST with minimal 
cytotoxic effects. Hence, it presents a suitable means of delivering NT3 since a 
single injection of the vector would ensure neurotrophin production for at least 1 
month in transduced neurons. Unfortunately this vector cannot directly transduce 
CST neurons.
The experiments outlined in this study set out to establish whether delivering 
NT3 to a chronically lesioned spinal cord by means of a highly disabled HSV-1 
vector have a positive impact on CST axonal regeneration. Additionally, and 
based on well documented reports that embryonic E l4 spinal cord segments
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transplanted within the lesion site are capable of inducing regeneration of CST 
fibres in the presence of biologically active NT3 (Schnell and Schwab, 1993; 
Bregman et al., 1997b), the ability of HSVl.pR19CMVrNT3 vector to mediate a 
comparable effect is also investigated. Finally, a brief study on the ability of a 
new generation of minimally disabled vectors to transduce CST neurons via 
either spinal cord or brain inoculation is outlined.
4.1.1 Anatomy of the corticospinal tract (CST) in the rat
Even though in lower mammals such as rodents, the location of the CST is 
anatomically different to that of primates (Lacroix et al., 2004), it has been 
extensively targeted for experimental paradigms focused on regeneration. One 
reason for this is the prime importance of this tract in carrying information 
regarding fine and precise movements. It is the single longest axonal pathway 
within the mammalian CNS and a schematic diagram of its overall location is 
shown in Figure 4.1.1-a. In rats, most CST fibres originate from the primary 
motor cortex (Frl and Fr3) (Tracey, 1994) with only a small proportion 
originating from the sensory cortex (Wise et al., 1979; Tracey, 1994). The CST 
fibres in the adult rat originate from the cell bodies of pyramidal neurons located 
either in layer V of the motor cortex, or to a lesser extent, in layer Vb of the 
primary sensory cortex (Hicks and D'Amato, 1968; Miller, 1987; Joosten, 1997; 
Brosamle and Schwab, 2000). Once generated around embryonic day 15 (E l5), 
(Berry and Rogers, 1965; Miller, 1987), neurons migrate to their final location in 
the cortex and initiate their axonal elongation. From layer V or Vb, axons pass 
through the internal capsule and cerebral peduncle to the ventral pons and on top 
of the pyramids in the medulla. CST axons reach the caudal medulla about the 
time of birth and then decussate (Tracey, 1994). On route, only 2% of CST fibres 
give off collaterals to other nuclei such as the red nucleus, pontine nuclei and the 
olivary complex (Akintunde and Buxton, 1992). From then on, the main tract 
crosses the midline and runs in the base of the dorsal columns (Tracey, 1994). In 
general, fibres originating from pyramidal neurons located in the forelimb areas 
of either sensory or motor cortices project to the cervical enlargement and those 
originating from neurons of the hind-limb area terminate in the lumbar 
enlargement of the spinal cord (Li et al., 1990; Tracey, 1994).
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HSV1 vector-mediated delivery of NT-3 in the injured corticospinal tract
A . O rig ins o f CST neurons & pro jections to the spinal cord
i: Sensorimotor cortex
ii: Cervical enlargement
iii: Lumbar Enlargement
B. D istribution o f CST projections in the sp inal cord
i: Cervical distribution
ii: Lumbar distribution
F igure 4.1.1-a P ro jections of the CST in the rat.
A: CST fibres originate from the sensorimotor cortex (Ai) and project to the spinal cord after 
decussating in the dorsal medulla. The main CST projects to the grey matter with the more dorsal 
neurons projecting to the cervical enlargement (Aii) while the lumbar enlargement receives 
projections from the more ventrally situated pyramidal neurons (Aiii). B: The distribution o f  CST 
fibres within the cervical (Bi) and lumbar (Bii) spinal cord enlargements is designated by 
increasing colour intensity reflecting denser projections in that area. (Adapted from: Tracey 1994 
and Joosten 1997).
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By postnatal day 14 (PI4) fibres have reached the sacral segments (Schreyer and 
Jones, 1982). Terminal arborisation with motor neurons (Liang et a l , 1991) and 
intemeurons within the grey matter is initiated soon after the arrival of CST fibres 
at each spinal cord segment (Schreyer and Jones, 1982). The final branching 
pattern and varicosity formation is fully achieved by day P28 (Karimi- 
Abdolrezaee et a l , 2002).
Some CST fibres do not cross contralaterally but instead continue their route 
ipsilaterally, either within the dorsomedial or the ventral funiculus in the white 
matter (Joosten et al., 1987; Joosten and Gribnau, 1988; Joosten et al., 1992; 
Joosten et a l , 1993; Brosamle and Schwab, 1997; Brosamle and Schwab, 2000). 
It was originally questioned whether the ipsilateral ventral projection had any 
functional significance past the developmental stages (Joosten et a l , 1992) but it 
has since been shown that this pathway projects throughout the spinal cord, is 
morphologically similar to the main dorsomedial CST and may be involved in 
fine movement control (Brosamle and Schwab, 1997; Brosamle et a l , 2000).
4.1.2 Assessment of CST regeneration
When it comes to evaluating the efficacy of the numerous attempts to induce the 
regeneration of CST axons, it is important to be able to separate spared axons 
from local sprouting and genuine regeneration. This is not always straightforward 
as different experimental paradigms are being used as CST models. Axons are 
flexible and a lot more resilient than they may look. They are not rigid structures 
within the spinal cord tissue and they can potentially be displaced and stretched, 
thus eluding an intended injury. Spared axons could potentially interfere with the 
interpretation of a regenerative outcome, especially those that follow a minimally 
invasive approach that often leaves the ventral CST component intact. Such 
lesions include: incomplete dorsal hemisections that fall short of totally ablating 
the dorsal columns and lateral hemisections that result in a unilateral lesion. 
Steward et al (2003) proposes that in order to confirm the origin of regenerating 
fibres, the criteria shown below should be applied:
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Criterion Abbreviation
I The axon extends from  the CNS tissue/lesion interface into the glial scar.
II
In the case o f  a graft/transplant being used, the 
regenerating axon can be seen entering and 
extending into the foreign tissue.
Ill The axon originates at or adjacent to  the CNS tissue/lesion interface.
IV The axon follows an uncharacteristic route through the tissue.
V
The axonal regeneration observed does not 
extend further than w hat can be justified  
according to regeneration rates.
VII The axonal m orphology is unlike that accepted for CST neurons (random  branching).
Table 4.1.2-a: Criteria for the assessment of regenerating CST axons.
The above criteria are show n here for consideration in relation to  the CST regenerative studies as 
lesioning o f  the descending com ponent is subject to  such variability  and w ere based on a review  
by Stew ard et al. (2003). These criteria apply to  all regenerative studies and they have been 
referred to  throughout the regenerative studies described in this thesis.
It therefore follows that reports of any functional recovery following partial 
lesions or lesions that leave the ventral component of the CST intact, could reflect 
mechanisms other than axonal regeneration. These mechanisms can involve 
functional compensation from spared pathways such as the rubrospinal tract 
(RST) that is also involved in fine movement control (Whishaw et al., 1990) or 
stimulation of the central pattern generators (CPGs) by serotonergic sprouting in 
the distal portion of the lesioned spinal cord. CPG is the collective term attributed 
to the networks of spinal neurons that are involved in locomotion. Normally, their 
actions are controlled and coordinated by the brainstem and the thalamus in 
response to peripheral stimuli. In case of injury, CPGs can act independently and 
allow some locomotion to take place (Bear et a l, 2001), although coordination 
between forelimbs and hind-limbs is lost. A recent study has demonstrated that 
after a T il spinal cord transection and transplantation of foetal raphe cells, 
segmental spinal cord plasticity contributes to weight support and bilateral foot 
placement (Ribotta et a l , 2000). Therefore, local plasticity is a factor that should 
always be considered when evaluating reports of CST regeneration accompanied 
by recovery of motor function.
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4.1.3 Responses of CST neurons to axotomy
The response of CST fibres and the chronological events preceding the formation 
of the glial scar within the lesion site as well as the type of cells involved are not 
dissimilar to those of other CNS tracts and have been examined in the main 
introductory Chapter of this study (Chapter 1). However this morphological 
similarity is accompanied by subtle differences at the molecular level that, to 
some extent, explain the low regenerative capacity of the CST compared to other 
CNS tracts. In adult rats, unlike the case in neonates (Bregman et a l , 1989), 
axotomised CST axons do not regenerate following a complete CST lesion that 
encompasses both the dorsal and ventral components of the pathway (Bernstein 
and Stelzner, 1983; Kuang and Kalil, 1990; Z'Graggen et al., 2000; Weidner et 
a l , 2001). Plasticity to the injured CST is however conferred if the ventral 
component of the tract is spared. Transection of the dorsal CST following a 
unilateral lesion is followed by spontaneous sprouting from injured ventral CST 
axons which can cross the midline in an attempt to compensate for lost 
connections (Weidner et a l, 2001).
Dorsal CST fibres are capable of very low level sprouting following axotomy but 
left unaided, growth arrests at the borders of the lesion site before any 
regenerative attempt is aborted (Bregman et a l, 1989; Schnell et a l, 1994) and 
end-bulbs make their appearance on retracting fibre tips (Ramon Y Cajal, 1928; 
Fishman and Kelley, 1984; Fishman and Kelly, 1984). Similarly there is 
considerable sprouting of the cut dorsal CST, proximal to a unilateral lesion. A 
mid-thoracic dorsal hemisection leads to axons arising from the dorsal CST at the 
cervical level to enter the grey matter where they form functional contacts with 
propriospinal motor neurons (Bareyre et a l, 2004).
4.1.3.1 Gene expression in lesioned CST neurons
The intrinsic capacity of CST neurons to regenerate is a reflection of their ability 
to initiate the production of multiple growth-associated proteins (Anderson et al, 
1998; Anderson and Lieberman, 1999) and sustain the expression of more than 
one of these molecules (Bregman et a l, 1989; Mason et a l, 2000; Bomze et a l,
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2001) long enough for them to overcome the inhibitory nature of the injured 
spinal cord environment (Fawcett and Asher, 1999; Sandvig et al., 2004). The 
gamut of proteins expressed following a CST lesion depends on the location of 
the lesion itself. Firstly, GAP43 transcription is up-regulated if axotomy is 
inflicted sub-cortically (Tetzlaff et al., 1994) but not if the lesion is at the level of 
the brain-stem (Kalil and Skene, 1986; Reh et al., 1987). Secondly, more 
prominent axonal sprouting is observed after a lesion is exacted sub-cortically 
compared to when it is inflicted in the medullary pyramids or spinal cord dorsal 
columns (Fishman and Mattu, 1993). In another, more detailed and extensive 
study it was demonstrated that mRNA levels of the axotomy-associated 
molecules GAP43 and SCG-10, the cell-recognition molecules LI and CHL1 as 
well as transcription factor c-Jun and ATF3 mRNA levels remain unaffected 
when a CST lesion is inflicted at the level of C3/C4 (Mason et al., 2003). In 
contrast, they are all up-regulated when the injury is inflicted within layer V of 
the neocortex and at a maximum distance of 300 to 500 pm from the neuronal 
cell bodies (Mason et al., 2003). In either case, CAP-23 and krox-24 mRNA 
levels appear unaltered. The above mentioned molecules are thought to be 
involved in the response mounted by neurons following an injury (Herdegen et 
al., 1993a; Herdegen et al., 1993b; Benowitz and Routtenberg, 1997; Herdegen et 
al., 1997; Takeda et al., 2000; Mason et al., 2000; Zhang et al., 2000; Tsujino et 
al., 2000; Chaisuksunt et al., 2000a; Chaisuksunt et al., 2000b; Mason et al., 
2002; Nakagomi et al., 2003; Campbell et al., 2005).
The fact that GAP-43 is not up-regulated in response to cervical level dorsal 
column injury confirms earlier reports regarding its patterns of expression in the 
injured CST (Anderson et al., 1998; Vaudano et al., 1998). Also, a CST lesion 
exacted within the posterior limb of the internal capsule leads to a 2.5 fold 
decrease in GAP-43 IR at six weeks p.i (Vizzard, 1999). Notably, Mason et al 
(2003) report that GAP-43, SCG-10, LI, CHL1, ATF3 and c-Jun mRNA are 
present in CST neurons in uninjured animals and in relatively high amounts. This, 
according to the authors, might explain the ability of CST fibres, axotomised at 
the spinal cord level, to produce local sprouts (Bregman et al., 1989; Schnell et 
al., 1994), despite the lack of any enhanced expression of growth-promoting
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molecules. In a recent study it was possible to enhance the regenerative response 
of axotomised CST neurons by causing inflammation around neuronal somata by 
means of a single lipopolysaccharide (LPS) application to the motor cortex. This 
resulted in the upregulation of c-Jun, ATF3, SCG-10 and GAP-43 expression in 
CST neurons which was maintained for two weeks following LPS administration 
(Hossain-Ibrahim et al., 2006). Moreover, the degree of inflammation appeared to 
correlate to the level of gene expression achieved. Despite this, the authors report 
a failure of CST neurons to mount a significant regenerative response and 
attribute this to the inability of this method to sustain a widespread and long-term 
expression of these growth-associated molecules.
4.1.4 Axonal regeneration approaches in CST regeneration
A lot of technically varied approaches have been utilised to bring about a 
potentially regenerative outcome on the injured spinal cord (Chapter 1 and for 
reviews: Hunt et al. 2003; Schwab 2004; Ramer et al. 2005; Teng and Tang 
2005). Targeting of myelin-associated inhibitors, cellular transplantation and 
neurotrophin delivery, have all been part of such attempts. Here, reports of the 
use of these techniques as they are applied to CST regenerative studies are 
summarised.
4.1.4.1 Counteracting myelin inhibitors in injured CST axons
The use of IN-1, the anti-Nogo A monoclonal antibody (Caroni and Schwab, 
1988a; Caroni and Schwab, 1988b) against the exon 3 encoded N’-terminal 
domain of Nogo-A (Fiedler et al., 2002), has been reported to have some promise 
at promoting regeneration in the rat CST injury model even though it has been 
less successful in other CNS tracts such as injured retinal ganglion neurons (Cui 
et al., 2004) and ascending dorsal columns (Oudega et al., 2000). Adult rats 
treated with IN-1, delivered by means of a hybridoma cell line, show enhanced 
sprouting with some axons apparently regenerating up to 11 mm caudal to the 
lesion (Schnell and Schwab, 1990) in treated animals, as opposed to 2.6 mm in 
control animals. However, most subsequent studies show no regeneration at all in 
the untreated CST. The effects of IN-1 infusion on CST regeneration was later
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shown to be enhanced when it was used in conjunction with foetal spinal cord 
grafts (Schnell and Schwab, 1993). This effect was further amplified with the co­
administration of NT3 (Schnell et al., 1994), with axotomised CST axons 
apparently regenerating up to 20 mm distal to the lesion site. In addition to its 
effects on CST regeneration, IN-1 administration also affects sprouting of 
uninjured as well as axotomised fibres. IN-1 infusion induces ipsilateral but 
aberrant CST sprouting rostral to a unilateral pyramidotomy and contralateral 
sprouting caudal to a pyramidotomy (Bareyre et al., 2002). This aberrant and 
ectopic growth of regenerating CST fibres following a pyramidotomy and 
subsequent IN-1 treatment, has been noted in an earlier study in which 
regenerating axons were found in the dorsal and lateral columns but did not 
follow the path of the uninjured CST fibres (Raineteau et al., 1999). Interestingly, 
IN-1 administration alone has been shown to lead to the up-regulation of a variety 
of growth-associated genes (GAP43, actin, myosin), growth factors (BDNF, 
vEGF) and transcription factors (STAT) in rat spinal cords. Administration of IN- 
1 following a pyramidotomy leads to the additional up-regulation of growth 
factors (Bone Morphogenic Proteins), growth factor receptors (GDNF receptor) 
and important axon guidance cues (semaphorins 3 and 6) (Bareyre et al., 2002).
Even though the study by Bareyre et al. (2002) does not provide a link between 
the observed up-regulation and regenerating CST fibres, it may be hinting to the 
fact that reports of functional recovery may result from the ability of IN-1 to 
enhance CST plasticity by counteracting its targets, thus favouring the creation of 
a more regeneration-friendly environment that can support re-growth around 
partial or incomplete lesions (Raineteau et al., 2002). This would be in line with 
the observation that CST cell bodies normally contain very high levels of ngr, 
nogo-66 and nogo-a mRNAs (Hunt et a l , 2002b; Hunt et a l, 2003), while CST 
fibres around the lesion site strongly express the Nogo-A protein (Hunt et a l,
2003). The application of IN-1 has now been extended to non-human primates, 
with regeneration being shown in marmosets that have previously received a 
unilateral CST lesion at the thoracic level. mAh IN-1 treated animals show 
sprouting and regeneration of injured CST fibres with a few fine axons growing 
through and up to 5 mm caudal to the lesion site (Fouad et a l, 2004).
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Generally, the use of the mAh IN-1 is not without its pitfalls since Nogo-A may 
not be its sole antigen. The exact nature of the molecules neutralised by the mAb 
IN-1 has not been thoroughly characterised. In order to overcome this drawback 
highly purified, monoclonal, mono-specific, IgG antibodies to Nogo-A have been 
produced: 11C7, raised against the rat sequence of amino acids 623 to 640 and 
7B12 targeting amino acids 1 to 979 (i.e. the C-terminal part of the Nogo-A 
specific region) (Oertle et al., 2003). Their use in vivo has recently been 
documented in the CST regeneration model. Two week long intrathecal infusion 
of 11C7 and 7B12 antibodies immediately following a CST dorsal column lesion, 
reportedly leads to enhanced CST regeneration with fibres following an aberrant 
route and growing around 2 to 5 mm caudal to the lesion site (Liebscher et al., 
2005). Some recovery of function was also reported but as in most studies of this 
type the effect that IN-1 has on local plasticity should be taken into account. 
Reports of success with antibodies against Nogo have been criticised with regards 
to the origin of regenerating fibres, as most studies employ partial dorsal column 
lesions (Hunt et al., 2002a; Schwab, 2004; Teng and Tang, 2005). This popular 
model unfortunately allows for the possibility that the apparently regenerating 
CST axons may originate from the intact ventral CST component which has been 
demonstrated to confer considerable plasticity to the injured CST if left unscathed 
(Weidner et al., 2001; Raineteau et al., 2001).
In addition to the use of IN-1, the Nogo extracellular peptide residues 1 to 40 
(NEP1-40 peptide), which competes with Nogo-66 for binding to the NgR, has 
also been shown to have an effect on CST regeneration. Intrathecal infusion of 
the antagonistic peptide via an osmotic mini-pump in adult rats with a mid- 
thoracic spinal cord dorsal hemisection resulted in a ~10 fold increase of CST 
axonal sprouting. This regeneration was accompanied by some degree of 
functional recovery (GrandPre et al., 2002). Interestingly, the CST regenerating 
fibres appeared to follow a random route through the white and grey matter of the 
spinal cord, perhaps reflecting their growth through a debris-filled substrate. 
Subcutaneous administration of NEP1-40 results in the extensive growth of 
corticospinal axons, up-regulation of axonal growth promoting protein small 
proline-rich repeat protein 1A (SPRRP1A) (Bonilla et al., 2002) and synapse re-
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formation following a thoracic level lesion in mice, an effect not abolished by a 1 
week delay between lesioning and NEP1-40 treatment (Li and Strittmatter, 2003). 
It has been suggested that NEP1-40 may block inhibitory responses to Nogo as 
well as to MAG and OMgp (Schwab, 2004). Intrathecal administration of 
NgR(310)ecto-Fc antagonist, the Fc bound, soluble, truncated form of the NgR 
(Fournier et al., 2002), following a mid-thoracic dorsal over-hemisection 
promotes significant CST and raphaespinal axonal sprouting which is 
accompanied by the recovery of electrophysiological function (Li et al., 2004a). 
A new anti-NgR monoclonal antibody capable of inhibiting the binding of Nogo, 
MAG and OMgp has now been discovered and has been shown to block myelin 
inhibition at least on early post natal DRG neurons in vitro (Li et al., 2004b). No 
reports of its effect in vivo exist as yet.
Other attempts at counteracting myelin inhibitors for CST regeneration target the 
second messengers activated downstream of NgR. Ligand-bound NgR associates 
with LINGO-1 and p75 or TROY to activate the RhoA GTPase. Rho has been 
shown to be activated by Nogo-66 binding to NgR in vitro (Fournier et al., 2003). 
The active, GTP-bound RhoA further activates ROCK, which in turn transduces 
the inhibitory effect of myelin to the neuronal cytoskeleton. This pathway has 
been targeted for the induction of CST regeneration using either C3-ADP- 
ribosyltransferase (C3 transferase) to inhibit RhoA (Aktories et al., 1989; 
Lehmann et al., 1999) or the pyridine derivative Y-27632 which targets ROCK. 
When C3 transferase, the RhoA specific inhibitor was delivered into the thoracic 
adult mouse spinal cord using a fibrin adhesive gel, extensive long distance CST 
regeneration and up-regulation of gap-43 mRNA levels in neurons within the 
motor cortex was observed (Dergham et al., 2002). The authors themselves 
acknowledge that they cannot discount the possibility that this was due to the 
enhanced plasticity of spared fibres since this was a dorsal over-hemisection 
lesion. Different results were obtained when C3 was used in a dorsal hemisection 
model in the adult rat but was instead applied utilising a mini-pump to gradually 
release it over a three-week period. In this case, C3 appeared unable to promote 
or sustain any long term CST regeneration but had a beneficial effect in reducing 
scar formation (Fournier et al., 2003). The authors suggest that this discrepancy
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between the two administration methods was due to the inability of C3 to gain 
access to the axotomised CST fibres. This suggestion is a valid possibility 
considering that the C3 24 kDa protein does not readily penetrate the cell 
membrane and may therefore be needed in high amounts in order to induce an 
effect. It would be interesting to see the effects of using the more permeable C3 
chimeric protein analogues, such as the C3-05 analogue, in terms of CST 
regeneration (Winton et al., 2002). Equally plausible is that the acute 
administration of a massive 50 pg dose of C3 immediately after lesioning had a 
greater neuroprotective effect than that possibly achieved with the slow infusion 
of 0.75 pg/hr over three weeks (Dergham et al., 2002; Fournier et al., 2003) and 
increased the number of spared fibres. This would also make sense since 
administering a C3-05 Rho antagonist within the transected spinal cord increases 
neuroprotection, with a 50% reduction of TUNEL labelled cells in mice or rats, 
perhaps by inhibiting the expression of p75NTR (Dubreuil et al., 2003). 
Unfortunately, in the same study no data were presented in relation to any 
regeneration of CST or other fibres. It has been shown that the NgR can activate 
Rho in a p75NTR dependent manner (Wang et al., 2002a; Yamashita and 
Tohyama, 2003). The role played by p75NTR in transducing an inhibitory signal 
via NgR is by no means clear as yet since contradictory reports exist as to its 
function. Lack of p75NTR expression in transgenic mice does not appear to 
promote a CST regenerative response (Song et al., 2004; Zheng et al., 2005). A 
recent in vitro study using siRNA technology to knock down the expression of 
p75NTR, NgR or RhoA demonstrated that reducing RhoA expression enhances the 
ability of DRG axons to grow in a myelin-extract substrate, more prominently 
than sole p75NTR or NgR silencing (Ahmed et al., 2005). It is worth pointing out 
that only Western blots were shown as proof of reduction in the levels of either of 
the proteins targeted. It would have been interesting to see a reduction in actual 
mRNA levels by northern blot analysis or rt-PCR since this would be a more 
sensitive detection method. Ahmed et al. (2005) go on to suggest that knocking 
down p75NTR and NgR does not block those inhibitory signals not derived by 
myelin, such as those derived by CSPG, semaphorins or ephrins, that also 
converge on RhoA and have been shown to cause growth cone collapse (Hunt et 
al., 2002a; Sandvig et al., 2004; Ahmed et al., 2005).
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Inactivation of ROCK via Y-27632 (Hirose et al., 1998), induced comparable 
CST regeneration despite the difference in species and administration methods. 
However, C3 appears to make a bigger impact on CST regeneration that Y-27632 
which could suggest that RhoA may be a more influential target than ROCK for 
CST regeneration studies. In another study, the protein kinase C Alpha inhibitor 
G66976 was used to block the activation of Rho via myelin components. When 
G66976 was administered intrathecally following a dorsal hemisection it lead to 
the regeneration of dorsal column axons but not CST fibres (Sivasankaran et al.,
2004). Myelin associated growth inhibitors can be counteracted by immunisation 
with myelin (Huang et a l, 1999). Adult mice immunized in this manner showed 
extensive regeneration of large numbers of CST axons after a dorsal hemisection 
of the spinal cord. This anatomical regeneration led to recovery of certain hind 
limb motor functions. Again, to which degree the functional regeneration 
observed was solely due to CST regeneration cannot be determined. 
Immunisation with recombinant Nogo-66 (Wang et al., 2002b) and rMAG 
(McKerracher et al., 1994) of adult mice that had previously received a dorsal 
hemisection resulted in sprouting and long distance regeneration of CST fibres 
(Sicotte et al., 2003). In animals that were immunised with the rNogo-66/rMAG, 
CST axons reached ~8.4 mm caudal to the lesion. The authors of this study 
acknowledge that the ventral CST component also sprouts in response to the 
rNogo-66/rMAG treatment. In another approach aiming to narrow the extensive 
range of molecules targeted by the myelin vaccine, a recombinant plasmid DNA 
vaccine was utilised (Xu et al., 2004). The vector was designed to express a 
fusion protein composed of 4 domains: the Ig 1-5 domain of rat MAG 
(McKerracher et al., 1994), the EGF-L domain of human TN-R (Xiao et al., 
1996) as well as the N-terminal and Nogo-66 domains of human Nogo-A 
(GrandPre et al., 2000) under the control of a CMV promoter (Xu et al., 2004). 
This study, reports successful CST regeneration with fibres reaching 5 and in 
some cases 12 mm caudal to a dorsal column microlesion site. Some functional 
recovery was also reported. The success achieved with studies targeting the 
disruption of the effects of Nogo or NgR at the protein level is not mirrored with 
attempts at disrupting these two factors at the genetic level (for a review: Teng 
and Tang, 2005). Disruption of the Nogo gene by different groups produced
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varied success in a dorsal hemisection paradigm ranging from significant CST 
regeneration in young adult mice lacking Nogo-A/B (Kim et al., 2003) to 
moderate CST regeneration in Nogo-A knock-out mice (Simonen et a l, 2003) to 
no effect observed in either Nogo-A,B or Nogo-A,B,C mutants (Zheng et al., 
2003). The same variable pattern is present in the case of NgR transgenic animals. 
In NgR null mutants that received a dorsal hemisection, no CST axonal 
regeneration was evident (Kim et al., 2004). However, there was a remarkable 
improvement in locomotor function, even in animals with a complete spinal cord 
lesion. This could be attributed to the successfully regenerating raphaespinal and 
RST fibres (Kim et al., 2004). A similar study, using a different strain of NgR 
null mice also reported no CST regeneration following a dorsal hemisection at the 
thoracic level (Zheng et al., 2005). It has been suggested that injured CST axons 
of NgR knock-out transgenic mice may be unable to mount a regenerative 
response, even if their environment favours it, due to their potential inability to 
up-regulate regeneration enhancing factors since they have never been exposed to 
an environment containing NgR in the first place (Teng and Tang, 2005). Studies 
in transgenic animals could also be viewed to reinforce the growing consensus 
that the interaction of Nogo-A and NgR is not a pure inhibitory one for axonal 
regeneration (Hunt et al., 2002a; Hunt et al., 2003; Sandvig et al., 2004; 
Raisman, 2004; Teng and Tang, 2005). Rather than having a purely inhibitory 
function, these molecules could have more of a guidance role on myelinated 
tracts such as the CST as a means of ensuring correct target innervations. 
Abolishing them, may hinder any regenerative attempt these fibres may mount 
(Raisman, 2004; Teng and Tang, 2005). Several studies have addressed the effect 
of extra-cellular matrix molecules on CST regeneration. Chondroitin sulphate 
proteoglycans (CSPGs) are inhibitory to axonal growth, a function attributed to 
the CS side-chains since their inhibitory effect can be opposed by the 
chondroitinase ABC (ChABC) enzyme (Rhodes and Fawcett, 2004). When 
ChABC was infused intrathecally into rats that had received a C5/C6 dorsal 
column crush lesion, resulted in some regeneration of CST axons accompanied 
by some arborisation into the grey matter with up-regulation of GAP43 
(Bradbury et al., 2002).
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4.1.4.2 Cellular transplantation and CST regeneration
Schwann cells (SCs), olfactory ensheathing glial cells (OEGCs), peripheral nerve 
(PN) and foetal spinal cord grafts as well as genetically modified non-neuronal 
cells have all been utilised to promote CST regeneration in either transection or 
contusion injury models.
Schwann Cells
When a peripheral nerve graft is transplanted into the cut stump of an axotomised 
optic nerve, regeneration of RGC axons occurs (Berry et a l, 1986; Vidal-Sanz et 
al, 1987). This effect was attributed to the presence of SCs surrounding the 
sciatic nerve axons (Hall and Berry, 1989). SCs have been shown to be capable of 
expressing BDNF (Meyer et a l, 1992), NGF (Assouline et a l, 1987; Tuszynski 
et a l, 1998) and CNTF (Friedman et a l, 1999). However, the regenerative ability 
of SCs has so far not been realised whenever they have been applied to CST 
regeneration paradigms. CST axons, along with Purkinje cells, show an inability 
to regenerate their axons into grafts that contain SCs (Richardson et a l, 1982). 
Studies that utilised SC-seeded guidance channels thus removing the possibility 
that other cells present in a PN, such as fibroblasts, could confound the 
experiment, confirmed the previous reports of no CST axonal regeneration into 
PN grafts (Houle, 1991; Xu et a l, 1999). This is true even when SC 
transplantation was accompanied by exogenous administration of neurotrophins 
such as NT3 (Xu et a l, 1995) or when SCs were transduced by a retroviral 
vector to secrete NGF (Tuszynski et a l, 1998), BDNF (Menei et a l, 1998) or 
NT3 (Blits et a l, 2003). However, it is worth pointing out that in a separate study 
when SC transplantation was accompanied by intrathecal infusion of NT3 or/and 
BDNF, regenerating axons were noted up to 6 mm into the distal stump (Bamber 
et a l, 2001). In this case, neurotrophic factors were infused at significantly higher 
amounts than the more biologically reasonable amounts in the case of virally 
transduced cells (Tuszynski et a l, 1998). This allows for the possibility that cells 
other than neurons are involved in this response. Indeed astrocytes and 
oligodendrocytes also express the truncated versions of the trkB and trkC 
receptor mRNAs (Condorelli et a l, 1995; Wang et a l, 1998; Bamber et a l, 
2001). Recent studies suggest that the classical view that the truncated forms of
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the trk receptors are detrimental to regeneration may not be the whole story. For 
example, it has been shown that truncated TrkB receptors can mediate the 
endocytosis of extracellular BDNF and storage into an intracellular pool 
(Alderson et a l, 2000). It therefore follows that despite their lack of tyrosine 
kinase activity truncated, Trk receptors may still be capable of some intracellular 
signalling. This is supported by the recent demonstration that the binding of 
BDNF to its truncated receptor on astrocytes activated the release of Ca from 
intracellular stores through a signalling pathway that involves an as yet 
unidentified G protein in vitro (Rose et al., 2003; Reichardt, 2003). Inducing SC 
grafts to over-express BDNF and NT3 by means of an adenoviral vector failed to 
induce CST axons to enter the graft and grow into the distal stump following a 
thoracic level lesion (Blits et a l, 2003). These results were contradicted when in 
a recent study, genetically modified NGF/BDNF over-expressing SC grafts were 
administered in combination with foetal spinal cord cell suspension in a 
contusion CST lesion model. The authors report that some CST axons extend into 
and beyond the lesion site. The functional recovery reported however cannot be 
attributed solely to CST arborisation (Feng et a l, 2005). Again, differences in the 
lesioning models used in these two studies could account for this discrepancy and 
the study by Feng et al (2005) would ideally need to be repeated.
Olfactory ensheathing cells
Like SCs, OEGCs have been shown to express neurotrophin factors and adhesion 
molecules (Barnett, 2004). Studies of purified OEGC cultures have detected 
mRNA for NT4/5, NGF, BDNF and neuregulin but not for CNTF or NT3 which 
would be beneficial for CST regeneration (Thompson et a l, 2000; Boruch et a l,
2001). Many contradictory reports have made it difficult to reach a conclusion as 
to the efficacy of OEGCs in regeneration studies. This may be related to 
differences in the lesion models employed, in the preparation of OEGC or 
differences in the mixture of cells in the OEGC population used. Some 
researchers suggest that OEGCs have the capacity to positively influence CST 
regeneration and avert secondary damage of the spinal cord by cavitation 
(Ramon-Cueto et a l, 2000; Nash et a l, 2002; Keyvan-Fouladi et a l, 2003). In a 
report of significant CST regeneration, a few fibres were able to grow up to 1.5
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cm caudal to the lesion site following complete spinal cord transection. In this 
experiment purified OEGCs were administered at 1 mm either side of the centre 
of the lesion (Ramon-Cueto et al., 2000). In these experiments, animals were able 
to recover some function. In another study by Keycan-Fouladi et al (2003), 
animals received a unilateral focal electrolytic lesion in the medioventral, 
descending dorsal columns in the C1-C2 level. Transplantation of OEGCs was 
carried out eight weeks following the injury. Regenerating CST fibres were 
reportedly present for up to 10 mm caudal to the lesion/OEGC transplantation 
sites. Even though there is the possibility that this was due to spared fibres, the 
authors report restoration of paw reaching function to about 50% of normal. The 
same can be said for an earlier study utilising this lesioning model but without the 
delayed transplantation and carried out by the same laboratory (Li et a l, 1997). 
Transplantation of OEGCs has recently been shown to enhance collateral 
branching from spared ventral CST branch (Chuah et a l , 2004), suggesting that 
recovery of function after partial lesions may be brought about by factors other 
than axonal regeneration.
Other reports contradict the OEGC’s regenerative effect with a distinct lack of 
any significant regenerative response. A contusion lesion of the descending CST 
that spares the lateral funiculi and subsequent OEGC transplantation failed to 
promote regeneration or dieback of injured descending CST axons. Some local 
sprouts attributed to local DRG or spinal intemeurons appeared to follow an 
irregular route following the also random migration pattern on the transplanted 
OEGCs (Nieto-Sampedro, 2003). These authors suggest that the CST may be 
one of the tracts that cannot be repaired by the sole transplantation of OEGCs. 
The authors suggested that whether or not OEGCs can promote regeneration or 
not depends on their ability to migrate within the injured CNS tissue while their 
high susceptibility to the ffee-radicals present within the environment of a 
contusion injury limits their ability to do so (Nieto-Sampedro, 2003). In another 
study, comparing the efficacy of SCs and OEGCs transplanted within a contusion 
lesion at the thoracic level, demonstrated that OEGCs did have a beneficial effect 
on reducing dieback, cavitation and promoting re-myelination but did not lead to 
any axonal regeneration through the transplant (Takami et a l, 2002). This
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discrepancy in achieved regeneration via the OECG transplantation approach is 
perhaps a reflection of the somewhat different lesioning models of spinal injury 
and transplantation paradigms utilised in the various studies. The less successful 
but more severe contusion lesion (Hill et al., 2001) is particularly effective at 
destroying dorsal CST axons over a distance of several millimetres and produces 
massive cavitation in the rat spinal cord whereas the more elegant but ambiguous 
electrolytic lesion (Li and Raisman, 1995) produces minor scaring. However, 
even though it might be expected that combining the scar penetrating properties 
of OEGCs and the axonal growth promoting effect of Schwann cells would have 
a greater potential for inducing CST regeneration, a recent report disputed that 
effect. In a complete transection model of regeneration, Schwann cell grafts were 
combined with OEGCs and chondroitinase ABC (ChABC) administration. 
Unlike other supraspinal populations, CST axons still failed to transverse the scar 
(Fouad et al., 2005). A number of experiments aimed at addressing the 
combinatorial approach of delivering OEGCs that have been transduced to 
express neurotrophic factors have recently been attempted. Using an adenovirus 
vector, OEGCs transduced to express NT3 were transplanted within the lesion 
site of a unilateral C4 transection encompassing the RST. The functional recovery 
reported may or may not be attributable to CST axonal regeneration (Ruitenberg 
et al., 2005) and could be attributed to regenerating RST fibres.
Foetal cell transplants
Foetal tissue has been used in studies targeting the axotomised CST on the 
assumption that it can provide permissive conditions for regeneration. However, 
unaided, CST axons cease any regeneration at the host/transplant interface 
(Bregman et al., 1997a). When E l4 spinal cord transplants are accompanied by 
the simultaneous intrathecal administration of NT3, NT4/5, BDNF supraspinal 
fibres appear to have an increased growth capacity (Bregman et al., 1997b). In 
this series of experiments, axons were able to enter and grow within the graft. 
This effect is amplified when the foetal transplant and neurotrophin treatment is 
delayed by 2-4 weeks after a complete spinal cord transection, suggesting that 
chronic injuries can still be addressed and intervention is still possible (Coumans 
et a l, 2001).
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Engineered fibroblasts
Ex vivo gene therapy employing modified fibroblasts has been used in many 
experiments with varied success as far as CST regeneration is concerned. When 
fibroblasts engineered via a retroviral vector to express NGF, BDNF, NT3 or 
bFGF were transplanted into the grey matter of a previously uninjured spinal 
cord, it was mostly sensory axons of DRG origin rather than CST axons that were 
induced to enter the transplant (Nakahara et al., 1996). A later study revealed that 
sensory axons are particularly attracted to the secreted NGF and they grow 
towards it in a directionally sensitive manner, while at the same time CST axons 
are not attracted by this neurotrophin (Giehl and Tetzlaff, 1996; Tuszynski et al., 
1997; Grill et al., 1997b). However, NT3 secreting fibroblasts able to support 
transgene expression for around three months, were able to stimulate CST axonal 
elongation following a dorsal column over-hemisection (encompassing the 
rubrospinal and coeruleospinal projections) (Grill et al., 1997a). These authors 
report that in the NT3 grafted animals, CST axons extended for up to a maximum 
of 8 mm caudal to the lesion site, a distance corresponding to the boundary of 
NT3 diffusion from the graft itself but this growth was based on the host ventral 
grey matter acting as a permissive growth substrate and was not supported by the 
collagen containing fibroblasts graft itself (Grill et al., 1997b). Unfortunately, 
even though this study does provide evidence that the transgene is expressed at 
the longest time point examined, the amount of NT3 protein produced was not 
measured (Grill et al., 1997a). The same laboratory went on to establish that 
delivering BDNF via genetically engineered fibroblasts transplanted into a sub- 
cortical lesion, does promote the survival of -89% of axotomised CST axons 
compared to only -36% in untreated animals (Lu et a l, 2001). The same grafts 
however failed to promote any CST axonal elongation when implanted either 
sub-cortically or within a thoracic dorsal column lesion.
Delaying grafting of NT3 secreting fibroblasts for three months following a 
dorsal column thoracic hemisection was reportedly still within the window of 
opportunity for inducing a regenerative effect in injured CST axons via this 
approach (Tuszynski et al., 2003). In this study, the authors report that following 
a three-month treatment with the transduced fibroblasts, CST axons were able to
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regenerate for up to an impressive 15 mm distal to the lesion site. Within the 
same year however a similar study published by a different group, report 
opposing results. Delaying the grafting of BDNF and NT3 secreting modified 
fibroblasts into a six week chronic CST cervical hemisection results in limited 
regeneration even though enhanced neuroprotection (attributed to BDNF) is 
reported (Shumsky et al., 2003). This is despite the use of both cyclosporin and 
methylprednisolone that may have contributed to the neuroprotection observed 
(Oudega et al., 1999; Diaz-Ruiz et al., 2000). The first study by Tuszynski et al. 
(2003) employed an incomplete lesion and therefore the possibility of the 
regeneration observed being from the ventral CST component cannot be 
discounted. At the same time however, the second study by Shumsky and 
colleagues (2003) fails to report the exact number of genetically engineered 
fibroblasts transplanted into the lesion site and it is, in this respect, difficult to 
compare the effectiveness of their approach to that of other laboratories 
employing this technique. Another difference between these two studies is that 
the Tuszynski group delivered their genetically engineered cells by means of an 
amorphous and relatively liquid preparation while the second group utilise foam 
gel soaked in the cells. The fact that these two materials have different physical 
properties would potentially have an impact the diffusion rate of the secreted NT3 
as well the viability of the transplanted cells. Over-expression of the cytokine 
leukaemia inhibitory factor (LIF), a modulator of neuronal and glial function 
during development, by means of transduced fibroblasts also leads to a growth 
promoting effect on axotomised CST axons (Blesch et al., 1999). When the 
modified fibroblasts are transplanted within the lesion site of adult rats, LIF 
appears to promote a selective increase of NT3 secretion at the lesion site. This is 
accompanied by modest CST regeneration through the grey matter of the host 
tissue. Interestingly, LIF over-expression has no effect on BDNF, CNTF, GDNF 
or NGF expression at the lesion site (Blesch et al., 1999).
Peripheral nerve grafts
Peripheral nerve implantation (Houle, 1991) especially when accompanied by 
neurotrophin administration, has also been shown to induce a CST regenerative 
response. Administration of aFGF mixed in with fibrin glue and transplanted
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along with 18 intercostal nerve pieces into a CST complete transection site, 
induced some regeneration into and through the graft (Cheng et a l, 1996). 
Similarly when intercostal nerves were transduced by means of an adenoviral 
vector to secrete NT3 transiently and then transplanted into a dorsal hemisection 
site, CST axons regenerated for up to 8 mm distal to the lesion site but using the 
host grey matter as a medium and not the graft itself (Blits et al., 2000). A few 
years later, the same laboratory utilised adeno-associated vectors expressing 
BDNF and NT3 to transduce intercostal nerves and then transplanted them into a 
complete thoracic spinal cord transection site. The authors report that CST axons 
were stimulated to sprout but none were seen to enter the tissue up to 16 weeks 
following transplantation and vector administration (Blits et a l, 2003).
4.1.5 Neurotrophins and CST regeneration
The effectiveness of different neurotrophic factors in promoting a regenerative 
effect in axotomised neurons of the CST has been addressed in many and varied 
experimental paradigms. In this study emphasis is placed on NT3 since, as 
explained in the following sections, it can promote a robust and consistent 
outgrowth of CST axons.
4.1.5.1 Neurotrophin 3
NT3 is a cysteine-knot neuronal growth factor (McDonald and Hendrickson, 
1993). The NT3 cDNA encodes a 258 amino acid long pre-pro-neurotrophin with 
a signal peptide and a pro-protein (pro-NT3), both of which are proteolytically 
processed to generate the -119 amino acid long mature protein (Hohn et a l, 
1990; Maisonpierre et a l, 1990b). The overall secondary structure of NT3 
(Figure 4.1.5-a, panel A) is similar to that of other neurotrophins (Hohn et a l, 
1990), with each protomer forming a four-stranded P-sheet and a small fraction of 
a-helix with three disulfide bonds (Butte et a l, 1998). X-ray crystallography 
studies have shown NT3 to be a non-covalently linked homodimer (McDonald 
and Hendrickson, 1993), whose formation is essential for NT3-specific TrkC 
receptor activation (Butte et a l, 1998). Residue Argl03 of the NT3 protein is
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important for binding affinity to the TrkC receptor (Figure 4.1.5-a, panel B) while 
specificity is attributed to residue Gln83 (Butte et a l , 1998). Both the mature and 
the pro-neurotrophin forms are thought to be capable of eliciting a biological 
effect. The pro-form appears to bind preferentially to the p75NTR receptor 
inducing apoptosis, while the mature form has a higher affinity for the TrkC 
receptor and promotes survival (Lee et a l, 2001). The intracellular processing, 
sorting and concomitant secretion routes of pro-NT3 have been the focus of 
debate with somewhat contradictory reports. Some researchers suggest that 
processing and sorting of pro-NT3 occurs primarily via the constitutive secretory 
pathway, where mature NT3 is released following the highly efficient, furin- 
mediated, pro-NT3 endoproteolytic cleavage in the trans-Golgi network (Mowla 
et a l, 1999; Farhadi et a l, 2000). Recent studies suggest that cells may be 
capable of shunting the processing of pro-NT3 to the regulated secretory 
pathway, which results in mature NT3 being stored in secretory granules. Over­
expressing of pro-NT3 by means of transient transfection methods can lead to 
such rerouting. This re-routing is consistent with the dual role of NT3. As a 
neuronal survival factor (Kalcheim et a l, 1992) it requires constant release via 
the constitutive secretory pathway while as a modulator of synaptic plasticity 
(Kang and Schuman, 1995) and depolarisation (Kafitz et a l, 1999) it is released 
in response to extracellular stimuli via the regulated secretory pathway instead 
(Farhadi et a l, 2000). NT3 is a target derived neurotrophic factor with survival 
promoting, differentiation and plasticity modulating functions. A deficiency in 
NT3 expression, as elucidated in mutant mice lacking NT3, results in an 
abnormal proprioception as cutaneous mechanoreceptors are lost during 
development while spinal afferents, muscle spindles and Golgi tendon organs 
never form (Airaksinen et a l, 1996). In addition, most classes of DRG neurons 
are severely reduced in numbers but are not totally absent (Airaksinen and 
Meyer, 1996). Other laboratories, employing different techniques for NT3 gene 
ablation have to come to similar conclusions, reporting severe movement deficits 
(Emfors et a l, 1994), an overall failure to thrive and early death (Tessarollo et 
a l, 1994). It was recently demonstrated that the ability of NT3 to promote axonal 
elongation may be due to the fact that it can inhibit the activation of glycogen 
synthase kinase-3 p (GSK3p) which normally deactivates the collapsing response
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mediator protein-2 (CRMP-2) (Yoshimura e/1 a/., 2005). CRMP-2 is involved in 
microtubule reorganisation and therefore axonal elongation and branching 
(Fukata et al., 2002) and the fact that NT3 can prolong its active state can be 
linked to its regenerative potential. Neurons of the CST express TrkC and TrkB 
receptors (Giehl and Tetzlaff, 1996; Giehl, 2001). In addition, TrkC protein and 
mRNA levels remain constant throughout human development and they are 
present in glial, pyramidal and non-pyramidal cells in the motor cortex (Beltaifa 
et al., 2005). Research in rodents has shown that trkC mRNA levels are not 
down-regulated in injured CST neurons examined following a T8 contusion 
injury model (Liebl et al., 2001). It therefore follows that NT3 administration 
would be expected to have a positive impact on CST regeneration.
The regenerative potential of NT3 was demonstrated early on in spinal cord 
regenerative studies following protein administration at the lesion site either 
acutely by means of a mini-pump (Schnell et al., 1994; Bradbury et al., 1999) or 
by slow release via a collagen implant (Houweling et al., 1998) or via viral vector 
mediated delivery (Dijkhuizen, 1999; Blits et al., 2003). Sprouting and axonal 
elongation was noted but no CST fibres were able to exit the scar tissue and grow 
distally. Even though the full-length TrkC and TrkB receptor levels do not seem 
to be affected by axotomy, expression of their truncated and inactive forms is 
apparently upregulated near the lesion site (Frisen et al., 1993a; Frisen et al., 
1993b; King et a l , 2000). Thus, larger amounts of NT3 would be necessary to 
induce a trophic effect in these neurons since the truncated receptors would mop 
up the neurotrophin but since they lack a catalytic domain they would be unable 
to convey their message. This is thought to be one of the reasons why sole 
administration of neurotrophic factors may not be enough to promote any 
meaningful CST regeneration. CST neurons exhibit marked atrophy (Giehl and 
Tetzlaff, 1996) and progressive axonal die-back, initiated as soon as 24 hours 
after injury (Sayer et a l , 2002). CST axonal die-back is relatively fast and it has 
been approximated to be 40 -  60 pm/day (Pallini et a l , 1988).
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HSVl vector-mediated delivery o f NT-3 in the injured corticospinal tract
A. N eurotrophin  3
B. T rk C  receptor
F igure 4.1.5-a: P red icted  s tru c tu re s  o f NT3 & the T rk C  recep to r-b ind ing  dom ain.
Three dimensional representations o f  the predicted structures o f  A: the A chain o f  human NT3 
(GI:4505469, M M D B10558) and B: the 5th domain (d5) o f  the human TrkC receptor 
(GI:5822441, M M D B11000) (Ultsch et a l,  1999) which is the binding site for human NT3 (Butte 
et al., 1998). Structures were obtained using the Cn3D4.1 software, available at the NCBI website 
(httD.7/www.ncbi.nlm.nih.gov). (Disulfide bridges are shown in red).
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One week after an internal capsule lesion, 49% of CST neurons have atrophied 
(Giehl and Tetzlaff, 1996). In addition to its trophic role, NT3 has been shown to 
exert a modest neuroprotective effect on axotomised CST axons (Namiki et a l , 
2000) but primarily when they are transected close to the cell body (Giehl and 
Tetzlaff, 1996; Hammond et a l , 1999). Interestingly, while most CST neurons 
express the TrkB receptor only few of them express BDNF. These expression 
patterns don’t change following axotomy or exogenous neurotrophin treatment 
suggesting that axotomised CSN are supported via a paracrine BDNF-mechanism 
which can be stimulated by NT3 (Schutte et a l , 2000) via its interaction with 
TrkB. A seven day intrathecal infusion of NT3 is reportedly capable of reducing 
CST end-bulb formation by 60% (Sayer et a l , 2002). NT3 has also been 
beneficial in promoting the plasticity of spared fibres following CST axotomy 
and thus indirectly contributing to the restoration of function following a lesion. 
As already stated previously, spared CST axons will sprout into the denervated 
grey matter when NT3 is over-expressed by means of an adenoviral vector (Zhou 
et a l , 2003). However, a recent report appeared to suggest that NT3 may in fact 
inhibit collateral sprouting of spared CST fibres originating from within the 
denervated side (Hagg et a l , 2005). Hagg et al (2005) went on to suggest that 
this unexpected effect may be a consequence of the upregulation of p75NTR, 
observed in axotomised CST neurons one week following either an internal 
capsule lesion (Giehl et a l , 2001) or in the epicentre of a contusion injury 
(Reynolds et a l , 1991).
Large diameter la  primary afferent sensory neurons have been shown to 
regenerate following dorsal root rhizotomy and anastomosis in response to 
adenoviral vector mediated NT3 transduction of local populations of neuronal 
and non-neuronal cells (Zhang et a l , 1998). This is logical considering that they 
do express the TrkC protein (McMahon et a l, 1994). In this experiment a 
conditioning peripheral lesion was also employed in order to enhance the 
expression of growth promoting molecules (Chong et a l, 1999) and activate the 
transcription factor, signal transducer and activator of transcription 3 (STAT3) 
(Qiu et a l, 2005). However, most regenerating axons did not exit the dorsal root 
entry zone (DREZ) possibly due to the presence of tenascin-R and NG2
203
//.VI / i l l  l m  - i f u J h l h t i  J i  l i Y t ’i I I>r \  /"• III i i l< Iiiiiirt'ii ' - t V l h  i n / u m f i  i n n
expressing cells which were found bordering the entrance to the CNS (Zhang et 
a l , 2001; Grimpe et a l , 2005). These findings were in later years repeated by 
another laboratory but this time using an intrathecal delivery system for 
administering NT3 (Ramer et a l , 2002). The efficacy of intrathecally delivering 
NT3 in a similar lesioning model appears to vary depending on the time that 
treatment is initiated (Ramer et a l, 2001). Ramer and colleagues (2001) talk 
about a “two tiered inhibition”. The first tier, the astrogliotic barrier, takes place 
immediately after injury and its effects are susceptible to the intrathecal delivery 
of NT3. The second tier, the degenerative barrier, sets in a week after the lesion is 
inflicted and coincides with the onset of myelin breakdown. Initiating NT3 
treatment at this point cannot overcome the inhibitory signals at the DREZ 
(Ramer et a l, 2001). Regeneration of ascending sensory, dorsal column fibres 
has been reported to occur following the in situ infusion via an osmotic mini­
pump of large amounts of NT3 for a period of four weeks (Bradbury et a l, 1999). 
The regeneration and elongation reported was impressive, with large myelinated 
ap regenerating axons just falling short of reaching their targets in the gracile and 
cuneate nuclei. These findings however, have not been replicated by another 
research group.
In addition to its effects on neurons, NT3 has an effect on glial cells. NT3 has 
been shown to be mitogenic for oligodendrocyte progenitors in vitro (Marmur et 
al, 1998). The in vivo role of NT3 with regards to activated microglia is not fully 
understood yet. These cells have the potential to express NT3 and TrkC 
themselves and they proliferate in response to exogenous NT3 administration 
(Elkabes et a l, 1996). This suggests that this neurotrophin has the potential to act 
both as a paracrine and/or autocrine factor (Nakajima and Kohsaka, 1998). One 
function of NT3 in these cells is to suppress the activation of the inducible form 
of nitric oxide synthase (iNOS) (Tzeng and Huang, 2003). This effect was 
elucidated in in vitro experiments and is as yet to be replicated in vivo but if true 
it would imply that NT3 can exert an anti-inflammatory effect that may be 
beneficial in the injured spinal cord environment.
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4.1.5.2 BDNF
BDNF appears to confer neuroprotection on axotomised CST neurons more 
efficiently than NT3, but it is significantly less efficient at promoting 
regeneration. This holds true when this neurotrophin is injected directly into the 
spinal cord (Schnell et a l , 1994). Primary fibroblasts, transduced by a retroviral 
vector to express BDNF, grafted into a dorsal hemisection lesion site, failed to 
attract axotomised CST fibres (Nakahara et al., 1996). Infusion of BDNF (12 
pg/day for 7 days) was able to prevent the onset of atrophy on axotomised CST 
neurons (Giehl and Tetzlaff, 1996) while a piece of gel foam soaked with BDNF 
enhanced the survival of axotomised CST neurons but failed to promote any 
axonal regeneration (Ye and Houle, 1997). Intracortical infusions of BDNF, 
initiated one week after CST axotomy and carried out for a following two weeks, 
promoted CST survival for a further 42 days after the injury was inflicted 
(Hammond et a l , 1999). The same method however failed to promote any 
regeneration, even in the presence of a peripheral nerve graft (Hiebert et al.,
2002). In a recent study, rat spinal cords lesioned by a contusion injury had a 
combination of foetal spinal cord grafts and genetically modified Schwann cells 
over-expressing NGF and BDNF transplanted within the lesion site (Feng et a l ,
2005). This combinatorial approach is capable of inducing some CST fibres to 
grow into and through the lesion site. BDNF is thought to exert these effects via a 
paracrine mechanism (Schutte et a l , 2000).
4.1.6 Rationale
This chapter describes the experiments employed to test the hypothesis that if 
vector HSVl.pR19CMVrNT3 is capable of transducing injured CST neurons to 
produce biologically active protein, then administration of this construct would 
lead to an increased regenerative response when used done and augment the 
response mounted by the injured CST neurons in the presence of El 4 spinal cord 
segments. This would suggest that the vector-mediated levels of NT3 positively 
influence the limited natural capacity of CST neurons to regenerate. For the 
purposes of testing this hypothesis vector HSVl.pR19CMVrNT3 was constructed 
and its ability to promote regeneration was evaluated either unaided, via sole
205
/ / .S ' / ' /  i v .  -n >r -Hiv. Hi in  -il < h i  i w n  <>! \ / ' . /  m  / l i t  / i i / i t / t / l  t < > r / n  f . j ' U i i / i  / / / i t
vector administration following a chronic lesion or in conjunction with an E l4 
spinal cord transplant. In addition, a new generation of minimally disabled HSV1 
vectors were briefly examined for their efficacy in delivering transgenes to the 
CST via a dorsal column or cortical injection in the adult rat.
4.2 Methods
4.2.1 Vectors utilised in this Chapter
The following vectors were used in this study, either to induce regeneration or for 
the delivery of marker genes to the chronically injured CST of adult rats.
V irus A b b rev ia tio n
1764/IC P277IC P47R L17pR 19CM VLacZ H S V 1 .pR l 9CM VLacZ
1764/1C P277ICP47RL1 VpRl 9CM VGFP H SV l.pR 19C M V G F P
1764/IC P277IC P47R L1 /pR l 9CM VratNT3 HSV  1 .pR l 9CM VrNT3
1764/IC P27+/IC P 47R L 1 +/pR l 9E F 1 a  GFPWPRE H S V l.p R 1 9 E F la  GFPWPRE
1764/IC P27+/IC P 47R L 1 +/pR  19E F 1 a  LacZWPRE HSV  1 .pR l 9 E F 1 a  LacZwpRE
T ab le  4.2 .1-a: V ecto rs used in C ST  reg en era tiv e  stud ies.
The construction and characterisation o f  vectors H SV l.pR 19C M V G FP and 
H SV l.pR 19C M V LacZ  has previously been published (Lilley et al., 2001b). Vectors 
H SV l.pR 19EFlaG FPw PR E and HSVl.pR19EFlaLacZW PRE w ere constructed by D r J.A. Palmer.
4.2.2 Construction and characterisation of HSVl.pR19CMVr/NT3
As discussed in Chapter 3, the vector backbone that allows efficient transgene 
delivery to both injured and chronically injured spinal cord was 1764/ICP27' 
/ICP4’/pR19CMV (HSVl.pR19CMV). In order to create a vector capable of 
delivering biologically active rat NT3 (rNT3) protein, it was first necessary to 
sub-clone the cDNA into the pR19CMV expression cassette, substituting the 
LacZ marker gene. This cassette is flanked by homologous HSV1 LAT sequences 
enabling it to be subsequently inserted into the viral genome by homologous 
recombination. Production of rNT3 and confirmation of its bioactivity was then 
confirmed in vitro and in vivo.
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4.2.2.1 Construction of plasmid pGEM5/pR19CMVrNT3
cDNA encoding for rNT3 (GeneBank accession number M33968) was originally 
cloned as a Xhol PCR generated fragment into pBluescript® SK (Maisonpierre et 
a l , 1990a). rNT3 cDNA (800bp) was removed by digesting first with Kpnl, 
blunted using T4 DNA Polymerase and finally cut with Hindlll. The fragment 
was then sub cloned into the pR19 shuttle plasmid flanked by LAT sequences, 
allowing insertion into the LAT region (Lilley et al., 2001b). The reporter gene 
GFP of the vector backbone pGEM5/pR19CMVGFP, was removed using Xhol 
followed by blunt ending with T4 DNA polymerase and digestion with Hindlll. 
Multiple pGEM5/pR19CMVrNT3 clones were screened for the correct restriction 
profile following Xhol digestion. Correct cloning of the neurotrophin 3 (Ntf3) 
gene was confirmed by sequencing, using a CMV forward primer as listed in 
Chapter 2.
4.2.2.2 Production of HSVl.pR19CMVrNT3 vector
Purified HSVl.pR19CMVGFP (1764/ICP277ICP47pR19CMVGFP) viral DNA 
was co-transfected with pGEM5/pR19CMVrNT3 plasmid DNA. The construct 
was recombined into the endogenous LAT of the HSVl.pR19CMVGFP 
backbone between the two BstXI sites («rl 20,220 and ntl 20,408) (Lilley et al., 
2001b). Recombinant plaques were detected by their white phenotype (no GFP 
expression), which is indicative of the correct insertion of the pR19CMVrNT3 
expression cassette in both LAT regions of the HSV genome. Plaque purification 
was carried out until all plaques had the recombinant, white phenotype. The new 
vector was termed HSVl.pR19CMVrNT3 (1764/ICP27 /ICP4/pR19CMVrNT3). 
Correct insertion of the rNT3 gene was confirmed by Southern blotting on 
recombinant plaques, each originating from separate recombination events. The 
recombinant vector was propagated by standard cell culture techniques on 
27/12/M:4 cells and viral stocks were produced as outlined in Chapter 2.
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4.2.23 Southern blotting on HSVl.pR19CMVrNT3 plaques
Each purified recombinant HSVl.pR19CMVrNT3 viral plaque was used to infect 
lxlO6 27/12/M:4 cells in a 36 mm well tissue culture plate. Viral DNA from each 
plaque was extracted as outlined in Chapter 2, digested with Xhol and run on a 
2% (w/v) agarose gel. HSVl.pR19CMVGFP viral DNA digested by 
Hindlll/Xhol (releasing a 600bp fragment corresponding to GFP) was used as a 
negative control while a Xhol digested plasmid pBKS-rNT3 was used as a 
positive control. The pBSK-rNT3 plasmid was digested with Xhol and the rNT3 
800bp fragment produced was purified and labelled with otP34-dCTP to create an 
rNT3 specific probe. A detailed account of the procedure is given in Chapter 2.
4.2.2.4 Isolation & concentration of secreted rNT3 from cultured BHKs
lx l06 BHK cells in a 36 mm well were infected at an MOI of 1. Two days later 
the infected monolayer was washed twice with 0.1M PB and 500 pi of DMEM 
were aliquoted in each well. The cells were subsequently returned to a 
37°C/5%CC>2 incubator. At the desired time point, the DMEM was collected and 
centrifuged at 2,000 rpm for 5 minutes to remove any cells present. The 
supernatant was then transferred onto a 500 pi Microcon column with a lOkDa 
molecular weight cut-off (G-10000, Green). The column was then spun at 
1 l,500g for 25 minutes at 4°C. The total volume of the concentrated sample was 
20-25 pi, which represents the amount of rNT3 secreted from lxlO6 BHK cells 
infected with HSVl.pR19CMVrNT3. These were used for further testing such as 
Western blotting, ELISA or neurite outgrowth assays.
4.2.2.5 ELISA assay on vector secreted rNT3 in vitro
Supernatants from lxlO6 BHK cells previously infected with 
HSV 1 .pRl9CMVrNT3 (n=6) or HSVl.pR19CMVGFP (n=2) at an MOI of 1 or 
were mock infected (n=2). Samples were obtained as outlined in the previous 
section with the exception that supernatants were not concentrated. Instead, they 
were serially diluted from 1:2 down to 1:10. Samples were analysed using the 
NT3 Emax® Immunoassay system (Promega) according to manufacturer’s 
instructions.
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4.2.2.6 Western blotting
Secreted rNT3 from lxlO6 BHK cells previously infected with 
HSVl.pR19CMVrNT3 at an MOI of 1 was obtained as outlined above. 
Expression was analysed at 2, 4 and 8-hour time points. An equal volume of 
protein sample buffer [5% (v/v) b-mercaptoethanol, 50mM Tris-HCl pH 8.0, 2% 
(w/v) SDS, 6% (v/v) glycerol and 0.005% (w/v) bromophenol blue] was added to 
each sample. Samples were placed on ice immediately and subsequently 
denatured by heating to 95°C for 4 min. They were then cooled on ice for 2 
minutes and either loaded onto a 15% SDS-polyacrylamide gel or stored at -20°C. 
SDS-PAGE, transfer and antibody incubations were performed as described in 
Chapter 2. The primary antibody used was obtained from rabbit polyclonal anti­
rat NT3 (1:200) (N-20, Santa Cruz Biotechnology, Inc., SC-547). Equal protein 
loading was confirmed by evaluating band intensity on a duplicate coomassie 
stained gel.
4.2.2.7 Neurite outgrowth assay on E14 rat DRG explants
Lumbar E14 rat DRGs were isolated, embedded in collagen and maintained in a 
chemically defined medium (DMEM/F12 (3:1) supplemented with 200 pg/ml 
transferrin, 200 pM putrescine, 40 nM progesterone, 60 nM selenium, 10 pg/ml 
insulin 0.01% (w/v) albumin) for 24 hrs. The supernatant from lx l06 BHK cells 
previously infected at an MOI of 1 with HSVl.pR19CMVrNT3 (n=3) or 
HSVl.pR19CMVGFP (n=3) (negative control) or mock-infected (n=2) was 
collected, clarified to remove cellular debris and concentrated as described in 
Chapter 2. The concentrated conditioned media was added to each collagen 
embedded DRG explant. This was repeated every day and neurite extension was 
compared 3 days later by immunofluorescent staining of the resulting neurites 
using mouse TUJ1 anti-neuron specific type III p tubulin antibody (1:5000, 
Cambridge Bioscience, UK). Recombinant human NT3 (R&D Systems, 267-N3) 
was used as a positive control for the experiment. Throughout the duration of the 
experiment, explants were supplemented with lOng/ml of NGF (2.5S) in order to 
ensure their survival.
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4.2.3 In vivo delivery of HSVl.pR19CMVrNT3
4.2.3.1 Corticospinal tract lesions
Lesions were performed on deeply anaesthetised adult female Lewis Rats, 
(~200g). A longitudinal incision was made in the skin at the midline over the 
cervical spine. A second incision was made the superficial muscle layers and the 
underlying muscles were separated by blunt dissection. The C6 vertebra was 
exposed and a bilateral laminectomy performed using malleus scissors. The dura 
mater was carefully cut with micro-scissors to expose a small segment of the 
spinal cord. At this point the animals were injected with 2.2mg/Kg of Finadyne 
(Schering-Plough) for analgesia. With the aid of irridectomy scissors, an incision 
extending to the central canal was inflicted severing both the ascending dorsal 
columns and the dorsal corticospinal tracts (Figure 4.2.3-a). The dura and 
musculature was repaired using silk sutures and finally the skin was closed with 
Michel clips. Post-operatively, the animals were kept in a clean cage and 
monitored every hour for the first 6 hours and twice a day after the first day, until 
stable.
4.2.3.2 Spinal cord Microinjection of disabled HSV1 vectors
Spinal cords were exposed as described in the previous section. The pia matter 
was gently pierced with a fine needle in order to prevent crushing the tissue it 
protects. A 25 pi Hamilton syringe fitted with a fine needle (outer 0  300 pm) was 
used to administer the vector. This was done by lowering the needle through the 
opening in the pia matter and 1.5 mm into the cord using the micromanipulator of 
a stereotaxic frame. After 5 min, the virus suspension was injected at a rate of 0.5 
pl/min using a micropump. HSVl.pR19CMVrNT3 or HSVl.pR19CMVLacZ 
vector was delivered in two 2.5 pi aliquots, about 5 mm apart and either side of 
the lesion site, along the rostro-caudal axis of the C6-C7 segments. Following 
injection, the virus was allowed to diffuse for a further 10 minutes prior to 
removing the needle. Once the needle was removed, the dura, spine muscles and 
the overlaying skin was repaired with Michel clips.
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CST Lesion
V irus In jection o r 
T ransp lan ta tion
BDA tra c e r
F igure 4.2.3-a: Schem atic d iagram  of the CST lesion experim ents.
The dorsal half o f  the spinal cord was transected bilaterally at the cervical level (1). In most 
experiments, any potentially therapeutic intervention such as vector administration or embryonic 
neural tissue transplantation (2) occurred at 1-month post lesion. BDA tracer was injected into the 
motor cortex (3) three days prior to the termination o f  the experiment. Spinal cords were 
sectioned at a thickness o f  40pm and analysed via microscopy.
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4.2.3.3 Transplantation of E14 rat spinal cord segments
Deeply anaesthetised adult female Lewis rats, received a CST lesion as described 
in section 4.2.3.1, with the exception that a 1.5-2 mm piece of gel foam was 
placed within the lesion site as soon as it was inflicted in order to prevent the 
creation of a large scar. Four weeks post injury the spinal cord was re-exposed 
and cleared of any scar tissue present at the lesion site by gently removing the 
piece of gel foam. This created a 2-3 mm gap within the lesion site. Whole E14 
embryonic spinal cords were extracted as needed and dissected into 1 - 3  mm 
segments which were then inserted within the newly created gap at the lesion site. 
Typically, one segment was necessary per animal. The dura was carefully sutured 
in order to keep the embryonic tissue in place. Muscle and skin were sutured in 
layers. Animals were kept in clean cages and 2 mg/Kg/day of Cyclosporin A 
(CsA) (Neoral®, Novartis, UK) was administered orally, one week prior to 
transplantation and throughout the four weeks following the transplant and vector 
administration when animals were terminated. CsA dosage was adjusted for the 
Rattus Norvegicus species and re-suspended in the animal’s drinking water 
(Wolfensohn and Lloyd, 1998). The preparation was altered daily to ensure that 
no bacterial contamination occurred.
Note: Prof. P.N. Anderson performed the E l4 spinal cord transplantations.
4.2.3.4 Tracing of CST fibres by biotin dextran processing
The cranium was exposed via a midline skin incision. Using a stereotaxic frame 
to hold a fine drill and to target the motor cortex, the brain was exposed by a hole 
through the cranium. The dura mater was delicately pricked to avoid crushing the 
tissue it protects. Using a 25 pi Hamilton syringe, 1 pi of the anterograde tracer 
10% biotinylated dextran amine (BDA; 10,000MW, Molecular Probes) in PBS, 
was injected in the motor cortex for labelling the CST. The following co­
ordinates were used for the CST (targeting the motor cortex at an angle of 10°): 
rostral-caudal 1-2 mm, medial-lateral 1-2 mm, dorsal-ventral 2.0 mm. Injections 
were made in 0.2 pi increments over two minutes. After a 10 min wait, to allow 
for the diffusion of the tracer, the needle was slowly withdrawn, muscles and the 
skin were sutured. Processing was carried out on free-floating sections for the
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visualisation of BDA. Labelling was visualized by incubating the tissue for 1 hr 
with an avidin-peroxide complex (ABC kit; Vector Laboratories, Burlingame) 
diluted 1:500 in PBS containing 0.25% Triton X-100 (PBT). The tissue was 
rinsed three times for lOmin in PBS and then stained with 0.05% 
diaminobenzidine hydrochloride (DAB; Sigma, St. Louis, MO) and 0.01% H2O2 
in PBS containing 0.01-0.02% nickel sulphate and 0.01-0.02% cobalt chloride. 
Sections were mounted on gelatinised slides and processed as already outlined in 
Chapter 2.
4.2.3.5 ELISA assay on vector secreted rNT3 in vivo
Deeply anaesthetised adult female Lewis rats received a unilateral CST lesion in 
the dorsal columns at the L5-L6 level. Three days later, animals were injected 
with 2.5x107 pfu/ml of either HSVl.pR19CMVrNT3 (n=6) or 
HSVl.pR19CMVGFP (n=3) or 5 pi of DMEM (n=3) 3 days after lesioning. 
Three weeks later, animals were decapitated and a spinal cord segment 5 mm 
distal x 5 mm proximal to the injection site was quickly dissected and dipped in 4 
volumes of ice cold DPBS to remove any excess blood. Tissue samples were 
immediately homogenised in lysis buffer (135 mM NaCl, 20 mM Tris/HCl pH 
7.5, 1% Nonidet P40, 10% Glycerol, 1 mM PMSF, 1 pg/ml Leupeptin, 0.5 mM 
Sodium Ortho vanadate) while kept at 4°C. Lysates were then centrifuged at 
15,000g for 10 min at 4°C. The amount of total protein in each of the lysate 
supernatants was established using a commercially available BCA protein assay 
kit (BioRad) (Smith et al., 1985). Free, total NT3 in the samples was detected 
using the NT3 Emax® Immunoassay system (Promega) according to 
manufacturer’s instructions and expressed in pg/mg of total protein.
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4.3 Results
4.3.1 Functional characterisation of vector HSVl.pR19CMVrNT3
Cloning of the M/3 gene into the pGEM5.pR19CMV plasmid in place of GFP 
was confirmed by sequencing the region following the CMV promoter. The 
ability of the HSVl.pR19CMVrNT3 vector to express the transgene was assessed 
both in vivo and in vitro. The correct molecular characteristics of the vector were 
assessed by ensuring that the white recombinant phenotype observed in infected 
cells was due to the correct insertion of the pR19CMVrNT3 expression cassette 
into each of the two endogenous LAT regions (Figure 4.3.1-a). This was 
confirmed by Southern Blot analysis on three recombinant plaques. As shown in 
Figure 4.3.1-b (panel A), all three plaques appear positive for the presence of the 
transgene, with an ~800bp band (Maisonpierre et a l, 1991) being present 
following Xhol digestion of the plaque viral DNA. This band corresponds to the 
one obtained via the same restriction on pBKS-rNT3 and 
pGEM5.pR19CMVrNT3 plasmid DNA which were used as positive controls.
To assess the capability of the HSVl.pR19CMVrNT3 vector to transduce cells, 
lx l06 BHK cells were infected at an MOI of 1 with either HSVl.pR19CMVGFP 
(n=2) or HSVl.pR19CMVrNT3 (n=2 per time point). Supernatants were 
collected at 8 hours in the case of HSVl.pR19CMVGFP (control) and at 2, 4 and 
8 hour time points in the case of HSVl.pR19CMVrNT3 infected cells (n=2 per 
time point). Conditioned media was analysed for the presence of secreted rNT3 
using standard ELISA or Western blotting techniques. ELISA analysis of the 8 
hour time point conditioned media confirmed that HSVl.pR19CMVrNT3 is 
capable of transducing non complementing cells to express the transgene (Figure
4.3.1-d, panel A). Expression is efficient with 13.5 ng ±1.3 (Mean ± SEM) of 
rNT3 produced per lxlO6 infected cells over an 8 hour period CP=0.00004). Even 
though this assay confirms the presence of rNT3, it does not provide any 
information about whether the protein detected corresponds to the mature form of 
the active protein or not. It was therefore necessary to assess the molecular 
weight migration profile of the bands recognised by an NT3 specific antibody.
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>ref|NW 047696.2|Rn4 WGA2219 3 Rattus norvegicus chromosome 4 genomic contig 
Length=39585501
Features in this part of subject sequence:
neurotrophin 3
Score = 1494 bits (777), Expect = 0.0 
Identities = 777/777 (100%), Gaps = 0/777 (0%)
Strand=Plus/Plus
Q u e r y 21 TCATGTTCTTCCGATTTTTCTTGACAAGGCACACACACAGGAAGTGTCTATTCGTATCCA 
II II 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 I I I I 1 1 I 
TCATGTTCTTCCGATTTTTCTTGACAAGGCACACACACAGGAAGTGTCTATTCGTATCCA
80
S b j c t 15539870 15539929
Q u e r y 81 GCGCCAGCCTACGAGTTTGTTGTTTTCTGAAGTCAGTGCTCGGACGTAGGTTTGCGACGT
1 I I  I I  I I  1 1 I I  1 I I  1 I I  I I  1 I I  I I  M 1 I I  I I  1 M I I  I I  M 1 1 M I I  I I  I I  1 1 1 1 1 1 1 1 1 1
140
S b j c t 15539930
1 1 1 1 1 1 1 II 1 I 1 1 II 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 I 1 1 I I II I 
GCGCCAGCCTACGAGTTTGTTGTTTTCTGAAGTCAGTGCTCGGACGTAGGTTTGCGACGT 15539989
Q u e r y 141 TTTGCACTGAGAGTTCCAGTGTTTGTCATCAATCCCCCTGCAACCGTTTTTGACTGGCCT 
1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 I I II 1 1 I 
TTTGCACTGAGAGTTCCAGTGTTTGTCATCAATCCCCCTGCAACCGTTTTTGACTGGCCT
200
S b j c t 15539990 15540049
Q u e r y 201 GGCTTCTTTACACCTCGTTTCATAAAAATATTGTTTCACAGGAGAGTTGCCGGTTTTGAT 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GGCTTCTTTACACCTCGTTTCATAAAAATATTGTTTCACAGGAGAGTTGCCGGTTTTGAT
260
S b j c t 15540050 15540109
Q u e r y 261 CTCTCCCAACACTGTAACCTGGTGTCCCCGAATGTCAATGGCTGAGGACTTGTCGGTCAC 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
CTCTCCCAACACTGTAACCTGGTGTCCCCGAATGTCAATGGCTGAGGACTTGTCGGTCAC
320
S b j c t 15540110 15540169
Q u e r y 321 CCACAGGCTCTCACTGTCACACACTGAGTACTCTCCTCGGTGACTCTTATGCTCTGCATA
1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
CCACAGGCTCTCACTGTCACACACTGAGTACTCTCCTCGGTGACTCTTATGCTCTGCATA
380
S b j c t 15540170 15540229
Q u e r y 381 GCGTTTCCTCCGTGGTGATGTTCTATTGGTTACCACCGGGTTGCCCACATAATCTTCCAT 
1 1 1 1 1 1 M 1 1 1 1 1 1 1 1 1 1 1 1 1 II II 1 1 I II 1 1 1 1 1 1 II 1 1 1 1 1 I I I 1 I I I I | | | | | | | | | 
GCGTTTCCTCCGTGGTGATGTTCTATTGGTTACCACCGGGTTGCCCACATAATCTTCCAT
440
S b j c t 15540230 15540289
Q u e r y 441 TAGATATAAGGGAGGGGGCTCCAAAGGGGTGCTGTCACTCAGCAGGACCCGGGGTGAATT 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
TAGATATAAGGGAGGGGGCTCCAAAGGGGTGCTGTCACTCAGCAGGACCCGGGGTGAATT
500
S b j c t 15540290 15540349
Q u e r y 501 GTAGCGTCTCTGTTGCCGTAGTAGTTCTGTGTCTGTTGCAATCATCGGCTGGAATTCTGA 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GTAGCGTCTCTGTTGCCGTAGTAGTTCTGTGTCTGTTGCAATCATCGGCTGGAATTCTGA
560
S b j c t 15540350 15540409
Q u e r y 561 CCTGGTGGCCTCTCCCTGCTCTGGTTCTCTGGGTGCCTCTGCTTTGGGCAGGGTGCTCTG 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I 1 I I 1 1 1 1 1 1 1 1 1 1 
CCTGGTGGCCTCTCCCTGCTCTGGTTCTCTGGGTGCCTCTGCTTTGGGCAGGGTGCTCTG
620
S b j c t 15540410 15540469
Q u e r y 621 GTAATTTTCCTTAACATCTACCATCTGCTTGGAGAGCTTGTTTTTCAAGATATCCGCCTG 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I I I 1 1 
GTAATTTTCCTTAACATCTACCATCTGCTTGGAGAGCTTGTTTTTCAAGATATCCGCCTG
680
S b j c t 15540470 15540529
Q u e r y 681 GATCAACTTGATAATGAGGGAATTGAGAGAGTCTTCTGGCAAACTCCTTTGATCCATGTT 
1 1 1 1 1 1 M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I | | | | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I | | I 1 
GATCAACTTGATAATGAGGGAATTGAGAGAGTCTTCTGGCAAACTCCTTTGATCCATGTT
740
S b j c t 15540530 15540589
Q u e r y 741 GTTGCCTTGGATGCCACGGAGATAAGCAAGAAATATCACATAAAACAAGATGGACAT 797
Sbjct 15540590 GTTGCCTTGGATGCCACGGAGATAAGCAAGAAATATCACATAAAACAAGATGGACAT 15540646
Figure 4.3.1-b: Alignment of the cloned rat 7V(/3gene against the draft rat genome.
The cloned rat Nt/3 sequence shown above is identical to that of contig NW 047696.2 from the 
Rattus Norvegicus genome.
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A. Southern blotting HSVl.pR19CMVrNT3
HSVl.pR19 "* 
pBKSrNT3 pGEM5rNT3 CMVGFP f ■S"
800 bp
B. W estern blotting
NT3 HSVl.pR19 
kDa S tandard  CMVGFP
66.0 —
45.0 —
30.0 —
21.1 —
14.3 —
HSVl.pR19CMVrNT3
(MOI=l)
2 hr 4 hr 8 hr
Figure 4.3.1-c: Functional characterisa tion  o f H SV l.pR 19C M V rN T3.
A. Southern blotting on three purified recombinant plaques o f  HSVl.pR19CMVrNT3 vector.
pBKSrNT3 and pGEM5pR19CMVrNT3 were used as positive controls while
HSVl.pR19CM VGFP was used as a negative control. The only band recognised from the 
rNT3 probe (pKS-NT3, Xhol digest) corresponds to the rNT3 gene (~800bp).
B. Western blot analysis o f  conditioned media from HSVl.pR19CM VGFP (n=2) or
HSVl.pR19CM VrNT3 (n=2 per time point) infected BHK cells, probed with Rabbit
polyclonal anti-rat NT3. Recombinant rNT3 was loaded at 10 pg/ml to act as a positive 
control. Conditioned media obtained from lxlO 6 BHK cells, infected with 
HSVl.pR19CM VGFP at the same MOI did not produce any bands that cross-reacted with 
the primary antibody used, endorsing its specificity to rNT3.
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Figure 4.3.1-d: In vitro & in vivo expression of rN T3 via H SV l.pR 19C M V rN T3.
In vitro and in vivo ELISA assay using the Promega NT3 Emax® Immunoassay system.
A. Supernatants from lx l0 6 BHK cells either uninfected (Mock, n=3) or previously infected with 
HSV 1 .pR 19CMVrNT3 (n=6) or HSVl.pR19CM VGFP (n=2) vectors at an MOI o f  1, were 
analysed in triplicate. HSVl.pR19CM VrNT3 infected cells appear to efficiently express and 
secrete the transgene with lx l0 6 BHK cells producing 13.5ng/ml ±  1.3 (Mean ± SEM O.D.) o f 
vector encoded rNT3, over 8 hours. Corresponding supernatants from cells infected with 
HSVl.pR19CM VGFP vector demonstrate no interference with the detection o f 
HSVl.pR19CM VrNT3 vector delivered rNT3 (Student’s T-test: ***P<0.001, compared to 
HSVl.pR19CM VGFP infected cells).
B. L5-L6 spinal cord segment was inoculated with either 2.5x106 pfu o f HSVl.pR19CM VrNT3 
(n=3) or HSVl.pR19CM VGFP (n=3) vector or with 5 pi o f DMEM (Mock, n=3). Three weeks 
after inoculation, spinal cords were assayed in triplicate. The amount o f  rNT3 produced in 
transduced spinal cords was found to be 497 pg/mg o f protein ± 19.4 (Mean ± SEM O.D.) 
(♦PO.OS compared to HSVl.pR19CM VGFP treated animals), which is significantly higher than 
that found in either control or Mock-injected spinal cords.
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Western blot analysis of conditioned media revealed the presence of a single, 
prominent band, corresponding to a molecular weight of 14.5 kDa, similar to that 
of recombinant rNT3 (10 pg/ml) (Figure 4.3.1-c, panel B). The amount of NT3 
detected appears to increase with longer time points, reflecting the efficient 
nature of NT3 transcription via the CMV promoter of the pR19 expression 
cassette (Lilley et al., 2001b). Even though faint, a band with an apparent 
molecular weight of ~35 kDa seen at the longer time points of four and eight 
hours, could correspond to the unprocessed precursor (pro-NT3) of mature rNT3 
which is reported to have a molecular weight of 33.5 kDa (Farhadi et a l , 2000). 
The increasing amounts of detected pro-rNT3, could suggest that at least some 
precursor evades proteolytic cleavage, perhaps by overwhelming the processing 
capacity of the cell (Mowla et al., 1999). Alternatively, it could be a reflection of 
inevitable cell lysis and concomitant release of unprocessed pro-NT3 in the 
conditioned media.
Thus far, evidence from the above in vitro experiments confirms the ability of 
HSVl.pR19CMVrNT3 vector to support the expression of the transgene in a non­
complementing cell line. The efficiency of this vector to transduce the lumbar 
spinal cord of animals that had previously received an L5-L6 unilateral dorsal 
column lesion, was assessed. Lesioned animals were injected with either 
HSV 1 .pRl9CMVrNT3 (n=3) or HSVl.pR19CMVGFP (n=3) or 5 pi of DMEM 
(n=3) three days after lesioning. Four weeks later, the injected portion of the 
lumbar spinal cords was excised and the amount of NT3 present estimated by 
ELISA assay. As shown in Figure 4.3.1-d (panel B), the amount of NT3 was 
found to be 497pg/total mg of protein ± 19.4 (Mean ± SEM) in 
HSVl.pR19CMVrNT3 treated animals, which is significantly different 
(P=0.012) to that measured in control or mock treated animals. The 4-week time 
point, selected for this analysis served the purpose of demonstrating that this was 
a viable point at which to assess any potential regeneration in experiments 
involving HSVl.pR19CMVrNT3. The amount of rNT3 detected in injected 
spinal cords may at first appear rather low when considering the strong 
expression levels obtained when delivering the marker gene LacZ via the same 
backbone. However, LacZ is an intracellular enzyme that, lacking any suitable
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signals, is not secreted, as is the case for NT3. Instead, it accumulates within the 
cell for the duration of the experiment and can distort the quantity of transgene 
converted to actual protein. In addition, since it is an enzyme, the depth of blue 
colour also depends on the amount of substrate available rather than just the 
levels of transgene expression. It is therefore an unreliable marker in terms of 
actual gene expression levels and it would be misleading to assume that the 
amount of NT3 protein produced by infected cells is comparable to that obtained 
for LacZ at similar time points.
Noticeably, the amount of NT3 present is approximately half of that found when 
adenoviral (Blits et a l , 2000) or adeno-associated (Blits et a l , 2003) vectors 
encoding NT3 under the control of a CMV promoter, are used either to transduce 
293 cells in culture (Blits et a l , 2000; Blits et a l , 2003) or injected into adult rat 
spinal cords (Dijkhuizen, 1999). Compared to a differently disabled but HSV1 
based vector however the amount of NT3 produced in vivo and in vitro, reported 
at 100 pg/mg of protein and 15 pg/10 cells respectively, is comparable in scale to 
the one achieved with vector HSVl.pR19CMVrNT3 (Chattopadhyay et al., 
2002). The disparity noted between adenoviral and HSV 1 based vectors could be 
due to the ability of HSVl.pR19CMVrNT3 to specifically transduce neurons 
compared to an adenoviral vector that can infect non-neuronal populations as 
well (Dijkhuizen, 1999; Blits et a l, 2000). NT3 secreted from non-neuronal cells 
could contribute to the total amount detected by the ELISA. To complicate 
matters even more, vectors are often utilised at different pfu, which is in turn 
determined by their overall toxicity in vivo. Differences in pfu would directly 
impact on the overall transgene expression levels thus complicating any direct 
comparison. Furthermore, the procedure used to measure the total amount of NT3 
present in spinal cord samples is prone to variations as it depends on the 
thoroughness of the operator and speed of tissue extraction. It is therefore very 
difficult to safely draw any solid conclusions regarding the relative ability of the 
HSVl.pR19CMVrNT3 vector to induce a biological effect based on its ability to 
transduce a target population. It is also unsafe to draw any definitive conclusions 
regarding this vector’s efficiency compared to that achieved with other vector 
systems used to deliver transgenes in the CST.
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The ability of HSVl.pR19CMVrNT3 vector to deliver biologically active NT3 
was evaluated on E l4 lumbar DRG explants. At E l4, DRGs have been shown to 
contain a subpopulation of NT3 responsive neurons (Maisonpierre et al., 1990b; 
Hory-Lee et a l , 1993) which could be stimulated to extend neurites in the 
presence of biologically active NT3 (Crowley et al., 1994; Smeyne et al., 1994). 
The ability of vector-encoded rNT3 to induce such a biological response was 
assessed by means of treating the explants with conditioned media obtained from 
transduced, non-complementing BHK cells. Collagen embedded E l4 explants 
were supplemented daily either with recombinant human NT3 (n=2 DRGs per 
well) or with media collected from lxlO6 BHK cells, previously infected with 
either HSVl.pR19CMVGFP (n=3) or HSVl.pR19CMVrNT3 (n=3) at an MOI of 
1. Conditioned media was obtained fresh each day and it was briefly clarified in 
order to remove cellular debris. Following three days of treatment, explants were 
fixed and immunostained with TUJ1 neurofilament antibody.
Figure 4.3.1-e (panel C) clearly demonstrates that vector-encoded rNT3 is 
capable of inducing the extension of a dense network of neurites radiating from 
E14 DRG explants treated with HSVl.pR19CMVrNT3 conditioned media. 
Moreover, vector encoded rNT3 appears to induce the outgrowth of thick neurite 
bundles which correspond to an NT3-specific biological response (Davies, 2000). 
It has previously been reported that mice lacking NT3 during development 
develop severe sensory neuron deficits in proprioceptive DRG neurons and 
demonstrate an inability to perform coordinated motor tasks (Farinas et al., 1994; 
Klein et a l , 1994; Tuttle et a l , 1995). Neurite elongation appears to be more 
robust than the growth promoted when using 50 ng/ml of recombinant NT3 
(panel B). This is not surprising as recombinant NT3 was not replenished for the 
duration of the experiment, unlike the HSVl.pR19CMVrNT3 conditioned media, 
which was replenished on a daily basis. Contrary to the dense growth observed in 
HSVl.pR19CMVrNT3 treated explants, bathing them in HSVl.pR19CMVGFP 
conditioned media mediates minimal neurite outgrowth. This experiment 
confirms that vector-encoded rNT3 is biologically active and capable of inducing 
a growth promoting effect, at least in vitro, and provides the basis for further in 
vivo regenerative attempts targeting the chronically injured corticospinal tract.
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Figure 4.3.1-e: Biological assay for vector encoded rN T3 on E14 ra t DRGs.
All E14 rat DRG explants (section 4.2.2.7) were supplemented with 10 ng/ml o f  NGF (2.5S) on 
which they depend on for survival at that age (Crowley et al., 1994; Smeyne et a l,  1994). TUJ1 
immuno-staining on collagen embedded E14 DRGs treated with either A, B or C.
A. Negative control (not infected) E14 explants supplemented with conditioned media from 
HSVl.pR19CM VGFP lxlO 6infected BHK cells, display minimal neurite outgrowth.
B. Positive control explants supplemented with 50 ng/ml o f  recombinant human NT3. 
(Maximal activity is reported at lOOng/ml, R&D systems protocol).
C. Explants supplemented with media from HSVl.pR19CM VrNT3 lx lO 6 infected BHK 
cells at an MOI o f 1 display a dense halo o f  thick neurite bundles.
Scale Bar: 500pm, applies to all figures.
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4.3.2 Effect of vector encoded rNT3 on CST regeneration
This study aimed to address whether HSVl.pR19CMVrNT3 is capable of 
promoting regeneration in the chronically injured spinal cord model. For our 
purposes, a chronic injury refers to an injury inflicted at least one month prior to 
any intervention and it is under these circumstances that the HSVl.pR19CMV 
based vectors have been evaluated in transducing the CST tract. In Chapter 3, it 
was demonstrated that simultaneous proximal and distal injection of the vector 
allowed the best transduction to occur in the chronic CST lesion model. 
Furthermore, it was shown that transgene expression persists for at least one 
month following inoculation (Lilley et al., 2001b). However, it also became 
evident that this generation of vectors did not have the ability to sustain transgene 
expression in the injured or uninjured CST neurons. Whether this method of 
administration would enable vector HSVl.pR19CMVrNT3 to mediate 
regeneration in the chronic CST model was explored in this study.
2.5x106 pfu of HSVl.pR19CMVrNT3 (n=8) or HSVl.pR19CMVLacZ (n=3) 
vector were injected both proximal and distal to the lesion site at the C6 level, in 
pre-lesioned animals (section 4.2.3.1). Four weeks following vector inoculation, 
very few axons can be found within the lesion site of HSVl.pR19CMVLacZ 
treated animals, most of which appear to have retraction bulbs, indicative of 
abortive growth (Figure 4.3.2-a, panel A). In three of the eight 
HSVl.pR19CMVrNT3 vector treated animals some evidence of proximal 
sprouting can be seen with only a few axons extending into the lesion site (Figure
4.3.2-a, panel B). However, proximally sprouting axons appear to follow an 
irregular route, seemingly turning away from the edge of the lesion site. The 
number of axons found within the lesion site is marginally higher than that 
observed in animals treated with HSVl.pR19CMVLacZ vector only (control). 
Also, abortive regeneration appears less prominent than that observed in control 
animals. Thus, it would be reasonable to conclude that HSVl.pR19CMVrNT3 
treatment appears to minimally enhance the number of regenerating, BDA 
positive axons and reduce the number of retraction bulbs found within the lesion 
site, compared to HSVl.pR19CMVLacZ treated animals.
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F igure 4.3.2-a: H SV l.pR 19C M V rN T 3 adm in istra tion  m inim ally induces CST regeneration .
Longitudinal sections o f  spinal cord showing BDA labelled CST axons at the site o f a CST lesion 
at the C6 level, made one-month previously. HSVl.pR19CM VLacZ vector (A) or 
HSVl.pR19CM VrNT3 vector (B) were injected both proximal and distal to the lesion site. A. 
Very few BDA labelled CST axons are present within the lesion site, most with retraction bulbs 
(▼). Low level, abortive sprouting can be seen proximally to the lesion. B. Three CST axons 
show low level sprouting proximally as well as into the lesion site. Proximal sprouting axons 
appear to follow an irregular route (*). The dotted line demarcates the proximal boundaries o f  the 
lesion site. Scale bars: 50pm, applies to A and B.
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The results from the three animals described here represent the best result 
obtained from a series of similar experiments that demonstrated no apparent 
anatomical difference between control and rNT3 treated animals. This distinct 
inability of vector delivered rNT3 to mediate any significant regeneration was 
noticed early in this study and prompted us to repeat this attempt in order to rule 
our any potential operator errors. The main error considered was the possibility of 
not delivering the correct amount of viral suspension, thus altering the total pfu. 
Over the course of these studies it became clear that the injection method and 
animal survival were the Achilles heel of these experiments. After having 
repeated this experiment numerous times (Total number of animals used 
HSVl.pR19CMVLacZ: n=6 and HSVl.pR19CMVrNT3: n=18) it became 
apparent that the lack of regeneration was unlikely to be due to an experimental 
discrepancy but rather reflects an underlying inability of vector-encoded rNT3 to 
promote any meaningful regeneration, anatomically at least, in the chronically 
injured CST. In addition to the simultaneous inoculation of the vector both 
proximal and distal to the lesion site described here, the effect of a single 
injection of HSVl.pR19CMVrNT3 vector either proximally or distally had 
previously been addressed (results not shown). This was done in order to explore 
the possibility that vector administration had to reflect the role NT3 will have to 
fulfil as a regeneration-promoting factor. Firstly, we examined the possibility that 
rNT3 had to be delivered distally in order for it to act as a chemo-attractant for 
the injured CST axons. Several reports suggest that for CST axons to regenerate 
they must have a guided growth towards an increasing concentration gradient of 
the neurotrophic factor (Bradbury et al., 1999). Therefore NT3 should be placed 
distally to the lesion so that axons are encouraged to transverse the lesion site and 
exit caudally towards the source of the neurotrophin. For sole delivery distally to 
the lesion site to be successful, the vector must be administered distally enough 
so that uninjured neurons in the spinal cord become transduced and secrete NT3, 
while at the same time close enough to the injured axons so that local virally- 
induced rNT3 over-expression can positively impact the axotomised CST fibres. 
It has proved technically very difficult to correctly deliver such an injection in the 
chronically injured CST model. Even though a stereotactic frame was used, 
demarcation of the lesion site in the living animal is often less that
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straightforward. Secondly, we examined the possibility that vector encoded rNT3 
had to be delivered in close proximity to the injured CST axons in order for them 
to have maximum stimulation towards regeneration. Proximal administration 
needs to target local neuronal somata that would produce an in situ pool of rNT3 
that would attract axotomised CST axons. Since HSVl.pR19CMVrNT3 vector 
preferentially infects neurons and NT3 can be transported bi-directionally 
(DiStefano et al., 1992; Altar and DiStefano, 1998), it was expected that either 
method would at least demonstrate some effect, if not regenerative then at least 
have an impact on the number of retracting bulbs present following axotomy. 
Disappointingly, none of these treatments produced any effect.
Even though frustrating, the inability of sole vector mediated NT3 administration 
to promote any meaningful CST regeneration is surprising. Perhaps the total lack 
of an effect suggests that delivering the vector in a single location might be an 
inefficient and irreproducible means of administration. It is logical to suggest that 
a single administration, compliant with such stringent criteria is just too difficult 
to achieve in a reproducible and reliable manner. For example, wrongful 
administration of the vector too close to the lesion site would result in minimal 
expression of rNT3. This is because HSVl.pR19CMV based vectors do not 
transduce glia or other non-neuronal cells, potentially predominating near the 
lesion. This negative result prompted us to carry out the double delivery 
experiments shown here where the vector was delivered both proximally and 
distally to the lesion site. As it was demonstrated in Chapter 3, vectors based on 
the HSVl.pR19CMV backbone were unable to directly transduce CST neurons 
after inoculation, either into upper motor neurons in layer V of the adult rat motor 
cortex or after delivery into the spinal cord. This appeared to be specific to the 
CST since targeting the rubrospinal tract produces significant retrograde labelling 
of red nucleus neurons (Chapter 5). The major advantage of HSV1 based vectors 
of being able to be retrogradely transported from the site of inoculation to 
neuronal somata could not be exploited. At the time these experiments were 
conducted however, vector HSVl.pR19CMV was the optimum vector for 
regenerative studies in terms of achieving highly efficient delivery while being 
minimally cytotoxic.
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4.3.3 Combining rNT3 delivery with E14 spinal cord transplants
In this set of experiments we set out to explore whether HSVlpR19CMV - 
mediated delivery of rNT3 is able to induce regeneration in the presence of an 
E l4 spinal cord segment, transplanted within the lesioned spinal cord of adult 
rats. This experimental approach was based on the Bregman et al (1998) 
paradigm in which transplanted E14 spinal cord segments within the lesion site 
appeared to work synergistically with co-administered NT3 to induce CST, 
raphaespinal and coeruleospinal axonal regeneration through the transplant 
(Bregman et al., 1998). Without acute neurotrophic administration (1 mg/ml), 
regenerating CST axons are confined to the host/transplant border (Bregman et 
al., 1989). In a later study Bregman and colleagues (2002) went on to show that 
delaying transplantation of embryonic tissue and neurotrophin administration for 
2 weeks following a transecting lesion, leads to an increase in the number of 
supraspinal and propriospinal regenerating axons as well as some recovery of 
locomotor function (Bregman et al., 2002). Based on the above series of 
experiments, this study employed HSVl.pR19CMVrNT3 vector as a means of 
delivering biologically active NT3 in conjunction with E l4 spinal cord segment 
transplants. Firstly, adult rats received a CST lesion with bi-lateral sectioning of 
the dorsal columns. Two weeks later, the lesion site was cleaned of scar tissue 
and all animals received one or two segments of E l4 spinal cord. Prof. Patrick 
Anderson (Dept, of Anatomy & Developmental Biology, UCL) performed the 
CST lesions and subsequent grafting of embryonic spinal cords.
Transplanted animals received 2.5x106 pfu of either control 
HSV1 .pRl9CMVLacZ vector (n=4) or HSVl.pR19CMVrNT3 vector (n=8). 
Four weeks later, animals were terminated and examined for any signs of 
regeneration. The boundaries of the transplant can be identified by the large 
number of dark oblong nuclei found around the perimeter of the lesion site. These 
could possibly correspond to fibroblasts and infiltrating macrophages (Figure
4.3.3-a, panel C). However, the boundaries of the lesion and injection sites were 
harder to define. For the purposes of this study the lesion site was identified by 
microscopy as lacking any tissue coherence with loose, often acellular patches 
where axons were absent or degenerating.
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Figure 4.3.3-a: Com bined H SV l.pR 19C M V L acZ  & E14 spinal cord  trea tm en t.
Efficient LacZ transduction in spinal cord, neurons following simultaneous vector injection and 
transplantation o f  E l6 spinal cord segments into a C6, dorsal column lesion site made 4 weeks 
previously (*). Vector (2.5x106 pfu) was injected within and proximally to the lesion site. Large 
numbers o f  LacZ transduced neurons are shown in a low magnification micrograph o f  a 
longitudinal section through the lesion site as well as proximally and distally to it (A). Ventral 
motor neurons near the injection site appear healthy (B). The transplant ( f)  in the lesion site can 
be distinguished from the rest o f the tissue (C).
Scale bars: A=500pm; B=200pm; C=500pm.
228
As demonstrated in control animals, the HSVl.pR19CMVLacZ vector is capable 
of maintaining the long-term expression of the transgene while retrograde 
transport of the vector has resulted in widespread expression (Figure 4.3.3-a, 
panel A) of the marker gene. Transduced neurons within the injection site appear 
normal (panel B) at four weeks following inoculation. Apart from two control 
animals examined for the expression of LacZ (one of which is shown in Figure
4.3.3-a, panel A), all others were processed for the detection of the BDA tracer. 
Animals that received vector HSVl.pR19CMVLacZ in conjunction with an E14 
transplant, demonstrate some sprouting proximal to the transplant and a very 
small number of axons, all with retraction bulbs, just within the transplant (Figure
4.3.3-b, panel A and Figure 4.3.4-c, panel A). In animals that had received an 
inoculum of HSVl.pR19CMVrNT3 vector, more regenerating CST axons appear 
to enter the transplant (Figure 4.3.3-b, panel B and Figure 4.3.3-c, panel B). The 
longest regenerating axon was placed at 600 pm within the lesion site (Figure
4.3.3-c, panel C). Moreover, CST axons found proximally as well as within the 
transplant appear to have fewer retraction bulbs than in control animals.
In panel C of Figure 4.3.3-b, a more ventral section of the transplanted spinal 
cord is shown. In this section no fibres can be seen entering the transplanted 
tissue but rather they bypass it by growing around the boundaries of the 
transplant. The possibility of these being spared CST axons that were displaced 
during transplantation (Steward et al., 2003) was discounted due to the fact that 
the lesion site was cleared prior to transplantation. Even if CST axons had 
survived the initial dorsal column lesion it is highly unlikely they would have 
survived the procedure of scar clearing and subsequent transplantation. It is more 
plausible that axons in this case did not cross the lesion site due to the fact that 
there is a larger acellular cavity present perhaps because the transplant did not 
extend so ventrally and the lesion site has refilled with a loose network of scar 
tissue. Therefore, the lack of substrates within the lesion site means that it cannot 
act as a support medium for CST axons that have been induced to regenerate.
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Figure 4.3.3-b: HSVl.pR19CMVrNT3 & E14 spinal cord transplantation treatment.
BDA labelled (light brown) CST axons present in longitudinal spinal cord sections of rats that 
had received a simultaneous vector injection (2.5x106 pfu of HSVl.pR19CMVrNT3) and E14 
segment the transplantation within the site of a dorsal hemisection performed one month 
previously. Control animals (A) that were injected with vector HSVl.pR19CMVLacZ 
(2.5x106 pfu) demonstrate a minimal regenerative response with very few axons entering the 
lesion site and none transversing the transplant (shown in Figure 4.3.3-c, panel A). In 
HSVl.pR19CMVrNT3 treated animals (B & C), many regenerating axons (▼) can be seen 
within the lesion site as well as transversing the transplant (Section B, shown Figure 4.3.3-c, 
panels Bi & Bii). This effect was observed in four of the six animals receiving this treatment. 
Panels B & C show sections from the same animal with section C being more ventral to 
section B. Axons appear to pass through the lesion site in the more dorsal layers (B). The 
dotted lines demarcate the proximal (left) and distal (right) boundaries of the lesion site.
Scale Bars: A=200pm; B=500|im, applies to C.
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Figure 4.3.3-c: E14 transplants & HSVl.pR19CMVrNT3 promote CST axonal regrowth.
B D A -labelled CST axons regenerating into the lesion site o f  the spinal cord o f  anim als 
receiving an H SV l.pR 19C M V LacZ /E 14 transplant (A) or H SV l.pR 19rN T3/E14 transplant (B) 
as seen at low er m agnification in Figure 4.3.3-b Few  axons are seen to  sprout across the border o f  
proxim al cord and lesion site (dotted  line) in the H SV l.pR 19C M V LacZ  treated anim al (A). 
However, m any axons sprout into the lesion site in the N T3 vector treated animal (red rectangle 
in Bi, show n at h igher m agnification in Bii) including one (* and arrowed) at 600pm  from  the 
proxim al boundary (dotted line). (T re g en e ra tin g  axons).
Scale bars: A =60pm , applies to  Bi; B ii=30pm .
232
HSl 7 vector-mediated delivery o f NT-3 in the injured corticospinal tract
A. E14 tra n sp la n t & H S V .pR 19C M V L acZ
Proxim al L esion site
*
• •  A
•_ •
- * •
• •
* rC '.
•
• r . "
• > ^
%
* - ** •? •  A  f
•
-A. •A  ^ -----------
B. E14 tra n sp la n t & H SV .pR 19C M V rN T 3
Proxim al L esion  site
Bii
T *
«*
%r  ,«
233
/ / . VI  7  n v / > > / • - / « < . /  d i ’h v t  r \  o ’ \  i  • i n  f i n  i i i / t / r ,  7  n o r i m n ' i p i n t i l  i n n
4.3.4 CST transduction via an HSVl.pR19EFlawPRE vector
Sole HSVl.pR19CMV mediated expression of rNT3 from neurons surrounding 
the lesion site was not sufficient to induce a regenerative effect. When the same 
vector was used in conjunction with an E14 embryonic transplant there was some 
evidence of regeneration but no axons exited the transplant caudally. Perhaps the 
lack of significant CST regeneration observed in both paradigms could be 
attributed to the lack of endogenous production of NT3 from axotomised CST 
neurons themselves. Endogenously produced factors may be more powerful at 
augmenting the limited growth capacity of axotomised CST neurons. This 
approach was not possible due to the fact that HSVl.pR19CMV based vectors 
turned out to be incapable of sustaining transgene expression in adult CST 
neurons following either a cortical or spinal cord injection (Chapter 3). However, 
in order for this type of technology to be realistically applicable in CST 
regeneration studies, vectors should be capable of directly transducing CST 
neurons via either of these routes.
As this study was reaching its completion, a new generation of less disabled 
HSV1 based vectors became available. These vectors designated 
1764/ICP27+/ICP47RL1 +/pR 19EF1 aWPRE (HSVl.pR19EFlaWPRE), carry the 
m l814 inactivating mutation on VP 16 (Ace et al., 1989) and are deleted for the 
ICP4 trans-activator. The HSV1 .pRl 9EF1 aWPRE backbone was based on the well 
characterised 1764/ICP277ICP47ICP34.5" genotype (Coffin et al., 1996; Lilley et 
a l , 2001b) and was produced by re-inserting the ICP27 and ICP34.5 genes back 
into the viral genome via homologous recombination. It should be made clear 
though that despite its level of disablement this vector is incapable of in vivo 
replication or trans-synaptic spread. It is however easier to propagate in culture 
and stocks can be grown in higher titres. Preliminary studies using dissociated 
E l4 cortical neurons demonstrated that even though the vector was less disabled, 
transgene expression was not associated with evidence of cytotoxicity, even when 
these were infected at an MOI of 5 (personal observations). The rationale behind 
using this generation of less disabled HSV1 vectors for transducing cortical 
neurons comes from a previously published study that demonstrated that the 
cortical pattern of expression following a striatum inoculation appeared to vary
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according to the level of vector disablement. Utilising the pR19CMV expression 
cassette inserted into the minimally disabled and relatively toxic 17+/ICP27‘ 
vector (Howard et al., 1998) significant transduction of cortical neurons was 
observed but only up to 1 week p.i. On the contrary, utilising the more disabled 
and non-toxic vector 1764/ICP277ICP4', cortical expression was minimal (Lilley 
et al., 2001b). Therefore, it is very likely that long-term expression in cortical 
neurons can be achieved by striking the right balance between the level of 
disablement and toxicity.
The HSVl.pR19EFlaWPRE vector employed the pR19 expression cassette 
(Lilley et al., 2001b) but two elements of the original construct were altered. 
Firstly, the CMV promoter was substituted for the human elongation factor I 
alpha (EFla) promoter (Kim et al., 1990). The EFla protein is a key component 
of a cell’s translational machinery as it is part of the elongation factor 1 complex 
promoting the GTP-dependent binding of aminoacyl-tRNA to the ribosome 
during peptide elongation. Synthesis of this component of the translational 
machinery occurs in all cells and is very likely that its promoter will also be 
active in most cell populations. It was recently reported that EFla mRNA is 
present in large amounts in the dendrites of layer V pyramidal neurons in the 
adult mouse (Huang et al., 2005). It therefore presented a suitable candidate for 
supporting transgene expression in the same population of neurons. The 
incorporation of the EFla promoter was part of a separate study that set out to 
explore different pR19 expression cassettes, each with a different promoter, for 
their effectiveness in transducing different neuronal populations in vivo. 
Secondly, the WPRE post-transcriptional regulatory element was inserted at the 
3’ location of the transgene. WPRE is required for the accumulation of wild type 
WHV RNAs (Donello et al., 1998) and has previously been shown indirectly to 
enhance transgene expression in retroviral and lentiviral vector systems, both in 
vitro (Zufferey et al., 1999; Loeb et al., 1999) and in vivo (Patema et al., 2000; 
Klein et al., 2002; Glover et al., 2003; Hlavaty et al., 2005). The WPRE element 
is thought to exert this effect by enhancing the nuclear export of mRNAs into the 
cytoplasm (Zufferey et al., 1999). Therefore it could result in even higher 
transgene mRNA levels with HSV1 based vector systems as well.
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4.3.4.1 Transduction of CST neurons via striatum inoculation
Successful transduction of cortical neurons that project to the spinal cord would 
assess whether HSVl.pR19EFlaWPRE vectors can sustain long-term transgene 
expression when administered to the somata of layer V upper motor neurons, 
following or preceding an acute or chronic lesion within the CST pathway. The 
transgene, such as NT3, should be endogenously produced and, depending on its 
properties, be transported throughout the injured axon. This would be ideal for 
injured spinal cord studies, as the already damaged tissue would be spared any 
further insult associated with local vector delivery. It would also be beneficial in 
studies designed to evaluate molecules thought to augment the growth capacity of 
CST neurons or to counteract any inhibitory influences. Attempts at delivering 
the vector directly into the cortex were not systematically pursued not only due to 
time constrains but also because the delivery technique itself would result in 
some mechanical damage. This is avoided by delivering the vector into the 
striatum where cortical neurons project thus reducing the possibility of them 
being lost through injury. 5xl07 pfu of HSVl.pR19EFlaWPRE vector (n=3) was 
inoculated into the striatum of adult rats. Transgene expression was examined on 
100pm parasagittal brain sections and at a single time point of one-month post 
injection.
Striatum inoculation of this vector appears to result in three distinct neuronal 
populations significantly expressing LacZ: the first are striatal neurons around the 
lesion site, the second are neurons in the primary motor cortex (Figure 4.3.4-a) 
and the third are substantia nigra neurons (not illustrated). Transduced neurons 
appeared in clusters with distinct cell bodies, axons and dendritic trees, which in 
the case of cortical neurons extended from layer V to layer I of the cortex (Figure
4.3.4-a, panel B). The results presented here, are part of a preliminary study and 
do not go as far as confirming that the cortical neurons transduced via this 
method do indeed project to the spinal cord. Some may be CST neurons but they 
may also be corticostriatal neurons. To confirm that any transduced pyramidal 
neurons of layer V of the motor cortex correspond to CST neurons, it was 
necessary to attempt their direct transduction from within the spinal cord.
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Figure 4.3.4-a: HSVl.pR19EFlaWPRE transduction of cortical neurons.
Low m agnification m icrograph o f  a  100pm  parasagittal section through rostral cortex and 
striatum  o f  a rat that received  a  vector injection into the striatum and survived for 1 month. 
Large num bers o f  H S V l.p R 1 9 E F laW P R E  transduced, LacZ positive neurons alm ost fill 
layer V o f  the entire rostral tip  o f  the  cortex. Groups o f  these transduced neurons (* and f )  
are shown at higher m agnification  in B and C  where their typical pyramidal cell m orphology 
is obvious. The m ajority  o f  these transduced neurons are likely to be corticostriate neurons. 
W hich o f  them  pro ject to  the spinal cord is not established. Very few neurons were 
transduced close to  the track  o f  the injection pipette in the striatum (*). M ost som a-sized 
blue dots in the striatum  (and  som e o f  those in the deeper layers o f  cortex) are LacZ positive 
peri-vascular m acrophages.
Scale bars: A =200pm ; B = 100pm ; C =75pm .
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4.3.4.2 Transduction of CST neurons via spinal cord inoculation
This experiment was designed to assess whether HSV1 .pRl 9EF1 aWPRE vectors 
can directly transduce cortical motor neurons. This would enable us to study the 
effects of vector application subsequently to a spinal cord injury, and evaluate the 
transgene of interest for its effectiveness in aiding regeneration in either the acute 
or chronic injury models. 5xl07 pfu of HSVl.pR19EFlaWPRE vector was 
inoculated into the dorsal column at the C3 level of adult rat spinal cords (n=5). 
Transgene expression was examined on 40 pm longitudinal spinal cord sections 
and at a single time point of 1-month post injection.
Expression of GFP is strong at that time point in all 5 animals (Figure 4.3.4-b). 
The marker protein was found not only immediately near the injection site 
(panels Ai & Aii), but also proximal (panel B) and distal (panel C) to it. GFP 
labelling was present in large numbers of neuronal cell bodies and axons 
throughout the entire spinal cord examined (approximately from C5 to medulla). 
Analysis of 40 pm coronal brain sections of motor cortex demonstrate that this 
vector allows the transduction of CST neurons following a direct dorsal column 
inoculation (panels D & E). Approximately 100 sections through the motor 
cortex of each animal were produced. These appeared uniform in terms of the 
numbers of transduced CST neurons present, with 20 to 40 found bilaterally in 
each 40 pm coronal section. The somata, characteristic apical dendrites and axons 
of some CST neurons appeared strongly labelled with GFP (panel F). A rough 
estimate of the numbers of CST cell bodies transduced in a single animal would 
be in the range of 200-400. Not all transduced neurons appear to express GFP 
with the same intensity. This may be a reflection of differences in the copy 
number found within each transduced cell. Transduced neurons were found 
throughout the brain in regions containing remote projections to the spinal cord, 
medulla, pons and midbrain. Even though the cortical neurons transduced via a 
single spinal cord injection form a small proportion of the 79,000 layer V cortical 
neurons that form the pyramidal tract and project to the C3 level (Gorgels et a l , 
1989), this approach is promising for regeneration studies targeting the CST. 
Optimisation of the injection technique could lead to the transduction of more 
upper motor neuron somata.
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Figure 4.3.4-b: HSVl.pR19EFlaWPRE mediated expression in CST pyramidal neurons.
Efficient expression of GFP by spinal cord neurons (A to C) and cerebral cortex (D, E) 
following vector delivered via a single injection into the dorsal columns at the C3 level, 1 
month previously. Large numbers of strongly transduced neurons fill the gray matter and 
many GFP positive axons line the white columns. Expression is strong in somata and axons 
close to the lesion site (f), which is revealed in the same section taken under dark-field 
illumination (Ai) and under fluorescence microscopy (Aii). Similar efficient transduction was 
observed several millimetres proximal (B) and distal (C) to the injection site. Note that the 
majority of transduced cells appear neuronal, not glial and that in A, the centre of the injection 
site (f) does not appear to be infiltrated with autofluorescent inflammatory cells or to be 
damaged by cavitations.
Transduced GFP positive corticospinal pyramidal neurons (D, E) in the motor cortex of the rat 
receiving HSV1.GFP vector in the dorsal columns of the spinal cord shown in A to C. 
Approximately 6 moderately to weakly labelled CST neurons are shown in D and a strongly 
GFP positive pyramidal neuron, filled with the virally delivered transgene, is shown at higher 
magnification in E where the thick apical dendrite, basal dendrites and axon are clearly seen.
Scale bars: Ai= 100pm, applies to Aii and C; B=200pm; D= 100pm; E=50pm.
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4.4 Discussion
The chronically injured CST of adult rats has been the focus of the regenerative 
attempts reported in this Chapter that employ the use of neurotrophins delivered 
by means of a highly disabled viral vector. This study was more qualitative in the 
sense that it was designed to explore the ability of this generation of vectors to 
induce an effect in the injured spinal cord model and in the transected CST model 
in particular. The vector backbone chosen for these experiments has previously 
been shown to be non-toxic to the injured spinal cord while at the same time 
capable of supporting transgene expression for at least one month (Lilley et al., 
2001b). The HSVl.pR19CMVrNT3 construct was shown to produce rNT3 
protein both in vitro, in transduced non-complementing cells and in vivo, in the 
adult rat spinal cord. In vector transduced spinal cords the amount of total NT3 
protein was found to be -500 pg/mg of total protein, one month following vector 
inoculation. Importantly, it was shown that the produced protein was capable of 
inducing a biological effect on embryonic DRG explants. Following confirmation 
of the bioactivity of vector encoded rNT3, its ability to promote regeneration in 
the chronically injured CST either alone or in conjunction with an embryonic 
spinal cord transplant was studied.
Sole HSVl.pR19CMV vector-mediated rNT3 delivery, both proximal and distal 
to the lesion site, appears to have minimal anatomical effects on inducing 
regeneration following a cervical level, chronic CST lesion. There was some 
evidence of a reduced number of end-bulbs, marginally enhanced sprouting 
proximally to the lesion site and very few fibres present within the lesion site per 
se. As the model utilised in this study involves the bilateral lesioning of the dorsal 
columns and the unilateral lesioning of the ventral funiculus and intervening grey 
matter, it is unlikely that the sprouting observed was due to spared fibres. Also 
the appearance of proximal axons adopting a random course, is in agreement with 
published regeneration criteria (Steward et a l, 2003). The findings described 
here re-enforce reports that sole administration of the NT3 is inadequate in 
promoting significant regeneration of CST fibres. A common denominator in 
reports of any regenerative success in the adult CNS with sole NT3 
administration is that the amount of recombinant protein used was biologically
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unreasonable. For example, following an intrathecal infusion of 12 
pg/day/4weeks of recombinant human NT3, dorsal column sensory axons, 
demonstrated extensive sprouting proximal to the lesion site and regeneration 
through the epicentre of the lesion (Bradbury et al., 1999). Even in this case 
though the path that growing fibres followed was random and no meaningful 
growth was observed. Intrathecal treatment of lesioned animals with 12 pg/day of 
NT3 for 4 weeks resulted in the up-regulation of the low affinity p75NTR receptor 
by glial cells within and around the lesion site. It has been suggested that this may 
alter the availability of NT3 to injured axons themselves (King et al., 2000). 
Also, NT3 has been shown to induce BDNF dependency of axotomised CST 
neurons by the simultaneous activation of TrkC and p75NTR (Giehl et al., 2001). 
Taken together these findings could suggest that, in cases where highly 
concentrated infusions of NT3 are administered into the injured CST, a 
regenerative response may be due to the ectopic regeneration of sensory afferents 
and may not be a true reflection of an NT3 elicited biological effect (Ramer et al., 
2002; Hagg et al., 2005). In the experiments described here the amount of rNT3 
present in rat spinal cords via HSVl.pR19CMVrNT3 vector mediated 
transduction was calculated as a function of pg/ml of total protein. It would have 
been better to analyse the amounts of NT3 present in vivo as a total amount of 
rNT3 present per grams of spinal cord. Future experiments should examine 
whether an NT3 gradient is produced at set distances around the lesion site (e.g. 
1mm). This would then be easier to correlate to the physical findings of this 
study.
Combining vector-mediated rNT3 administration with the grafting of an E14 
spinal cord transplant does result in increased regeneration probably due to 
augmenting the natural capacity of axotomised CST neurons to regenerate. When 
vector-mediated administration of rNT3 is accompanied by an E14 spinal cord 
transplant, regeneration of chronically axotomised CST axons was somewhat 
enhanced compared to control animals. There was increased proximal sprouting 
with many more CST fibres found within the lesion site. The longest regenerating 
axon was found -600pm from the host/transplant border but no CST axons were 
found to exit the transplant distally. On the contrary, animals that received an
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embryonic transplant without an injection of rNT3 expressing vector 
demonstrated some proximal sprouting but minimal axonal elongation. Again this 
finding is in agreement with reports that have attempted to promote regeneration 
via similar routes (Bregman et al., 1997b; Bregman et al., 1998).
Overall it becomes apparent throughout this study that even though trying to 
induce regeneration following a chronic CST bilateral lesion may be the ultimate 
test for a potential regenerative tool, with hindsight, it was perhaps too ambitious. 
After all, the purpose of this study was primarily to assess the capabilities of this 
vector system in inducing an effect. Even though the obtained results did not 
demonstrate CST regeneration of the envisaged and perhaps unrealistic scale, 
efforts should have been focused in evaluating the extent of the achieved 
regeneration. In terms of evaluating the ability of this gene therapy system to 
induce a regenerative effect it may have been more productive to deliver the 
vector prior to inflicting the injury. This would have allowed CST somata, as well 
as other neuronal populations within the vicinity of the injection site, to already 
be producing the transgene. This means that the potentially therapeutic transgene 
would have been present in significant amounts as soon as the lesion was 
inflicted. This may have augmented the regenerative capacity of the injured CST 
neurons (Cai et al., 1999) since priming neurons with neurotrophins enables them 
to resist the inhibitory cues present within a lesion environment via a rise in 
intracellular cAMP levels (Cai et al., 2002; Spencer and Filbin, 2004). In any 
case, after four weeks of transplant and vector treatment it would be expected that 
regenerating CST axons would be growing through the lesion site and perhaps 
even traverse the transplant (Steward et al., 2003). Even though the exact number 
of fibres extending into the transplant was regrettably not established in every 
section and for every animal, an approximate count of the number of axons 
regenerating into the lesion site in the rNT3 treated animal shown in Figure 4.3.3- 
b (panel B), revealed 15 axons compared with just 3 located in the LacZ treated 
animal shown in panel A. Thus, the regenerative response achieved, indicates that 
vector-delivered rNT3 is capable of producing some regeneration when used in 
conjunction with an E14 spinal cord graft. This is encouraging if one takes into 
account that Bregman et al (1997) used a 1 mg/ml concentration of rNT3
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compared to the estimated -500 pg/mg delivered by this vector system. It is 
possible then that in the presence of an embryonic transplant, excessive amounts 
of the neurotrophin may not be a requirement. Alternatively, delivering NT3 via 
gel foam could be very inefficient, leaving a lot of the protein unutilised. 
Specifically, in the case of the Bregman et al. (1997) paradigm a piece of gel 
foam soaked with 1 mg/ml of NT3 was implanted dorsally to the transplant itself 
(Bregman et a l , 1997b; Bregman et al., 2002). Even though there are no data 
regarding the bioavailability of gel foam delivered NT3, it is not reasonable to 
suggest that this approach allows for only a short treatment span. Studying the 
bioavailability of recombinant NT3 released from a fibrin gel showed that 95% of 
the protein was released within 3 days (Taylor et al., 2004). In addition, with NT3 
having a half-life of just 1.28 min (Poduslo and Curran, 1996), it quickly looses 
its bioactivity as it succumbs to inevitable inactivation via non-specific 
proteolytic cleavage. Thus, the effect observed in the Bregman et al. (1997) 
paradigm could have been induced by a very small fraction of the total NT3 
delivered by the gel foam. On the contrary, vector mediated delivery achieves 
stable expression levels of biologically reasonable amounts of rNT3 that are 
maintained for at least a month post injection, giving a more realistic idea of the 
regenerative potential of axotomised CST fibres.
Both host and donor animals were from the Lewis strain of inbred rats. Unlike the 
more expensive Fischer 344 rats, Lewis rats are not a pure inbred strain (Festing 
and Bender, 1984). Therefore, all the animals included in this study were treated 
with a daily dose of Cyclosporin A (CsA) at 2 mg/Kg, both prior and subsequent 
to transplant/vector administration in an effort to reduce the possibility of the 
transplant being rejected. The use of CsA in regenerative experiments is quite 
common despite well documented reports that it promotes neuroprotection by 
limiting the extent of demyelination and neuronal cell death that ensues an injury 
resulting in a better motor outcome (Diaz-Ruiz et al., 1999; Ibarra et al., 2003; 
Okonkwo et al., 2003; Diaz-Ruiz et al., 2005). Even though the amount utilised 
here is within the range that is reported to have such an effect (Ibarra et al.,
2003), control animals could easily be distinguished from rNT3 treated animals in 
terms of regeneration. This could be due to the fact that CsA was administered
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via the somewhat variable oral route as opposed to the intraperitoneal, 
intravenous or intrathecal route followed in most documented cases. With 
hindsight, it would perhaps have been more suitable to utilise the Fischer 344 
strain for this experiment in order to eliminate this potentially confounding factor. 
Previously in our laboratory the use of cyclosporin failed to show a positive 
impact on the length of transgene expression in DRGs transduced via a sciatic 
nerve or footpad injection with virus 1764/pR20.5/UL43 (work carried out by Dr 
R.H. Branson, not published). The same pattern has been observed by other 
laboratories that showed that cyclosporin treatment failed to enhance the amount 
of vial genome present in trigeminal ganglia (Halford and Schaffer, 2000). 
Similarly, another group showed that using cyclosporin does not promote an 
increase in transgene levels in hypothalamic neurons transduced with an 
adenoviral vector (Geddes et al., 1996). However, the transgene in this case was 
LacZ and as discussed in Chapter 3 histological methods of detection may not be 
accurate enough to detect minor differences. There is one report however that 
reports some beneficial effect in the length of LacZ expression with the use of an 
HSV1 vector deleted for ICP4, inactivated for VP 16 and vhs, but this utilised the 
hamster model of viral latency in sympathetic neurons (Mabon et a l , 1999).
All the experiments described in this Chapter were based on the chronic model of 
CST lesion in which treatment with vector or transplant and vector occurred after 
at least four weeks following the dorsal column lesion. Delaying treatment with 
embryonic transplants and NT3 by two to four weeks was shown to promote 
regeneration and some functional recovery in the injured CST (Coumans et a l , 
2001). However, delaying treatment for six (Shumsky et a l , 2003) or eight (von 
Meyenburg et a l, 1998) weeks post lesion results in only minimal recovery of 
function. The time point selected here is therefore within the window of 
opportunity for intervention as far as the CST is concerned while at the same time 
the inhibitory environment of the lesion site are also in place (Shibayama et a l,
1998). The identification of the lesion site in this set of experiments was 
performed by phase contrast and dark-field microscopy on longitudinal sections. 
The location of the injury was pinpointed as being the opaque tissue in between 
the rostral and caudal parts of the spinal cord. Even though in the majority of
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animals establishing the boundaries of the lesion site using microscopy of this 
kind was clear-cut, additional analysis should have been employed so that results 
between animals were evaluated on a common basis. For example, the staining of 
alternate sections for the expression of GFAP would label the astrocytic barrier 
formed at sites of injury and it would thus allow a clear demarcation of the lesion 
site. Alternatively, dissection of tissue blocks that include the lesion site (e.g. 3 
mm caudal/3 mm rostral to the lesion site) and subsequent weighting prior to 
camera Lucida reconstruction of Nissl-stained sections would ensure some degree 
of standardisation between samples. Any effect on the actual number of end- 
bulbs or the extent of their retraction should also have been better characterised 
with statistical analysis supporting the histological data shown here and providing 
a more accurate picture. In addition, since the levels of regeneration obtained 
were so limited, some immunohistochemistry should have been carried out in 
order to ascertain the extent to which vector administration may have altered the 
post-treatment expression profiles of growth associated proteins such as GAP43. 
A technical aspect that may have had a negative impact on these studies was the 
potential inconsistency in viral pfu administered, which in turn resulted in an 
unpredictability of rNT3 levels subsequently secreted within the inoculated spinal 
cord. At the time this study was performed there was a distinct lack of NT3 
specific antibodies that were sensitive enough to detect it in vivo. Perhaps to 
compensate for this unavoidable variability, the levels of rNT3 expression should 
have been established by immuno-histochemistry with respect to the vector 
injection site. This would have also provided valuable data on the relationship 
between proximity of vector inoculation and transgene expression with relation to 
any regenerative effect on axotomised CST fibres. Sampling a vector-injected 
spinal cord at regular intervals proximally, within and distally to the lesion site 
would provide more information regarding the expression patterns of the 
transgene as well as the extent of diffusion of the secreted protein itself. 
Correlating this data with different inoculation sites would perhaps provide a 
better model of vector administration for this type of experiment.
The potential of being able to deliver transgenes to CST neurons via either of 
these routes has been the focus of other vector systems with varied degrees of
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success. A canine serotype-2 adenoviral vector (CAV-2) delivered into the 
striatum does result in the retrograde transduction of cortical neurons. Even 
though the study is not clear as to the time points examined the authors report 
~104 cortical neurons transduced following a 2xl09 pfu striatum inoculation 
(Soudais et al., 2001). Another study employing a serotype-5 rAAV vector 
(rAAV5), led to transduction of only three layer V neurons, ten days following 
inoculation of 6xl06 pfu of vector into the frontal cortex of adult rats (Tamamaki 
et al., 2000). A similar approach whereby lxlO6 pfu of a disabled CMV vector 
were delivered into the striatum, yielded very limited and short-lived transduction 
of cortical neurons 3 days p.i. (van Den Pol et al., 1999). One study that does 
report considerable cortical transduction is that conducted by Sandler and 
colleagues (2002) who used 2xl05 pfu of an HSV1 amplicon vector to 
retrogradely transduce clusters of layer V pyramidal neurons via a single striatum 
injection. The transgene was visible from 18 hours to at least five weeks post­
injection, but no data were presented regarding the exact number of transduced 
neurons (Sandler et al., 2002). Hermens et al. (1997) infused 5xl07 pfu of an 
adenoviral vector in the corpus callosum of adult rats and successfully transduced 
pyramidal neurons including some layer V neurons. Expression was noted at 4 
days p.i. (Hermens et al., 1997). Neither of the above studies provides any 
information in relation to the proportion of transduced cortical neurons that form 
the CST tract. Following the spinal cord route of administration, Burger et al. 
(2004) injected 2x1010 pfu of serotype recombinant AAV type 2 pseudotyped for 
serotype 5 (rAAV2/5) vector into the C4 spinal cord level. In this case some 
cortical labelling was present at one month p.i but the report is too vague in order 
to be able to draw any conclusions regarding its effectiveness (a single GFP 
positive neuron is shown) (Burger et al., 2004).
Sum m ary
Vector-mediated transduction of rNT3 alone proved insufficient to promote 
regeneration in the chronically injured CST. It did however appear to augment 
the regenerative capacity of CST in the presence of E14 spinal cord transplants 
placed within the lesion. The findings presented in this chapter could be 
interpreted to support the notion that, given the highly inhibitory nature of the
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injured CNS, it is unlikely that a single approach could lead to functionally 
successful regeneration (Bunge, 2001). Delivering biologically achievable 
amounts of neurotrophins, as is possible with the vectors employed here, may 
need to be coupled with factors that counteract the inhibitory molecules found in 
myelin and in the injured CNS milieu in general. The vectors used in the 
regeneration approaches presented here as well as the new generation of less 
disabled constructs briefly explored in section 4.3.4.2 (page 239) present a 
powerful tool from which to explore these interactions.
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C h a pter  5
E f f e c t s  o f  h s v I v e c t o r -m e d ia t e d
DELIVERY OF BDNF OR CNTF TO THE INJURED 
RUBROSPINAL TRACT
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5.1 Introduction
The regenerative attempts outlined in this chapter are focussed on inducing 
rubrospinal tract neurons to regenerate their axons following a unilateral lesion. 
Like some other long descending tracts in the CNS, adult red nucleus neurons in 
the caudal magnocellular portion of the red nucleus (MPRN) display significant 
and progressive atrophy following axotomy resulting from a spinal cord lesion, 
but do not die (Prendergast and Stelzner, 1976; Barron et al., 1989; McBride et 
al., 1990). This atrophy is progressive and even though the expression of 
molecules such as neuronal Ta-1 tubulin are transiently up-regulated after 
axotomy, there is a gradual decline in regeneration-associated gene (RAG) 
expression, including GAP43 and other cytoskeletal proteins (Barron et al., 1989; 
Tetzlaff et al., 1991). The sharp decline in RAG expression is accompanied with 
the onset of severe atrophy that reaches its peak around 2 weeks following a 
lower cervical or upper thoracic lesion (Egan et al., 1977; Tetzlaff et al., 1994). 
The present study was based on the fact that neurotrophin delivery has been used 
to minimise (Kobayashi et al., 1997) and even overcome (Ruitenberg et al., 2004) 
post-axotomy neuronal atrophy (Kwon et al., 2002). BDNF administration to red 
nucleus neurons has been shown to stimulate the expression of genes associated 
with regeneration and boost the limited ability of axotomised rubrospinal tract 
fibres to extend their axons into a peripheral nerve graft (Kobayashi et al., 1997; 
Kwon et al., 2002). Similarly, CNTF has the potential to enhance recovery of 
axotomised rubrospinal tract neurons (Ye et al., 2004). Delivery of neurotrophins 
by engineered fibroblasts (Tobias et al., 2003), neural progenitors (Xiao et al., 
2005), foetal transplants (Mori et al., 1997; Bregman et al., 1998) as well as viral 
vector based systems other than HSV1 (Koda et al., 2004; Ruitenberg et al., 
2004), have been shown to induce a beneficial response of varying extent. This 
chapter examines whether delivering neurotrophic factors to the injured 
rubrospinal tract by utilising highly disabled HS V 1 vectors is capable of limiting 
the extent of red nucleus atrophy and promoting axonal elongation.
Firstly, the ability of a highly disabled HSV1 vector (HSVlpR19CMV) to 
transduce red nucleus neurons 4 weeks after a lesion of the lower cervical 
unilateral rubrospinal tract lesion was examined. Once it was confirmed that this
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vector backbone was suitable for transgene delivery via this route, two separate, 
neurotrophic factor expressing vectors were constructed: 
HSVlpR19CMVmCNTF, expressing a secretable form of the murine CNTF 
(mCNTF) and HSVlpR19CMVrBDNF vector expressing rat BDNF (rBDNF). 
Both of these vectors were used either alone or in combination to promote 
rubrospinal tract axonal regeneration following direct spinal cord delivery. 
Regeneration was assessed by analysing anterogradely labelled rubrospinal tract 
axons within sections of spinal cord. Additionally, vector 
HSVl.pR19CMVrBDNF was used to explore the possibility of rescuing red 
nucleus neurons from post-traumatic atrophy. One month following vector 
inoculation and two months post-axotomy, the size of red nucleus neuronal cell 
bodies was measured and the extent of regeneration with and without treatment 
was examined.
5.1.1 Anatomy of the rubrospinal tract
The rubrospinal tract is a white matter tract that originates from the red nucleus, 
which is located in the midbrain just dorsal to the substantia nigra at the level of 
the superior colliculus. The red nucleus or “ruber”, so-called due to the high iron 
content and extensive vascularisation that gives it its characteristic reddish 
colour, can be divided into two regions: pars-magnocellularis and pars- 
parvocellularis. Rubrospinal neuron somata are not distributed uniformly 
throughout the red nucleus. In rodents, the cell bodies of rubrospinal neurons are 
larger and are found at a higher density within the magnocellular rather than 
parvocellular parts of the red nucleus (Shieh et a l , 1983; Daniel et al., 1987; 
Tracey, 1994). There appears to be a degree of somatotopic organisation in the 
rubrospinal projections from the red nucleus, with its ventro-lateral parts 
projecting mainly to the lumbar and the dorso-medial parts projecting to the 
cervical segments of the spinal cord respectively. This division is not absolute 
and some red nucleus neurons apparently project to both areas of the rat spinal 
cord (Antal et al., 1992; Tracey, 1994).
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Effects o f USE I vector-mediated delivery o f  BDNF or CNTF to the injured rubrospinal tract
F ig u re  5 .1 .1-a: P ro jec tio n s o f  th e  ru b ro sp in a l t r a c t  in th e  ra t.
The rubrospinal tract is confined to a small region o f  the lateral w hite colum n in the spinal cord. 
H ere the contralateral projection (dark purple) lies w ith a  sm all ipsilateral projection (light 
purple). A xons o f  the tract term inate in the ventral h a lf  o f  the dorsal horns. The rubrospinal tract 
displays som atotopic arrangem ent (Tracey, 1994; Joosten, 1997).
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Rubrospinal axons decussate just caudal to the red nucleus, travel through the 
brain stem and enter the spinal cord where they travel in the lateral funiculus 
close to the lateral corticospinal tract. Within the spinal cord, rubrospinal 
processes cross from the lateral funiculus to the ventral horn to terminate on 
intemeurons, which in turn synapse on lower a-motor neurons (Figure 5.1.1-a). 
The rubrospinal tract is thought to work with the corticospinal tract to co-ordinate 
fine motor movement.
5.1.2 Response of red nucleus neurons to axotomising lesions
In line with the behaviour of other neuronal populations intrinsic to the CNS, 
axotomised adult rubrospinal tract neurons are not capable of unaided 
regeneration (Barron et al., 1989). Even though rubrospinal tract neurons have 
been shown to be capable of some sprouting (Houle and Ziegler, 1994; 
Kobayashi et al., 1997; Kwon et al., 2002) especially when compared to other 
CNS intrinsic neurons, they too fail to regenerate, becoming severely atrophied in 
the weeks following axotomy (Egan et al., 1977; Barron et al., 1989; Barron et 
al., 1990; Tetzlaff et al., 1991). However, rubrospinal neurons, unlike 
corticospinal neurons, readily regenerate their axons into nerve grafts placed in 
the cervical spinal cord (Richardson et al., 1982; Richardson et al., 1984).
5.1.2.1 Morphological changes following rubrospinal tract axotomy
In newborn rats, lesions that injure the rubrospinal tract result in profound 
neuronal cell death in the red nucleus (Prendergast and Stelzner, 1976; Bregman 
and Reier, 1986). Early experiments addressing the response of adult red nucleus 
neurons to axotomy report an average neuronal loss of «40% in the subsequent 
two to eight weeks following a lateral funiculus lesion at the upper cervical level 
(Goshgarian et al., 1983; Feringa et al., 1988; Mori et a l, 1997). However it is 
now widely accepted that adult magnocellular neurons of the red nucleus undergo 
severe atrophy following either a cervical or thoracic level lesion but with only 
limited cell death (Egan et a l, 1977; Barron et a l, 1989; Tetzlaff et a l, 1991). 
The extent of somal shrinkage that follows an upper cervical rubrospinal tract 
lesion ranges from -25%  (Novikova et a l, 2000) to ^40% (Mori et a l, 1997;
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Murray et al., 2002) reduction in cell body size in surviving neurons at 2 weeks 
and 2-4 months respectively. It is important to emphasise that there has long been 
a lot of disagreement between research groups as to the extent of atrophy and the 
suitability of the methods used to measure it (Tetzlaff et al., 1994; Kobayashi et 
al., 1997; Kwon et al., 2002). Experimental differences between the different 
studies, in terms of where the axotomising lesion is localised or which part of the 
red nucleus is assessed for atrophy, can also significantly affect the reported 
mean somal areas. For example 2% of the magnocellular red nucleus neurons are 
giant cells (Mori et al., 1997). Mori and colleagues report that red nucleus 
neurons become atrophic in a non-uniform manner. The majority of neurons that 
undergo the more profound atrophy following an axotomising lesion belong to 
that 2% and are the so-called “giant neurons”. They become so severely atrophied 
that they are reported as being almost absent by the 8th month post lesioning 
(Mori et al., 1997). Understandably, atrophic changes will be more profound in 
this class of neurons and even though they only represent a 2% of the population, 
counting studies that exclude them will report different findings to those that 
include them in any statistical analysis. Several groups acknowledge the fact that 
they may have overestimated the extent of neuronal death due to the inability to 
detect severely atrophied red nucleus cell bodies (Tetzlaff et al., 1994; Mori et 
al., 1997). This is an important factor that was taken into consideration during the 
design of this study and is further examined in section 5.4 (page 312). 
Nevertheless some neuronal death does occur in rubrospinal tract axotomy but its 
extent declines with increasing distance of the lesion from the red nucleus somata 
(Liu et al., 2003). Moreover, recent studies, utilising the latest counting 
techniques have questioned whether there is any neuronal loss at all within the 
adult red nucleus following axotomy. Specifically, a closed rubrospinal tract 
axotomy that preserves BBB integrity, inflicted at the level of the brain stem, 
results in a -57% red nucleus neuronal loss within the first two weeks, with an 
additional -18% reduction in from week two to week 10 following the injury 
(Liu et al., 2003). This is significantly higher than the -7% loss noted following a 
C2 level axotomy which rises to a modest -8% within the same time frame 
(Wang et al., 2002; Liu et al., 2003). These dissimilar morphological responses 
are accompanied by molecular differences. For example, neuronal nitric oxide
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synthase (nNOs) expression is upregulated more strongly when an rubrospinal 
tract lesion is located at the brainstem rather than the C2 level while nNOs 
upregulation is not detected following a T10 level injury (Liu et al., 2004). The 
increased production of nitric oxide (NO) plays an important part in the 
significant neuronal loss that follows rubrospinal tract lesions close to the red 
nucleus somata, since inactivating nNOs leads to a reduced red nucleus neuronal 
death from ~55% down to -33% by the end of the second week post lesion (Liu 
et al., 2004).
In addition to changes to the neurons in the axotomised red nucleus, there are also 
changes to the astrocyte and microglial populations. For example, following 
axotomy there is an increase in the density of processes of both these glial 
populations within the red nucleus. It has been suggested that this may affect the 
ability of red nucleus neurons to regenerate their axons (Tseng et al., 1996a; 
Tseng et al., 1996b). The extent of the astrocytic and microglial responses that 
follow a rubrospinal tract lesion also depend on the level of the lesion and may be 
related to the regenerative failure of red nucleus neurons (Barron et al., 1990; 
Tseng et al., 1996a; Tseng et al., 1996b). An upper cervical, lateral funiculus 
lesion does not cause microglial hyperplasia (Barron et al., 1990). Tseng and 
colleagues (1996a and b) assessed the difference in the microglial and astrocytic 
response that ensues a cervical versus a lower thoracic rubrospinal tract 
axotomising lesion. These studies revealed that following either a C1-C4 or a 
lower thoracic (T10) level rubrospinal tract lesion in young adult rats, there is a 
relatively modest and biphasic activation of microglia (Tseng et al., 1996a; 
Novikova et al., 2000) and astrocytes (Tseng et al., 1996b), with both phases 
being more prominent after a cervical level lesion. The biphasic response is by far 
weaker than that observed in the case of a peripheral nerve lesion (Barron et a l,
1990) and can be divided into an early phase, spanning the first 2-5 days and a 
late phase between 2-8 weeks post lesioning (Tseng et al., 1996a; Tseng et al., 
1996b). Even though no mitotic proliferation occurs, microglial and astrocytic 
processes become denser following a rubrospinal tract axotomy, which as 
discussed in Chapter 1, is indicative of their activation. However, the microglial 
and astrocytic processes do not appear to wrap the red nucleus neuronal somata
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(Tseng et a l , 1996a; Tseng et al, 1996b) as they do in the case of motor neurons 
axotomised by a peripheral nerve injury that allows regeneration of their axons 
(Streit et a l, 1988). Tseng and colleagues (1996a) suggested that the lack of 
microglial hyperplasia could be related to the inability of red nucleus neurons to 
regenerate (Streit et a l, 1988; Barron et a l, 1990). This is in line with the lack of 
such a response in other non-regenerative tracts such as the CST (Leong et al, 
1995). Interestingly, following either an axotomising cervical or thoracic lesion 
the limited microglial and astrocytic response that does follow occurs not only in 
the contralateral red nucleus as expected but it is equally present in the ipsilateral 
nucleus (Tseng et a l, 1996a). The authors of this finding argue that this may be 
due to axotomised bilateral projecting red nucleus neurons with axons projecting 
bilaterally (Huisman et al, 1981). Lesioning of rubrospinal tract axons causes 
retrograde retraction of neuronal terminals from the lesion site that differs from 
the progressive degenerative response seen in the case of axotomised CST 
neurons (Pallini et a l, 1988). Chronically injured cervical rubrospinal tract axons 
begin to undergo retraction soon after lesioning with over 60% of terminals found 
at 400-500 pm from the lesion site at 1-week post operatively (Houle and Jin,
2001). This retraction is non-progressive, even when examined at 14 weeks 
postoperatively. Even at such a distant time point 50% of red nucleus retraction 
bulbs can be found within 500 pm from the lesion site (Houle and Jin, 2001).
5.1.2.2 Molecular changes following rubrospinal tract axotomy
Undoubtedly, as with other neurons that are intrinsic to the CNS, there are 
various reasons why injured red nucleus neurons do not regenerate their axons. 
Many molecules including c-Jun, ATF3, GAP43, and Trks charge their 
expression patterns in response to axotomy. These changes as well as how they 
impact the regenerative potential of axotomised red nucleus neurons is examined 
below.
From 7 days following cervical axotomy, magnocellular red nucleus neurons 
upregulate GAP43 and al Tubulin mRNA levels while they down-regulate 
neurofilament mRNA, as detected by in situ hybridisation (Tetzlaff et a l, 1991; 
Fernandes et a l, 1999). However, this is neither a uniform nor a sustained
257
/  / / i V / . s  I II  / / . M  / v e c t o r  H H ' d i i i t c i i  t h ' l i v ,  r \  l l i ' \ l  n r  i ' Y /  /  m  I h r  i n / i i r r . l  r u h i  n y n u i /  i r n r l
response with mRNA levels diminishing as atrophy sets in (Tetzlaff et a l, 1991). 
Subsequent to the initial burst of activity, mRNA levels decline to subnormal 
levels, seven weeks after a C3 level axotomy (Tetzlaff et a l , 1991; Fernandes et 
al., 1999). This upregulation of growth-associated proteins does not occur at all if 
the rubrospinal tract lesion is carried out at the thoracic level (Fernandes et al., 
1999). In this case, red nucleus neurons fail to upregulate GAP43 or Tal-Tubulin 
transcription while neurofilament mRNA levels decline following either a 
cervical or thoracic lesion (Fernandes et al., 1999). Additionally, even though 
cervical axotomy leads to the upregulation of c-Jun expression in red nucleus 
neurons, a similar lesion of the thoracic spinal cord fails to do so (Jenkins et al., 
1993; Houle et al., 1998). Levels begin to rise within the first 24 hours, reach 
their peak at 10 days and persist for at least 4 weeks following a C3 level lesion 
(Jenkins et al., 1993; Houle et al., 1998). Upregulation of the c-Jun transcription 
factor has been associated with neurons that are capable of at least initiating a 
regenerative response (Houle et al., 1998; Mason et al., 2003). This difference 
between cervical and thoracic lesions and their potential in up-regulating growth 
associated proteins may not translate to an increased ability to regenerate 
spontaneously but correlates to their ability to regenerate into, but not through, a 
peripheral nerve, transplanted within the lesion site (Richardson et al., 1980; 
Richardson et al., 1982; Kwon et al., 2002).
Non-axotomised magnocellular red nucleus neurons have been shown to express 
NgR (Hunt et al., 2002b) and Nogo-A mRNA (Hunt et a l, 2003) as detected by 
in situ hybridisation, albeit weakly. In ngr-/- mutant rats, red nucleus neurons are 
capable of axonal regeneration following a thoracic level spinal cord transection 
(Kim et a l, 2004). The authors argue that this may point to the fact that NgR 
signalling plays a part in the limited ability of red nucleus neurons to mount a 
successful regenerative response. Healthy red nucleus neurons are positive for the 
presence of a7, aV and pi integrin receptor subunit mRNA (Pinkstaff et a l, 
1999). Integrins are responsible for interaction of neuronal growth cones both 
with other cells and ECM components and can therefore define the nature of the 
neuron’s response to injury (Letoumeau et a l, 1994; Jones, 1996; Condic and 
Letoumeau, 1997). Expression is high in the embryonic stages and early postnatal
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period (Letoumeau er al., 1994; Jones, 1996; Condic ef a/., 1999) but ceases in 
the adult CNS (Jones, 1996). Different subunit combinations are responsible for 
ligand specificity of the integrin receptor. For example, in DRG neurons 
following a conditioning lesion, it is only the expression of subunits a7 and pi 
that are upregulated, at least in vitro but no axonal regeneration occurs in the 
presence of anti-pl subunit neutralising antibodies, even in the presence of the 
a7pl specific ligand: laminin-1 (Ekstrom et al., 2003). The authors of the above 
study suggest that this points to the importance of the pi subunit in axonal 
elongation, at least in peripheral neurons. Restoration of integrin levels to those 
found in the early postnatal period of development can induce adult neurons to 
display axonal regenerative abilities similar to those seen in the embryonic and 
postnatal stages (Condic, 2001). Following a C3 level rubrospinal tract axotomy 
in adult animals only subunit pi is upregulated to levels detectable by in situ 
hybridisation. Even though this may create an abundance of subunit pi, 
formation of functioning heterodimers is either not possible as the a subunits are 
not upregulated in the same manner, or subunit pi interacts with an as yet 
unidentified a subunit (Plantman et a l , 2005). This may be one of the factors 
contributing to the inability of red nucleus to regenerate their axons.
In addition to the expression patterns described above, the behaviour of another 
molecule of emerging interest has also been examined with respect to its 
expression in the axotomised mbrospinal tract. Following a C4 level axotomy, 
Galectin-1 (Gal-1) mRNA levels decline in red nucleus neurons within seven to 
fourteen days, as assessed by in situ hybridisation (McGraw et a l , 2004b). This 
notion, put forward by McGraw and colleagues, is supported by the fact that the 
expression of Gal-1, positively correlates with the ability of adult (Fukaya et a l ,
2003) as well as developing (Regan et a l, 1986) neurons to successfully up 
regenerate their axons. Injured adult spinal motor neurons can significantly up- 
regulate the production of Gal-1 within 24-hours following facial nerve axotomy 
that precede the subsequent regenerative response (Akazawa et a l, 2004). 
Moreover, in the adult, application of recombinant human, oxidised version of 
Gal-1 can potentiate the regenerative response of both sensory and spinal motor 
neurons (Fukaya et al., 2003).
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Magnocellular red nucleus neurons display strong immunoreactivity for TrkC and 
TrkB, both of which are significantly down regulated over the weeks following a 
cervical level rubrospinal tract lesion (Kobayashi et al., 1997; Yan et al., 1997; 
Novikova et al., 2000). Levels begin to decline from 7 days post axotomy and 
continue to do so over the next two weeks, coinciding with the onset and 
progression of red nucleus atrophy (Kobayashi et al., 1997). On the contrary, 
TrkA is absent from uninjured red nucleus neurons and present in very few red 
nucleus neurons following a C4 level, rubrospinal tract axotomy (Kobayashi et 
al., 1997; Yan et al., 1997). In addition, p75NTR mRNA expression is 
undetectable in uninjured red nucleus neurons but appears marginally increased at 
7 days but not at 3 weeks post lesion. The expression patterns of the above 
neurotrophin receptors support the notion that BDNF and NT3 but not NGF 
treatment has the potential to positively influence the response of axotomised red 
nucleus neurons (Kobayashi et al., 1997).
Attempts at achieving regeneration in the rubrospinal tract injury model often 
involve the transplantation of growth permissive substrates and/or removal of 
scar tissue at the lesion site. This approach is relatively invasive and may result in 
a secondary axotomy being inflicted, which may in turn lead to an upregulation 
of growth-associated proteins. Re-lesioning the rubrospinal tract at 28 days after a 
C3 level axotomising lesion enhances the mRNA levels of GAP-43 and pll- 
Tubulin in red nucleus neurons and this response in maintained for at least 7 days 
(Storer and Houle, 2003). The onset of this response appears to be more rapid and 
proportionally higher than that observed following the acute phase of the primary 
lesion (3 days). Storer and Houle (2003) suggest that the ability of these neurons 
to respond to injury is indicative of the fact that chronically injured red nucleus 
neurons are still able to mount a response to secondary axotomy, at least at the 
mRNA level. A second axotomy carried out eight weeks after the primary lesion, 
leads to the upregulation of c-Jun expression, even though this appeared to be 
silenced four weeks after the primary C3 lesion was inflicted (Houle et al., 1998). 
Small neurons of the magnocellular portion of the red nucleus appear to be more 
sensitive to the effects of a second lesion (Houle and Ye, 1999).
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5.1.3 Promoting regeneration in the injured rubrospinal tract
As with other tracts of the CNS various methods have been employed to 
encourage axonal regeneration or to prevent/reverse the atrophy of the 
axotomised perikarya (Egan et al., 1977; Barron et al., 1989; Tetzlaff et al.,
1991). Most of these attempts are centred on the administration of neurotrophic 
factors, the effects of which are considered in more detail in section 5.1.4. 
Undoubtedly, the implantation of the end of a peripheral nerve into a lesion site 
in the lateral funiculus leads to a modest regeneration of rubrospinal tract axons 
into the graft (Richardson et a l, 1982; Houle, 1991). Regeneration of rubrospinal 
axons into the grafts is more extensive if the graft is implanted into the cervical 
rather than the thoracic spinal cord (Richardson et a l, 1984), presumably because 
of a more vigorous cell body response (Fernandes et a l, 1999). The results may 
vary depending on the time between injury and grafting. For example, immediate 
grafting of a peripheral nerve into the lesion site of a C3 level hemisection lesion 
site appears to be more effective in limiting red nucleus atrophy than the same 
procedure 3 weeks or more after injury (Richardson et a l, 1984; Decherchi and 
Gauthier, 2000). Similarly, the unaided transplantation of foetal spinal cord into 
the lesion site of a similar injury is not sufficient to promote any meaningful 
rubrospinal tract regeneration (Bregman and Reier, 1986; Mori et a l, 1997). On 
the other hand, human adult olfactory neural progenitor cells have been shown to 
be able to rescue red nucleus neurons from atrophy following a C3-C4 axotomy, 
possibly because they are capable of endogenously producing significant amounts 
of neurotrophic factors such as BDNF (Xiao et a l, 2005; Xiao et a l, 2007). This 
is in contrast to mouse olfactory ensheathing cells, which failed to produce 
regeneration of rubrospinal axons in the rat or mouse model (Ramer et a l, 2004).
5.1.4 Neurotrophin treatment and red nucleus neuron regeneration
Neurotrophic factors have been assessed for their effects on rubrospinal tract 
regeneration as well as red nucleus survival and atrophy. Research has been 
focused primarily on the effects of BDNF, CNTF and NT3 with a few studies 
examining the role of NT4/5, GDNF and FGF2. Most of the studies involving the 
use of neurotrophic factors to induce regeneration of the lesioned rubrospinal 
tracts are focused on adult rather than neonate animals.
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5.1.4.1 CNTF
As discussed in section 5.1.2.2 (page 257), a rubrospinal tract lesion is 
accompanied by changes in expression of various molecules detected in red 
nucleus somata. Like other CNS neurons that are involved in motor control, intact 
red nucleus neurons are positive for the presence of the CNTF receptor 
(CNTFRa) (Davis et a l , 1993; Ip et a l , 1993; Curtis et a l , 1994; MacLennan et 
al, 1996) and could therefore be responsive to exogenous CNTF. However, in 
line with other neurotrophic factors, CNTF has a very short serum half-life of 
about ~3 minutes, does not cross the BBB and can cause significant cytokine-like 
effects if administered systemically (Dittrich et a l, 1994). These limitations 
suggest that delivery by means of viral vectors should be particularly effective, 
allowing the de novo synthesis of CNTF by red nucleus neurons. Furthermore, 
CNTF is retrogradely transported to the neuronal somata and the rate of this 
transport has been shown to increase following an axotomising sciatic nerve 
lesion (Curtis et a l, 1993). The CNTF gene employed in the experiments 
described in this Chapter, encodes a secretable form of this factor as it has a 
secretory signal (discussed later). It is therefore possible that being able to 
synthesise the factor by the axotomised red nucleus neurons themselves, would 
add to its beneficial potential by also acting in adjacent neuronal cell populations.
CNTF has been shown to support the survival of motor neurons both in vitro (Ip 
et a l, 1991; Sendtner et a l, 1992; Sendtner et a l, 2000) and in vivo (Friedman et 
al, 1992). Following cord hemisection at T2, CNTF and CNTFRa mRNA levels 
increase in motor neurons within 1 hour post injury and then rapidly decline to 
subnormal levels by day 10 (Mata et a l, 1993; Oyesiku et a l, 1997). The initial 
burst of CNTF mRNA expression is seen both rostral and caudal to the lesion 
whereas CNTFRa mRNA upregulation is confined to motor neurons caudal to the 
lesion site (Oyesiku et a l, 1997). The parallel pattern of CNTF/CNTFRa 
upregulation is in line with the role of CNTF as a survival and regeneration- 
promoting factor for local injured motor neurons and that may be released from 
axotomised neurons or reactive astrocytes surrounding the lesion site (Sendtner et 
al, 1992; Oyesiku and Wigston, 1996; Oyesiku et a l, 1997). CNTF may also 
have a stimulating effect on mature astrocytes leading to gliosis in the adult brain
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Effects oj l/Sl'I vector-mediated delivery o f  UDNh or C W77- to the injured rubrospinal tract
A. P re d ic ted  s tru c tu re  o f  h u m a n  C N T F
B. P re d ic te d  b in d in g  d o m a in  o f  h u m a n  C N T F  - R a
F ig u re  5 .1 .4-a: P re d ic te d  s t ru c tu re  o f  C N T F  &  its C N T F -R a  b in d in g  d o m ain .
Three dim ensional representations o f  the predicted  structures o f  A: the four dom ains o f  hum an 
CN TF (GI: 25952136, M M D B 5903) (M cD onald  et a l 1995) and B: the C -terminal dom ain o f  
the hum an C N TF receptor (C N T F-R a) (GI: 180710, M M D B 29135) w hich is the binding site for 
hum an C N TF (M an et al., 2003; He et al., 2005).
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(Clatterbuck et a l, 1996; Levison et al., 1996; Lisovoski et a l, 1997). Mature 
astrocytes are able to respond to CNTF despite their lack of CNTFRa expression. 
This is potentially due to the illegitimate binding of CNTF to the leukaemia 
inhibitory factor receptor (LIFR), present on astrocytes (Sendtner et al, 1990; 
Friedman et a l, 1992; Monville et a l, 2001; Monville et a l, 2002). In addition, 
the local increase in the soluble form of the CNTFRa may still play a role in the 
regulation of CNTF activity as it might function as a soluble mediator for CNTF, 
since it can be released from muscle cells in response to peripheral nerve injury 
(Davis et a l, 1993). It has been suggested that upon its release from the cell 
plasma membrane the soluble CNTFRa component can confer responsiveness to 
cells that express only the other two transmembrane components of the CNTF 
receptor and are therefore unresponsive to CNTF. The ligand to these 
“incomplete” receptors is formed only when CNTF associates with the soluble 
CNTFRa receptor. CNTF appears to have a neuroprotective effect on the survival 
of axotomised red nucleus neurons with some reports showing a CNTF mediated 
functional recovery. For example, intrathecal administration of recombinant 
CNTF over a 10-day period following a contusion lesion at the T10 level, 
increases the number of red nucleus neurons that remain capable of retrograde 
transport (Ye et a l, 2004). In terms of recovery of function, Ye and colleagues 
(2004), reported that these animals displayed some improvements in motor skills, 
but only for the first two weeks following treatment. After this initial period no 
further improvement in CNTF treated animals relative to controls was noted. The 
authors suggested that this could be related to the negative impact of the 
astrogliosis that follows such an insult and is amplified by the CNTF 
administration, as manifested by the dose-related increase in GFAP 
immunoreactivity (Ye et al, 2004). However, the exact impact of this response 
remains somewhat unclear. The beneficial effects of CNTF on axotomised 
lesioned red nucleus neurons as seen in the contusion experiments of Ye et al 
(2004), were replicated when CNTF was administered to animals with a chronic 
axotomy. Administration of recombinant CNTF, 8 weeks after an upper cervical 
rubrospinal tract lesion, enhanced regeneration of injured rubrospinal neurons 
into a peripheral nerve graft (Houle and Ye, 1997). In this model however, the 
response was complicated by the fact that placing a CNTF-soaked gel foam pad
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within the lesion site caused a second axotomising lesion that also plays a role in 
the response of red nucleus axons to this factor. Thus when a secondary 
rubrospinal tract lesion is followed by the administration of CNTF, there is an 
increased survival of red nucleus neurons (Houle and Ye, 1999), accompanied by 
a greater increase in the extent of c-Jun upregulation than that is seen with re­
injury alone (Houle et al, 1998).
5.1.4.2 BDNF
The decision to construct a BDNF-expressing HSV1 based vector targeting the 
injured rubrospinal tract was based on a series of studies that are briefly reviewed 
in the paragraphs that follow. These studies document the ability of this 
neurotrophic factor to rescue red nucleus neurons from axotomy-induced atrophy 
(Plunet et al., 2002; Liu et al, 2002; Kwon et a l, 2002; Storer et a l, 2003; 
Lynskey et a l, 2006).
The increased rubrospinal tract survival achieved with the administration of 
BDNF (Kobayashi et al, 1997; Kwon et a l, 2002) reflects changes in the 
expression of regeneration and survival-associated genes. In contrast to the 
response seen in injured motor neurons, the expression of TrkB in axotomised 
rubrospinal neurons declines over the subsequent weeks following a lesion 
(Novikova et al, 2000; Kwon et a l, 2004). On closer analysis, however, it 
appears that TrkB expression within red nucleus neuronal cell bodies never 
completely ceases. Low levels of full length TrkB immunoreactivity were present 
in the cell bodies of axotomised red nucleus neurons even at 12 months following 
axotomy (Kwon et al, 2002). This was also the case in a contusion model of 
rubrospinal tract injury. In this paradigm, full length TrkB-IR was still present in 
the red nucleus somata at 42 days post injury. At the site of the lesion and in 
degenerating white matter, the truncated form of the receptor was upregulated 
(King et a l, 2000; Liebl et a l, 2001). This increased expression of the truncated 
form of TrkB has been mapped to the oligodendrocytes and astrocytes that 
surround the lesion site (Frisen et a l, 1992; Frisen et a l, 1993).
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The continuous infusion of BDNF (-10 jig/day) into the subarachnoid space 
during postoperative weeks 5-8, appears to prevent the axotomy-induced decline 
of full length TrkB in red nucleus neuronal somata (Novikova et al., 2000). This 
is in line with reports that the administration of BDNF in close proximity to the 
red nucleus neuronal somata is able to reverse the axotomy-induced atrophy 
(Kwon et a l , 2002). In contrast, delivering BDNF close to the lesion site 2 
months following a cervical level rubrospinal tract axotomy, failed to prevent the 
subsequent neuronal atrophy or promote any axonal regeneration into a peripheral 
nerve graft (Kwon et al., 2004). Interestingly, the application of BDNF at the 
lesion site was capable of preventing the increase in the expression of the 
truncated form of the TrkB receptor found in oligodendrocytes and astrocytes 
surrounding the lesion site of a thoracic level spinal cord hemisection (King et 
al., 2000).
The studies described above appear to suggest that targeting of BDNF delivery to 
neuronal cell bodies may be more efficient at promoting red nucleus neuron 
survival and axonal regeneration than delivery to axons. Further evidence 
supporting this suggestion comes from the fact that exposure of red nucleus 
somata to high concentrations of BDNF leads to an increase of GAP43 and Tal- 
Tubulin expression at the site of axonal injury. This upregulation in regeneration- 
associated gene expression may correlate with an increased ability of rubrospinal 
axons to regenerate into a peripheral nerve graft, that is induced by the BDNF 
treatment (Kobayashi et a l , 1997; Kwon et a l , 2002). It is interesting to note that 
neither GAP43 nor Tal-Tubulin mRNA levels are upregulated when BDNF is 
administered at the site of a cervical level rubrospinal tract lesion (Kwon et a l , 
2004). The lack of up-regulation of these two molecules does not imply that red 
nucleus neurons are totally refractory to BDNF when it is administered at the 
lesion site. Infusion of BDNF near a unilateral C4 rubrospinal axotomy site up- 
regulates the expression of another molecule: Gal-1 (McGraw et a l , 2004b) 
which as discussed in section 5.1.2.2, declines following an rubrospinal tract 
axotomising lesion. It has been suggested that the oxidized form of Gal-1 (Gal- 
1/OX) may positively correlate with the ability of motor as well as sensory 
neurons to initiate a regenerative response (Horie and Kadoya, 2004; McGraw et
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al., 2004a; McGraw e/ a/., 2004b). Even though the mechanism of Gal-1/OX 
action is still unclear it is thought that at least in the PNS it stimulates 
macrophages to secrete a factor that is involved in axonal growth and/or Schwann 
cell migration leading to enhanced regeneration (Fukaya et al., 2003; Horie et al.,
2004).
Overall, the administration of BDNF, be it near the somata or at the lesion site, 
has the potential to influence red nucleus neuronal survival and axonal 
regeneration, although greater effects are to be expected if BDNF is made 
available in the red nucleus. Several reports support the potential of BDNF within 
this context. These involve experiments employing BDNF infusions, OECs, 
genetically engineered fibroblasts or direct transduction with viral vectors. 
Normal OECs have been shown to be unable to promote significant rubrospinal 
axonal regeneration in the spinal cord (Ruitenberg et al., 2003; Ramer et al.,
2004). However, when primary OECs were transduced by means of an 
Adenoviral Vector (AdV) to express rBDNF and were subsequently implanted at 
the site of a C4 rubrospinal tract lesion more rubrospinal tract sprouting, together 
with regeneration into the lesion site was observed (Ruitenberg et al., 2003). It 
should be emphasised that even though this pattern of regeneration was reported 
at the four month time point, the AdVrBDNF vector enabled the rBDNF 
expression from transduced OECs for a maximum of 30 days. Ruitenberg et al. 
(2003) noted that relatively few rubrospinal tract axons entered the lesion site. 
The majority of sprouting axons remaining at the lesion site/graft interface and 
this was attributed to the presence of inhibitory factors within the lesion site 
(Fawcett and Asher, 1999; Ruitenberg et al., 2003; Sandvig et a l, 2004). In 
another study by Xiao et al. (2005), olfactory neuroepithelium (ONe) derived - 
neurosphere forming cells (NSFCs) shown to constitutively secrete BDNF, were 
transplanted at the site of a C3-4 unilateral rubrospinal tract lesion. Two weeks 
following transplantation, red nucleus neuronal somata appeared to have evaded 
atrophy. There was only a 7% reduction of mean somal area in treated animals as 
opposed to a 27% reduction in control animals. In terms of axonal regeneration, 
rubrospinal tract axons were reportedly able to regenerate into and through the 
ONe-NSFC transplant and extend into the spinal cord for 3-4 segments caudal to
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Effects ofH Sl'l vector-mediated delivery o f  BDM- or C ’.V'/'/•' to the injured rubrospinal tract
A. P red ic ted  B D N F s tru c tu re
N2
B. P re d ic ted  s tru c tu re  of the  T rk B  re c e p to r , B D N F  b in d in g  site
F ig u re  5.1 .4-b: P re d ic ted  s tru c tu re s  o f  B D N F &  its b in d in g  d o m a in  on th e  T rk B  rec ep to r .
Three dim ensional representations o f  the predicted structures o f  A: the A chain o f  hum an BDNF 
(G I:584184, M M D B 9670) and B: the 5th dom ain (d5) o f  the hum an TrkB receptor (G I:5822440, 
M M D B 10999) (U ltsch et al., 1999) w hich is the b ind ing  site for hum an B D N F (U rfer et al., 
1995). S tructures w ere obtained using the Cn3D4.1 softw are, available at the N CB I website: 
h ttp://w w w .ncbi.nlm .nih.gov (D isulfide bridges are show n in red).
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the lesion (Xiao et al, 2005). It should be pointed out though that despite the fact 
that ONe-NSFCs were shown to innately secrete BDNF, it is possible that they 
also secrete factors that enable them to further support regeneration and allow 
axons to evade the inhibitory signals of the lesion site.
Fibroblasts, genetically engineered to express BDNF have been used with some 
success in promoting red nucleus neuron survival and axonal regeneration 
following axotomy. Liu et al (2002) employed a retroviral vector to transduce rat 
fibroblasts to express the human version of BDNF (Fb/hBDNF). Transplantation 
of these Fb/hBDNF cells into the site of a C3-4 rubrospinal tract lesion was 
shown to limit the extent of red nucleus neuronal loss and reduce somal atrophy. 
Specifically, two months following this intervention there was reportedly a 15% 
red nucleus neuron loss with the surviving neurons displaying a 20% reduction of 
somal size. The magnitude of this effect becomes evident when one considers 
that in control animal there was a 45% loss of red nucleus neurons and a 40% 
reduction in the somal size of surviving neurons (Liu et a l, 2002). However, the 
effectiveness of this approach in reducing neuronal loss and somal atrophy is not 
mirrored in terms of rubrospinal tract axonal regeneration. Even though transgene 
expression lasted for 2 months post transplantation and was sufficient to promote 
a regenerative response, there was no persuasive evidence for the regeneration of 
rubrospinal tract axons through the lesion site (Murray et a l, 2002; Liu et a l,
2002). Other studies performed using this technology support the above findings 
(Liu et a l, 1999; Kim et a l, 2001; Murray et a l, 2002; Liu et a l, 2002). 
However, the paradox of these studies is that despite the lack of hard evidence for 
rubrospinal tract axonal regeneration, the experimental animals appear to regain 
some of the function lost by the axotomy. This could be due to the fact that 
BDNF can promote the re-organisation of descending pathways leading to some 
functional recovery that was not dependent on rubrospinal regeneration (Tobias et 
al, 2005).
One problem with the therapeutic use of BDNF is that it has the shortest plasma 
half-life of all other neurotrophic factors at ~0.92 minutes and does not cross the 
intact BBB (Poduslo and Curran, 1996). These characteristics may hinder its
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application in vivo. The application of HSV1 viral vector technology however can 
help circumvent this limitation and exploit the regeneration promoting abilities of 
this factor. The potential of the HSVl.pR19CMV vector backbone employed in 
this study to facilitate the de novo synthesis of BDNF from red nucleus neuron 
somata would complement the suggested mode of action of this factor in these 
neurons. The same principle has shown promise when applied by means of a 
BDNF expressing adeno-associated virus (AAV) vector. Ruitenberg et al (2004) 
showed that the direct administration of AAV-BDNF at the level of the red 
nucleus at the time of the lesion cannot prevent the onset of neuronal atrophy but 
it has the potential to reverse the atrophy that follows a cervical rubrospinal tract 
axotomising injury. Specifically, at the two month time point following AAV- 
BDNF administration, the mean red nucleus neuron somal area was -395 pm in 
AAV-BDNF treated animals as opposed to -251 pm in AAV-GFP, control 
animals (Ruitenberg et al., 2004). The highly disabled HSV1 vector used in this 
study could in theory achieve a similar outcome, especially since it preferentially 
targets neurons where it can establish a long term and stable expression of BDNF.
Other tissues that secrete BDNF have differing effects on injured rubrospinal 
neurons. For example, transplantation of foetal spinal cord segments into the site 
of a C3-4 rubrospinal tract axotomising lesion, can lead to a -50% reduction in 
cell loss but does not lead to any meaningful rubrospinal axonal regeneration into 
or through the lesion site (Mori et al., 1997). On the other hand, rubrospinal 
axons can regenerate into a peripheral nerve graft placed within the cervical 
spinal cord (Richardson et al., 1984).
5.1.4.3 Neurotrophin 3
Exogenous administration of NT3 has been shown promote the survival of 
axotomised red nucleus neurons in newborn rats but only in the short term 
(Diener and Bregman, 1994). In the adult animal, NT3 encourages the axonal 
elongation of red nucleus neurons into a peripheral nerve graft placed rostral to 
the lesion, four weeks after an upper cervical axotomy. (Ye and Houle, 1997).
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When fibroblasts engineered to stably express NT3 were transplanted into a 
cervical over-hemisection, which included the rubrospinal tract, some recovery of 
function occurred over the following three months (Grill et a l , 1997). However, 
this may not have been purely due to the effects of NT3. Evidence supporting this 
comes from studies employing a different substrate to regeneration. For example, 
combining the use of embryonic transplants and co-administration of NT3 one 
month following a C5/C6 rubrospinal tract axotomy, appeared to encourage 
axons to sprout at the margin of the lesion site but with minimal growth into the 
transplant (Lynskey et a l , 2006). Despite the somewhat expected, marginal 
nature of the axonal response, it was nevertheless accompanied by improvements 
in motor function probably due to the plasticity of local, spared fibres (Grill et a l , 
1997; Shumsky et a l , 2003; Tobias et a l , 2003; Lynskey et a l, 2006). After all, 
spared CST axons in the vicinity of an rubrospinal tract axotomising lesion have 
been shown to be capable of some sprouting in the presence of exogenously 
derived NT3, albeit only in the superficial dorsal horn (Jeffery and Fitzgerald, 
2001) and this phenomenon may underlie the improvements in motor function 
observed in these experiments. This is supported by the fact that in the case of a 
complete unilateral C3/C4 hemisection that eliminates the ipsilateral motor 
pathways, no improvements in motor function were observed in BDNF/ NT3 
treated animals (Shumsky et al, 2003). Since this type of lesion ablates the 
descending motor and pre-motor neuronal projections that regulate the function 
of forelimb muscle groups, it follows that any improvement noted in models that 
spare these tract could be due to spared ipsilateral fibres (Shumsky et a l, 2003).
The above studies appear to suggest that NT3 may not be as efficient as other 
factors in promoting the regeneration of axotomised red nucleus neurons. This is 
supported by the fact that NT3 treatment, administered either at the lesion site or 
at the level of the red nucleus cell bodies, is not associated with an increased 
expression of GAP43 and al Tubulin. At the same time there is only a marginal 
increase in full-length TrkC mRNA levels at 7 days following a cervical 
rubrospinal tract lesion (Tetzlaff et a l, 1991; Kobayashi et a l, 1997; King et a l,
1999). In addition, administration of NT3 alone does not protect against atrophy 
to the extent observed after BDNF infusion (Kobayashi et a l, 1997; Houle and
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Ye, 1999). This does not mean that red nucleus neurons are totally unresponsive 
to NT3. Prolonged administration of NT3 appears to have a restorative effect on 
TrkB levels which decline following a rubrospinal tract axotomy (Novikova et 
al., 2000). Treatment with NT3 following a C3 level lesion, augments the 
expression of mRNA transcripts of the pi subunit of the integrin receptor in red 
nucleus neurons, a putatively pro-regenerative response (Plantman et al., 2005). 
No such upregulation occurs as a result of BDNF administration. NT3 alone, and 
to greater extent NT3 administration combined with a foetal spinal cord 
transplant to a thoracic level rubrospinal tract lesion site, leads to an increase in 
the expression of c-Jun (Broude et al., 1999).
The combination of BDNF and NT3 infusions at 5-8 weeks following axotomy, 
can lead to reductions in red nucleus somal atrophy following a cervical level 
lesion, pointing to a potentially synergistic relationship between those two factors 
(Novikova et al., 2000). When the same combination was infused acutely and 
following a C3 lesion it failed to have an impact on neuronal somata. The authors 
of this study deduced that the extent of the effect of these neurotrophins depends 
on the timing of their administration with respect to the initial injury. This 
however is in contrast with reports based on the use of modified BDNF and NT3 
expressing fibroblasts. For example, Tobias et al (2003) report that it is the acute 
rather than delayed (by 6 weeks) transplantation of BDNF and NT3 fibroblasts 
that produce a maximal effect in terms of preventing red nucleus cell body 
atrophy. There is therefore a disagreement on the correct timing of this 
intervention with one group favouring the acute (Tobias et al., 2003) and the 
other the delayed (Novikova et al., 2000) intervention with a combination of 
BDNF and NT3. This discrepancy could be explained by taking into 
consideration the significant differences between research groups with respect to 
the methods employed in order to identify, count and measure the somal size of 
axotomised red nucleus neurons (Tobias et al., 2003).
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5.1.4.4 GDNF
In addition to the studies described previously, there have been a few studies on 
the potential therapeutic effects of other factors after lesions of the rubrospinal 
tract. Following a lesion of the rubrospinal tract at C3 and a subsequent 60- 
minute exposure to recombinant GDNF within the lesion site, in situ 
hybridisation analysis revealed upregulation of pill Tubulin mRNA levels within 
the first three days following exposure (Storer et al., 2003). In addition, GAP43 
mRNA also increased, accompanied by an increase in red nucleus neuronal cell 
body size. It is worth noting that GDNF was applied to a second aspiration lesion, 
which was in turn carried out four weeks after the initial lesion. It is therefore 
plausible that the increase in mRNA levels noted was due to the effects of the 
second lesion inflicted rather the result of the GDNF administration per se.
In a previous study the same research group report that pill Tubulin mRNA 
levels are increased within 6 hours after a secondary axotomy and remain stable 
for the next 5 days without any further intervention (Storer and Houle, 2003). The 
same authors report that GAP43 mRNA levels also increase within six hours after 
the secondary lesion and reach a steady state within the subsequent 7 days. The 
results from these studies however must be interpreted with caution because, as 
the authors acknowledge, there is a lack of statistical significance in their findings 
(Storer et al., 2003).
In another experiment, GDNF was administered acutely after an axotomising 
lesion by means of a gel foam application (Dolbeare and Houle, 2003). These 
authors report that at one week following the initiation of GDNF treatment, there 
is a marked reduction in the extent of dieback of injured axons. Furthermore, 
after a month-long treatment, rubrospinal tract axons were present ~240 pm from 
the rostral margin of the lesion site compared to ^=480pm in PBS treated animals 
(Dolbeare and Houle, 2003).
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5.1.4.5 bFGF
Several research groups have attempted to map the presence of bFGF and its 
receptor in distinct neuronal populations including the red nucleus. Uninjured, 
adult red nucleus neurons are immunopositive for the presence of bFGF (Grothe 
et al., 1991; Matsuyama et al., 1992; Grothe and Janet, 1995; Fuxe et al., 1996). 
No data are as yet available as to the expression of bFGF and its receptor after 
lesion of the rubrospinal tract and very few attempts have been made to examine 
the potential of this growth factor to promote the regeneration of axotomised red 
nucleus neurons. Local application of bFGF, accompanied by removal of the glial 
scar, at either 4 or 8 weeks following a lesion at the C3 level, fails to promote an 
increase in the levels of c-Jun in red nucleus neurons (Houle et al., 1998). In 
another study using the same lesioning model, the application of bFGF at four 
weeks following the initial lesion had no effect on the survival of axotomised red 
nucleus neurons (Houle and Ye, 1999).
5.1.5 Rationale
This study describes experiments employed to test the hypothesis that if vectors 
HSV1 .pRl 9CMVrBDNF and HSVl.pR19CMVmCNTF are capable of 
transducing injured RST neurons to de novo synthesise biologically active 
rBDNF and mCNTF, then these constructs may lead to a more favoured 
regenerative response in injured RST neurons. This relationship could be
measured as reduced somal atrophy in red nucleus neurons when using the
HSVl.pR19CMVrBDNF vector and increased axonal regeneration when 
targeting the lesioned rubrospinal tract model with both HSVl.pR19CMVrBDNF 
and HSV 1 .pRl 9CMVmCNTF.
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5.2 Methods
5.2.1 Vectors utilised in this Chapter
The following vectors were used in this study, either to induce regeneration or for 
the delivery of marker genes to the chronically injured rubrospinal tract.
V irus A bbrev ia tion
1764/ICP277ICP47RL17pRl 9CM VGFP H S V 1 .pRl 9CM VGFP
1764/ICP277ICP47RL1 VpRl 9CM Vrat BDNF H S V 1 .pR l 9CM VrBDNF
1764/ICP277ICP47RL1 VpRl 9CM Vm ouse CN TF-N G F chim era5 HSV 1 .pR l 9CM VmCNTF
Table 5.2-a: Vectors used in rubrospinal tract regenerative studies.
The construction and characterisation o f  the vector backbone H SV l.pR 19C M V  has been 
previously published (Lilley et al., 2001b) and characterised in vivo in Chapter 3.
5.2.2 Construction of rBDNF or rCNTF expressing vectors
As discussed in Chapter 3, the vector backbone that allows efficient transgene 
delivery to the chronically injured spinal cord was 1764/ICP277ICP47pR19CMV 
(HSVl.pR19CMV). As is the case for other neurotrophin expressing vectors, 
such as those described in Chapter 4, in order to create vectors capable of 
delivering biologically active rBDNF or mCNTF proteins, the corresponding 
cDNA had to be first sub-cloned into the pR19CMV expression cassette, 
substituting the GFP marker gene. Insertion of the new expression cassette into 
the host viral genome was subsequently achieved via homologous recombination. 
Production of functional protein and confirmation of transgene product 
bioactivity was then confirmed in vitro and in vivo.
5.2.2.1 Construction of plasmid pGEM5/pR19CMVrBDNF
cDNA encoding for rBDNF (Gene Bank accession number M61175) was 
obtained from Dr B. Haupt (Dept, of Immunology & Molecular Pathology, UCL, 
London). The cDNA was originally cloned as an EcoRl, PCR generated fragment 
(Maisonpierre et al., 1991) into pSP72/rBDNF plasmid. The reporter gene GFP 
of the plasmid backbone pGEM5/pR19CMVGFP, was removed by digesting first 
with Hindlll followed by blunt ending with T4 DNA polymerase and subsequent 
restriction with Xhol. A single rBDNF corresponding fragment (~1137bp) was 
removed from pSP72/rBDNF by digesting with EcoRV/Xhol. The fragment was
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then sub-cloned into the pR19CMV shuttle plasmid, flanked by LAT sequences 
which allow for the subsequent homologous recombination into the LAT region 
(Lilley et al., 2001b). pGEM5/pR19CMVrBDNF clones were screened by a 
single EcoRl digestion. Clones containing the rBDNF gene produced a single 
~1127bp band (Maisonpierre et al., 1991) and were selected on the basis of 
having this restriction profile.
5.2.2.2 Construction of plasmid pGEM5/pR19CMVmCNTF
The mCNTF cDNA (Gene Bank accession number NM_170786) utilised for the 
production of the recombinant vector employed in this study was a kind donation 
from Prof M. Sendtner (Dept, of Neurochemistry, Max-Planck-Institute for 
Psychiatry, Martinsried, Germany), in the form of plasmid pCNTF-chim5 
encoding a secretable form of mCNTF obtained by the fusion of the murine 
NGF-p subunit secretory signal with the mCNTF cDNA (Sendtner et al., 1992). 
The mCNTF chimeric protein is therefore capable of being exported from 
transduced cells. The cDNA fragment (2150bp) was excised from the pCNTF- 
chim5 plasmid via an Xbal/T4/Hindlll digest and sub-cloned into 
pGEM5/pR19CMVGFP. The GFP reporter gene was previously removed from 
the same plasmid backbone via a Xhol/T 4/Hindlll restriction. 
pGEM5/pR19CMVmCNTF recombinant clones were screened for the presence 
of mCNTF via a HindlU/Xmnl digestion which yielded a single ~1200bp band. 
Out of all the positive clones a single colony was selected and further confirmed 
by sequencing.
5.2.2.3 Production of HSVl.pR19CMVrBDNF and mCNTF vectors
Purified HSVl.pR19CMVGFP (1764/ICP277ICP47pR19CMVGFP) viral DNA 
was co-transfected with pGEM5/pR19CMVrBDNF or 
pGEM5/pR19CMVmCNTF plasmid DNA. Each of the constructs was 
recombined into the endogenous LAT of the HSVl.pR19CMVGFP backbone 
between the two BstXI sites (ntl20,220 and nt\20,408) (Lilley et al., 2001b). 
Recombinant plaques were detected by their white phenotype (no GFP 
expression), which is indicative of the correct insertion of the pR19CMVrBDNF
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or mCNTF expression cassettes in both LAT regions of the HSV genome. Plaque 
purification was carried out until all plaques had the recombinant, white 
phenotype. The two new vectors were termed HSVl.pR19CMVrBDNF 
(1764/ICP277ICP47pR19CMVrBDNF) and HSVl.pR19CMVmCNTF 
(1764/ICP277ICP47pR19CMVmCNTF). Southern blotting confirmed the correct 
insertion of the rBDNF gene on recombinant plaques, each originating from 
separate recombination events. Recombinant vectors were propagated by 
standard cell culture techniques on 27/12/M:4 cells and viral stocks were 
produced as outlined in Chapter 2.
5.2.3 Characterisation of HSVl.pR19CMVrBDNF & mCNTF vectors
Correct transgene insertion and the ability of these vectors to secrete biologically 
active protein was evaluated using a non-complementing cell line.
5.2.3.1 Southern blotting on HSVlpR19CMVrBDNF plaques
Each purified recombinant HSVl.pR19CMVrBDNF viral plaque was used to 
infect lxlO6 BHK cells. Viral DNA from each plaque was extracted as outlined in 
Chapter 2, digested with EcoRl and run on a 2% (w/v) agarose gel. 
HSVl.pR19CMVGFP viral DNA digested by Hindlll/Xhol (releasing a 600bp 
fragment corresponding to GFP) was used as a negative control while an EcoRl 
digested plasmid pSP72/rBDNF was used as a positive control. The same plasmid 
digest was used to produce the rBDNF probe, which was subsequently purified 
and radiolabelled with aP34-dCTP. A detailed account of this procedure is given 
in Chapter 2.
5.2.3.2 Southern blotting on HSVl.pR19CMVmCNTF plaques
The purification procedure was carried out as outlined above. In the case of 
HSVl.pR19CMVmCNTF plaques, the extracted viral DNA was digested with 
Hindlll/Xmnl (releasing a -951 bp fragment corresponding to the 5’ end of 
mCNTF which includes the NGF secretory sequence). HSVl.pR19CMVGFP 
viral DNA, digested as described above, was used as a negative control, while a 
Hindlll/Xmnl digested plasmid pmCNTFchim5 was used as a positive control.
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5.2.3.3 Concentration of rBDNF/mCNTF from transduced BHKs
lxlO6 BHK cells in a 36 mm well were infected at an MOI of 1 with either 
HSVl.pR19CMVGFP or neurotrophic factor encoding vector: 
HSVl.pR19CMVrBDNF or HSVl.pR19CMVmCNTF. Two days later, the 
infected monolayer was washed twice with 0.1M PB and 500 pi of DMEM was 
placed in each well. The now infected cells were returned to a 37°C/5%C02 
incubator. At the desired time point, the DMEM was collected and centrifuged at
2,000 rpm for 5 minutes to remove any cells present. The supernatant was then 
transferred onto a 500 pi Microcon column with a lOkDa molecular weight cut­
off (G-10000, Green). The column was then spun at ll,500g for 25 minutes at 
4°C. The total volume of the concentrated sample was 20-25 pi, which represents 
the amount of recombinant protein, rBDNF or mCNTF, secreted from lxlO6 
virally transduced, non-complementing cells. These were used for further testing 
via Western blotting or neurite outgrowth assay.
5.2.3.4 Western blotting for vector rBDNF/ or mCNTF detection
The Western blotting analysis carried out in this Chapter involved screening for 
the presence of rBDNF or mCNTF in conditioned media as well as, in some 
instances, their presence in cell lysates. Both techniques employed have been 
extensively described in previous chapters (Chapters 2 and 4), while protein 
isolation from conditioned media is outlined in the previous section. rBDNF 
expression was analysed at 2, 4, 6 and 8-hour time points in conditioned media 
and at a single time point of 8 hours in the case of whole cell lysates. Secreted 
mCNTF, expression was assessed in conditioned media, at a single time point of 
6 hours. Cell lysates or concentrated samples from conditioned media were mixed 
with SDS-PAGE sample buffer and processed as described in Chapter 2. In the 
case of the mCNTF electrophoresis, the sample buffer used did not contain any p- 
mercaptoethanol. Instead it contained DTT at a final concentration of 2mM in 
order to partially preserve disulfide bonds and dimer integrity. The primary 
antibody used for the detection of rBDNF was rabbit polyclonal anti-human 
BDNF (working dilution 1:200, N-20, Santa Cruz Biotechnology Inc., SC-546), 
which cross-reacts with the rat species of the protein and significantly recognises
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the unprocessed 32 kDa pro-BDNF, the 28 kDa intermediate and the 14.5 kDa 
mature BDNF proteins. For detecting mCNTF, the primary antibody used was 
goat polyclonal anti-rat CNTF (working dilution 1:200, R-20, Santa Cruz 
Biotechnology, Inc., SC-1912) which also cross-reacts with CNTF of murine 
origin. Equal protein loading was confirmed by visually evaluating band intensity 
on a duplicate, coomassie G-250 stained gel.
5.2.3.S rBDNF neurite outgrowth assay on E14 rat DRG explants
This assay was described in detail in section 4.2.2.7 of Chapter 4. Briefly, rat E14 
lumbar DRGs were isolated, embedded in collagen and maintained in a 
chemically defined medium. The supernatant from lx l0 6 BHK cells previously 
infected at an MOI of 1 with HSVl.pR19CMVrBDNF (n=3) or 
HSVl.pR19CMVGFP (n=3) (negative control) or mock-infected (n=2) was 
collected, clarified to remove cellular debris and concentrated as described in 
section 5.2.3.3. Concentrated, conditioned medium was added to each collagen- 
embedded DRG explant and replenished every day. Neurite extension was 
compared 3 days following the initiation of treatment by immunofluorescence 
staining of neurites using mouse TUJ1 anti-neuron specific type III p tubulin 
antibody (1:5000, Cambridge Bioscience, UK). Recombinant human BDNF 
(R&D Systems, 248-BD) was used as a positive control for the experiment at a 
concentration of 5 ng/ml.
5.2.4 Cell proliferation assay
This assay was employed in order to confirm the biological activity of vector 
encoded mCNTF and was based on the use of the cell line TF-l.CN5a.l (ATCC®, 
Cat. No: CRL-2512). These cells have been engineered to express the alpha 
subunit of the human CNTF-Ra receptor and proliferate in the presence of minute 
quantities of biologically active CNTF (in the picogram/ml range). lxlO6 BHK 
cells in a 36 mm well were infected at an MOI of 1 with either 
HSVl.pR19CMVGFP or HSVl.pR19CMVmCNTF. Two days later the infected 
monolayer was washed twice with 0.1M PB, aliquots of 500 pi of DMEM were 
placed in each well and the infected monolayer was returned to a 37°C/5%C02
279
/ / i  i i s  <>l 1 I S  I i Yccior-m'tlioicd  < I c h w i v  <>l H i  > \ /  <>r ( '  \  I /■ /< > t i n ■ m h n  >y >m<il m w i
incubator overnight. The following day the supernatant was removed and spun at
12,000 rpm at 4°C for 30 min to pellet cell debris or free viral particles. In order 
to confirm the removal of virus, 1 Ojul of this supernatant was titrated on the 
complementing cell line 27/12/M:4 and the cells were monitored for the 
appearance of viral plaques. Purified conditioned supernatants were kept at 4°C 
and used immediately after purification. 5, 25 and 50 pi aliquots from each 
conditioned media was analysed in triplicate for its ability to induce the 
proliferation of 3xl04 TF-l.CN5a.l cells. Conditioned media from 
HSVl.pR19CMVGFP infected cells served as a negative control while 2ng/ml of 
recombinant human CNTF (rhCNTF, R&D systems, Cat.No: 257-NT) was used 
as a positive control. Cell numbers were monitored at three time points: prior to 
the addition of conditioned media or rhCNTF (t/pO) and at 3 and 6 days following 
sample addition (t/p3 and t/p6 respectively). Cell numbers were assessed using a 
haemocytometer and Microsoft® Excel was utilised for analysis.
5.2.5 HSVl.pR19CMV mediated in vivo delivery of rBDNF or mCNTF
Two sets of experiments were carried out during the course of these studies. The 
first set was designed to examine the effect of vector-mediated rBDNF and 
mCNTF delivery on lesioned rubrospinal tract axons (section 5.3.3, page 300). 
The second set aimed to assess the ability of vector mediated rBDNF delivery on 
red nucleus axotomy induced somal atrophy (5.3.4, page 306). The above 
experiments are represented schematically in Figure 5.2.5-a and Figure 5.2.5-b 
respectively.
5.2.5.1 Rubrospinal tract lesions
Lesions were performed on deeply anaesthetised adult female Lewis rats (~200g). 
A horizontal incision was made in the skin at the midline over the thoracic spine. 
A second incision was made in the superficial muscle layers and the underlying 
muscles were separated by blunt dissection. The mid-thoracic vertebrae (~T4 to 
T6) were exposed and a bilateral laminectomy, performed using malleus scissors. 
The dura mater was carefully cut with micro-scissors and at this point, animals 
were injected subcutaneously with 2.2 mg/Kg of Finadyne (Schering-Plough).
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With the aid of iridectomy scissors, the left lateral funiculus was transected. This 
severed the descending rubrospinal tract, sparing the ascending dorsal columns 
and the descending dorsal corticospinal tract. The dura matter and overlying 
musculature was repaired using silk sutures and the skin was closed with Michel 
clips.
5.2.5.2 Spinal cord Microinjection of disabled HSV1 vectors
Spinal cords were exposed as described in the previous section and injections 
were carried out as described in the general methods chapter (Chapter 2). 
Briefly, a 25 pi Hamilton syringe fitted with a fine needle (outer 0  300 pm) was 
used to administer either of the vectors at a 1.5 mm depth into the cord just 
proximal and distal to the rubrospinal tract lesion site. Viral suspensions were 
injected at a rate of 0.5 pl/min using a micro-pump. HSVl.pR19CMVrBDNF, 
HSVl.pR19CMVmCNTF or HSVl.pR19CMVGFP control vectors were 
delivered in two 2.5 pi aliquots, 5 mm apart and either side of the lesion site, 
along the rostro-caudal axis of the T4-T6 segments. Ten minutes later the needle 
was removed, the dura, spine muscles and the overlaying skin was repaired with 
Michel clips.
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R ubrosp ina l tra c t 
Lesion
V irus in jection
In jection
T im e lin e  D iagram, ,  x P ro ced u re  P erfo rm ed  0 r(days)________________________________________   Sign
0 Unilateral rubrospinal tract axotom y at T4 -T 6  1
Injection: HSV 1 .pR19CM VrBDNF/m CNTF 
30 mixture or HSV 1 .pR 19CM VLacZ, both 2
proximal and distal to the lesion site.
Injection o f  the BDA anterograde tracer, close ^
to the contralateral red nucleus45
60 Termination
F ig u re  5.2.5-a: E x p erim en ta l design: effects o f rB D N F & m C N T F  on the  axotom ised RST.
The tim eline shown above was followed for the experim ents described in section 5.3.3 (page 
300). BDA tracer was injected into the red nucleus, contralateral to the location o f  the lesion site, 
15 days prior to term ination o f  the experiment.
BDA tr a c e r
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1
2
3
Tim e line 
(days) P ro c ed u re  P e rfo rm e d
D iagram
Sign
0 Unilateral rubrospinal tract axotom y at T4 -T 6  and 1
DiAsp crystal insertion. 2
1 Termination o f  “N on-atrophied” controls.
30
Injection o f  H SV l.pR 19C M V rB D N F or 
H SV l.pR 19C M V LacZ both proxim al and distal to 
the lesion site.
3
60 Termination
F ig u re  5.2.5-b: E xperim en ta l design: effects o f  rB D N F on red  nucleus neu ron  a tro p h y .
The tim eline shown above was followed for the experim ents described in section 5.3.4 (page 
306). For identifying the neuronal somata o f  axotom ised red nucleus neurons, a single crystal o f  
DiAsp was placed within the rubrospinal tract lesion site, immediately after the lesion was 
inflicted.
R u b ro sp in a l tra c t 
Lesion
D iA sp P lacem en t
I
V iru s In jec tion
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5.2.5.3 Tracing of rubrospinal tract fibres by BDA or DiAsp
Administration of BDA into the rodent brain was carried out using a stereotaxic 
frame and the details of the procedure have already been described in Chapter 4 
as well as in Chapter 2. Using a 25 pi Hamilton syringe, 1 pi of 10% (v/v) BDA 
tracer (BDA; 10,000MW, Molecular Probes) in PBS, was injected in the red 
nucleus. The following co-ordinates were used for targeting the rubrospinal tract: 
rostral-caudal 4.9 mm, medial-lateral 1.4 mm, dorsal-ventral 7.8 mm and at an 
angle of 5 degrees (Kuchler et al., 2002). Injections were made in 0.2 pi 
increments over two minutes. After a 10 min wait, to allow for the diffusion of 
the tracer, the needle was slowly withdrawn and muscles and the skin sutured. 
Processing was carried out on free-floating sections for the visualisation of the 
BDA tracer using the HRP-DAB method. Sections were mounted on gelatinised 
slides and processed as outlined in Chapter 2.
5.2.5.4 DiAsp retrograde labelling of red nucleus neurons
In experiments designed to assess the effects of BDNF on somal atrophy, the 
BDA tracer was substituted by the lipophilic tracer DiAsp (4-(4- 
dihexadecylaminostyryl)N-methylpyridium iodide or 4-Di-lO-ASP, Molecular 
Probes Inc., Cat. No: D291). This tracer was applied at the same time that the 
lesion was inflicted. A small piece of Sterispon (Allen and Handbury, London, 
UK) saturated with a 20% solution of DiAsp in distilled water, was placed within 
the lesion site. The pia, dura and overlying musculature was repaired using silk 
sutures and the skin was closed with Michel clips.
5.2.5.5 SCG10 immunostaining of spinal cord sections
Longitudinal spinal cord sections (40pm) were immunostained for the presence 
of superior cervical ganglion-10 (SCG10) protein as described previously 
(Chapter 2). The primary antibody was SCG10 polyclonal antibody (raised in 
rabbit) obtained from Dr G. Grenningloh (University of Lausanne, Switzerland), 
used at a dilution of 1:3000. Colour development was carried out using the 
avidin-biotin complex (ABC) kit as per manufacturer’s instructions (Vectastain, 
Burlingame, CA, USA).
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5.2.5.6 Microscopy and quantitation of red nucleus neuron somata size
In experiments designed to explore the effects of vector mediated delivery of 
rBDNF on atrophy of axotomised red nucleus neurons, it was necessary to 
employ an automated algorithm-based technique for assessing somal atrophy. 
Control and treated rat brains were sectioned in the coronal plane at 40 pm and 
sections thought the midbrain sections were viewed using a Zeiss Axiophot 2 
fluorescent microscope (Carl Zeiss Ltd., UK) fitted with a Hamamatsu ORCA 
285 digital camera (Hamamatsu Photonics Ltd., UK) and Open-Lab Software 
(Improvision, University of Warwick, UK).
Software programming was performed in collaboration with Dr G. Campbell 
(Dept, of Anatomy and Developmental biology, UCL), based on the method 
described in Kobayashi et al (1997). The DiAsp labelled neurons found 
contralateral to the lesioned red nucleus on each midbrain section were 
photographed in both control and treated animals. To quantify the labelled 
neurons, an automated series of photographs was taken at a magnification of lOx 
through the entire section thickness at 1pm spacing, using the Automator module 
of the Open-Lab software. Deconvolution of the collected images and subsequent 
merging produced a single sharp image of the neurons and resulted in the 
removal of any out-of-focus structures. This single sharp image was similar to a 
confocal image and showed all labelled neurons in focus throughout the depth of 
the section (see Figure 5.3.4-a). The surface area of all DiAsp positive neurons in 
the contralateral lesioned red nucleus in both treated and untreated animals was 
measured on these single deconvolved images. These measurements were 
performed using the automated Measuring Module function of the Open-Lab 
software, ensuring that all the somata measured had a visible nucleus. To avoid 
the possibility of counting the same neuronal cell body from two adjacent 
sections (e.g. if the microtome blade bisected the cell by passing through its 
nucleus), a gap of at least one section (40 pm) between measured neurons was 
allowed, while on average three to five sections were used in order to quantitate 
the DiAsp positive red nucleus neurons present in each animal. In order to 
identify which neurons were to be measured, suitable somata were identified 
based on the intensity of their fluorescence. This was assessed based on two
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separate criteria: an upper and then a lower intensity threshold value. In other 
words the analysis was run twice, once with the upper threshold in place and once 
with the lower threshold in place (see Figure 5.3.4-b and Figure 5.3.4-c).
Using the Density-Slice tool of the Open-Lab software an upper and a lower 
threshold value for the intensity of fluorescence was set. The upper threshold 
value was such that it allowed measuring the area of the majority of neurons 
present on a deconvolved slice, ensuring that all bright areas did not exceed the 
fluorescent intensity of the brightest neuronal soma. Similarly, the lower 
threshold value used for the second density slice allowed neuronal cell bodies that 
display weaker labelling to be included in the measurements (Figure 5.3.4-c). 
When two labelled cell bodies were in such close proximity to each other that the 
software failed to differentiate between them, these were measured manually 
using the Region O f Interest (ROI) tool. All profiles less than 8 pm2 in diameter 
were filtered out in order to stop any spurious particles from being measured. All 
measured areas were entered as raw data into the Microsoft® Excel program and 
statistical analysis was performed as detailed below.
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5.3 Results
5.3.1 Functional characterisation of vector HSVl.pR19CMVrBDNF
Prior to proceeding with attempts to insert the rBDNF gene into the viral DNA 
backbone, it was necessary to confirm its correct insertion into the 
pGEM5.pR19CMV plasmid. This was done by sequencing the nucleotides on the 
3’ end of the CMV promoter with a corresponding primer (the primer sequence is 
outlined in Chapter 2). The plasmid sequence obtained was then compared via 
BLAST to the rat genome and was found to be compatible (Figure 5.3.1 -b). The 
cloning steps and subsequent recombination events that led to the production of 
the recombinant vector HSVl.pR19CMVrBDNF are shown schematically in 
Figure 5.3.1-a. Successful recombinant plaques were selected firstly on the bases 
of their white phenotype under fluorescence and secondly by molecular screening 
using Southern blotting analysis (Figure 5.3.1-c, panel A). iscoRI restriction of 
the recombinant plaque viral DNA and subsequent probing with an rBDNF 
specific probe, led to the identification of three plaques which were positive for 
the presence of a ~1130bp band corresponding to the full length rBDNF gene 
(Maisonpierre et al., 1991). This band corresponds to the one obtained via an 
iscoRI restriction of pSP72/rBDNF and pGEM5.pR19CMVrBDNF plasmid DNA 
which were used as positive controls. No bands were identified when the 
similarly digested HSVl.pR19CMVGFP vector backbone (negative control) was 
exposed to the same rBDNF probe.
Following the identification of successful recombinants, the 
HSVl.pR19CMVrBDNF vector was propagated to a concentrated stock and its 
ability to transduce non-complementing cells was assessed in vitro. The 
procedure of sample collection is similar to that described elsewhere (Chapter 4, 
section 4.3.1). lx l06 BHK cells were infected (MOI=l) with either 
HSV 1 .pRl9CMVGFP (n=2) or HSVl.pR19CMVrBDNF (n=8 in total). 
Supernatants were collected only at 8 hours in the case of HSVl.pR19CMVGFP 
(control) and at 2, 4, 6 and 8 hour time points in the case of 
HSVl.pR19CMVrBDNF infected cells (n=2 per time point). In addition, the cell 
lysate from the 8-hour time point (n=l) was collected and analysed along with the 
conditioned media (supernatants) by Western blotting analysis.
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Figure 5.3.1-a: Construction of vector HSVl.pR19CMVrBDNF.
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(BDNF) mRNA, c o m p l e t e  c d s ,  a l t e r n a t i v e l y  s p l i c e d
L e n g th = 3 7 9 4
S c o r e  = 1 2 9 3  b i t s  ( 7 0 0 ) ,  E x p e c t  = 0 . 0  
I d e n t i t i e s  = 7 0 0 /7 0 0  (1 0 0 % ), G a p s  = 0 /7 0 0  (0%)
S t r a n d = P l u s / P l u s
Q u e r y 1 CAGTTCCACCAGGTGAGAAGAGTGATGACCATCCTTTTCCTTACTATGGTTATTTCATAC 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 II 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 II 1 1 1 1 1 1 1 1 1 1 1 
CAGTTCCACCAGGTGAGAAGAGTGATGACCATCCTTTTCCTTACTATGGTTATTTCATAC
60
S b j c t 1 4 0 1 9 9
Q u e r y 61 TTCGGTTGCATGAAGGCTGCGCCCATGAAAGAAGCAAACGTCCACGGACAAGGCAACTTG 
1 1 1 1 1 1 II 1 1 1 II 1 1 1 1 1 II 1 1 II 1 1 1 1 II II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 
TTCGGTTGCATGAAGGCTGCGCCCATGAAAGAAGCAAACGTCCACGGACAAGGCAACTTG
1 2 0
S b j c t 2 0 0 2 5 9
Q u e r y 1 2 1 GCCTACCCAGCTGTGCGGACCCATGGGACTCTGGAGAGCGTGAATGGGCCCAGGGCAGGT 
I I I i I i I I i i i I i i i i i I i I i I I I I I i i I i i i ii i i i i ii i i i i i i m i i i i i i i i i i i i
1 8 0
S b j c t 2 6 0
1 I I  1 1 II  I I  1 II  I I  1 I I  1 I I  I I  I I  1 1 I I  I I  I I  1 I I  I I  I I  1 1 I I  1 I I  1 I I  I I  II  1 1 I I  I I  1 
GCCTACCCAGCTGTGCGGACCCATGGGACTCTGGAGAGCGTGAATGGGCCCAGGGCAGGT 3 1 9
Q u e r y 1 8 1 TCGAGAGGTCTGACGACGACGTCCCTGGCTGACACTTTTGAGCACGTGATCGAAGAGCTG 
1 1 1 1 1 1 1 1 1 1 1 1 1 II II 1 1 1 1 1 II 1 1 II 1 1 1 1 II 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II
TCGAGAGGTCTGACGACGACGTCCCTGGCTGACACTTTTGAGCACGTGATCGAAGAGCTG
2 4 0
S b j c t 3 2 0 3 7 9
Q u e r y 2 4 1 CTGGATGAGGACCAGAAGGTTCGGCCCAACGAAGAAAACCATAAGGACGCGGACTTGTAC 
i I I I i i I I i i i ii i i i i > i i i i i I I I i i i ii i i i i i ii i i i i i i ii i i i i i i i i i i i i i i
3 0 0
S b j c t 3 8 0
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
CTGGATGAGGACCAGAAGGTTCGGCCCAACGAAGAAAACCATAAGGACGCGGACTTGTAC 4 3 9
Q u e r y 3 0 1 ACTTCCCGGGTGATGCTCAGCAGTCAAGTGCCTTTGGAGCCTCCTCTGCTCTTTCTGCTG 
I I II I I I I I I M I I I I II II 1 i I I I I I I II II I i 1 i ii i i i i i i i i i i i i i i i i i i i i i i
3 6 0
S b j c t 4 4 0
I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 I I  1 1 1 1 1 1 1 1 
ACTTCCCGGGTGATGCTCAGCAGTCAAGTGCCTTTGGAGCCTCCTCTGCTCTTTCTGCTG 4 9 9
Q u e r y 3 6 1 GAGGAATACAAAAATTACCTGGATGCCGCAAACATGTCTATGAGGGTTCGGCGCCACTCC 
1 1 1 1 1 1 1 II 1 II 1 1 1 1 1 1 1 II 1 1 1 1 1 1 II 1 II 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 II II 1 1 1 
GAGGAATACAAAAATTACCTGGATGCCGCAAACATGTCTATGAGGGTTCGGCGCCACTCC
4 2 0
S b j c t 5 0 0 5 5 9
Q u e r y 4 2 1 GACCCCGCCCGCCGTGGGGAGCTGAGCGTGTGTGACAGTATTAGCGAGTGGGTCACAGCG 
I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I i ii I i i i i i i i i i i i i i i i i i i i i ii i i i
4 8 0
S b j c t 5 6 0
1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GACCCCGCCCGCCGTGGGGAGCTGAGCGTGTGTGACAGTATTAGCGAGTGGGTCACAGCG 6 1 9
Q u e r y 4 8 1 GCAGATAAAAAGACTGCAGTGGACATGTCCGGTGGGACGGTCACAGTCCTGGAGAAAGTC 
1 1 II 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GCAGATAAAAAGACTGCAGTGGACATGTCCGGTGGGACGGTCACAGTCCTGGAGAAAGTC
5 4 0
S b j c t 6 2 0 6 7 9
Q u e r y 5 4 1 CCGGTATCAAAAGGCCAACTGAAGCAATATTTCTACGAGACCAAGTGTAATCCCATGGGT 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 
CCGGTATCAAAAGGCCAACTGAAGCAATATTTCTACGAGACCAAGTGTAATCCCATGGGT
6 0 0
S b j c t 6 8 0 7 3 9
Q u e r y 6 0 1 TACACGAAGGAAGGCTGCAGGGGCATAGACAAAAGGCACTGGAACTCGCAATGCCGAACT 
1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 II 1 
TACACGAAGGAAGGCTGCAGGGGCATAGACAAAAGGCACTGGAACTCGCAATGCCGAACT
6 6 0
S b j c t 7 4 0 7 9 9
Q u e r y 6 6 1 ACCCAATCGTATGTTCGGGCCCTTACTATGGATAGCAAAA 7 0 0  
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ACCCAATCGTATGTTCGGGCCCTTACTATGGATAGCAAAA 8 3 9S b j c t 8 0 0
Figure 5.3.1-b: Alignment of the cloned rBDNF gene against the rBDNF mRNA.
The sequence cloned corresponds to  the B D N F sequence found in the rat genom e. BLA ST 
sequence com parison o f  the cloned sequence in plasm id pG EM 5/pR19C M V rB D N F and the rat 
sequence from  the Rattus Norvegicus genom e corresponding to  rBDNF.
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As can be seen in Figure 5.3.1-c (panel Bi) all conditioned medium time points 
are positive for the presence of a -14.5 kDa band that according to the literature 
corresponds to the fully processed, mature and potentially bioactive rBDNF 
(Mowla et al., 2001). The -32 kDa band corresponding to the pro-form of 
rBDNF and is attributed to the glycosylation that increases the stability of the pro 
form (Mowla et al., 2001). According to Mowla and colleagues (2001), some 
pro-BDNF can be released extracellularly and is biologically active since it has 
been shown to mediate TrkB phosphorylation. Comparison between the amount 
of pro-rBDNF present in the supernatant (Figure 5.3.1-c, panel Bi) and in the cell 
lysate (Figure 5.3.1-c, panel Bii) for the 8-hour time point sample (n=l) suggests 
that the immature form is mostly intracellular but its presence extracellularly is 
increased with increasing time points. The increasing presence of the pro-rBDNF 
-32 kDa band in the medium at later time points may be attributed to two factors. 
Firstly, the inevitability of cell lysis, which is a direct result of not only the high 
MOI used but also of the fact that the infected monolayer has been deprived of 
serum for a significant amount of time. Secondly, it could be a reflection of the 
efficiency of the CMV promoter in transcript production that results in large 
amounts of the pro-rBDNF protein. This accumulation may overwhelm the 
downstream processing mechanism in the trans-Golgi network, responsible for 
the N-glycosylation and N-terminal cleavage that leads to the production of the 
mature BDNF form (Mowla et a l, 2001). The intracellular 28 kDa rBDNF band 
noted in cell lysates could correspond to an intermediate of the pro-rBDNF form, 
which has also been reported by other researchers. Even though not an obligatory 
intermediate to the conversion of pro-BDNF to its mature counterpart, the 28 kDa 
intermediate has been previously reported to occur due to alternative processing 
mechanisms that are still under investigation (Mowla et a l, 2001). As it is 
apparent from the Western Blot analysis described above, the 
HSVl.pR19CMVrBDNF vector can deliver and drive the expression of rBDNF 
in a non-complementing cell line. Moreover the vector produces the full-length 
transcript capable of being processed from the full-length 32 kDa pro form and its 
28 kDa intermediate, to the 14.5 kDa mature rBDNF form. Significantly, the 
mature form is secreted from the transduced cell and could therefore affect 
adjacent cells.
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A. Southern blotting
a  p_ HSVl.pR19 CMVrBDNF
g  S f e  (MOI=l)
(S ^
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B. Western blotting
HSVl.pR19CMVrBDNF 
(MOI=l)
HSVl.pR19
CMVGFP 2 hr 4 hr 6 hr 8 hr
HSVl.pR19CMVrBDNF 
(MOI=l)
8 hr T/p
kDa
30.0
21.5 __
14.3 —
i. Conditioned Media (supernatants)
pro BDNF 
32 kDa
— 28 kDa BDNF
Mature BDNF 
14.5kDa
ii. Cell Lysates
Figure 5.3.1-c: Functional characterisation of vector HSVl.pR19CMVrBDNF.
A. Southern blotting on three purified recom binant plaques o f  vector HSV l.pR19CM V rBDN F. 
pSP72/rBDNF and pG EM 5/pR19CM V rBD N F plasm ids were used as positive controls while 
H SV l.pR 19C M V G FP viral DNA was used as a negative control. The single -1 1 3 0  bp band 
recognised by the rBDNF probe used (pSP72/rBDNF, EcoRl digest) corresponds to the rBDNF 
gene (M aisonpierre et al., 1991) and is present in the recom binant vector genome.
B. W estern blotting using a rabbit polyclonal anti-rat BDNF capable o f  recognising the 32 kDa 
pro-BDNF form, 28 kD a intermediate form and the fully processed 14 kD a mature form, i: 
Conditioned m edia from lx lO 6 BHK cells, infected (M O I= l) with either H SV l.pR19C M V G FP 
(negative control) or H SV l.pR 19C M V rB D N F. Secretion o f  the 14.5 kD a mature rBDNF form in 
the medium increases with longer tim e points (2, 4, 6 and 8 hours), ii: Cell lysate from the 8-hour 
time point reveals the presence o f  the pro-rBD N F processing intermediate as well as 
accumulation o f  some mature rBDNF that has not been secreted possibly due to the fact that the 
amount o f  protein exceeds the processing or secretory capacity o f  the cell.
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In order to prove the bioactivity of vector produced rBDNF, collagen embedded 
E14 explants were supplemented daily with medium collected from lx l06 BHK 
cells, previously infected with HSVl.pR19CMVrBDNF vector (n=3, MOI=l). At 
E l4, some small DRG neurons have been shown to be BDNF responsive 
(Barakat-Walter, 1996), and could therefore be stimulated to extend neurites in 
the presence of biologically active rBDNF. 10 ng/ml of recombinant human 
BDNF (rhBDNF) (n=2) was directly added to some explants to serve as a 
positive control. Vector-conditioned medium was replenished daily following the 
removal of cellular debris. Positive control and conditioned explants were fixed 
and immunostained with a TUJ1 neuron specific anti-tubulin antibody.
Figure 5.3.1-d (panels B & C) demonstrates that HSVl.pR19CMVrBDNF 
encoded rBDNF, promotes the extension of neurites from E l4 DRG explants. 
Comparing the extent of neurite outgrowth achieved with the addition of 25 pi of 
HSVlpR19CMVrBDNF-conditioned media with that obtained with the 
application of 10 ng/ml of rhBDNF (panel A), it becomes evident that the degree 
of outgrowth is similar. It is also important to point out that the neurite extension 
observed in the case of the positive control is the result of a single medium 
administration as opposed to the multiple administration of vector-encoded 
rBDNF.
This experiment therefore confirms that vector-encoded rBDNF is biologically 
active and capable of inducing axonal elongation in a dose dependent manner. 
Therefore, the HSVl.pR19CMVrBDNF vector is capable of producing 
biologically active rBDNF.
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Jfects o f  US] 7 vector-mediated delivery o f  BDNF o. NTF to the injured rubrospinal tract
F ig u re  5 .3 .1-d: B io logical assay  fo r  v e c to r  en co d ed  rB D N F  on E l 4 r a t  D R G s.
TUJ1 im m unolabelled neurites o f  co llagen  em bedded  E14 D R G s treated  w ith A, B or C  media.
N ote that collagen em bedded  explants w ere supplem ented  w ith 10 ng/m l o f  N G F (2.5S) which
acts as a survival factor. A ll im ages show  TUJ1 im m unosta in ing  on explants.
A. Positive control E14 explan ts supplem ented  w ith 10 ng/m l o f  recom binant hum an 
BDNF, display  a d istinctive neurite extension. (M axim al activ ity  is reported  at 50 ng/ml, 
R& D system s protocol).
B. Explants supplem ented w ith 25 pi o f  m edia from  lx lO 6 BH K  cells infected with 
H S V l.pR 19C M V rB D N F  cells at an M OI o f  1 d isplay  a  dense halo o f  th ick  neurite 
bundles.
C . The halo o f  neurites appears denser and the individual fibres ex tend  further w hen lOOpl 
o f  conditioned m edia is added to  the explants dem onstrating  the dose dependent effect o f  
vector-expressed rB D N F on neurite elongation.
Scale Bar: 500pm , applies to  all figures.
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5.3.2 Functional characterisation of vector HSVl.pR19CMVmCNTF
Construction of vector HSVl.pR19CMVmCNTF is diagrammatically outlined in 
Figure 5.3.1-a, while the overall procedure has been already described for two 
other vectors. As explained in section 5.2.2, the mCNTF gene utilised in this set 
of experiments is a chimera that contains the murine NGF-p subunit secretory 
signal (Sendtner et al., 1992). This enables the protein to be exported from the 
transduced cell.
Correct insertion of the mCNTF gene was confirmed by restriction digest 
analysis and sequencing from the pGEM5/pR19CMVmCNTF plasmid, using a 
primers specific to the CMV promoter. The resulting sequence was then entered 
into a BLAST search and homologous sequences were identified automatically. 
As shown in Figure 5.3.2-b, the sequence contains the NGF-P secretory signal 
and the mCNTF gene in succession and on the 3’ end of the CMV promoter. 
Following recombination of the pGEM5/pR19CMVmCNTF plasmid with an 
HSVl.pR19CMVGFP backbone, successful recombinant populations were 
identified, initially based on their white phenotype and subsequently by Southern 
blotting analysis. Two recombinant plaques of white phenotype were digested by 
Hindlll/Xmnl and probed with a mCNTF probe. They were both found to have a 
-951 bp fragment corresponding to the 5’ end of mCNTF, which includes the 
NGF secretory sequence (Figure 5.3.2-c, panel A). Viral DNA from the vector 
backbone HSVl.pR19CMVGFP was used as a negative control while 
pmCNTFchim5 and pGEM5/pR19CMVmCNTF plasmid DNAs were used as 
positive controls. The new vector was termed HSVl.pR19CMVmCNTF.
The ability of this vector to transduce BHK cells thus enabling them to produce 
mCNTF, was assessed by Western blotting. In addition, the ability of this protein 
to produce a biological effect was assessed by a cell proliferation assay on a 
CNTF responsive cell line. For sample collection, 1x106BHK cells were infected 
(MOI=l) with either HSVl.pR19CMVGFP (n=12) or HSVl.pR19CMVmCNTF 
(n=12). Supernatants from HSVl.pR19CMVGFP (negative control) or 
HSVl.pR19CMVmCNTF infected cells were collected at a single time point of 6 
hours. It was thought that at this time point there would be potentially enough
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bioactive mCNTF present while at the same time the amount of denatured protein 
would be relatively low. This would be ideal in terms of inducing a biological 
response. All samples were cleared of cellular debris prior to analysis.
The partially reducing Western blotting analysis performed, shown in Figure 
5.3.2-c (panel B), clearly shows the presence of two distinct bands: a low 
molecular weight band of -23 kDa, representing the monomeric form of the 
protein and a high molecular weight band of ^46 kDa which represents the 
mCNTF dimer. The simultaneous detection of these forms was possible because 
the SDS-PAGE gel used for the analysis partially disrupts disulfide bridges. Rat 
as well as human CNTF has been shown to exist primarily as a monomer but 
significant dimer formation occurs at protein concentrations exceeding 40pM 
(McDonald et al., 1995; Narhi et al., 1997) perhaps reflecting an artificial 
association. However, it should be made clear that the presence of dimers in the 
murine version of CNTF has not been directly examined. Even though the role of 
dimeric-CNTF is not clear, it has been proposed that it plays a role in the efficient 
storage of CNTF within Schwann cells in peripheral neural tissue (McDonald et 
a l , 1995). Whether dimeric CNTF is capable of CNTF-Ra receptor activation is 
also not clear. However, McDonald and colleagues (1995) suggest that the fact 
that CNTF binds to its receptor with a 1:1 stoichiometry in solution (Panayotatos 
et al., 1994) makes it unlikely that dimers can bind and activate the receptor. The 
significance of dimer formation with the secreted form of CNTF is currently 
unclear but it might not be related to the ability of this neurotrophic factor to 
activate its receptor.
Overall, this experiment demonstrates that the HSVl.pR19CMVmCNTF vector 
can transduce a non-complementing cell line such as BHK cells and drive the 
production of a secretable form of mCNTF that is capable of dimer formation. 
Significantly, the transduced cells can secret the monomeric form of CNTF which 
is thought to be responsible for CNTF-Ra receptor activation (Ip et al., 1993; 
Panayotatos et al., 1994).
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A: pGEM5/pR19CMVGFP: Xhol/TA DNA polym erase/Z /m JIII
X oc
IT
Xhol £  n> " Hind III
GFP LAP1 L A T P 2 p G E M 5p G E M 5 LAP1 LA T P2 CM V
B: pCNTF-chim5: XbaMTA D N A  polymerase////ra/111
pChim mo u s e  C N T F  c h i m5
Xmnl
Hin dill Xbal
pChim
C: Recombination event for the production of HSVl.pR19CMVmCNTF
r -  K  
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IX x  xnzzznzx—x
ICP34.5 V P 1 6 ICP27 ICP34.5 ICP4 ICP4
Figure 5.3.2-a: Construction of vector HSVl.pR19CMVmCNTF.
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q i I  7 3 0 5 3 1 2 |r e f |N M  0 1 3 6 0 9 . 1 1 Mus m u s c u lu s  n e r v e  g r o w th  f a c t o r ,  b e t a  (N g fb ) , mRNA 
L e n g th = 1 1 8 1  
S c o r e  = 3 0 2  b i t s  ( 1 5 7 ) ,  E x p e c t  = l e - 7 8
I d e n t i t i e s = 1 5 7 /1 5 7  (1 0 0 % ), G a p s  = 0 /1 5 7  (0%)
S t r a n d = P l u s / P l u s
Q u e ry 1 1 GCATGCTGGACCCAAGCTCACCTCAGTGTCTGGGCCCAATAAAGGTTTTGCCAAGGACGC
i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i t i t i i i i i i i i i i i i i
70
S b j c t 2 0 2
1 1 1 II 1 II II 1 1 1 1 1 II 1 1 II 1 1 II II 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 
GCATGCTGGACCCAAGCTCACCTCAGTGTCTGGGCCCAATAAAGGTTTTGCCAAGGACGC 2 61
Q u e ry 71 AGCTTTCTATACTGGCCGCAGTGAGGTGCATAGCGTAATGTCCATGTTGTTCTACACTCT
1 II II 1 1 II 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1
130
S b j c t 2 62 AGCTTTCTATACTGGCCGCAGTGAGGTGCATAGCGTAATGTCCATGTTGTTCTACACTCT 321
Q u e ry 131 GATCACTGCGTTTTTGATCGGCGTACAGGCAGAACCG 1 6 7
t i i i i i i i i i i i i i t t i i t i i i i i i i i i t i i i i i i i i
S b j c t 32 2
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GATCACTGCGTTTTTGATCGGCGTACAGGCAGAACCG 3 58
q i I  1 6 5 0 7 2 4 6 | r e f [NM 0 5 3 0 0 7 . 1 | Mus m u s c u lu s  c i l i a r y  n e u r o t r o p h i c  f a c t o r  ( C n t f ) ,  
t r a n s c r i p t  v a r i a n t  2 ,  mRNA 
L e n g th = 1 8 9 3  
S c o r e  = 1 1 6 1  b i t s  ( 6 0 4 ) ,  E x p e c t  = 0 . 0  
I d e n t i t i e s  = 6 0 4 /6 0 4  (1 0 0 % ), G a p s  = 0 /6 0 4  (0%)
S t r a n d = P l u s / P l u s
Q u e ry 1 6 7 GATGGCTTTCGCAGAGCAAACACCTCTGACCCTTCACCGCCGGGACCTCTGTAGCCGTTC 
I I I I I I I I I I I I I I I I I I I I I I I I I I M  i I I I i i I i i  i i i i i m  i i i i i i i i i i i i i i i i
2 2 6
S b j c t 77
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 
GATGGCTTTCGCAGAGCAAACACCTCTGACCCTTCACCGCCGGGACCTCTGTAGCCGTTC 136
Q u e ry 227 TATCTGGCTAGCAAGGAAGATTCGTTCAGACCTGACTGCTCTTATGGAATCTTATGTAAA 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
TATCTGGCTAGCAAGGAAGATTCGTTCAGACCTGACTGCTCTTATGGAATCTTATGTAAA
2 8 6
S b j c t 137 1 96
Q u e ry 287 ACATCAGGGCCTGAATAAAAATATCAACCTTGACTCAGTGGATGGTGTACCAGTGGCAAG
I I I I I I I I i I I I I  i I I I i i I i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
3 4 6
S b j c t 197
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ACATCAGGGCCTGAATAAAAATATCAACCTTGACTCAGTGGATGGTGTACCAGTGGCAAG 2 5 6
Q u e ry 347 CACTGATCGTTGGAGTGAGATGACTGAGGCAGAGCGACTCCAAGAGAACCTCCAGGCTTA 
I I I I I I I I I I I I I i I I I I i I I I i i I I i i i i i i i i i i i i i i i i i i  i i  i i i i i i i i i i i i i i
40 6
S b j c t 25 7
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II  1 1 1 1 1 1 II 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
CACTGATCGTTGGAGTGAGATGACTGAGGCAGAGCGACTCCAAGAGAACCTCCAGGCTTA 3 1 6
Q u e ry 407 CCGTACCTTCCAAGGGATGTTAACCAAGCTCTTAGAAGACCAGAGAGTACATTTCACCCC 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
CCGTACCTTCCAAGGGATGTTAACCAAGCTCTTAGAAGACCAGAGAGTACATTTCACCCC
4 66
S b j c t 317 3 7 6
Q u e ry 467 AACTGAAGGTGACTTCCATCAGGCAATACATACTCTTATGCTCCAAGTTTCTGCCTTTGC 
I I I I I I I I I I I I i i I I I I i I I I I i I I I i i I I i i i I i i i i i i  i i i i i i i i i i i i i i i i i i i
52 6
S b j c t 377
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
AACTGAAGGTGACTTCCATCAGGCAATACATACTCTTATGCTCCAAGTTTCTGCCTTTGC 43 6
Q u e ry 527 CTACCAGCTAGAGGAGTTAATGGTGCTTCTGGAACAGAAGATCCCTGAAAATGAGGCTGA
I I i i I I i i i I I I i i I I I i i I I i i i I i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
58 6
S b j c t 437
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 I I | I 
CTACCAGCTAGAGGAGTTAATGGTGCTTCTGGAACAGAAGATCCCTGAAAATGAGGCTGA 49 6
Q u e ry 587 TGGGATGCCTGCCACAGTTGGAGATGGTGGTCTCTTTGAGAAGAAGCTATGGGGCTTGAA
I I i i I I I i i I i I i i I I I i i I I I i i I I i i i I I i i i I I i i i i i i i i i i i i i i i i i i i i i i i i
646
S b j c t 497
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 
TGGGATGCCTGCCACAGTTGGAGATGGTGGTCTCTTTGAGAAGAAGCTATGGGGCTTGAA 55 6
Q u e ry 647 GGTCCTTCAAGAGCTCTCACAGTGGACTGTGAGGTCTATCCATGACCTTCGTGTCATTTC
I I I I I I I I i I I I 1 i I I I I I I I I I I I I I I I I I I I i I I I i i I I i i i i i i i i i i i i i i i i i i i
7 06
S b j c t 557
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 
GGTCCTTCAAGAGCTCTCACAGTGGACTGTGAGGTCTATCCATGACCTTCGTGTCATTTC 6 16
Q u e ry 70 7 TTCTCATCAGATGGGAATCTCAGCACTTGAGAGCCATTATGGGGCCAAAGATAAGCAGAT 
1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 
TTCTCATCAGATGGGAATCTCAGCACTTGAGAGCCATTATGGGGCCAAAGATAAGCAGAT
76 6
S b j c t 617 676
Q u e ry 7 6 7 GTAG 7 7 0  
1 1 II
GTAG 68 0S b j c t 677
Figure 5.3.2-b: Alignment of the mCNTFchimS gene with BLAST identified sequences.
The m C N TF gene sequence (Sendtner et al., 1992) cloned into the pGEM 5/pR19CM V vector was 
m atched v ia a  B LA ST search to the secretory portion o f  N G F-P subunit (Query nt 11 to 167) and 
the m C N TF (Q uery nt 167 to  770).
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In order to demonstrate that HSVl.pR19CMVmCNTF-transduced cells are 
capable of secreting biologically active protein, a proliferation assay was 
employed based on the TF-l.CN5a.l cell line. Medium collected from 
HSVl.pR19CMVmCNTF-infected BHK cells was compared to medium 
collected from HSVl.pR19CMVGFP infected cells (negative control) for its 
ability to promote TF-l.CN5a.l cell division. Control or mCNTF conditioned 
medium (n=3) were assessed at 5, 25 and 50pl aliquots (n=3 per aliquot per time 
point tested) for their ability to induce proliferation in 3xl04 TF-l.CN5a.l cells. 
Cell numbers were assessed in triplicate. Recombinant human CNTF (rhCNTF) 
was used as a positive control at a final concentration of 2 ng/ml. Figure 5.3.2-c 
(panel C) demonstrates that addition of mCNTF vector-conditioned medium, 
induces the TF-l.CN5a.l cells to divide in a dose-responsive manner. The effect 
observed with the addition of 50 pi of HSVl.pR19CMVmCNTF conditioned 
medium at the 6-day time point is higher than that observed with the addition of 
rhCNTF at the same time point. Six days after the addition of 
HSVl.pR19CMVmCNTF conditioned medium in 3x104 TF-l.CN5a.l cells the 
number of cells had increased to 11.8xl04 cells (± 0.37) (Mean ± Standard error 
of the mean). On the contrary there were 3.17xl04 (± 0.41) and 8.32xl04 (±0.33) 
cells counted when the cell line was supplemented with HSVl.pR19CMVGFP 
conditioned medium or rhCNTF (positive control) respectively. Untreated cell 
numbers were recorded at 3.63x104 cells (± 0.34) at the 6-day time point. As it 
can be seen from the graph in Figure 5.3.2-c (panel C), the number of TF- 
l.CN5a.l cells present at the 6-day time point following the addition of 2 ng/ml 
of rhCNTF is significantly lower than the numbers present when the cells are 
stimulated with the addition of 50 pi of HSVl.pR19CMVmCNTF vector 
conditioned medium. This is probably due to the fact that the vector conditioned 
medium was replenished daily while the more expensive rhCNTF was not. 
Addition of HSVl.pR19CMVGFP conditioned medium failed to promote cell 
division, re-enforcing the fact that cell division is specific to the mCNTF vector 
encoded protein and not a non specific effect of the backbone vector itself. This 
experiment demonstrates that non-complementing cells, infected by vector 
HSVl.pR19CMVmCNTF, are capable of synthesising and secreting biologically 
active mCNTF.
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A. S o u th e rn  b lo ttin g
HSVl.pR19
CMVmCNTF
(M OI=l)
m C N T F
(950bp)
B. W e ste rn  b lo ttin g
kD a
97.0
65.0
45.0  —
30.0  —
20.5
(6 hrs t/p)
d im e r
46kD a
m o n o m e r 
23 kD a
■  T/pO
1. P ro life ra tio n  A ssay  o f  th e  T F - l .C N 5 a . l  C ell line B y/p \
11.08
H S V l.p R 1 9 C M V m C N T F
50u
H S V l.p R 1 9 C M V G F P
P o s i t i v e  
U n t r e a t e d  C o n t r o l  
C o n tro l rh C N T F
2 n g / m l
F ig u re  5.3.2-c: F u n c tio n a l c h a ra c te r is a t io n  o f  v e c to r  H S V l.p R 1 9 C M V m C N T F .
A. Southern b lo tting  on tw o  purified  recom binan t p laques o f  vector H SV l.pR 19C M V m C N T F. 
pm C N TFchim 5 and  pG E M 5/pR 19C M V m C N T F  p lasm ids w ere used as positive controls w hile 
H S V l.pR 19C M V G F P  v iral D N A  w as used as a negative control. The single 950bp m C N T F band 
recognised by the  m C N T F  probe (Hindlll/Xmnl d igest) is p resent in the viral genom e.
B. W estern b lo tting  (w ith  m in im ally  reducing  conditions) analysis o f  conditioned m edia from 
lx lO 6 BH K  cells p rev iously  in fected  at an M OI o f  1 w ith  H S V l.pR 19C M V m C N T F  and probed 
w ith a goat po lyc lonal an t-ra t C N TF.
C . P ro lifera tion  assay  on the T F - l.C N 5 a .l  cell line. T F - l.C N 5 a .l cells divide w hen bathed in 
virally  cond itioned , m C N T F  con tain ing  m edia. C ell div ision  is dose-dependent and resem bles the 
response no ted  w hen m edia w as supplem ented  w ith 2 ng/m l o f  rhC N T F  (positive control). No 
such response is elic ited  w ith  m edia obtained from  H S V l.pR 19C M V G F P  infected BH K cells 
(negative contro l).
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5.3.3 Effect of vector rBDNF & mCNTF on lesioned rubrospinal axons
In Chapter 4, it was concluded that the HSVl.pR19CMV vector backbone lacks 
the ability to transduce pyramidal neuron cells following inoculation into the CST 
at the mid-thoracic spinal cord level. It was therefore necessary to assess whether 
the same backbone was capable of retrogradely transducing red nucleus neurons 
following direct inoculation into the lateral funiculus at the T4-T6 level. Red 
nucleus neurons atrophy following an rubrospinal tract axotomy but do not die 
(Egan et al., 1977; Barron et al., 1989; Tetzlaff et al., 1991). Firstly, it was 
decided to examine the HSVl.pR19CMV mediated transgene delivery in 
uninjured as opposed to pre-lesioned animals as this would give a more accurate 
representation of the true ability of this backbone to sustain transgene expression. 
Red nucleus neuron somata (Figure 5.3.3-a, panel Aii, n=4) appear healthy and 
strongly express the transgene at 1 month after a single 5xl06 pfu inoculation into 
the T6 level. In addition, axons are filled with the transgene (Figure 5.3.3-a, panel 
Ai), demonstrating not only the efficiently of transgene expression but also the 
integrity of neuronal machinery following vector infection. Based on this finding, 
vector backbone HSVl.pR19CMV presented a suitable vehicle for studies of 
regeneration on the rubrospinal tract lesion model and was used for the rBDNF 
and mCNTF expressing constructs. The ability of a combination of vectors 
HSVl.pR19CMVrBDNF and mCNTF to promote axonal regeneration and 
survival was assessed in animals that had been previously lesioned at T4-T6. The 
exact time line of the surgical interventions carried out in this experiment is 
shown in Figure 5.2.5-a. Briefly, unilateral rubrospinal tract lesions were carried 
out 1 month prior to administration of a 5x106 equal mixture of vectors 
HSVl.pR19CMVrBDNF and mCNTF, delivered both proximal and distal to the 
lesion site. Two months post-lesion, 40 pm horizontal spinal cord sections were 
reacted for BDA, the anterograde tracer injected close to the red nucleus ~2 
weeks prior to termination, in order to label any potentially regenerating 
rubrospinal tract axons. In rBDNF/mCNTF treated animals (Figure 5.3.3-a, panel 
Bi, n=ll), a number of BDA positive axons were found within as well as 
proximal to the lesion site (v). They appear to follow an irregular route around 
the lesion site with only a few axons present within the lesion site.
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Figure 5.3.3-a: HSVl.pR19CMVrBDNF/mCNTF minimally promotes regeneration.
A. HSVl.pR19CMVGFP vector was delivered at a single injection site (t) into the T4-T6 level 
of the spinal cord, targeting rubrospinal tract axons. At one month post-injection, strong GFP 
labelling can be seen in rubrospinal tract axons (coursing left to right) at the spinal cord level 
(Ai) and also on the transduced red nucleus neurons (Aii).
B. HSV1 .pRl9CMVrBDNF/mCNTF vector mixture (Bi) or HSVl.pR19CMVLacZ vector (Bii) 
were injected both proximal and distal to the site of a unilateral rubrospinal tract lesion the 
animals had received 1 month previously. BDA labelled axons (▼) can be seen sprouting into 
the lesion site of the HSVl.pR19CMVrBDNF/mCNTF treated animal (Bi) with rather fewer 
sprouts apparent in the HSVl.pR19CMVLacZ treated animal (Bii).
Scale bars: Ai=200pm; Aii= 100pm; Bi=60pm, applies to Bii.
301
Effects of HSl 7 vector-mediated delivery of BDNF or CNTF to the injured rubrospinal tract
Lesion site
Nuos
-3
>
uo\
5Q.
>inX
Lesion siteProximal
302
Effects of HSl 7 vector-mediated delivery of BDSF or CNTF to the injured rubrospinal tract
Proximal Lesion site
♦ *
F igure 5.3.3-b: H SV l.pR 19C M V rB D N F /m C N T F  m inim ally prom otes regeneration.
BDA labelled axons (▼) in an additional animal from the same series shown in Fig. 5.3.3-a (B) 
injected with a mixture o f  HSVl.pR19CM VrBDNF/mCNTF vectors. A. a number o f BDA 
labelled axons in box i can be found around the lesion site (upper right). The enlargement o f box i 
(panel beneath) shows that their route is irregular. Note that the actual lesion site has been lost 
during processing. Scale bars: A=50pm; enlarged inset i=30pm.
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In another rBDNF/mCNTF treated animal (Figure 5.3.3-b), the few axons seen 
within the lesion site follow an irregular route around the perimeter of the lesion 
site rather than through it. In HSVl.pR19CMVLacZ treated animals (Figure
5.3.3-a, panel Bii, n=4), very few axons can be seen around the lesion site 
boundaries.
Even though vector mediated administration of rBDNF and mCNTF appeared to 
only slightly affect rubrospinal tract axonal regeneration it was decided to 
examine whether this modest effect is accompanied by the up-regulation of the 
growth-associated protein neuron specific protein SCG10 (Stein et al., 1988). 
SCG10 has been shown to accumulate in axonal terminals and is involved in 
elongation (McNeill et al., 1999) by modulating the interaction of neuronal 
microtubules (Riederer et a l, 1997). It has been proposed that this feature allows 
it to play a role as a synaptic plasticity regulator in the developing and adult CNS 
(McNeill et al., 1999). As shown in Figure 5.3.3-c (panels A and B) SCG10 
expression is upregulated in animals treated with the 
HSVl.pR19CMVrBDNF/mCNTF vector mixture. Even though there is some 
SCG10 positive labelling in HSVl.pR19CMVLacZ control animals (panel C), it 
appears to be less prominent than that observed in 
HSVl.pR19CMVrBDNF/mCNTF treated animals (panel B). However, this up- 
regulation of SCG10 in treated animals does not appear to correlate with any 
anatomically significant regeneration, as is evident in previous sections.
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F igure 5.3.3-c: rB D N F/m C N T F delivery  & SC G 10 expression on rub rosp inal tra c t axons.
A. SCG10 immunolabelled axons in a sagittal section through the lesion site in a spinal cord o f an 
animal receiving the HSV l.pR19CM V rBDN F/m CN TF mixture (B shows the lesion site at higher 
magnification). Note that the majority o f  axons appear to congregate on the proximal side o f the 
lesion site (delineated by the dotted line). Also, there are more axons present within and distally 
(arrowheads) to the lesion site o f  the H SVl.pR19CM VrBDNF/m CNTF treated animal than there 
are in the control, H SV l.pR19C M V LacZ vector treated animal (C).
Scale bars: A=200pm; B= 100pm, applies to C.
305
/ < i s  i i j  I  /  S  I I w e n  ' r - i i i c c h t i r e i l  i l c / t w r v  n j  H i ) \ / -  ^ >/■ ( ' A  /  / -  „  ■ / / / l ' i i i / i n v i l  n t h i  i i s p m a l  i r
5.3.4 Effect of rBDNF on cell body atrophy of red nucleus somata
Previous reports suggested that exogenous BDNF is able to reverse the atrophy of 
red nucleus neurons that follows axotomy when delivered close to their cell 
bodies (Kobayashi et al., 1997; Novikova et al., 2000; Kwon et al, 2002). In this 
series of experiments red nucleus neurons were transduced with vector 
HSVl.pR19CMVrBDNF in an attempt to reproduce this effect after chronic 
injury of the rubrospinal tract in the rat. The ability of the HSVl.pR19CMV 
backbone to retrogradely transduce these neurons (Figure 5.3.3-a, panel A) 
presented the opportunity to target BDNF to the cell bodies, while avoiding the 
invasiveness of a direct injection into the red nucleus. A schematic representation 
of the timeline regarding the surgical interventions that were performed in this 
experiment is shown in page Figure 5.2.5-b. Briefly, the rubrospinal tract was 
transected in control and treated animals via a unilateral laminectomy at T4-T6 
(section 5.2.5.1, page 265). Lesion site integrity was maintained by placing a 
small piece of Sterispon® soaked in DiAsp within the lesion site. This allowed the 
subsequent visualisation of axotomised red nucleus neurons and prevented the 
formation of a dense scar. Twenty-four hours following axotomy and DiAsp 
administration, one animal (Rat A) was terminated and used as a healthy, non­
atrophied control. Four weeks later, in all other animals, the lesion site was re­
exposed and 5xl06 pfu of HSVl.pR19CMVrBDNF (treated, n=5) or 
HSVl.pR19CMVLacZ (control, n=2) vector was delivered proximally to the 
lesion site. The animal numbers given here reflect those animals finally included 
in the statistical analysis of somal areas. Originally, 15 animals were allocated in 
the HSVl.pR19CMVrBDNF group, 6 animals in the HSVl.pR19CMVLacZ 
group and 3 animals in the non-atrophied negative control groups. Animals that 
died or not displaying any DiAsp labelled red nucleus neurons were excluded. 
After 30 days, treated and control animals were killed and 40pm coronal sections 
of the magnocellular part of the caudal, contralateral red nucleus were examined 
under fluorescence for the presence of DiAsp positive neurons (Figure 5.3.4-c, 
panel A). DiAsp positive neurons contralateral to the lesion were photographed 
and images were then deconvolved so that all positive neurons were brought to 
focus in a single plane (Figure 5.3.4-a).
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F igure 5.3.4-a: Deconvolved im ages o f DiAsp labelled red  nucleus neurons.
A. A wet 40pm  section, photographed at a single plane o f  focus, appears to have few DiAsp 
labelled neurons in the red nucleus contralateral to a labelled rubrospinal tract lesion. B. Merging a 
series o f  deconvolved images o f  the same neurons shown in A yields a focused image which 
shows more neurons throughout the depth o f  the section. Arrows mark the same neurons out o f 
focus in a single non-deconvolved image (A) and in focus in the merged, deconvolved image (B). 
Scale bar =  250pm.
Effects ofHSVl vector-mediated delivery o f BDNF or CNTF to the injured rubrospinal tract
A. H SV l.pR 19C IM V LacZ
B. H S V l.pR 19C M V rB D N F
F igure 5.3.4-b: DiAsp labelling  in con tro l an d  H S V l.pR 19C M V rB D N F  trea ted  anim als.
Red nucleus neurons retrogradely labelled with DiAsp viewed in wet, unmounted sections. 
Animals received a rubrospinal tract injury 4 weeks prior to the injection o f  either 
H SV 1 .pR l9C M V LacZ (A) or H SV l.pR19C M V rB D N F (B) proximal to the rubrospinal tract 
lesion. Note that there are more labelled neurons in the BDNF vector treated animal (B) compared 
with the LacZ treated animal (A). Scale bar: A =250pm , applies to B.
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Figure 5.3.4-c: Softw are based acquisition  o f red  nucleus som al areas.
Deconvolved sections from the magnocellular part o f  the red nucleus were used. A schematic 
representation o f  their location is shown in A (adapted from Ruitenberg et al. 2004). Neurons 
were photographed in wet, unmounted sections and a merged deconvolved image (B) was used to 
generate 2 sets o f  density slices (C, E). Based on these and using the Open-Lab software it was 
possible to calculate actual somal areas (listed in D). The threshold for the density slice in C  was 
chosen because it adequately filled the outlines o f  the somata o f  neurons 1, 3, 7 and 10 without 
overlapping their perimeters. Because this threshold was too low for neurons 5, 6, 8 and 9 their 
somata were not adequately filled (shown in E) a second threshold was taken and density slice in 
D obtained.
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From the deconvolved images obtained (Figure 5.3.4-b) cell body areas were 
calculated using the Open-Lab software (Figure 5.3.4-c, panels B-D). Mean cell 
body areas (pm ) measured in treated and untreated animals were further 
analysed and shown as Mean red nucleus neuron somal areas ± Standard Error of 
the Mean (SEM) (Table 5.3-a and b). Despite the large number of animals 
initially included in this study, only a small proportion survived to the end of the 
experiment. This was unfortunate but somewhat anticipated especially due to the 
repeated surgery these animals had to undergo in a relatively short period of time. 
Mean red nucleus neuron cell body areas for control and treated animals were 
measured at two months following axotomy and one month following injection of 
HSVl.pR19CMVLacZ or HSVl.pR19CMVrBDNF expressing vectors (Table
5.3-a). Red nucleus neurons from HSVl.pR19CMVLacZ treated animals 
displayed a mean somal area of 425.30±72.08 pm2 (Rat 1) and 430.63±20.76 pm2 
(Rat 2) giving a range of 353.22 to 497.38 pm2 (Rat 1). The grand mean of the 
red nucleus somal areas from HSVl.pR19CMVrBDNF treated animals was 
found to be 538.25±34.72 pm2, which represents a range of 503.53 to 572.97 pm2 
(Rats 3-6, n=4, Table 5.3-b). Even though the sample sizes precluded any further 
statistical evaluation, overall, the mean red nucleus cell body areas in 
HSVl.pR19CMVrBDNF treated animals (Rats 3-6) appear to be somewhat larger 
that those of HSVl.pR19CMVLacZ controls (Rats 1&2). It is important to 
emphasise that even though this result may be suggestive of a beneficial effect of 
BDNF on red nuclei neurons following a lesion of the RST, clearly larger 
samples would be needed before firm conclusions can be drawn.
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Animal Group RatNo
Mean Cell Body Area (pm2)
(Mean ± SEM) Counts
Jm Immediate lesion A 700.94 ±29.71 49
k.+*e HSV 1 .pRl 9CM VLacZ 1 425.30 ± 72.08 5
u Control (n=2) 2 430.63 ± 20.76 39
3 485.22 ± 17.55 85
’o a>
«8 HSV 1 .pRl 9CMV rBDNF 4 471.56 ±22.68 44a>lmH Treated (n=4) 5 593.73 ±21.62 62
6 602.51 ± 17.26 169
Table 5.3-a: Mean cell body after LacZ or HSVl.pR19CMVrBDNF treatment.
Mean red nucleus cell body areas pm2 ± Standard Error of the Mean (SEM).
. . . ~ Mean Somal Area (urn2)
An,mal Group (Mean ± SEM)
HSV1 .pR19CMVLacZ Ratl 425.30 ±72.08
(Controls) Rat2 430.63 ±20.76
HSVl.pR19CMVrBDNF *
Treated (n=4) Rats 3 - 6 548.25 ± 34. U
Table 5.3-b: Mean red nucleus somal areas in control versus BDNF-treated animals.
While the mean somal size for the two control animals (Rat 1 and Rat 2) lie below 
and outside the range of the treated group (n=4), the sample sizes precluded 
statistical evaluation. Nevertheless, this may suggest a beneficial effect of BDNF on 
red nuclei neurons following lesioning of the RST. However, larger samples would 
be needed before any conclusions can be drawn.
*Note: The mean somal area value shown for the HSVl.pR19CMVrBDNF treated 
animals represents the Grand mean value obtained from the individual 
mean red nucleus neuron somal areas of each of the four treated animals 
(Rats 3-6, detailed in Table 5.3-a).
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5.4 Discussion
The rubrospinal tract has been the focus of many recent studies of spinal cord 
regeneration. The relative ease of surgical manipulation of this tract has been 
exploited in these in vivo experiments to investigate both the capabilities and 
limitations of neurotrophin expressing, highly disabled HSVl.pR19CMV-based 
vectors in preventing atrophy of red nucleus neurons and promoting regeneration 
of their axons. Two new neurotrophin-expressing vectors were constructed: 
HSVl.pR19CMVrBDNF and HSVl.pR19CMVmCNTF. These were based on 
the well characterised, highly disabled 1764/ICP277ICP47RL1 '/pRl 9CMV 
backbone (Lilley et al., 2001b). This backbone can retrogradely transduce red 
nucleus somata and support transgene expression for at least one month following 
a single inoculation into the adult rat rubrospinal tract, at the thoracic level 
(Figure 5.3.3-a). BDNF and CNTF were selected based on previous in vivo 
evidence that these factors have the potential to prevent red nucleus somal 
atrophy and support axonal regeneration (reviewed in sections 5.1.4.1 and 
5.1.4.2). Each of these vectors was shown in vitro to be able to stably transduce a 
non-complementing cell line and support the expression and secretion of 
biologically active rBDNF (section 5.3.1) or mCNTF (section 5.3.2).
Following the characterisation of these vectors it was decided to examine their 
effects on axonal regeneration and on atrophy of red nucleus neuronal cell bodies. 
In the first series of experiments (section 5.3.3), an equal mixture of vectors 
HSVl.pR19CMVrBDNF and HSVl.pR19CMVmCNTF was inoculated both 
proximally and distally to the site of a 1 -month-old thoracic lesion, in an attempt 
to promote rubrospinal tract axonal regeneration. Two months following the 
application of the rBDNF/mCNTF vector mixture there was no evidence of any 
significant axonal regeneration despite a modest increase in SCG10 expression in 
HSVl.pR19CMVrBDNF/HSVl.pR19CMVmCNTF treated animals. Although 
disappointing the lack of regeneration observed in these experiments was in 
agreement with other reports of lack of axonal regeneration following the local 
infusion of BDNF at the spinal cord level. In particular, Kwon et al (2004) report 
that delivering BDNF at a cervical rubrospinal tract injury site 2 months after 
lesion, fails to prevent the red nucleus somal atrophy that sets in over the
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subsequent weeks and does not lead to any axonal regeneration (Kwon et a l , 
2004). The notable lack of rubrospinal tract axonal regeneration could be due to 
the fact that there is a time-limited window of opportunity for influencing axonal 
regeneration via BDNF administration (Kwon et a l , 2004). Axons of red nucleus 
neurons, unlike their somata, cease to express full length TrkB following 
axotomy and would therefore be unresponsive to locally supplied BDNF (Liebl et 
a l , 2001; Kwon et a l , 2004). In our case however it was anticipated that the use 
of the HSVl.pR19CMV based vectors would circumvent this problem since it 
would allow the injured neuron to synthesise de novo the transgene BDNF that 
would be made available at the cell body level which maintains full-length 
expression of TrkB for at least one year post-injury (Kwon et a l, 2002). 
Alternatively, the failure in axonal elongation could be attributed to the by now 
widely accepted notion that any meaningful axonal regeneration would require 
additional molecules counteracting lesion site inhibitory signals (Fawcett and 
Asher, 1999).
As in the case of the CST experiments described in Chapter 4, the approach 
followed in these studies may also have been too ambitious. Thoracic level 
lesions, as employed in this series of experiments do not provoke the same degree 
of upregulation of growth associated proteins, such as GAP43 and a-Tubulin, as 
cervical lesions do (Tetzlaff et a l, 1991; Tetzlaff et a l, 1994; Fernandes et al,
1999). It may therefore have been more appropriate to focus our rBDNF and 
mCNTF, vector mediated regenerative attempts on the cervical rather than 
thoracic rubrospinal tract lesion model. Alternatively it might also have been 
more reasonable to transduce intact red nucleus neurons first and then inflict a 
thoracic or cervical rubrospinal tract lesion a few days later i.e. once transgene 
expression was established. Admittedly, this approach may not have properly 
addressed the true potential of these vectors and the neurotrophic factors they 
encode to promote regeneration in a realistic, chronic rubrospinal tract lesion 
setting. It would however have allowed us to examine whether or not 
rBDNF/mCNTF vector mediated delivery is capable of influencing the extent of 
atrophy or examine any possible effects on the pattern of growth associated 
protein up-regulation.
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The second line of experimentation focused on the question of whether vector 
mediated rBDNF delivery could prevent the atrophy of axotomised red nucleus 
neurons. Previous reports have suggested that BDNF can prevent atrophy when it 
is administered to the cell bodies of red nucleus neurons acutely after injury and 
promote the upregulation of GAP43 and Tal tubulin (Kobayashi et al., 1997; 
Kwon et al., 2002). As shown in Table 5.3-b, administration of the rBDNF- 
expressing vector one month following a T4-T6 rubrospinal tract lesion does 
appear to have some beneficial effect in red nucleus cell body atrophy. The mean 
soma area was 425.30±72.08 pm2 (Rat 1) and 430.63±20.76 pm2 (Rat 2) for 
HSVl.pR19CMVLacZ controls (n=2) and 538.25±34.72 pm2 for 
HSVl.pR19CMVrBDNF treated animals (n=4). The above results suggest that 
treatment of axotomised rubrospinal tract neurons with vector 
HSVl.pR19CMVrBDNF at one month following a thoracic level lesion may 
have a beneficial effect in reversing the red nucleus neuronal atrophy that ensues 
an rubrospinal tract lesion. This result would appear to be in line with previous 
reports that document the ability of rBDNF to reverse red nucleus atrophy when 
delivered by either an infusion pump (Kobayashi et al., 1997; Novikova et al., 
2000; Kwon et al., 2002) or an AAV vector (Ruitenberg et al., 2004) close to the 
red nucleus somata.
Despite the fact that the results presented here represent true differences, due to 
the technical complexity of these experiments the comparisons were based on 
only two HSVl.pR19CMVLacZ controls and four HSVl.pR19CMVrBDNF 
treated animals. It therefore follows that, though encouraging, the results of this 
study should be interpreted conservatively. This is mainly because they are based 
on a comparison with only two negative control animals that received the 
HSVl.pR19CMVLacZ vector. At best the results described here can only serve 
as an indication that HSVl.pR19CMV vector mediated delivery of rBDNF may 
hold promise as a way of transducing lesioned red nucleus neurons with 
potentially beneficial effects on neuronal atrophy. Several attempts were made to 
repeat this series of experiments but due to persisting technically difficulties it 
was not possible to reproduce this response within the time frame of this study.
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In a single animal, chorea-like movements were observed within 5 days following 
rBDNF vector administration. At the time this was noted only in Rat 6 and 
affected the upper limb, ipsilateral to the lesion site. It is possible that this was 
simply due to an unrelated event such as an intracranial haemorrhage. 
Alternatively, it could be due the fact that vector mediated rBDNF expression 
occurs in areas closely associated with structures that regulate fine movement and 
may cause aberrant sprouting in these areas. The onset of these effects would also 
coincide with the vector mediated production of sufficient amounts of rBDNF 
from transduced red nucleus neuronal somata (Lilley et al., 2001b). For example 
the substantia nigra pars-compacta is closely associated with the red nucleus, 
which is potentially overproducing rBDNF due to vector-mediated transduction. 
This observation is in line with other reports of similar viral vector studies. 
Ruitenberg and colleagues report that some of the animals that had received an 
AAV-BDNF expressing vector via direct injection into the red nucleus exhibited 
rotation-like behaviour (Ruitenberg et a l , 2002; Ruitenberg et a l , 2004). In 
addition, BDNF infusion (Altar et a l , 1992) or substantia nigra transduction via 
an AAV-BDNF vector (Klein et a l , 1999) apparently led to increased rotational 
behaviour and locomotor activity. These reports support the proposed role of 
BDNF as a modifier of basal ganglia output by affecting dopaminergic neuron 
output and potentiating the effects of glutamaergic neurotransmission (Arenas et 
a l , 1996). Long term BDNF over-expression is associated with increased 
vulnerability of these neurons to ischemic damage (Gustafsson et a l , 2003).
In addition to the explanations above, there are certain features specific to animal 
6 that may also help explain why this occurred in this particular animal. The 
number of DiAsp labelled red nucleus neurons found in animal 6 (169 counts) is 
nearly double the number found in the other three similarly treated animals 
(Table 5.3-a). One possibility is that vector inoculation was more efficient in this 
animal, leading to the transduction of a higher number of axotomised red nucleus 
neurons. On the other hand, the larger number could simply indicate that DiAsp 
labelling was more efficient in this animal. Unfortunately it was not possible to 
co-localise DiAsp and rBDNF expression, as subsequent processing would have 
abolished the DiAsp signal.
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Su m m ary
It was originally hypothesised that if vectors HSVl.pR19CMVrBDNF and 
HSVl.pR19CMVmCNTF are capable of transducing injured RST neurons to de 
novo synthesise biologically active rBDNF and mCNTF, then these constructs 
may lead to a more favoured regenerative response in injured RST neurons. In 
terms of regeneration within the context of the injured rubrospinal tract, the 
combination of HSVl.pR19CMVrBDNF and HSVl.pR19CMVmCNTF did not 
lead to any meaningful axonal regeneration in the chronically injured rubrospinal 
tract, despite inducing upregulation of SCG10 and enhancing axonal sprouting. In 
addition, HSVl.pR19CMVrBDNF transduction of chronically injured red 
nucleus neurons does appear to somewhat limit the extent of red nucleus somal 
atrophy even though this should be considered a preliminary experiment that 
should be repeated with larger animal groups.
Overall, the experiments described in this chapter lead to the conclusion that the 
highly disabled HSVl.pR19CMV based vectors can serve as a powerful platform 
to evaluate potentially therapeutic molecules such as BDNF and CNTF. Further 
improvements in the surgical procedures employed would in theory allow for a 
more detailed evaluation of potentially therapeutic molecules and the extent of 
their impact within more closely defined and reproducible experimental 
parameters.
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C h a pt er  6
VECTOR - MEDIATED NEUROTROPHIC FACTOR 
DELIVERY IN OPTIC NERVE REGENERATION
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6.1 Introduction
Due to its well-defined anatomical structure and ease of accessibility, the rodent 
optic tract has been intensively used in attempts at promoting neuronal survival, 
plasticity and regeneration of injured retinal ganglion cells (RGCs). This valuable 
animal model enables researchers to explore somal and axonal responses to injury 
separately. RGCs of adult mammals, unlike their fish and amphibian counterparts 
(Reier and Webster, 1974; Murray and Edwards, 1982), die in response to injury 
and fail to successfully regenerate (Ramon Y Cajal, 1928). Intraorbital 
transection of the adult rat optic nerve results in an 85% loss of RGCs within two 
weeks (Villegas-Perez et a l, 1993). Following an optic nerve crush, a very small 
number of RGC axons are able to spontaneously regenerate through the lesion 
site (Campbell et a l, 1999). This inability of RGCs to regenerate is most likely 
the result of a combination of inhibitory molecules present in the injured CNS 
milieu, lack of trophic factor support and changes in the growth capacity of adult 
mammalian neurons. Cell death and regenerative failure can potentially be altered 
by manipulating the injured axon environment (Levin and Gordon, 2002). 
Lesioned adult RGCs are responsive to a variety of neurotrophic and growth 
factors in vivo. Intraoccular administrations of BDNF, CNTF, GDNF or FGF 
have been shown to be beneficial in enhancing survival of axotomised RGCs and 
in supporting axonal regeneration (Sievers et a l, 1987; Mey and Thanos, 1993; 
Mansour-Robaey et a l, 1994; Sawai et a l, 1996; Cui et a l, 1999). Vectors 
expressing each of the above neurotrophins were used in various combinations to 
promote axonal regeneration in the crushed optic nerve paradigm. The ability of 
these constructs to deliver marker genes in the retina via retrograde transport is 
characterised in the adult albino rat visual system.
6.1.1 Anatomy of the rat visual system
The gross anatomy of the rat eye is demonstrated in Figure 6.1.1-a (Fischer et al,
2000). For the purposes of this study, emphasis is placed on the microscopic 
anatomy of the retina and the projections of retinal ganglion neurons to their 
corresponding targets in the rat visual centres.
318
W 'dor-  Dh'dhiU’il ih' tirotroplm Jiu lor d c h w r v  in o/Un iwrrr rrprih 'inHon
6.1.1.1 Anatomy of the rat retina
The rodent retina is composed of five types of neuronal cells: photoreceptors, 
bipolar, horizontal, amacrine and ganglion cells and two types of glial cells: 
Muller glia and astrocytes. Retinal cells exhibit a laminar organisation with layers 
referenced to the middle of the eye-ball (Figure 6.1.1-b). This laminar 
organisation involves three layers of cell bodies separated by two plexiform 
layers of axons and dendrites. The inner-most layer is the ganglion cell layer, 
containing the somata of RGCs, amacrine cells and astrocytes. The next layer is 
the inner nuclear layer, containing the cell bodies of bipolar, horizontal and 
amacrine cells as well as the cell bodies of Muller glia. Next follows the outer 
nuclear layer containing photoreceptor cell bodies. In addition to these cellular 
layers of the retina, there are also several distinct layers of neuropil. In between 
the ganglion cell layer and the inner nuclear layer is the inner plexiform layer 
containing the synaptic contacts between RGC dendrites and axons of bipolar and 
amacrine cells. Similarly between the outer nuclear layer and inner nuclear layer 
is the outer plexiform layer where photoreceptors synapse with bipolar and 
amacrine cells (Bear et a l , 2001). The outer-most layer is the layer of 
photoreceptor outer segments containing the light responsive elements of the 
retina. Muller glia (Chao et a l, 1997) extend their processes towards both the 
ganglion cell layer and the outer nuclear layer. The outer photoreceptor segments 
are embeded in a pigmented epithelium, which serves to minimise light reflection 
within the eye. The phenotype of the albino rat is attributed to the absence of 
melanin in the pigmented epithelium rather than the iris (Lund et a l, 1974; Creel 
and Giolli, 1976).
A light stimulus reaching the layer of photoreceptor outer segments initiates a 
signal, which is then relayed to the bipolar and horizontal cells in the outer 
plexiform layer. Amacrine and bipolar cells project laterally to the inner 
plexiform layer and relate the signal to the ganglion cell layer. RGCs propagate 
the impulse via their axons in the optic nerve, to the primary visual centres in the 
thalamus and midbrain.
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F ig u re  6 .1 .1-a: A n a to m y  o f  th e  ro d e n t eye.
(B ased on the dim entions given in F ischer et al. 2000). The roden t eye is surrounded by a tough 
fibrous outer layer, the sclera. B etw een sclera and retina lies the vascular choroid. The anterior 
cham ber lies betw een the cornea and the lens and is filled w ith  an aqueous hum or o f  a  slightly 
alkaline nature. The rodent lens is enclosed in a transparen t and highly elastic capsule that 
occupies m ost o f  the posterio r eye cavity  and is suspended by ligam ents attached to the cilliary 
body. The vitreous body, a  viscous je lly -like  fluid, separates the lens from  the retina. The axonal 
processes o f  R G C s exit the retina via the optic disc and form  the optic nerve. The optic nerves 
from  each eye decussate at the optic chiasm  and term inate in the  superior colliculus and lateral 
geniculate nucleus.
Note: Intraocular structures are show n in proportion  for an adult ra t o f  approxim ately 200g.
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Figure 6.1.1-b: The laminar organisation in the retina.
H orizontal cells interconnect photoreceptors and bipolar cells and aid the function o f  am acrine 
cells. B ipolar cells co-ordinate the responses o f  m any rods w ith a  single RGC thus enhancing 
sensitiv ity  (summation). A m acrine cells interconnect b ipo lar cells and RGCs. (A dapted from  
G ray s’s A natom y, 2005, student licence agreem ent).
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6.1.1.2 Retinal Ganglion Cells in the Rat
RGCs comprise only 1% of the total retinal cell population (Young, 1985) and 
constitute 57 -  70% of the ganglion cell layer (Perry, 1981), with the remaining 
cells being primarily displaced amacrine cells of various morphological subtypes 
(Hughes, 1977; Perry and Walker, 1980). The adult albino rat retina contains an 
average of 100,000 RGCs with an average density of about 2,000 RGCs/mm2 
over a total area of 50mm2 (Perry, 1979; Mansour-Robaey et al., 1994; Peinado- 
Ramon et al., 1996; Isenmann and Bahr, 1997). Golgi studies on rat retinas 
(Perry, 1979) have revealed three major classes of RGCs (Table 6.1.1-a). RGC 
density in the rat retina displays a level of eccentricity. In the rat, there is a 5:1 
decrease in distribution from the central (3,000 RGCs/mm ) to peripheral retina 
(600 RGCs/mm2) (Perry, 1979; McCall et al., 1987). As demonstrated in Table 
6.1.1-a, most RGCs have their somata located in the ganglion cell layer. However 
a small number of cells termed “displaced ganglion cells” have their cell bodies 
in the inner nuclear layer bordering the inner plexiform layer (Bunt et al., 1974). 
They constitute less than 1% of all RGCs in the rat, are located in the peripheral 
temporal retina (Perry and Cowey, 1981; Perry, 1981), and they project 
controlaterally to the tectum. It has been suggested that they may become 
displaced during development as a result of failing to migrate in time to the 
ganglion cell layer after dividing (Drager and Olsen, 1980).
RGC Type Dimentions Dendrites
Type I
Soma: 16-32pm 
A xon 0 :0 .9 p m
2-4%  o f  all RG Cs 
Dendritic tree: 220-790pm .
3-7 long prim ary dendrites 
Radiating branching pattern
Type II
.  AV &  
*
Soma: 11 -22pm  
Axon 0 :0 .6 p m
Dendritic tree: 140-250pm 
1 -4 short prim ary dendrites 
M any short & spinny branches
Type III
\
r 7 f b
Soma: 6-15 pm 
Axon 0 :0 .3 5 p m
D endritic tree: 410-540pm  
Fine, long prim ary dendrites 
Some branching present.
Table 6.1.1-a: Classes of retinal ganglion cells in the rat retina. 0 :  diam eter. N ot to scale. 
D isplaced ganglion cells are m orphologiacally sim illar to type I RGCs. (Perry, 1979)
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6.1.1.3 Histological features of the intact rat optic nerve
It has been estimated that the optic nerve of an adult albino rat contains 100,000 
axons (Fukuda et a l, 1982; Sefton and Lam, 1984). RGC axons course along the 
optic fibre layer on the top of the ganglion cell layer and exit the retina at the 
optic disc. Until they reach the optic disc, axons remain unmyelinated 
(transparent) and the nerve bundles are surrounded only by astrocytes. However, 
in the orbital optic nerve virtually all axons become myelinated by 
oligodendrocytes (Fukuda et al., 1982). Electron micrographs have demonstrated 
that axons are tightly packed within the optic nerve such that no connective tissue 
and little extracellular space is present (Dezawa and Adachi-Usami, 2000). The 
optic nerve contains the same glial organisation as the rest of the CNS with 
oligodendrocytes, astrocytes and microglia, organised in a manner similar to all 
other CNS white matter tracts. Their cell bodies lie in rows, parallel with the 
fascicles of RGC axons (Bussow, 1980; Suzuki and Raisman, 1992). Optic nerve 
astrocytes are interconnected by gap junctions with their longitudinal and radial 
processes forming an integrated meshwork (Dr G. Campbell, unpublished 
observations). They have numerous processes, some of which end as footplates 
just beneath the pial surface, forming the glial limiting membrane. There 
astrocytes appear thicker and have basement membranes (Massa and Mugnaini, 
1982; Dezawa and Adachi-Usami, 2000).
6.1.1.4 The retinofugal pathway in the rat
RGCs represent the only output from the retina relaying visual stimuli to the 
primary visual centres via the retinofugal pathway. All RGC axons exit each 
retina at the optic disc where they cluster together forming the optic nerve. Both 
optic nerves meet at the optic chiasm where RGC axons decussate and form the 
optic tract. The degree of decussation at the optic chiasm varies between species. 
In the albino rat only 1% of all RGCs project to ipsilateral retino-recipient 
regions involved in the binocular representation of the visual field (Lund, 1975; 
Dreher et a l , 1985). This small percentage of RGCs originate from the temporal 
retina (Isenmann et a l, 2003). In albino rats, information from the ipsilateral eye 
is relayed via commisural projections from the controlateral visual cortex 
(Silveira et al., 1989). After the optic chiasm, optic tract axons peel off to form
323
1 1r / o / - -  H H 'ih tilt'tl i i c u r o n o / ’/ih  h u  l o r  i / W / i v / t  in  .>/>//< n c n r  /v<_,v//cr<///<)//
connections with a number of hypothalamic and pretectal nuclei before finally 
terminating in the midbrain tectum. Hypothalamic targets include the 
suprachiasmatic nucleus (SCN), which lies just dorsally of the optic chiasm. 
Receiving direct retinal innervation, the SCN is thought to be responsible for 
synchronising circadian rhythms with the daily light-dark cycle. Pretectal nuclei 
such as the olivary pretectal nucleus (OPT) participate in both direct and 
consensual pupillary light reflexes by receiving information relevent to the light 
intensity reaching the retinal surface (Tracey, 1994). In addition, approximately 
30% of all rat RGCs send collaterals to the lateral geniculate nucleus (LGN) in 
the dorsal thalamus (Dreher et al., 1985). By receiving direct synaptic input from 
the retina and relaying information to the visual cortex, LGN is the gateway to 
conscious visual perception. Unlike primates, the LGN of rodents does not 
demonstrate the same level of structural complexity. In almost all primates, 
controlateral/ipsilateral and nasal/temporal RGC projections synapse with LGN 
neurons located in six separate layers (Hubei and Livingstone, 1990; Bear et al, 
2001). In the rat however, only a very basic level of segregation exists keeping 
controlateral and ipsilateral synapses in just two separate groups of LGN neurons.
The final synaptic target of optic nerve fibres is the superior colliculus located in 
the midbrain tectum (Perry et al., 1983). RGC axons synapse in the superficial 
layer of superior colliculus (stratum griseum superficiale). Receiving a direct 
input from RGCs the superior colliculus, via the cranial nerves, coordinates the 
eye muscles for saccadic and smooth pursuit movements. During development, 
axonal guidance molecules such as ephrins and their receptors follow graded 
expression patterns in both retina and superior colliculus (Sperry, 1963; Knoll et 
al., 2001; Isenmann et al., 2003; Oster and Sretavan, 2003). As a result, 
retinotectal projections are highly organised topographically (Mueller, 1999) and 
are conserved between species (Thanos and Mey, 2001; Heiduschka et al., 2001). 
A retinotectal map with both a dorsal-ventral and nasal-temporal orientation is 
used to describe this retinotopic relationship. For example, ventral retina axons 
project to dorsal superior colliculus while dorsal retina axons project to ventral 
superior colliculus. Similarly, nasal retina projects to posterior while temporal 
retina projects to anterior superior colliculus (Isenmann et al., 2003).
324
i d l e r -  iih'ilitih'd ih’iirotrojihn Un lor th ’/ n v r v  in oplu n c r w  iv ^cn r n i l io n
6.1.2 Responses of the optic nerve to axotomy
Several types of axonal injury can lead to RGC degeneration. These have been 
classified as: optic nerve compression (or crush), transection, glaucomatus optic 
neuropathy, papilledema, inflammation and de-myelination (Farkas and 
Grosskreutz, 2001; Levin and Gordon, 2002). Even though glaucomatus optic 
neuropathy is the most clinically relevant axonal injury, optic nerve transection 
and compression are by far the most extensively characterised experimental 
degeneration and regeneration models in the rodent visual system. The following 
sections outline the morphological and molecular changes that adult rat RGCs 
undergo following optic nerve injury, with emphasis on the compression model.
6.1.2.1 Effects of optic nerve compression on adult rat RGCs
Optic nerve injury results in RGC loss, the extent of which varies depending on 
the type and severity of the lesion, proximity to the retina and the age of the 
animal. Well-defined crush lesions divide the optic nerve into the distal segment, 
between the lesion and the optic chiasm and the proximal segment between the 
lesion and the retina. RGC responses following axotomy share a degree of 
similarity between transection (Villegas-Perez et al., 1993) and compression 
(Berry et al., 1999; Campbell et a l, 1999; Selles-Navarro et al., 2001) injury 
models. RGC death appears to follow a well-defined temporal pattern regardless 
of the way the lesion was inflicted. Complete transection of the optic nerve 
results in extensive ischemia and necrosis accompanied by a large region of 
cavitation extending proximally to the lesion site (Grafstein and Ingoglia, 1982). 
Although a crush lesion has a smaller injurious impact on morphology and RGC 
viability, scar formation and cavitation still develops in the central optic nerve 
extending proximally (Berkelaar et al., 1994) to the optic disc.
24 hours following a crush lesion, the majority of RGC axons appear to have 
variably retracted 30 to 200pm from the lesion site while very little evidence of 
an injury can otherwise be seen (Frank and Wolburg, 1996). One possible 
explanation for this axonal retraction stems from the following studies, performed
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on white matter axonal injury. These suggest that voltage-gated sodium channels 
might provide a route for sodium influx into axons that triggers reverse operation 
of the Na+/Ca2+ exchanger (NCX) and subsequent influx of damaging levels of 
intra-axonal Ca2+ (Craner et al., 2004), ultimately leading to cytoskeleton 
depolymerisation (Meller, 1987; LoPachin and Lehning, 1997; Campbell et al., 
1999). Overall, there is no significant decline in retinal cell numbers (Misantone 
et al., 1984) at this time.
At 7 days post lesion, neurofilament immunoreactivity (NF-IR) begins to decline 
in the distal stump. This decline is gradual, signalling the onset of Wallerian 
degeneration (Ohlsson et al., 2004). Towards the end of the first week, RGC loss 
increases with 68% (Selles-Navarro et a l , 2001) of crushed RGCs surviving. 
Axons proximal to the lesion begin to sprout vigorously demonstrating increased 
GAP43 immuno-reactivity (Ohlsson et al., 2004). These sprouts appear very 
small with a diameter ranging between 100 and 200nm (Campbell et al., 1999).
^  I
Unexpectedly, the Ca influx, reported to be responsible for the axonal retraction 
observed at 24 hours post lesion, is also thought to contribute to this axonal 
sprouting. There is evidence to suggest that in fact this elevation in intracellular
^  j j
Ca concentrations activate a group of Ca -depended proteases known as 
calpains. Even though their role is controversial (Wang and Yuen, 1994), several 
studies have suggested that calpains play a role in membrane resealing after 
injury (Xie and Barrett, 1991) and in restoration of dendritic structures after 
excitotoxic injury (Faddis et al., 1997). In addition, transient and localised 
elevation in cytoplasmic proteolytic activity is capable of inducing growth cone 
formation (Ziv and Spira, 1997; Ziv and Spira, 1998). By 14 days post crush, 
only 28% of RGCs are still viable (Selles-Navarro et al., 2001). In the case of a 
complete optic nerve transection, the number of surviving RGCs falls to 10% at 
two weeks post injury (Bray et al., 1991; Villegas-Perez et al., 1993; Berkelaar et 
al., 1994; Zeng et al., 1994; Selles-Navarro et al., 2001). This vigorous sprouting 
noted by the end of 7 days post injury, becomes largely abortive once the axons 
encounter the scar tissue of the lesion. Very few spontaneously regenerating 
axons can be seen entering the lesion and extending distally up to 200pm while 
one or two axons were found to have extended up to 700pm distally (Campbell et
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al, 1999). The majority of regenerating axons appear to run parallel to the 
longitudinal axis of the optic nerve. Some of them however appear to run 
indirectly, making sharp turns, or occasionally looping back on themselves. At 20 
days post crush the distal segment of the optic nerve appears devoid of GAP43 
immunoreactivity, while abundant neurofilament (RT-97) positive debris can be 
seen (Berry et a l, 1996). The few spontaneously regenerating axons found at 
200-900pm distal to the lesion, are unmyelinated (Campbell et a l, 1999). Eight 
weeks after crush injury, only low levels of neurofilament immunoreactivty are 
detected in the distal stump (Ohlsson et a l, 2004). Regenerating axons extending 
between 1.5 to 2.0mm distally, were found in clusters of 2-10 surrounded by 
astrocytic processes beneath the glia limitans.
RGCs continued to demonstrate a very limited ability for long term regeneration 
with one or two axons found at 6mm and 8mm distally at four and sixteen months 
post lesion respectively (Campbell et a l, 1999). Approximately 5% of RGCs still 
survive 20 months after intraorbital nerve section (Villegas-Perez et a l, 1993).
6.1.2.2 The glial reaction to optic nerve injury
Similarly to other tracts of the CNS, the permanent impairment that follows a 
crush injury involves alterations in non-neuronal cells including the formation of 
a glial scar. The cellular events leading to the formation of the glial scar appear to 
occur within defined chronological boundaries. Even though there appear to be 
differences in the literature regarding the onset and extent of morphological 
alterations within the crushed optic nerve, these are primarily due to the different 
experimental approaches used to inflicting the crush lesion. A crush lesion 
inflicted with a suture ligature (microcrush) (Selles-Navarro et a l, 2001) 
produces a far more focal point of lesion compared to the more extensive 
disruption generated when applying constant pressure with a fine pair of forceps 
(Ohlsson et a l, 2004). However, qualitatively the cellular alterations that follow 
are very similar.
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Within 24 hours of crushing using fine forceps, the optic nerve appears swollen 
with an intact pia matter. The cellular architecture of the nerve is disrupted 
including the destruction of blood vessels. The pattern of GFAP 
immunoreactivity denotes the absence of astrocytes from the lesion centre and 
their presence in the immediate proximal and distal zones. No microglia or 
macrophages were found to be present in either the lesion centre or in the 
proximal or distal segments (Frank and Wolburg, 1996) after staining for either 
EDI or lysozyme. EDl-positive/lysozyme-positive cells of round shape enter the 
lesion centre after 2 days with a higher concentration found around disrupted 
blood vessels. Immunocytochemistry revealed that the EDI antigen was localised 
to the membranes of phagosomes, consistent with the role of these cells in 
clearing debris. In the case of a microcrush a clearly defined focal lesion is 
produced that appears to be populated by leptomeningeal cells (Selles-Navarro et 
al., 2001). These authors propose that the presence of leptomeningeal cells, 
migrating into the lesion site from the pia matter, points to their potential 
implication in creating a non-permissive environment. Indeed, leptomeningeal 
cells have previously been shown to be non-permissive to axonal growth (Hirsch 
and Bahr, 1999). In addition, NGF, secreted by the large number of astrocytes 
that re-populate the lesion site (Ishikawa et al., 1991) a week post injury, has 
been shown to stimulate process outgrowth in these cells (Frisen et al., 1998).
Five to seven days after the lesion microglia, macrophages, astrocytes and 
fibroblasts begin to infiltrate the crush site. Co-localisation of BrdU and 0X42 
immunoreactivity has confirmed intense proliferation of microglia (Ohlsson et 
al., 2004). The numbers of EDl-positive/lysozyme-positive cells peak and 
increase in diameter due to the incorporation of large amounts of cellular debris. 
EDl-positive/lysozyme-negative activated microglia and macrophages with a 
branched morphology begin to populate the distal segment of the crushed optic 
nerve but demonstrate little phagocytic activity. Astrocytes begin to re-enter the 
lesion site while at the edges of the lesion, reactive astrocytes enclose axonal and 
myelin debris (Frank and Wolburg, 1996).
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Two weeks after injury, blood vessels extensively invade the lesion site, as 
indicated by an increase in laminin immunoreactivity and branch both distally 
and proximally from the centre of the lesion (Selles-Navarro et a l , 2001). 
Astroglia undergo hypertrophy and proliferate based on BrdU and GFAP co­
localisation studies (Ohlsson et al., 2004). Over the next 20 to 30 days, the distal 
segment is packed from the lesion edge with myelin basic protein (MBP, a 
general myelin marker) and myelin proteolipid protein (PLP or lipophilin, a CNS 
specific myelin marker) containing degenerating myelin. The actual lesion site 
contains islands of degenerating myelin. Amongst the degenerating myelin, 
CAII-positive oligodendrocytes are present in the distal and proximal segments 
but not at the lesion site. The basal lamina, which appears to be continuous with 
the glia limitans externa, is underlaid by several layers of astrocyte processes and 
a single layer of end-feet (Berry et al., 1999). Reactive astrocytes are present in 
both segments of the optic nerve. Few astrocytic processes bridge the lesion, 
which contains unstained regions circumscribed by GFAP positive glia limitans. 
EDI-positive macrophages accumulate in the lesion and perilesion regions of the 
proximal and distal segments. However, EDI-positive microglia are found in the 
rest of the optic nerve (Berry et a l , 1996).
After 8 weeks, a meshwork of blood vessels is in place, creating a mechanical 
barrier to regenerating axons. GFAP immunoreactivity is restored within the 
lesion site and appears uniform (Selles-Navarro et a l , 2001). Microlia and 
astrocytes still appear to proliferate along the entire portion of the distal optic 
nerve (Ohlsson et a l , 2004). The glial scar that has formed is encapsulated by a 
convoluted basal lamina whose well vascularised central core of connective tissue 
(Fawcett and Asher, 1999) is rich in heamatogenous macrophages, astrocytes, 
reactive microglia and fibroblasts. The precise sequence of events following optic 
nerve trauma can vary and largely depends on the site and severity of the lesion 
(Fawcett and Asher, 1999). Nevertheless, the glial scar that forms in the optic 
nerve presents a significant barrier to RGC axonal regeneration. This is clearly 
evident when considering the fact that not even olfactory bulb axons, which have 
an exceptional capacity for regeneration, can regenerate their axons through a 
transplanted optic nerve glial scar (Anders and Hurlock, 1996).
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6.1.3 Reasons for the regenerative failure of adult RGCs
After axotomy RGCs demonstrate a capacity for spontaneus regeneration, albeit 
fruitless. This has been reported in vivo after optic nerve crush and optic nerve 
transection (Zeng et a l , 1994; Campbell et a l , 1999). Also, retinal explants from 
adult rats that have been pre-lesioned by a crush injury (Tsai et a l , 1998) or 
transection (Johnson et a l , 1988a; Johnson et a l , 1989), do exhibit an enhanced 
intrinsic ability to extend neurites compared to non-pre-lesioned animals 
(Johnson et a l , 1988b). However, this ability declines rapidly 10 days post 
axotomy (Tsai et a l, 1998). The factors that render fruitless any spontaneous 
RGC regenerative attemps are, as in the rest of the CNS, multifactorial. 
Retrograde transport of axotomy-induced signals and loss of axonal target 
derived trophic support are thought to contribute to the initiation of intrinsic 
signalling pathways, ultimately leading to RGC apoptosis (Berkelaar et a l, 1994; 
Garcia-Valenzuela et a l, 1994). In addition, myelin-associated and other glial 
scar inhibitory molecules are additional factors detrimental to regenerative 
attempts.
6.1.3.1 Loss of target-derived neurotrophic support
RGCs depend on the retrograde trophic support they receive from their targets in 
order to survive (Purves et a l, 1988), inkeeping with other CNS neurons. This is 
supported by the relationship exhibited between the length of the surviving optic 
nerve stump and the speed of cell death onset (Villegas-Perez et a l, 1993). In 
addition, trophic molecules present in an axotomised optic nerve can still exert 
their neuroprotective effect on the cell bodies of axotomised RGCs, as suggested 
by the fact that a pre-lesioned transplanted optic nerve in the vitreous is capable 
of transiently delaying the onset of RGC death in adult hamsters (Cho et a l ,
2001). The longer the surviving optic nerve, the more neurotrophic factors are 
present to support survival (Herdegen et a l, 1997). The mechanism underlining 
this loss of trophic support is poorly understood. There is growing evidence to 
imply that loss of target-derived trophism is not the sole factor playing a part in 
the resulting cell death. Firstly, kainate lesion of the superior colliculus, with 
sparing of RGC axons, does not lead to RGC death (Carpenter et a l, 1986) even
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though sparing of connections to other retinorecipient targets cannot be ruled out 
in this study. Secondly, intraoccular administration of FGF (Cui et a l , 1999), 
CNTF, BDNF (Mey and Thanos, 1993; Mansour-Robaey et a l, 1994; Di Polo et 
a l, 1998) or GDNF (Klocker et a l, 1997) can support survival of axotomised 
RGCs but only transiently.
The inability of neurotrophic factors to sustain a functional effect could be 
attributed to the failure of injured RGCs to respond to these signals. This could be 
explained by the existence of different Trk isoforms that although capable of 
binding their high affinity ligands are not capable of transducing the stimulatory 
signal. The levels of TrkA and TrkB mRNA begins to gradually decline folowing 
optic nerve injury, reaching a minimum after 1 month (Cui et a l, 2002; Cheng et 
a l, 2002). This observation, could explain the ephemeral effect of NT4/5 and 
BDNF administration in enhancing the survival of injured RGCs (Clarke et a l, 
1998; Di Polo et a l, 1998). Similarly, despite the fact that TrkC levels in injured 
RGCs appear to remain unaltered for up to five weeks post lesion (Cui et a l,
2002), administration of NT3 has a minimal impact on both RGC survival and 
axonal regeneration (Peinado-Ramon et a l, 1996; Sawai et a l, 1996). Several 
TrkC forms have been identified including one that completely lacks a catalytic 
domain (Tsoulfas et a l, 1993). It is therefore logical to hypothesize that failure of 
RGCs to regenerate involves not only the declining access to factor availability 
but also to a reduced ability to respond to any potential trophic signals. This 
reduced responsiveness of axotomised RGCs to trophic signals has also been 
attributed to declining cAMP levels (Shen et a l, 1999), caused in turn by the loss 
of synaptic input (Harwerth et a l, 2002). It would therefore seem possible that 
the elevation of cAMP levels on its own would be enough to enhance survival 
and regeneration of injured RGCs, as it would indirectly lead to a higher 
responsiveness to trophic factors. However, there are conflicting reports on the 
ability of cAMP administration in promoting survival and/or regeneration of 
injured RGCs in vivo. On the one hand, cAMP elevation alone, by means of the 
CPT-cAMP (8-(4-Chlorophenylthio)adenosine-3 ’ ,5 ’ -cyclic monophosphate-
cAMP or CPT-cAMP) analogue administered intraocularly, was reported not to 
be sufficient to increase either the number of surviving RGCs or the number of
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regenerating axons into a peripheral graft (Cui et a l , 2003a). When cAMP 
elevation is accompanied by CNTF administration however, a significant increase 
in both survival and axonal regrowth is observed. This finding is in agreement 
with previous reports where adult RGCs in culture were found to be intrinsically 
unresponsive to trophic factor stimulation unless they were depolarised (Meyer- 
Franke et a l , 1998), or levels of their intracellular cAMP were elevated 
pharmacologically. In vitro studies are suggestive of a possible involvement of 
cAMP in increasing the recruitment of TrkB receptors (Meyer-Franke et a l ,
1998), hence indirectly enhancing the responsiveness of axotomised RGCs to the 
available neurotrophic agents. Indeed, when TrkB gene transfer was combined 
with BDNF delivery, RGC survival was increased by 76% three weeks after 
axotomy as opposed to 10% of RGCs surviving without treatment (Cheng et a l ,
2002). In vitro studies on rat cerebellar granule neurons have demonstrated that 
elevation of intracellular cAMP levels leads to the phosphorylation and inhibition 
of glycogen synthase kinase 3p (GSK-3p) by protein kinase A (PKA) (Li et a l, 
2000). These findings, hint to the fact that RGC death following axotomy can not 
be explained solely by the loss of retrograde, glial and target derived trophic 
stimuli but also by a decline in trophic responsiveness (Shen et a l, 1999). On the 
other hand, recent reports contradict the above findings. Monsul and coleagues 
report that a single intraocular injection of the cAMP analogue Dibutyryl-cAMP 
(N6, 2’-0- Dibutyryladenosine-3’, 5’-cyclic monophosphate-cAMP or Db-cAMP) 
is sufficient to promote RGC axon regeneration in the adult rat crush model but 
had no effect in preventing RGC death (Monsul et a l, 2004).
However, several reports point out the pitfalls regarding the use of both Db- 
cAMP and CPT-cAMP. Firstly, in its native form Db-cAMP is not a substrate for 
PKA and needs to split off one of its butyryl groups in order to adopt the kinase 
active form of monobutyryl-cAMP. The released butyrate can carry out its own 
distinct effects in second messenger pathways and can shift the focus from PKA 
(Rivero and Adunyah, 1998). Butyrate can alter gene expression by suppressing 
histone deacetylation leading to increased gene expression. This effect of butyrate 
appears to be type specific and in cerebellar granule neurons for example, sodium 
butyrate leads to apoptosis by the activation of caspase-3 protease (Salminen et
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a l, 1998). This is indicative of the fact that a different pathway may be at play 
inducing the effects of sodium butyrate considering that CPT-cAMP can promote 
survival of cerebellar granule neurons by directly activating PKA (Li et al., 
2000). Since the effects of Db-cAMP can be attributed to the butyryl moiety of 
this compound rather than to the cyclic nucleotide itself, it would be more 
appropriate that the use of Db-cAMP be accompanied by control experiments 
using sodium butyrate. This was not performed in the Monsul study and therefore 
doubt can be cast over the correlation of the observed regeneration and the direct 
involvement of PKA activation. Secondly, the 8-CPT-cAMP analogue is also 
associated with pitfalls as it is reportedly not specific for cAMP. It has been 
implicated in the activation of cGMP-dependent protein kinase (Geiger et al., 
1992) and it raises basal cGMP levels by inhibiting phosphodiesterase 5 
(Connolly et a l, 1992). A more specific analogue of cAMP such as the Sp-isomer 
of 8-CPT-cAMP (Sp-5,6-DCl-cBIMPS) could provide a more definitive answer 
on the involvement of cAMP levels in promoting survival and/or regeneration of 
axotomised RGCs.
6.1.3.2 Death signals in axotomised RGCs
The retrograde RGC death that follows optic nerve injury, appears to display the 
characteristic trademarks of apoptosis (Berkelaar et a l, 1994; Garcia-Valenzuela 
et a l, 1994; Isenmann et a l, 1997), including cell body shrinkage and DNA 
fragmentation in the absence of an inflammatory response (Gavrieli et a l, 1992; 
Garcia-Valenzuela et a l, 1994). However, it is worth noting that some necrosis 
also takes place as a result of the immune response taking place at the site of a 
mechanical lesion. Axotomy also initiates a cascade of microglia-mediated 
responses, which culminate in degradation of injured, but obviously surviving 
neurons (Thanos et a l, 1993).
Initiation of the apoptotic cascade can occur either via the intrinsic mitochondrial 
pathway (Kroemer et a l, 1997) or by the activation of cell surface death 
receptons (Ashkenazi and Dixit, 1998). Both routes exert their effects via two 
main gene families: the caspases (Kenner et a l, 1999; Kenner et a l, 2000) and
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the Bel-2 family (Kroemer, 1997) (Figure 6.1.3-a). In response to an apoptotic 
signal, an alteration in the permeability of the membranes of the cell’s 
mitochondria occurs. This event causes the translocation of the apoptogenic 
protein cytochrome c into the cytoplasm. This in turn activates death-driving 
proteolytic proteins known as caspases. The role of caspaces in initiating 
secondary RGC death has been well documented. Caspase-3 (CASP3) and it’s 
activator CASP9, have been shown to be activated in degenerating RGCs 
(Kenner et al., 1999; Kermer et al., 2000). Interestingly, the timing of their 
activation, pin pointed at 3 days post axotomy, coinsides with the onset of RGC 
death. It is thought that the PI3K/Akt pathway may serve as an endogenous 
regulator of caspase activation in axotomized RGCs (Cheung et al., 2004). The 
use of CASP3 inhibitors can reduce the extent of RGC death but the effect is 
short-lived (Kermer et al., 1999), further indicating the complexity of the 
mechanisms underlying neuronal death and survival following trauma.
The Bcl-2 family of proteins, whose members may be pro-apoptotic (BAX, BAD, 
BID, BAK, BCL-Xs, BIK, BIM, HRK) or anti-apoptotic (BCL-2, BCL-Xl , BCL- 
W, MCL-1, Al), regulate cell death by controlling mitochondrial membrane 
permeability during apoptosis (Farrow and Brown, 1996; Kroemer, 1997). 
Overexpression of the apoptosis repressor Bcl-2 in transgenic mice, supports 
sustained survival of RGCs after intracranial optic nerve transection (Cenni et al.,
1996). However, studies in Bcl-2 knockout mice (-/-), demonstrated that it is not 
a requirement for the survival of the subpopulation of axotomised adult RGCs 
that manage to survive unaided 14 days after axotomy (Dietz et al., 2001). These 
results further support the notion that the naturally low levels of Bcl-2 do not play 
a detrimental role in delaying the onset of RGC degeneration. Similarly, over 
expressing the anti-apoptotic protein Bcl-XL by means of an adenoviral vector, 
may promote axonal regeneration on axotomised RGCs, but fails to ensure 
functional regeneration (Kretz et al., 2004).
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Figure 6.1.3-a: Role of mitochondria in apoptotic signalling.
There are two m ajor apoptotic pathways in m am m alian cells: The death receptor mediated 
pathway via the activation o f  caspase 8 and the m itochondria pathway via the activation o f  
caspase 9. Cytochrom e c is released from m itochondria in response to apoptotic signals and 
activates the A poptosis activating factor-1 (Apaf-1), a protease also released from mitochondria. 
A ctivated Apaf-1 activates caspase-9 and the rest o f  the caspase pathway. Smac/DIABLO is 
released from  m itochondria and inhibits Inhibitors o f  A poptosis Proteins (LAP) that normally 
interact w ith caspase-9 to inhibit apoptosis (Srinivasula et al., 2001). The TNF family o f  receptors 
cause apoptosis by directly activating the caspase cascade, but can also activate Bid, a Bcl-2 
fam ily m em ber. This in turn initiates m itochondria-m ediated apoptosis. Bax, another Bcl-2 family 
m em ber, is activated by this pathway and localises to the m itochondrial membrane. Bcl-2 prevent 
m em brane pore form ation thus blocking apoptosis. A IF (Apoptosis inducing factor) is another 
m itochondrial factor that is released into the cytoplasm  to  induce apoptosis in a non caspase 
dependent m anner (Joza et al., 2001). (Diagram  adapted from http://w w w.biocarta.com ).
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The ratio of anti- to pro-apoptotic molecules such as Bcl-2/Bax (Bax stands for 
Bcl-2 associated protein X), determines the downstream response to a death 
signal (Oltvai et a l , 1993). Oltvai and colleagues further report that when Bax 
predominates, apoptosis is accelerated and the protective effect conferred by Bcl- 
2 is counteracted. Bax induction, shown to be a prerequisite for the execution of 
RGC apoptosis following ON axotomy (Isenmann et al., 1999b), involves both 
Bcl-2 and p53 and results in a downstream process that leads to mitochondrial 
dysfunction as well as activation of caspases (Miyashita and Reed, 1995). Bax 
protein, expressed in most ganglion cells at moderate baseline levels, is sharply 
increased as early as 30 min after a crush, reaches peak levels after 3 days, and 
remains up-regulated for at least 1 week thereafter (Isenmann et a l , 1997). Intra- 
vitreal delivery of Bax antisense oligonucleotides has been shown to reduce 
axotomy-induced retinal ganglion cell death in vivo (Isenmann et a l , 1999b).
A variety of transcription factors, belonging to the basic region leucine zipper 
super family (bZip), are involved in initiating the apoptotic fate of axotomised 
RGCs. These include, among many others, the JUN family and the ATF family 
(Karin et a l, 1997; Hai et a l, 1999; Shaulian and Karin, 2002). Under normal 
conditions, c-Jun is not expressed in RGCs. Prolonged expression of c-Jun has 
been linked to apoptosis in many models of neurodegeneration both in vitro and 
in vivo. For example, overexpression of c-Jun results in neuronal apoptosis (Ham 
et a l, 1995) but only in vitro (Lu et a l, 2003) while suppression of c-Jun 
prevents death in NGF deprived sympathetic embryonic neurons in vitro (Estus et 
a l, 1994). Additionally, c-Jun and GAP43 are co-expressed in axotomised RGCs 
found regenerating into a peripheral graft (Schaden et a l, 1994), thus supporting 
later reports that c-Jun is involved in regulating the expression of GAP43 (Lu et 
a l , 2003). However, the extent and contribution of c-Jun in the degenerative and 
regenerative process of axotomised RGCs is not clear as it appears to modulate 
both pro-apoptotic and regeneration signals (Herdegen et a l, 1997). Axotomy 
causes a rapid induction of c-Jun which persists in those RGCs that manage to 
survive and/or regenerate (Robinson, 1994; Hull and Bahr, 1994a), as well as 
RGCs that appear to undergo apoptosis (Isenmann and Bahr, 1997). Survival and 
expression of c-Jun in rat RGCs appears to be independently regulated by the
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length of the optic nerve stump, with c-Jun up-regulation beginning later and 
declining faster after distal axotomy compared to proximal transection of the 
optic nerve (Hull and Bahr, 1994a). c-Jun expression begins to decline at 8 days 
post axotomy but can be re-induced if regenerating RGC axons are subjected to 
secondary axotomy (Hull and Bahr, 1994b). Moreover, when retinas from c-jun 
deficient mice were co-cultured with the superior colliculus of newborn rats, they 
managed to survive and elongate their axons to the same extent as wild type 
retinas (Herzog et al., 1999), indicating that c-Jun is essential neither for 
programmed cell death nor axonal elongation. This dual role of c-Jun can be 
explained if the observed upregulation in both degenerating and regenerating 
RGCs is interpreted as a common cell body response, with the eventual fate of 
axotomised RGCs being decided by the specific homo/hetero-dimers formed by 
c-Jun, and the phosphorylation of these complexes by Jun N-terminal kinases 
(JNK), which are part of the cellular stress response (Herdegen et a l , 1997). 
There is evidence to support the notion that N-terminal phosphorylation of c-Jun 
contributes to RGC apoptosis following axotomy, since blocking both the c-Jun 
serine phosphorylation sites affords a larger number of surviving RGCs (Yoshida 
et al., 2002). Also, it is reported that c-Jun can form heterodimers with the ATF 
family of bZip transcription factors and, via binding to specific DNA sequences, 
control the fate of axotomised RGCs. ATF-3 for instance has emerged as a 
modulator of c-Jun transactivation showing a high specificity for a subset of 
surviving RGCs following an optic nerve crush (Takeda et a l , 2000).
6.1.3.3 Intrinsic growth capacity of axotomised RGCs
In addition to the factors outlined above, like all other neurons of the CNS, RGCs 
also demonstrate the same low levels of intrinsic growth capacity. Decreased 
anterograde transport of cytoskeletal components to the site of injury hinders any 
potential for axonal regeneration. The level of tubulin and neurofilament protein 
in non-regenerating axotomised RGCs is reportedly significantly lower than that 
found in regenerating RGCs, following of a peripheral graft (Fournier and 
McKerracher, 1995). Notably, slow component a (Sea) transport of tubulin in a 
crushed optic nerve decreases from a normal rate of 0.5 mm/day to 0.06 mm/day,
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resulting in a failure of tubulin and neurofilament levels to reach the site of 
axonal injury (McKerracher et a l , 1990b). In RGCs that do regenerate into a 
peripheral nerve graft anastomosed to the transected optic nerve, the rate of Sea 
increases to 1 mm/day (McKerracher et al., 1990a).
Another molecule implicated in the decreased growth capacity of RGCs is 
GAP43, thought to influence the re-organisation of the axonal cytoskeleton 
(Benowitz and Routtenberg, 1997) in a mechanism involving its phosphorylation 
by protein kinase C (PKC) (Akers and Routtenberg, 1985). GAP43 is not 
normally present in adult RGCs but a small proportion appears to express the 
protein following axotomy (So and Yip, 1998). It is these GAP43 expressing 
RGCs that appear capable of regenerating their axons into a peripheral nerve graft 
anastomosed to the transected optic nerve, demonstrating a direct link between 
GAP43 expression and axonal regeneration (Schaden et a l , 1994; Ng et a l ,
1995). Studies in GAP43 (-/-) null mice reveals that even though RGC axonal 
elongation pauses for 6 days at the optic chiasm, axons still reach their 
retinorecipient targets (Strittmatter et a l, 1995), thus demonstrating that GAP43 
is not essential for axonal elongation but plays a role in axon guidance and path 
finding, at least during development (Zhang et a l , 2000). This observation is in 
accordance with previous data, which suggest that over-expressing GAP43 in the 
adult CNS is not enough to support regeneration (Mason et a l, 2000). Studies 
using GAP43 promoter elements in transgenic zebrafish, indicate that the 
signaling pathways regulating GAP43 activation after CNS axotomy are different 
to those acting during developmental axonal elongation (Udvadia et a l, 2001). In 
mammals, overexpression of GAP43 in the rat cerebellum using the Purkinje 
specific L7 promoter, enhances sprouting of Purkinje axons after knife cut injury, 
but does not promote axonal regeneration into growth permissive substrates of 
embryonic neurons grafted within the lesion site (Buffo et a l, 1997). Hence, gene 
expression during axonal regeneration may involve a separate pathway that may 
share a degree of similarity with that acting during development (Bulsara et a l, 
2002; Isenmann et a l, 2003). Interestingly, no RGC axotomy experiments have 
been performed using GAP43 transgenic animals. It is also worth noting that 
sciatic nerve injury in GAP43 overexpressing transgenic mice, results in
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motomeuron death, but has no effect in non-transgenic animals. The authors 
suggest that continued growth of motor axons renders adult motomeurons 
susceptible to nerve injury and compromises their long-term survival potential 
(Harding et al., 1999). Whether this is true for RGCs or not has not been 
addressed, but it is a factor that should be considered in regenerative attempts 
such as long-term delivery of GAP43 as a transgene.
6.1.3.4 Growth hindering molecules in the glial scar
In addition to the loss of trophic support and reduced growth capacity, surviving 
RGCs are also faced with a plethora of inhibitory molecules present in astrocytes 
(McKeon et al., 1991; Bahr et al., 1995) myelin and oligodendrocytes (Berry, 
1982; Caroni et al., 1988; Schwab and Caroni, 1988; Caroni and Schwab, 1988b; 
Bandtlow et al., 1990; Bahr and Przyrembel, 1995), anyone of which appears 
sufficient to inhibit regeneration (Wang et al., 2002a). These include MAG 
(McKerracher et al., 1994; Mukhopadhyay et al., 1994; Li et al., 1996), OMgp 
(Mikol et al., 1988; Wang et al., 2002b; Vourc'h and Andres, 2004) as well as the 
Nogo family of proteins (Chen et al., 2000; GrandPre et al., 2000), acting via 
their high affinity receptor Nogo 66 (Fournier et al., 2001) and p75NTR 
(Domeniconi et al., 2002; Wang et al., 2002a), all of which have been discussed 
in Chapter 1. Here, the focus is directed to evidence of the involvement of these 
molecules in inhibiting regeneration of axotomised RGCs.
When axonal growth cones from mature rat RGCs are confronted by rat central 
myelin in vitro, they either undergo growth cone collapse or avoid the myelin by 
altering the direction of axonal elongation (Vanselow et al., 1990; Bahr and 
Przyrembel, 1995). Hence, just like for the rest of the adult CNS neurons, myelin 
does present an overall non-permissive environment to regeneration for 
axotomised RGC, at least in vitro. Neurons co-express Nogo-A, NgR and OMgp 
(Habib et al., 1998) while MAG is primarily localised in glia (Martini, 1994). In 
their uninjured state, RGCs strongly express Nogo-A, found primarily in the 
somata rather than axons either in the fibre layer of retina or in the optic nerve 
(Huber et al., 2002; Hunt et al., 2003), possibly due to the rapid trafficking of
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Nogo-A along the axon (Hunt et al., 2002a). Nogo66 is present in the ganglion 
cell layer of the retina and in scattered cells within the optic nerve, presumed to 
be oligodendrocytes (Chen et al., 2000; Huber et a l , 2002; Wang et al., 2002b; 
Hunt et al., 2002b). Four days after an optic nerve crush, Nogo-A protein appears 
absent from the lesion site itself but seems to accumulate at the proximal and 
distal boundaries of the lesion (Hunt et al., 2003). It is not clear if the apparent 
upregulation coincides with increased RGC axonal Nogo-A mRNA levels or 
whether it can be attributed to oligodendrocytes. Axotomised RGCs sprouting 
into the lesion site after axotomy appear to weakly express Nogo-A (Hunt et al.,
2003).
The role that Nogo-A and its receptor play in inhibiting regeneration is not fully 
understood. Several studies however, have reported some degree of success in 
blocking the interaction of NgR with its ligands (Domeniconi et al., 2002; Wang 
et al., 2002a; Wang et al., 2002b). In the RGC model, delivering a dominant 
negative form of NgR (NgRDN) by means of an AAV vector, demonstrated that 
inactivating NgR enhances regeneration in adult RGCs both in vivo and in vitro 
(Fischer et al., 2004). However, this approach was only successful when the 
intrinsic growth state of axotomised RGC was previously boosted via 
macrophage activation as a result of puncturing the lens (Fischer et al., 2000; Yin 
et al., 2003). Even though RGCs in adult rats show strong NgR mRNA 
expression, sole delivery of IN-1 (Caroni and Schwab, 1988a; Rubin et al., 1994) 
in vivo has failed to produce any regeneration in the optic nerve crush model. The 
combinatorial delivery of IN-1 and BDNF or FGF, on the other hand, increased 
regeneration after an intracranial optic nerve crush lesion in young rats. Even in 
this experiment however, a very small proportion of regenerating axons were 
found at no more than 1.9 mm or 2.5 mm beyond the lesion site when co­
delivered with BDNF or FGF respectively (Weibel et al., 1994). A synergistic 
effect is also reported for IN-1 and CNTF in the intraorbital and intracranial optic 
nerve crush paradigms (Cui et al., 2004). This study confirmed previous findings 
proposing that IN-1 delivery alone fails to promote regeneration of axotomised 
RGCs.
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The fact that counteracting NgR on its own does not lead to regeneration is not 
surprising. NgR undoubtedly plays a key part in the inhibitory nature of the 
injured CNS but it is unlikely that central myelin components are the only 
contributing factor. Evidence supporting that this is the case for the injured optic 
nerve, comes from a set of studies where frozen sections of different 
developmental stages were used as substrates for RGC axonal growth assays. 
Tissue sections taken from unmyelinated optic nerves of embryonic (E18-E20) 
rats, failed to support neurite extension of either neonatal RGCs or both neonatal 
and adult DRG neurons (Shewan et al., 1993). This observation is replicated in 
vivo, when no axonal regeneration is achieved after optic nerve injury in adult 
Browman-Wyse mutant rats in which both the oligodendrocytes and CNS myelin 
are absent. Taken together, these findings prompted Berry and colleagues to 
suggest that central myelin is not an absolute requirement for regenerative failure 
of adult axotomised RGCs (Berry et al., 1992). Moreover, in vitro results re­
enforce the hypothesis made by many research groups that the injured neuron is 
subject to a complex combination of inhibitory signals, not reproducible in vitro. 
For example, the effect of vaccination in RGC regeneration was demonstrated 
first by Schwartz and colleagues who showed that vaccinating with myelin 
derived peptides can lead to neuroprotection for axotomised RGCs but has no 
effect on fibre regeneration (Fisher et al., 2001). A later study, using transgenic 
mice overexpressing CNS-reactive T cells, has cast doubt on the original 
suggestion that activated T-cells are responsible for the vaccine’s effect on RGC 
neuroprotection (Yoles et a l , 2001). CNS injury on its own can invoke a T-cell 
dependent neuro-protective response and it is therefore possible that any 
neuroprotection afforded by myelin-reactive T-cells may be an indirect effect, 
mediated by other, non-CNS-reactive lymphocytes (Jones et a l , 2002b). In 
another experiment, optic nerve micro-crush injured animals were injected with 
spinal cord homogenate. In this study, there was no enhancing effect on RGC 
survival but axonal regeneration was promoted (Ellezam et a l , 2003). Previous 
studies from the same lab have prompted the authors to form the hypothesis that 
this effect was mediated by the presence of antigens to myelin associated growth 
inhibitory proteins. Interestingly, sera from vaccinated animals appeared to have 
very low levels of antibodies for NogoA, Nogo66, MAG or CSPG (Ellezam et
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al., 2003). This re-enforces the hypothesis that the inability of RGCs to 
regenerate through the post injury inhibitory environment involves factors, which 
are as yet unknown.
In addition to the morphological alterations involving myelin associated growth 
inhibitory factors taking place in the lesioned optic nerve, the upregulation of 
extracellular matrix proteins and their poorly understood interactions, are thought 
to also contribute to the inhibitory nature of the glial scar. CSPGs, shown to be 
inhibitory to axonal growth in several CNS injury models (Fawcett and Asher, 
1999; Logan and Berry, 2002; Sandvig et a l, 2004), are secreted by reactive 
astrocytes by 24 hours after an optic nerve micro-crush lesion (Selles-Navarro et 
al, 2001). However, the CS-56 antibody used in this study, was non-specific and 
did not provide any definitive data regarding which member of the CSPG family 
is upregulated or contributes to the inhibitory environment in vivo. A number of 
specific CSPGs have been implicated in axonal growth inhibition. Neurocan and 
phosphacan are capable of inhibiting RGC outgrowth, at least in vitro (Inatani et 
al, 2001). NG2, present in oligodendrocyte precursors in the adult mammalian 
optic nerve (Butt et al., 1999), is reportedly upregulated following optic nerve 
injury (Chierzi and Fawcett, 2001) and is inhibitory to axonal growth in vitro for 
various CNS neurons (Dou and Levine, 1994; Fidler et a l, 1999; Jones et al., 
2002a) although in vivo its ihibitory nature is uncertain (Rezajooi et al., 2004). 
Versican, is considered a potential inhibitor of axonal re-growth for the optic 
nerve that is also expressed by oligodendrocytes and oligodendrocyte precursor 
cells (Asher et al., 2002).
Nogo, MAG and Omgp as well as CSPGs, seemingly exert their inhibitory effects 
via the Rho/ROCK pathway and its downstream effectors (McKerracher et al., 
1994; Monnier et al., 2003). Rho has been shown to modulate axonal growth by 
altering cytoskeleton dynamics in the growth cone (Dickson, 2001) and their 
activation leads to growth cone collapse in RGCs (Lehmann et al., 1999). 
Targeted inactivation of Rho using the C3 bacterial co-enzyme (Aktories et al., 
1989) allows adult RGC axons to grow both in vivo after an optic nerve crush and 
in vitro on myelin (Lehmann et al., 1999) or CSPG substrates (Monnier et al.,
2003).
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Another family of extracellular matrix proteins that has been implicated in the 
inhibition of adult RGC axonal elongation is the tenascin family (Fournier and 
Strittmatter, 2001). Tenascin-R (TN-R) inhibits adult and embryonic mouse RGC 
neurite extension in vitro, even in the presence of laminin (Bates and Meyer,
1997), while it persists in the adult mouse lesioned optic nerve for at least 63 days 
post lesion (Becker et a l , 2000). In contrast, tenascin-R quickly disappears from 
the regenerating optic nerve of salamanders (Becker et al, 1999). A phosphacan- 
related ligand that co-localises with tenascin-R in the retina and optic nerve of 
adult rodents has been identified as a proteoglycan that, when offered as a 
substrate in vitro, neutralises the growth cone repulsion induced by TN-R (Xiao 
et a l, 1997). Recently, Te38, a proteoglycan that co-purifies with tenascin C 
(Bartsch et a l, 1992), was also found to inhibit neurite extension in vitro 
(Henke-Fahle et a l , 2001).
Each glial cell type in the developing optic nerve i.e astrocytes oligodendrocytes 
and their precursors, differentially express members of the semaphorin family 
(Goldberg et a l, 2004). Sema-5A, expressed by oligodendrocytes and their 
precursors in the developing optic nerve (Oster et a l , 2003), can induce growth 
cone collapse in both embryonic, postnatal and adult RGCs when presented as a 
substrate in vitro. Moreover, RGC axons extend 50% further on P8 optic nerve 
explants in the presence of sema-5A blocking serum (Goldberg et a l, 2004). 
After a complete optic nerve transection in adult rats, sema-3A is quickly 
upregulated, reaching its peak at 3 days post lesion, and then gradually declining 
to normal levels. Intravitreal delivery of a sema-3A neutralising peptide, 24 hours 
after axotomy, appeared to rescue the majority of RGCs from death (Shirvan et 
a l, 2002). Semaphorins appear to also play a role in the inability of RGCs to 
regenerate and therefore present good targets for regeneration experiments.
6.1.4 Regeneration & neuroprotection in axotomised RGCs
A variety of different approaches have shown some degree of success in 
encouraging axotomised RGCs to regenerate. The following sections review the 
reported application of these techniques with regards to the injured optic nerve 
paradigm, placing emphasis on the use of neurotrophins.
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6.1.4.1 Peripheral nerve grafts
A peripheral nerve (PN) graft, transplanted either into the retina (So and Aguayo, 
1985; So et a l , 1986) or onto the transected optic nerve itself (Berry et a l , 1986; 
Aguayo et a l , 1987; Bray et a l, 1987; Vidal-Sanz et a l, 1987; Berry et a l, 
1996), is capable of promoting axonal regeneration of axotomised RGCs for 
considerable distances along the PN graft. A small number of axons succeed in 
forming functional synapses in the superior colliculus (David and Aguayo, 1981; 
Keirstead et a l, 1989). Berry and co-workers showed that Schwann cells, present 
in the PN graft, and the trophic molecules they secrete (Friedman et a l, 1999; 
Dezawa and Adachi-Usami, 2000), are the key elements behind this regenerative 
response (Berry et a l, 1988a; Berry et a l, 1988b). Later studies revealed that 
fibroblasts, also present in the PN, secrete a number of trophic molecules, 
including NGF and BDNF (Acheson et a l, 1991), and may contribute to the 
overall therapeutic effect. There are some reports that suggest that PN fibroblasts 
are even able to rescue axotomised RGCs (Yip and So, 2000), but there is not 
enough supporting data to substantiate that claim. Interestingly, re-axotomising 
the regenerated axons within the PN does not result in significant RGC death 
(Schuetz et a l, 2003). This finding has led the authors of the study to propose 
that the reduced vulnerability of these RGCs is a property afforded by the 
Schwann cells engulfing the RGC axons and supporting them with the growth 
promoting factors they secrete.
Intravitreally transplanted optic nerve segments can also have growth promoting 
effects on RGC axons. Cho and colleagues have demonstrated that following 
intravitreal transplantation of either optic nerve or sciatic nerve segments, similar 
numbers of RGC axons can regenerate along a PN graft, anastomosed to an 
intraorbitally transected optic nerve (Cho et a l, 2001). When a sciatic and optic 
nerve segments are co-transplanted intravitreally, there appears to be a synergistic 
effect on the numbers of regenerating RGC axons, compared to the effect 
obtained following either graft on its own (Cho et a l, 1999b). However, only 
transplanted optic nerve segments were found to increase the survival of 
axotomised RGCs. On the contrary, optic nerve transplantation alone did not 
have any effects on RGC sprouting, be it growth promoting or inhibitory, despite
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the fact that injured optic nerve slices have been shown to be inhibitory to RGCs 
in vitro (Cho et a l , 1999b). Cho and colleagues hypothesise that the mechanism 
by which grafted optic nerve segments enhance the regenerative effect of the 
transplanted peripheral nerve, relies on the fact that the optic nerve graft is able to 
slow down the rate of axotomised RGC death thus leaving more axons receptive 
to the diffusible growth promoting molecules emanating form the PN graft. This 
study also showed that in vivo, the optic nerve does not impede axotomised RGC 
survival (Cho et al., 2001).
The experiments described above, have dealt with the regeneration of RGC axons 
through PN grafts attached to the optic nerve or retina. Berry and co-workers 
demonstrated for the first time that it was possible for RGC axons to regenerate 
through the optic nerve of an adult mammal. The optic nerve was crushed 
intraorbitally and sciatic nerve segments were transplanted into the vitreous body. 
Over a period of 20 days, a large number of RGC axons had grown across the 
crush site and up to 3-4mm along the distal optic nerve (Berry et al., 1996). This 
definitive experiment was the inspiration for the set of experiments that are 
described in the following sections, and demonstrate even more substantial 
regeneration of RGC axons.
6.1.4.2 Cataractogenic lens injury
Unaided and significant regeneration appears to be achieved after intravitreal 
trauma. Simply puncturing the lens or lens capsule (Fischer et al., 2000; Leon et 
al., 2000) is successful in promoting the survival and inducing axotomised RGCs 
to survive and regenerate their axons through the inhibitory environment of the 
lesioned optic nerve. This has been demonstrated following either intraorbital 
crush (Leon et al., 2000) or transection (Fischer et al., 2001) injuries. When a 
lens injury is performed 3 days after an optic nerve lesion, 49% of axotomised 
RGCs still survive 14 days later (Fischer et al., 2000). The extent of axonal 
regeneration is also impressive. Five weeks after the lesion, up to 30% of RGCs 
have elongated their axons, from the site of the intraorbital lesion, through the 
inhibitory environment of the optic nerve and terminated at their retinorecipient
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targets in the superior colliculus (Fischer et al., 2001). These regenerated axons 
function sufficiently to allow modest luminance detection. The exact mechanism 
by which the lens puncture is able to afford such survival and regenerative 
properties is not clear. The infiltration into the eye of activated macrophages, a 
result of puncturing the lens structure, appears to be a contributing factor. Firstly, 
because activated macrophages secrete a cocktail of trophic factors (Barouch et 
al., 2001a; Barouch et al., 2001b), and secondly because injection of Zymosan, a 
potent monocyte activator (Fitch et al., 1999), into the vitreous mimics the effects 
of a lens puncture even when no axotomy has been performed (Leon et al., 2000; 
Lorber et al., 2002). Interestingly, if Zymosan is intravitreally injected 3 days 
after an optic nerve crush, the number of RGC axons regenerating into the optic 
nerve was even greater than after lens injury (Yin et al., 2003). Somewhat 
surprisingly, pre-stimulating macrophages with Zymosan 7 days before an 
intraorbital optic nerve crush lesion is inflicted does not aid RGCs in 
regeneration, indicating that a factor, additional to those secreted by 
macrophages, is at play (Yin et al., 2003). Studies of goldfish RGC regeneration 
revealed that non neuronal cells of the ON secrete a small molecular weight 
molecule, termed axogenesis factor 1 (AF-1), that can promote significant 
regeneration of RGCs in culture (Schwalb et al., 1995). A small 15 kDa protein, 
originating from activated macrophages can induce RGC regeneration in vitro, 
and potentates the effect of forskolin and the mammalian equivalent of AF-1 (Yin 
et al., 2003).
Compromising the lens also triggers production of neurotrophic factors from 
Muller glia (Leon et al., 2000) which are known to express growth supporting 
molecules, such as CNTF in vitro (Jo et al., 1999). Interestingly, attempts to 
block the effects of either CNTF, BDNF or bFGF with neutralising antibodies has 
no effect in diminishing the beneficial effect of the lens injury (Leon et al., 2000). 
Lorber et. al. proposed that this approach doesn’t address the potential 
combinatorial effect these molecules may have in vivo as only one of them was 
targeted at a time (Lorber et al., 2002). The same authors went on to demonstrate 
that blocking the trk receptor and CNTF still does not abolish the ability of RGCs 
to extend neurites in the presence of media conditioned by lesioned lenses.
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Whether this holds true in vivo is not known as yet but is nevertheless suggestive 
of the existence of a growth promoting molecule that is neither a neurotrophic 
factor nor CNTF (Lorber et al., 2002). This line of thought follows the one 
proposed by Fischer and colleagues (Fischer et al., 2001), who suggested that the 
survival promoting factors diffusing from the punctured lens epithelium, may 
account for the neuro-protective effect on axotomised RGCs. The impact of an 
intravitreal compromise may, to some extent, explain the reported effects of an 
intravitreal transplantation of nerve segments.
6.1.5 Neurotrophic factors and their effects on axotomised RGCs
Several neurotrophic factors are reportedly capable of promoting survival and/or 
regeneration in the adult, mammalian lesioned optic nerve with variable degrees 
of success. Some neurotrophins that appear to have an impact on either survival 
or regeneration of RGCs in vitro appear to be effective only transiently in vivo. 
Here, the effects of each neurotrophic factor on neuroprotection and regeneration 
as well the various experimental approaches developed for their efficient delivery 
are discussed.
Survival of RGCs Regeneration of RGCs
Factor
In vitro In vivo In vitro In vivo
BD N F + + - -
N G F + + + -
NT3 + - - -
N T-4 + + + -
C N TF + + + +
FGF + + + -
G D N F ? + + ?
N eurturin  (N TN ) + + ? ?
Table 6.1.5-a: Effects of retinotrophic factors in RGC survival & regeneration.
(Adapted from Yip and So, 2000). + Positive effect, - No effect, ? Unknown.
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6.1.5.1 BDNF
BDNF, produced in the superior colliculus (or lateral geniculate nucleus in 
primates) binds to trkB receptors and is retrogradely transported to the RGC cell 
bodies in microsomal vesicles (DiStefano et al., 1992; von Bartheld et al., 1996b; 
von Bartheld, 1998). After intravitreal delivery, exogenous BDNF is transported 
anterogradely along the RGC axons and released at their targets (von Bartheld et 
al., 1996a). During development, RGCs exhibit an increased dependency on 
BDNF for survival as they approach maturity and innervate their targets (Johnson 
et al., 1989; Thanos and Vanselow, 1989). Delivering purified BDNF in the 
superior colliculus of neonatal hamsters, protects embryonic RGCs at a time 
when they are most susceptible to death (Ma et al., 1998). A later study however, 
has cast a doubt over that claim. Isenmann and co-workers found that delivering 
BDNF by means of an adenoviral vector to the superior colliculus of neonatal 
animals did appear to rescue RGCs from death but only in the short term 
(Isenmann et al., 1999a). This transient neuro-protective effect of BDNF is 
mirrored in adult axotomised RGCs. In vivo studies have established that BDNF 
can avert apoptotic death of axotomised adult RGCs (Mey and Thanos, 1993; 
Mansour-Robaey et al., 1994; Peinado-Ramon et al., 1996), but has no effect in 
axonal elongation (Mansour-Robaey et al., 1994; Cui et al., 1999). The neuro- 
protective effect of BDNF seems to be independent of the timing of its delivery, 
with the same number of RGCs rescued when exogenous BDNF is intravitreally 
delivered either 6 days prior or 5 days after optic nerve transection (Mansour- 
Robaey et al., 1994). However, BDNF fails to confer long-term survival to 
RGCs. Even though repeated intraocular injections of BDNF increase the number 
of viable RGCs, surviving RGC numbers after 6 weeks of treatment resemble 
those in untreated animals (Mansour-Robaey et al., 1994). In addition to 
intravitreal injection of purified BDNF, several other methods have been used to 
induce neuroprotection in injured RGCs. A trk oncogene-containing plasmid 
injected into the superior colliculus was reported to rescue axotomised RGCs 
from apoptotic death (Garcia-Valenzuela and Sharma, 1998).
Successful gene transfer and subsequent neuroprotection has also been 
demonstrated using electroporation in vivo. Mo and colleagues report that
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delivering mouse BDNF cDNA via electroporation into the eye of adult rats, 
prevented RGC apoptotic death, with 32.5% still alive 6 weeks after axotomy 
(Mo et a l, 2002). Delivering BDNF to intraorbitally axotomised RGCs by 
means of an adenoviral vector is also reported to promote survival (Isenmann et 
al, 1998). However this study does not shed any light on the reasons behind the 
lack of sustainability of BDNF neuroprotection. Assessment of survival was 
performed at a fairly early time point (14 days post lesion) thus providing no 
information regarding the sustainability of this effect. This appeared to have been 
out of necessity since the vector ceases to express after only 10 days, most likely 
due to immune system clearance, common with this type of vector (Wood et a l,
1996). Virally mediated expression appeared to be non-specific, giving rise to the 
possibility that the neuro-protective effect observed was a result of the delivered 
BDNF acting on either RGCs or Muller glia or both. A study published in the 
same year and using a similar adenoviral vector that targeted the delivery of 
BDNF to Muller glia for a period of 10 days, demonstrated some short lived RGC 
neuroprotection (Di Polo et a l, 1998). Neurotrophins, including BDNF, have 
been shown to directly activate intracellular signalling pathways in Muller glia 
(Wahlin et a l, 2000). This temporal nature of neuroprotection can be perceived 
as an indication that even though BDNF can inhibit the onset of the apoptosis 
following axotomy (Kermer et a l, 1999; Kermer et a l, 2000; Klocker et a l,
2000), it fails to completely block it (Cui and Harvey, 1995).
The fact that BDNF is expressed in uninjured RGCs and is upregulated following 
optic nerve axotomy, suggests that endogenous BDNF may contribute to a natural 
neuro-protective process (Gao et a l, 1997). BDNF is reportedly a blocker of the 
death inducing caspase CASP9 and a potent inhibitor of CASP3 phosphorylation 
(Kermer et a l , 2000; Klocker et a l , 2000). Endogenous upregulation of BDNF 
following axotomy, or exogenous BDNF delivery, can result in indirect adverse 
effects that hinder rather than promote survival. Firstly, BDNF can enhance the 
production of nitric oxide (NO) in the retina and its neuro-protective action can 
be enhanced its production is inhibited (Klocker et a l, 1998). However, the 
BDNF and NO relationship appears to be more complicated since inhibition of 
NO also causes the down-regulation of growth promoting signals, such as
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GAP43, which are known to be upregulated in response to BDNF (Klocker et a l ,
2001). Klocker and co-workers went on to propose that the mechanism by which 
BDNF controls the expression of growth promoting molecules involves NO and 
is separate to that involved in neuroprotection (Klocker et al., 2001). Another 
possible reason behind this transient nature of BDNF neuroprotection is that after 
axotomy, the capacity of RGCs to process and respond to this neurotrophin is 
compromised (Di Polo et al., 1998). After binding to theTrkB receptor, two major 
signalling pathways are involved in transducing the endogenous and exogenous 
BDNF signal: MAPK and PI3 kinase/Akt/PKB (Klocker et a l , 2000; Nakazawa 
et al., 2002). Axotomy induces a rapid decrease in TrkB mRNA synthesis, down 
to 50% that of intact retinas (Cheng et al., 2002). Notably, when TrkB expression 
is upregulated via AAV gene delivery combined with intravitreally delivered 
BDNF, 76% of RGCs remain alive 2 weeks after axotomy (Cheng et al., 2002). 
The same authors report that in this case, signal transduction is carried via the 
MAPK pathway only. It is therefore possible that when trkB receptors are 
saturated, a different downstream signalling pathway is involved in signal 
transduction (Isenmann et al., 2003). A recent study has assessed the expression 
levels of both full-length (TrkB.FL: 145KDa) and truncated (TrkB.Tl: 95KDa) 
TrkB receptors, following an optic nerve crush and/or exogenous BDNF delivery. 
Intravitreal BDNF delivery in normal animals has no effect on TrkB.Tl receptors 
but rapidly causes a significant and prolonged reduction in TrkB.FL protein. 
Optic nerve crush on its own, also resulted in TrkB.FL down regulation but was 
only apparent two weeks after axotomy, when 80-90% of RGCs had undergone 
apoptosis as expected. Combining the two treatments, resulted in down- 
regulation of TrkB.FL protein, comparable to that observed after the intravitreal 
delivery of BDNF in normal animals (Chen and Weber, 2004). It is therefore 
plausible that BDNF hinders its own ability to induce long term neuroprotection 
by quickly down regulating the levels of its high affinity receptor. Successful 
RGC survival might rely in combining BDNF with other neuro-protective 
molecules that utilises a different pathway for signal transduction such as CNTF 
(Chen and Weber, 2004).
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6.1.5.2 GDNF and Neurturin
GDNF (Lin et al., 1993) and Neurturin (Kotzbauer et al., 1996) members of the 
TGF-p super family, transduce their signals via initially binding to the a subunit 
of the GFRa co-receptor (Jing et al., 1996) and then activating the 
transmembrane tyrosine kinase c-Ret receptor (Trupp et al., 1996). Both GFRal 
and GFRa2 are responsible for mediating the signal from GDNF and NTN (Jing 
et al., 1996; Buj-Bello et al., 1997), even though each seems to demonstrate a 
preference for GFRal or GFRa2 respectively (Lin et a l, 1993; Airaksinen and 
Saarma, 2002). In the uninjured animal, Ret is expressed in the cell bodies and 
axons of a small proportion of RGCs, while co-localisation studies have revealed 
that only 14% of RGCs also express Ret even though TrkB is expressed by most 
RGCs (Jelsma et al., 1993). GFRal protein has also been detected in the plasma 
membrane of cell bodies and axonal fascicles of RGCs as well as Muller glia 
(Koeberle and Ball, 2002). In situ hybridisation studies show the presence of Ret 
mRNA and GFRal in RGCs while GFRa2 mRNA is localised in the inner 
nuclear layer (Jomary et al., 1999; Lindqvist et al., 2004).
Following an optic nerve transection, GFRal and GFRa2 mRNA levels in the 
retina increase 2 fold at 14 days after injury compared to normal levels. On the 
contrary, Ret mRNA levels in the retina decline steadily over 14 days following 
optic nerve transection and this time course appears to follow that of RGC death 
(Lindqvist et a l, 2004). What happens to mRNA or protein expression of either 
of these receptors with respect to RGCs is not clear from this report as total retina 
mRNA extracts were examined and no in situ hybridisation or 
immunohistochemistry was performed. In uninjured animals, GDNF mRNA is 
localised in the somata and axons of RGCs while protein levels are reportedly 
very low. Under normal conditions, GDNF mRNA was not detected in the 
superior colliculus, indicating that GDNF is not a target-derived factor in adult 
RGCs (Lindqvist et al., 2004). A sharp decline in GDNF mRNA in RGCs 
following optic nerve transection (Koeberle and Ball, 2002), suggests that the 
lack of GDNF might pay a role in the onset of RGC death following injury. 
Notably, the GDNF mRNA decline in RGCs is accompanied by an increased 
expression of GDNF mRNA in the superior colliculus (Lindqvist et al., 2004).
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This study suggests that GDNF might function locally within the retina as part of 
a neuroprotective mechanism that is initiated in response to injury. Just as is the 
case for BDNF, this neuroprotective effect appears to be transient, even if 
prolonged delivery of the factor is achieved. Intraocular (Klocker et al., 1997) or 
superior colliculus (Yan et a l, 1999) administration of purified GDNF is capable 
of rescuing axotomised RGCs in vivo in a dose dependent manner (Koeberle and 
Ball, 1998; Yan et a l, 1999) for up to 14 days after axotomy. Intravitreal 
transplantation of recombinant fibroblasts expressing GDNF was able to confer 
some degree of neuroprotection after optic nerve axotomy (Lindqvist et a l,
2004). In this study however, transplanting fibroblasts that do not express GDNF 
still results in neuroprotection. This could mean either that the presence of 
fibroblasts stimulates macrophage activation or that diffusible factors secreted by 
the cells themselves can protect axotomised RGCs. Exposure of axotomised 
RGCs to GDNF by means of an adenoviral vector over 14 days following injury, 
enhanced the survival of RGCs in a dose dependent manner (Schmeer et al,
2002). However, as this vector does not specifically target neurons, no 
conclusions can be drawn about whether the neuroprotection afforded by GDNF 
is a result of its direct effect on RGCs or an indirect effect mediated by other 
retinal cells, such as Muller glia which also express GFRal (Koeberle and Ball,
2002). It has been reported that GDNF can reduce glutamate excitoxicity in 
axotomised RGCs by increasing the expression of the glutamate/aspartate 
transporter in retinal Muller glia and astrocytes (Koeberle and Ball, 2002). The 
hypothesis that GDNF does not exert its effect by directly acting on RGCs might 
explain why neuroprotection afforded to GDNF-treated RGCs in vivo, is not 
mirrored in vitro using purified RGC cultures (Meyer-Franke et a l, 1995).
When GDNF and BDNF are simultaneously delivered to the superior colliculus, 
they appear to rescue axotomised RGCs in an additive and not synergistic manner 
(Yan et a l, 1999). This could indicate that they act through separate mechanisms. 
Interestingly, the neuroprotective effect of GDNF is dependent on the PI3K 
pathway while its ability to induce neurite sprouting depends on the MAP 
pathway (Ho et a l, 2000). On the contrary, BDNF neuroprotection involves 
either the PI3K or ERK pathways, depending on the type of cellular injury and
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death signals involved (Hetman et al., 1999). Additionally, sole intraocular 
administration of neurturin has been shown to rescue 33% of axotomised RGCs 
from apoptosis at 14 days post lesion (Koeberle and Ball, 2002). In the same 
study, the combined intraocular delivery of neurturin and BDNF appeared to 
confer stronger neuroprotection than when combining either neurturin and GDNF 
or GDNF and BDNF (Koeberle and Ball, 2002). Neurturin, GDNF and BDNF 
could therefore display an additive effect in promoting survival because they 
transduce independent signals not only in axotomised RGCs but also in other 
retinal cells.
6.1.5.3 CNTF
The effects of CNTF are mediated via a receptor complex consisting of the ligand 
binding, non-signalling, a  subunit of the CNTF surface receptor (CNTFRa ) and 
the LIFR and gpl30 signal transduction subunits (Stahl and Yancopoulos, 1994). 
Both CNTF and CNTFRa are involved in the development and differentiation of 
RGCs (Ip et al., 1993). In the normal adult retina, CNTF immunoreactivity is not 
detected in RGCs, in contrast to the strong labelling found in astrocytes and weak 
signal in Muller glia (Kirsch et a l , 1997; Ju et a l , 1999; Sarup et a l , 2004). 
CNTFRa immunoreactivity is also absent in the normal adult retina while LIFR 
labelling is present in RGCs and Muller glia (Sarup et a l , 2004). One to three 
days following optic nerve transection, CNTFRa is sharply upregulated in RGCs 
with LIFR levels remaining unaltered while CNTF expression is increased in 
Muller glia and astrocytes (Sarup et a l , 2004). The CNTFRa upregulation in 
RGCs following axotomy indicates that they could be responsive to the signals 
transduced by CNTF. Since CNTF is also upregulated after axotomy but RGC 
apoptotic death still occurs, it is possible that endogenous CNTF production is 
not enough to promote regeneration or survival. Therefore, exogenous delivery of 
CNTF could theoretically overcome this problem.
In vitro studies have demonstrated the ability of CNTF to rescue RGCs from 
apoptotic death and induce neurite elongation (Lehwalder et a l , 1989). However, 
the ability of exogenously delivered CNTF to enhance survival and regeneration 
in axotomised RGCs is less clear as the available litterature contains
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contradictory reports. In terms of regeneration, repeated intravitreal injections of 
CNTF but not BDNF, FGF2, NGF, NT3 or NT4, allowed regeneration of 
intracranially or intraorbitaly axotomised RGCs into a peripheral nerve graft (Cui 
et a l, 1999; Cho et al., 1999a). Cho and colleagues (Cho et a l, 1999a) report that 
the effect of CNTF is dose dependent (Cui et a l, 1999). This regenerative ability 
of CNTF is closely correlated to the observed upregulation of GAP43 (Cho et al, 
1999a) and c-Jun (Lu et a l, 2003) in the RGCs that regenerate their axons into 
the periferal graft (Jo et a l, 1999). More relevant to the experiments employed in 
this study, it was shown recently that multiple intravitreal injections of CNTF 
enable a significant mumber of axotomised RGCs to regenerate their axons into 
the distal stump of a crushed optic nerve (Cui et a l, 2004). However, a single 
intravitreal injection of CNTF has proven unsufficient to promote regeneration of 
axotomised RGCs past an optic nerve crush (Leon et a l, 2000).
In terms of cell death in vivo, intravitreal delivery of recombinant CNTF, 
enhances RGC survival 2-3 fold, three weeks after axotomy, although this effect 
diminishes after 7 weeks (Mey and Thanos, 1993; Meyer-Franke et a l, 1995). 
Another group have reported that repeated intravitreal injections of CNTF fail to 
rescue RGCs from axotomy induced apoptosis following intraorbital or 
intracranial optic nerve crush (Cui et a l, 1999; Cho et a l, 1999a). However a 
recent study from the same laboratory claims that such an injection regime does 
lead to significant RGC survival, especially when accompanied with elevated 
levels of cAMP (Cui et a l, 2003b). This discrepancy between the two reports 
may be due to the different method used in assessing surviving RGC numbers, 
even though the authors do not address this possibility.
More confusion arises when recent gene delivery experiments are considered. In 
a set of experiments, a secreted form of CNTF (Sendtner et a l, 1992), delivered 
by means of an adenoviral vector, was reported to rescue RGCs from axotomy 
induced apoptosis but failed to promote regeneration into a peripheral nerve graft 
(Weise et a l, 2000). However, the involvement of Muller glia, which upregulate 
CNTFRa following axotomy, cannot be discounted given the fact that this vector 
does not display a neuron specific delivery. Also, intravitreal delivery of this type 
of vector can cause the activation of macrophages which, since they also secrete
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survival factors (Barouch et a l , 2001a), would mask the specific effects of 
CNTF. This could explain why the authors found a significantly higher 
neuroprotective effect after intravitreal rather than optic nerve delivery. 
Nevertheless, it has also been reported that CNTF delivery via a self inactivating 
lentivirus vector to RGCs, also promoted survival (van Adel et a l , 2003). It is 
possible that the inconsistencies in the literature reflect differences between the 
effects of exogenously delivered CNTF versus endogenously produced CNTF 
facilitated by gene delivery approaches. After all, intravitreal delivery of purified 
neurotrophic factors may not be the best mechanism to assess their function since 
they have a very short half-life and multiple and frequent injections are required. 
This could further compromise the eye and can make results harder to interpret. 
The exact mechanism by which CNTF exerts its effects is not fully understood. 
For example it is not known whether CNTF is secreted from Muller glia and 
astrocytes after axotomy and translocated to RGCs (Sarup et a l , 2004). The fate 
of CNTFRa in RGCs after axotomy is also elusive. Davis and colleagues 
hypothesise that CNTFRa, might function as a soluble mediator for CNTF since 
it can be released from the cells in response to injury (Davis et a l , 1993).
6.1.5.4 NGF
Unlike the extensively studied effects of BDNF on neuroprotection of axotomised 
RGCs, the precise role of NGF as a survival factor for RGCs is unclear, with 
contradicting reports regarding its efficiency. NGF mRNA is present in adult 
RGCs and their targets (Lauterbom et a l , 1994), while its high affinity receptor 
TrkA appears to be absent from adult RGCs (Cui et al., 2002). Following 
axotomy, TrkA levels are upregulated for a brief period (3-5 days post lesion), 
but rapidly decrease over the three weeks following the lesion (Cui et a l , 2002). 
Repeated intraocular delivery of NGF in neonatal and adult rats can reportedly 
confer neuroprotection for 7 weeks following intracranial optic nerve transection 
(Carmignoto et a l , 1989). However, several studies have failed to conclusively 
reproduce this finding either in vitro (Cohen et a l, 1994) or in vivo (Cui and 
Harvey, 1995). Because of this, exogenous delivery of NGF on its own is 
unlikely to be beneficial for either survival or axonal regeneration.
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6.1.5.5 NT3 & NT4
NT3 and low levels of its high affinity receptor TrkC, have both been localised in 
the normal adult rodent retina (Allendoerfer et a l, 1994; Cui et a l, 2002). 
Following axotomy, TrkC expression is upregulated in injured RGCs and after 
reaching its maximum after 5 days, high level expression is maintained for the 
next 3 weeks (Cui et a l, 2002). When axotomy is accompanied by an intravitreal 
transplantation of an optic nerve segment, regenerating RGCs express even 
higher levels of TrkC (Cui et a l, 2002). However, NT3 delivery alone seems to 
have only a minimal influence on rescuing adult axotomised RGCs from 
apoptosis in vitro (Cohen et a l, 1994), and no effect in vivo (Peinado-Ramon et 
al, 1996). Intravitreal delivery of NT3 fails to promote axonal elongation 
following either an intraorbital or intracranial optic nerve lesion (Cui et al,
1999). NT4 shares its TrkB receptor with BDNF and has been shown to promote 
the survival of RGCs and neurite outgrowth in vitro (Cohen et a l, 1994; Bosco 
and Linden, 1999). The fact that co-administration of BDNF and NT4, even at 
saturating concentrations does not augment the survival effect of either of these 
factors alone in vitro, indicates that they act via the same TrkB-mediated 
mechanism (Bosco and Linden, 1999) in rescuing RGCs in vitro. In vivo, NT4 
can rescue axotomised RGCs but the effect is transient even when prolonged 
delivery is achieved via the use of minipumps (Clarke et a l, 1998). As far as 
axonal elongation is concerned, intravitreal delivery of NT4 is not effective in 
enabling RGC axon regeneration after intracranial or intraorbital optic nerve 
transection (Cui et a l, 1999).
Even though delivery of either NT3 or NT4 alone fails to avert apoptotic death or 
regeneration (Cui et a l, 1999), both seem to contribute to RGC survival when 
they are used in combination with other neurotrophic factors such as BDNF, 
CNTF and FGF. For example, the use of a gene activated matrix to deliver a 
combination of NT3, FGF2 and BDNF promotes and sustains the survival of 
axotomised RGCs for a period of 3 months (Berry et a l, 2001). Following this 
study, the authors reported briefly that fibroblasts engineered to express either 
FGF2, NT3 or BDNF, promote axonal regeneration of axotomised RGCs (Logan 
et a l, 2002). Either of these factors on their own only marginally increased
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regeneration with no axons extending past the lesion site. In animals that received 
all three neurotrophins, GAP43 positive RGC axons were reported to elongate up 
to 5 mm into the distal stump. However this response seems to disappear after 20 
days (Logan et al., 2002). It would therefore appear useful to include NT3 and 
NT4 among a cocktail of neurotrophic factors in order to assess survival and 
regeneration of axotomised RGCs.
6.1.5.6 bFGF
Basic FGF (bFGF or FGF2) is a well characterised member of the large family of 
fibroblast growth factors and is reportedly a potent stimulator of neurite extension 
in embryonic and postnatal RGCs in vitro (Bahr et a l, 1989; Dingwell et al.,
2000). bFGF transduces its signal via the FGF-1 receptor (FGFR-1), which is 
required for the correct formation of retinal projections (Brittis et al., 1996). FGF 
has a high affinity for heparan sulphate proteoglycans (HSPGs) and requires the 
presence of heparan sulphate in order to activate the FGFR-1 receptor (Lin et al.,
1999). In the uninjured adult mammalian retina, bFGF has been localised to 
Muller glia, the retinal ganglion layer and to the inner and outer nuclear layers 
(Gao and Hollyfield, 1992; Ohsato et al., 1997). Even though FGFR-1 and HS 
have been localised to adult RGCs (Sapieha et al., 2003), bFGF is absent from 
both axons and RGC somata (Kostyk et al., 1994). This is an indication that 
RGCs have the potential to respond to the presence of FGF. Following axotomy, 
bFGF is upregulated not only in the GCL and the INL of the retina (Cao et al., 
1997b), but also in the lesioned optic nerve itself (Wen et al., 1995) and 
specifically in the glia around the lesion site (Sapieha et al., 2003). However, 
bFGF is not upregulated in injured RGCs (Kostyk et al., 1994; Sapieha et al.,
2003). The FGFR-1 receptor is only marginally upregulated following a 
mechanical injury in the retina (Cao et al., 1997b) but no reports as yet detail its 
fate after RGC axotomy. It has been suggested that Muller cells in vivo also 
respond to the available bFGF by producing even more bFGF, regardless of 
whether it is released from endogenous stores or delivered exogenously (Cao et 
al., 1997a). bFGF has been shown to promote survival and neurite extension in 
adult rat, retinal explant cultures (Bahr et al., 1989). Intravitreal, AAV mediated
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delivery of bFGF, has been shown to stimulate only transient survival (up to 2 
weeks post injury) and a limited axonal elongation of RGCs (less than 1 mm past 
the lesion site) after an optic nerve crush (Sapieha et a l , 2003). The authors 
discount the possibility of a macrophage-mediated response as a result of lens 
damage, though these observations are stated as unpublished. In another report, 
intravitreal delivery of bFGF was reportedly not sufficient in promoting axonal 
elongation in vivo (Cui et al., 1999). It is possible however that the bFGF levels 
declined too quickly for it to be effective due to the short half life of bFGF 
(Culajay et a l, 2000; Sapieha et al., 2003). Again, as has been the case with all 
the neurotrophic factors examined so far, sole bFGF is not sufficient to promote 
permanent and meaningful survival or regeneration. When used in combination 
with other neurotrophic factors, its effects are augmented (Berry et a l, 2001; 
Logan et a l , 2002) and it would therefore make a worthy component of a group 
of exogenous delivered factors to injured RGCs.
6.1.6 Rationale
This chapter was designed to test the hypothesis that if the axonal regeneration of 
RGCs is dependent on the presence of a combination of growth promoting 
molecules then by transducing injured RGCs to synthesise a cocktail of 
neurotrophin expressing vectors (rBDNF, mCNTF, rGDNF, rNTN, bFGF), it 
may be possible to enhance the regenerative response mounted by injured RGCs. 
This could be measured in terms of regeneration of axotomised RGCs into and 
through the lesion site. In order to test this hypothesis, a number of different 
combinations of neurotrophin expressing vectors were tested for their ability to 
promote axonal regeneration. Their effect was compared to either uninjected 
animals or animals injected with control vectors expressing GFP or LacZ marker 
proteins. It was also hypothesised that if there is a correlation between the pattern 
of transgene expression in RGCs and the severity of IE gene deletions, then 
utilising a less disabled construct, such as HSVl.RLl+/pR19CMV or 
HSVl.ICP27+/RLl+/pR19CMV, may lead to a more efficient transgene 
expression in these neurons. This could in turn translate into measurable 
difference in both longer and more widespread transgene expression compared to 
the more disabled HSVl.pR19CMV construct.
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6.2 Methods
6.2.1 Vectors used for RGC regeneration experiments
A variety of viruses were used in this study, either to induce regeneration or for 
the delivery of marker genes to injured or uninjured animals.
V irus A b brev ia tion
1764/IC P277IC P47pR l 9CM VLacZ HSV 1 .pR l 9CM VLacZ
17 6 4 /IC P 27 /IC P 4 /pR l 9CM VGFP HSV  1 .pR l 9CM VGFP
1764/ICP277ICP47pR 19CM  VratBD NF HSV1 .pR19CM VrBDNF
176 4 /IC P 27 /IC P 4 /pR l 9CM VratNT3 H SV 1 .pR l 9CM VrNT3
1764/ICP277ICP47pR 19CM Vm urineCNTF HSV1 .pR19CM Vm CNTF
1764/ICP277ICP47pR 19CM  VratNeurturin H SV  1 .pR l 9CM VrNTN
17 6 4 /IC P 27 /IC P 4 /pR l 9CM VratGDNF H SV 1 .pR l 9CM VrGDNF
1764 /IC P 27 /IC P 4 /pR l 9CM VratFGFb H SV  1 .pR l 9CM VrFGFb
1764/ICP27+/IC P47R L 1 +/pR l 9CM VLacZW PRE H SV 1.27+/R L 1 +/pR  19CM  VLacZ W PRE
F ig u re  6.2.1-a: V ecto rs used in R G C  reg e n ra tio n  stud ies.
The construction and characterisation of vectors HSVl.pR19CMVrNT3 (Chapter 
4), HSV1 .pRl9CMVmCNTF and HSVl.pR19CMVrBDNF (Chapter 5) has been 
described. Constructs HSVl.pR19CMVrGDNF, HSVl.pR19CMVrNTN, and 
HSVl.pR19CMVrFGFb were produced by Dr B. Haupt (Dept, of Immunology 
and Molecular Pathology, UCL). Vector HSV1.27+/RLl+/pR19CMVLacZWPRE 
was constructed by Dr J.A. Palmer in our laboratory.
6.2.2 Injections in the superior colliculus
Adult female Lewis rats (180-250g) were kept under stable anaesthesia using 5% 
Halothane, delivered by Oxygen throughout the procedure. An incision was made 
along the midline to expose the cranium. Using a stereotaxic frame to hold a fine 
drill, the brain was exposed. The dura mater was pricked without crushing the 
tissue it protects and using a 25 pi Hamilton syringe with a 33-gauge stainless 
steel needle (RN7762-06), 5-8 pi of the virus was stereotaxically injected at a rate 
of 0.5 pl/min using a micro pump. The following coordinates were used: rostral- 
caudal 5.5 mm, medial-lateral 2.0 mm, dorsal-ventral 3.0 mm (Paxinos, 1994). 
The virus was allowed to diffuse for a further 10 minutes prior to removing the 
needle. A piece of sterile gel-foam was placed on top of the craniotomy and the 
skin was sutured.
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6.2.3 Injections in the optic nerve
Adult Lewis rats, 6-8 weeks old and weighing between 180-250 g were used for 
these experiments. The left optic nerve of each animal was exposed by means of 
a parasaggital 10-15 mm long incision above the eye and halfway between the 
upper eyelid and the midline. The deep facia, medial to the orbital contents was 
incised close to the skull, immediately anterior to and in line with the temporal 
crest. Dissection was continued, using forceps, in the plane between the skull and 
the hardenian gland. The most anterior part of the fleshy origin of the temporalis 
muscle, which encroaches into the orbital region, was scraped away, in an 
anteroposterior direction. The cone of the extraocular muscles was brought into 
view by further blunt dissection between the hardenian gland and the smaller 
darker intraorbital lacrimal gland (Kieman, 1985). Snipping these tissues exposed 
the optic nerve.
A slit of 1-1.5 mm was made dorsally in the dural sheath of the optic nerve using 
fine micro scissors. Using a 0.5 ml (29G) insulin syringe needle, the pia mater 
and arachnoid were carefully pricked to leave a fine slit of about 0.5 mm on the 
dorsal surface of the optic nerve. A fine glass micropipette, with a tip diameter of 
approximately 200 jam, was then inserted into the optic nerve proper using a 
micromanipulator. Using a micro pump holding a 10 pi Hamilton syringe 
attached to the glass micropipette with fine plastic tubing, 2.5 pi of vector was 
slowly injected into the optic nerve at a rate of 0.1-0.2 pl/min. After a wait of 5 
min, the micropipette was inserted 0.5 mm deeper into the optic nerve whereupon 
a further 2.5 pi of vector was injected. After a further wait of 5 min, the 
micropipette was slowly withdrawn, the area was cleaned and the skin was 
sutured. The integrity of the retinal blood supply was confirmed postoperatively 
by inspection of the retinal and iris vasculature, which derives its blood supply 
directly from the ophthalmic artery. An impeded blood supply to the retina can 
affect the survival of retinal ganglion neurons and interfere with attempts for 
optic nerve regeneration (Tilgner, 1968).
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6.2.4 Optic Nerve Crush
The left optic nerve was exposed as described in the previous section. The dural 
sheath of the optic nerve was opened with microscisors and the optic nerve was 
crushed for 20 seconds with fine No.7 curved forcepts -1-1.5 mm behind the 
eyeball. The ophthalmic artery was identified at operation within the optic nerve 
sheath and was not damaged during surgery. Ocular vasculature was was checked 
as described in the previous section. Animals were allowed to survive between 3 
and 21 days post crush, after which they were transcardially perfused with 4% 
(w/v) paraformaldehyde (Chapter 2).
6.2.5 Tracing of retinal axons
Three days prior to sacrifice, 5 pi of 1% cholera toxin subunit B (CTB) tracer was 
slowly injected using a 5 pi Hamilton syringe into the vitreous body of the left 
eye, avoiding the lens structure. Following perfusion with 4% (w/v) 
paraformaldehyde, retinas were carefully extracted and examined as wholemount 
preparations for the presence of GFP or LacZ. Brains were extracted, 
cryoprotected, cut into 70 pm sections using a freezing microtome and processed 
for marker gene expression. Optic nerves were embedded in paraffin wax and cut 
into 12 pm sections, which were then processed for CTB.
6.3 Results
6.3.1 Identification of suitable vector administration route
Based on previous experiments in the spinal cord (Chapter 3), it was decided that 
the vector most appropriate for transgene delivery to RGCs was 
HSVl.pR19CMV (1764/ICP277ICP47pR19CMV). This vector demonstrated the 
optimum long term delivery to the spinal cord or brain, as transgene expression 
was significantly more efficient than that achieved with vector HSV1/P2' 
.pR20.5vhs (Lilley et al., 2001b).
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In order to determine the ability of the HSVl.pR19CMV backbone to transduce 
RGCs, vectors expressing either the LacZ or GFP marker genes were delivered to 
the superior colliculus. The rationale behind this was to exploit the innate ability 
of HSV 1 to be retrogradely transported to the somata of RGCs and allow them to 
express the transgene in a specific manner. This route of administration would be 
ideally suited for assessing the effects of neurotrophins in the injured optic nerve 
paradigm, as it would exclude any interference caused by the effects of an 
intravitreal delivery such as a macrophage response or any non-specific 
tranduction of other retinal cells such as Muller glia. Intravitreal and sub-retinal 
delivery of HSVl.pR19CMVLacZ and HSVl.pR19CMVGFP was assessed but 
no transduction of neurons was achieved. A very small number of Muller glia 
was transduced (no more than 10-20 per retina) via intravitreal injection but not 
enough to warrant further exploration of this route of administration (results not 
shown).
Wild type HSV1 does cause a strong immune response when injected into the 
anterior chamber of the eye (Ganatra et a l , 2000). However the 
HSVl.pR19CMV vector is highly disabled and there is no evidence from our 
studies in the spinal cord and brain that it is associated with a detrimental immune 
response. It has also been reported that even for minimally disabled HSV1 
vectors, an inflammatory response is initiated when the lens structure is damaged 
and that this response subsides 3-10 days after delivery (Spencer et al., 2000). No 
lens injury was inflicted in these experiments. Also, the fact that infected RGCs 
efficiently express the transgene for at least 20 days, even in the case of LacZ, 
which has itself been associated with an inflammatory response (Isenmann et a l ,
2001), is an indication that such a response is not a major factor affecting 
transgene expression from this vector. 5 xlO6 pfu of HSVl.pR19CMVLacZ were 
injected into the superior colliculus of a group of animals (n=ll). Expression of 
the transgene was assessed in wholemount retinas and in brain sections.
As shown in Figure 6.3.1-a (panel A), the virus enters the RGC axon terminals 
projecting to the superior colliculus and is retrogradely transported to RGC 
somata. Transgene expression is evident at 20 days post injection and LacZ
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staining can be seen throughout the length of the transduced axons. In the retinal 
ganglion cell layer, only RGCs are found to express the transgene (Figure 6.3.1-a, 
panel B). This was expected as expression can only occur in the somata of 
neurons projecting to the superior colliculus where the viral injection took place, 
which is expected since the vector is incapable of replicating. It cannot therefore 
exit the RGC somata and infect other neurons or glial cells within the retina itself. 
Additionally, the vector does not demonstrate a preference for specific RGC 
morphological classes. Types I, II and III are equally transduced (Figure 6.3.1-c). 
Examples of all three morphological types of RGCs were successfully transduced 
in both central and peripheral retina. In terms of examining responses to 
neurotrophic factors, the fact that all RGC types are transduced can be an 
advantage as it allows the possibility of targeting the maximum number of RGCs. 
No difference in the regeneration capacity of the three different RGC types in 
rodents have been reported but it has been suggested that due to the eccentric 
organisation of RGCs within the retina, central RGCs are more susceptible to 
axotomy induced death during an optic nerve crush (Yan et al., 1999). Notably, 
the co-localisation of transduced RGCs is directly related to the stereotaxic co­
ordinates of the injection procedure (Figure 6.3.1-a, panel C). In this example, 
two separate injections of vector into two different sites in the superior colliculus 
led to two patches of densely packed, transduced RGCs. As RGCs display a 
topographic organisation throughout the visual pathway, injecting the superior 
colliculus at different rostro-caudal sites allows the targeting of specific groups of 
RGCs. This further demonstrates that this vector’s characteristics allow for 
specific neuronal targeting.
The efficiency of transfection achieved with HSVl.pR19CMVLacZ (Figure 
6.3.1-a), is replicated when GFP (Figure 6.3.1-b) is delivered by the same 
backbone. Hoewever, in order to establish a baseline for these vectors in the 
retinotectal system, it was decided to use the LacZ expressing vectors as they 
provide a permanent record and allow for easier microscopic examination of 
transduced cells.
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F igu re  6.3.1-a: D elivery o f L acZ  to  R G C s v ia re tro g ra d e  H S V .pR 19C M V  tra n sp o r t.
A. P arasag itta l, 70pm  section , sho w in g  the in jec tion  site  (* ) o f  H S V .p R 1 9 C M V L acZ  into the 
rostral su p erio r co llicu lu s ( f )  o f  a sing le  an im al. R G C  ax o n s are  filled  w ith  L acZ  th ro u g h o u t the ir 
length and  are  seen  co u rs in g  th rough  the  o p tic  ch iasm  ($ ) and  te rm in a tin g  in the  op tic  tha lam us 
(▼ ) and su p erio r co llicu lu s ( t ) .  B. S tab le  ex p ressio n  in tran sd u ced  R G C s is o bserved  a t 20  days 
p.i. on a  w h o lem oun ted  re tina . L acZ  ex p ressio n  can  be seen  in th e  cell bod ies  o f  R G C s in the 
gang lion  cell layer and  the ir axons rad ia tin g  to w ard s  the  o p tic  d isc  (cen tre  b o ttom ) w ith in  the 
fibre layer. C . R etinal w h o lem oun t d isp lay in g  dense  seg reg a ted  p a tches o f  tran sd u ced  R G C s and 
the ir axons, d em o n stra tin g  tha t to p o g rap h ic  d e liv ery  to  R G C s can  be ach iev ed  by tw o  separa te  
in jections o f  H S V .pR 19C M V L acZ  a t tw o  d iffe ren t sites w ith in  the  su p e rio r co llicu lu s o f  the sam e 
anim al. Scale  bars: A = 2 0 0 0 p m ; B = 500pm ; C = 2 5 0 p m .
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F ig u re  6.3.1-b: G F P  tra n sd u c tio n  o f  R G C s v ia H S V .pR 19C M V  v ec to r  re tro g ra d e  tra n sp o r t.
A. G F P  postive  axons close  to  the  in jec tion  site  (* ) o f  th e  H S V .p R 1 9 C M V G F P  vec to r into the 
su p e rio r co licu lu s show n in a  parasag itta l, 70pm , b rain  sec tion . B. show s th e  o rig in  o f  these  axons 
as G F P  positive  R G C s in a  re tina l w h o lem o u n t 20 days p.i. S cale  bars: A =50pm ; B=20pm .
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F igu re  6.3.1-c: D ifferen t classes o f  R G C s a re  tran sd u c ed  by H SV .pR 19C M V .
All th ree  c lasses  o f  R G C s w ere tran sd u ced  by  H S V .pR 19C M V L acZ  vecto r in jected  into the 
superio r co llicu lus. L acZ  exp ression  is s trong ly  m ain ta ined  at 20 days post-in jec tion . A &  B: 
T ype I R G C s, charac te rised  by th e ir  rad ia tin g  b ranch ing  pattern  o f  long prim ary  dendrites. C & 
D: T ype II R G C s recogn ised  by th e ir  sh o rt p rim ary  dend rites w ith  m any  sp iny  branches. E . T ype 
III R G C s, h ave  fine, long  p rim ary  d end rites  w ith  very  few  branches. Scale bars: A, B and 
E = 1 0 0 |im ; C  and  D = 25pm .
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63.2  Effect of vector delivered neurotrophins on axotomised RGCs
The beneficial effects o f a combinatorial treatment in inducing regeneration and 
neuroprotection of axotomised RGCs has been established in the introductory 
section of this chapter. The possibility of inducing such an effect on axotomised 
RGCs when delivering a mixture of neurotrophic and neuroprotective factors by 
means of the current HSVl.pR19CMV vectors was assessed. This study 
represents a quantitative rather than qualitative study. Therefore, the effects of 
administering the mixture as a whole, rather than the individual factors 
composing it, were examined.
Healthy animals (n=8) were injected with a mixture of vectors, each expressing 
one neurotrophic factor: HSVl.pR19CMVrBDNF, HSVl.pR19CMVmCNTF, 
HSV 1 .pRl9CMVrbFGF, HSVl.pR19CMVrGDNF, HSVl.pR19CMVrNT3 or 
HSV 1 .pRl 9CMVrNTN. The cocktail, proportional for each neurotrophic factor, 
was delivered via multiple stereotaxic injections into the superior colliculus. In 
order to ensure that any positive effect observed was not a consequence of the 
vector backbone itself, animals (n=3) were injected with HSV.pR19CMVLacZ 
vector alone and subsequently treated identically to the cocktail-treated 
experimental animals. Three days after injection, allowing for retrograde 
transport and transgene expression to take place, the optic nerve was crushed. 
Animals were sacrificed 33 days post lesion and optic nerves were examined for 
anterogradely labelled, regenerating, and GAP43 positive axons.
In some animals that received the cocktail of neurotrophins, a number of RGC 
axons can be seen regenerating through the lesion site and into the distal stump 
(Figure 6.3.2-a). In the course of these studies different cocktails were used. Their 
effects with regards to regenerating axon numbers are varied (Table 6.3.2-a). For 
example, in one animal (#5), in a single 12 pm longitudinal section of an optic 
nerve that was crushed following the administration of the neurotrophin cocktail, 
24 CTB-labelled regenerating axons were found within the lesion site. In the 
distal stump, 17 axons were counted at 300 pm past the lesion site, 3 axons at 600 
pm and 1 axon at 1 mm. With the assumption that the diameter of the crush optic 
nerve is about 600 pm, an approximate estimate of the number of regenerating
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axons in an entire optic nerve would therefore be 1200 in the crush site, 850 at 
300 pm past the lesion site, 150 at 600 pm and 50 at 1mm. Many of the 
regenerating axons were found in bundles. This may be due to the ability of 
HSV.pR19CMV to transduce clusters of RGCs that project to specific regions of 
, the superior colliculus. Of course, this estimation assumes a uniform distribution 
of RGC axons in the optic nerve.
Regenerating RGC axons, found crossing the lesion site into the distal stump, are 
strongly expressing GAP43. This is further confirmation of their regenerating 
status. For example in a single 12 pm thick longitudinal section of the optic nerve 
of one animal (#2, see Figure 6.3.2-b panel A), there were 28 GAP43 
immunopositive axons in the crush site. Out of these, 14 were found at 300 pm 
and 1 was found at 1 mm into the distal stump (Figure 6.3.2-b). An approximate 
estimate of the number of GAP43 regenerating RGC axons per optic nerve would 
be as follows: 1400 in the crush site, 700 at 300 pm and 50 at 1 mm into the 
distal stump. Both CTB and GAP43 positive RGC axons displayed a variety of 
morphological features. They were usually beaded with irregural, non-straight 
course while some appeared to curve sharply and give rise to short branches 
(Figure 6.3.2-b). Regenerating GAP43 axons were also found in the pia matter 
(#1, Figure 6.3.2-b, panel B, inset). On the contrary, injection of 
HSV.pR19CMVLacZ prior to injury, does not promote RGC regeneration 
(Figure 6.3.2-a). In a single section, only 6 axons were counted as having entered 
the lesion site and none were found into the distal stump. This is expected as 
axotomy-induced apoptosis claims the majority of injured RGCs by the end of 
two weeks.
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Table 6.3.2-a: Neurotrophic factor expressing vector cocktail used.
Total num ber o f  anim als treated with com binations o f  neurotrophic factor expressing vector: n=8
Total num ber o f  animals that received vector encoding the LacZ m arker protein: n=3
Total num ber o f  anim als not treated w ith any vector: n = l
All the above anim als (n=12) received an optic nerve crush
f  N um ber o f  regenerating axons found
* 1-5 axons per section
** 6-10 axons per section
*** 11-19 axons per section
**** >  20 axons per section
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Bright field (i)
Proximal________ Crush Site_______ Distal
k * *
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Figure 6.3.2-a: Regeneration of in jured  R G C s by vec to r delivered BDNF, C N TF & NTN.
Dark-field (Ai, Bi, Ci) and phase-contrast (Aii, Bii, C ii) images o f  CTB-labelled RGC axons 
show minimal regeneration in non-vector injected animals (Ai &Aii) and in animals injected with 
the control, LacZ vector (Bi & Bii). However, in animals treated with a cocktail o f  neurotrophin 
vectors (Ci & ii) there are significantly more regenerating axons (T) and they have grown further 
into the lesion site and distal stump than those in control animals. For example, in single 12pm, 
longitudinal optic nerve sections, the LacZ vector treated animal (Bi & Bii) revealed only 6 axons 
in the distal stump, whereas the neurotrophin vector treated animal displayed 24 axons in the 
crush site and 17 axons in the distal stump. These sections from non-injected, LacZ vector 
injected and neurotrophin vector injected animals represent animals c4, c2 and 5, respectively in 
Table 6.3.2-a. Dotted line represents the border between proximal stump o f  optic nerve on the left 
and lesion site on right. (Note: Even though control animals were injected with 
HSV.pR19CMVLacZ, it was not possible to react the tissue for LacZ detection, as the product is 
lost during the paraffin embedding procedure preceding optic nerve sectioning.) Scale bars: 
A= 100pm; Bi and Ci= 100pm; Bii and Cii= 100pm.
Phase Contrast (ii)
Proximal________ Crush Site_______ Distal
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Crush Site
Proximal Distal
Figure 6.3.2-b: GAP43 expression in regenerating  R G C  axons.
Bright-field (A) and dark-field (B) micrographs o f  a section through the crush site and distal 
stump o f an optic nerve o f an animal (#2, Table 6.3.2-a) treated 30 days previously with vectors 
expressing rBDNF, mCTNF, bFGF and rGDNF. This animal demonstrates substantial 
regeneration o f  GAP43 immunopositive RGC axons (arrowheads) through the crush site and up to 
a distance o f 600pm into the distal stump. C. shows a dark-field image o f  GAP43 positive, 
regenerating RGC axons in the distal optic nerve stump (right), and in the pia mater (arrowheads) 
in animal #5 in table 6.3.2-a, * crush site. Scale bars: A and B= 100pm; C=250pm.
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6.3.3 Delivery to RGCs via HSVl.pR19CMVwPRE vector
In addition to the need for both neuroprotective and regenerative signals, another 
element thought to contribute to successful regrowth of axotomised RGCs is the 
actual levels at which these factors are present. Even though the vector appears to 
give a good marker gene expression for both LacZ and GFP, it is not possible to 
correlate this with actual transgene mRNA levels. Also, in the animals shown 
here, direct estimation of neurotrophic factor expression was not possible due to 
either lack of reliable antibodies or unsuitability of the tissue for protein 
extraction methods. All animals receiving neurotrophin encoding vectors also 
received an intravitreal injection of tracer. This procedure renders the retina less 
than adequate for the demonstration of neurotrophin mRNA levels by in situ 
hybridisation or alterations in protein expression by immunohistochemistry.
A new vector was recently developed in our laboratory, which even though less 
disabled, still showed minimal cytotoxicity and good transgene expression. The 
vector, termed HSV1.27+/RLl+pR19CMVwPRE, is not deleted for ICP27 or 
ICP34.5 and incorporates the post transcriptional regulatory element WPRE that 
has been shown in our hands (unpublished observations) and in other vector 
systems to enhance gene expression (Zufferey et a l , 1999). The Woodchuck 
Hepatitis Virus (WHV) post-transcriptional regulatory element (WPRE), inserted 
at the 3’ end of the transgene is normally required for the accumulation of wild 
type viral mRNAs (Donello et a l, 1998) and has previously been shown to 
enhance transgene expression in other vector systems both in vitro (Zufferey et 
a l, 1999; Loeb et a l, 1999) and in vivo (Patema et a l, 2000; Klein et a l, 2002; 
Glover et a l, 2003; Hlavaty et a l, 2005). Therefore it could, in theory, result in 
even higher transgene mRNA levels with HSV1 based vector systems. This has 
been shown to be true in our in vitro studies utilising these vectors (manuscript 
submitted). It was decided to assess whether this combination of backbone 
deletions would transduce a higher number of RGCs via superior colliculus or 
direct ON injection and whether the inclusion of the WPRE element would 
increase transgene expression levels. This vector was easier to propagate in 
culture and thus higher titres were obtained.
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Optic
chiasm
F igure  6.3.3-a: HSV1.277RLl+/pR19CMVLacZwpRE m ed ia ted  tra n sd u c tio n  o f R G C s via a 
single su p e rio r  colliculus in jection .
W hole mount preparations dem onstrating strong LacZ staining in large clusters o f  RGC somata, 
dendrites and axons in the retina (A) and in RGC axons throughout the optic nerve and chiasm 
(B). Scale bars: A and B=500pm.
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Injection site
-  .  ' *
T o the retina T o  the superior c o l l icu lu s
F igu re  6.3.3-b: T ra n sd u c tio n  o f  R G C s via a single HSVl/27+/R L I+/pR19CMVLacZwpRE optic 
nerve in jection .
W holemounted retina (A) dem onstrates substantial num bers o f  LacZ positive RGCs and axons 
expressing transgene (seen at higher m agnification in C). LacZ positive RGC axons fill the region 
o f  the injection site in the optic nerve in the w holem ount preparation (B). Scale bars: A =500pm ; 
B=250pm ; C =250pm .
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2xl07 pfu of HSV1.27+/PRL1+ pR19CMVLacZwPRE vector were administered 
either in the superior colliculus or directly into the ON. This vector successfully 
transduces a large number of RGCs within the retina when it is administered into 
the superior colliculus with strong expression achieved one week after injection 
(Figure 6.3.3-a). In the case of direct ON administration, expression is also very 
strong at 7 days post injection (Figure 6.3.3-b). By the time this study came to an 
end, a new set of vectors utilising this backbone and each expressing one of 
BDNF, CNTF, NT3 and GDNF were produced and later shown to be biologically 
active. However, it was not possible to utilise them in vivo due to time constrains 
and they are therefore not presented here.
6.4 Discussion
This study demonstrates for the first time that HSVl.pR19CMV vectors are 
capable of inducing a regenerative effect in axotomised RGCs when used to 
deliver a combination of neuroprotective and regenerative factors. No other HSV 
vector with this level of disablement has reportedly been successful in inducing 
RGC regeneration in vivo. Even though this result is encouraging as it confirms 
that a combinatorial delivery promotes re-growth and rescue, it sheds little light 
on the role that each of the neurotrophic factors used play in RGC 
neuroprotection and regeneration. This should be the natural progression of this 
study and the HSVl.pR19CMV vector can be effectively used to explore their 
interactions.
The fact that expression is allowed to proceed for three days prior to inflicting the 
optic nerve crush may be enough time to prime RGCs with sufficient amounts of 
survival and regeneration promoting factors so that they have an enhanced 
growth capacity once the injury is inflicted. The enhanced survival promoting 
effects of simultaneously delivering BDNF, GDNF and NTN (Koeberle and Ball,
2002) combined with neuroprotective and regenerative signals of CNTF, bFGF 
and NT3 allows for a favourable regeneration environment. Since the 
regeneration shown here is achieved at 33 days after injury, it is logical to suggest
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that neuroprotection was successful to some degree. With hindsight, the numbers 
of surviving RGCs should have been accurately determined so that the actual 
rescue effect can be compared to that reported for each of these factors. Similarly, 
the exact number of regenerating RGC axons in each treated optic nerve should 
also have been established and compared to that obtained in the literature. 
However, as already stated, this study was focused more on the ability of these 
vectors to induce an overall biological effect when delivered in combination, 
since previous attempts at spinal cord regeneration delivering a single 
neurotrophic factor proved fruitless.
Disappointingly, only a small number of animals yielded any respectable RGC 
axon regeneration following NT-vector administration. This could be due to a 
number of reasons. Firstly, from the preliminary experiments conducted using 
marker gene delivery (LacZ or GFP) we found the stereotaxic injection into the 
RGC terminals within the superior colliculus to be unreliable. This may be due to 
the fact that even though the superior colliculus is a large area, its retinorecipient 
layer is very thin. It is therefore technically difficult, even with a good stereotaxic 
frame and co-ordinates, to reliably localise the site of an injection to this layer. 
Multiple injections into the superior colliculus generally yielded higher numbers 
of transduced RGCs. Secondly, the optic nerve crush procedure used may not be 
as reliable as one would like. For example, too much pressure applied via the 
forceps could yield a crush site that resembles a transection. This would not be as 
conductive to regrowth along the distal stump as a crush. On the other hand it is 
necessary to apply adequate pressure as an incomplete crush may result in some 
RGCs being spared axotomy. However, it is unlikely that this was the case in the 
vector treated animals that did demonstrate robust axonal regeneration. Spared 
RGC axons have a smooth morphology, follow a straight course through the optic 
nerve and more importantly they are present throughout the length of the optic 
nerve. The regenerating axons found in the neurotrophin treated animals in this 
set of experiments were beaded and branched with a highly irregular course. 
They were also of limited length and never observed more than 1 mm along the 
distal stump of the optic nerve. Thirdly, the standard method of intravitreally 
injecting the CTB tracer may not be as reliable as it is easy for it to leak out from
376
I e e lo r -  n i c i h a i e J  n e u r o /r o p h i c  U ic to r  d e l i v e r y  in  o p i ie  n e r v e  r e g e n e r a t io n
the puncture wound in the limbus, thus limiting the amount available for uptake 
by RGCs. We have tried to overcome this problem by processing alternate 
sections for both CTB and GAP43 immunohistochemistry. However, this was not 
performed for every animal.
In terms of inducing regeneration in the already injured optic nerve, which would 
be of more interest in terms of clinical relevance, further developments in the 
design of the HSV.pR19CMV vector have presented the possibility of directly 
targeting the optic nerve itself. By utilising a newly developed vector that is not 
disabled for the expression of ICP27 or ICP34.5 and incorporates the use of a 
WPRE element, this vector allows for not only higher expression of transgenes in 
the retina but also allows targeting of the optic nerve milieu itself. This would 
allow even more direct targeting of the vector to only RGCs rather than other 
neuronal populations that may inevitably be transduced when the vector is 
delivered in the superior colliculus. It would be interesting to assess the 
differences that the WPRE element makes to the protein levels of these factors 
and more importantly how these correlate to their biological effect.
S u m m a r y
In summary, this chapter demonstrates that the viral mediated transduction of 
RGCs with a combination of survival (rBDNF, rGDNF and rNTN) and 
regeneration (mCNTF, bFGF and rNT3) promoting signals enhances the 
regenerative response mounted by injured RGCs. This response is accompanied 
by evidence of GAP43 upregulation and RGC axonal elongation into the lesion 
site. In addition, the use of less disabled constructs such as 
HSVl.RLl+/pR19CMV or HSVl.ICP27+/RLl+/pR19CMV leads to a more 
efficient transgene expression in these neurons in terms of RGC numbers 
transduced and length of transgene expression.
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C h a pter  7.0
EFFECTS OF INTERLEUKIN 10 ON VECTOR MEDIATED 
TRANSGENE EXPRESSION IN DRG NEURONS
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7.1 Introduction
In previous chapters, (Chapters 3, 4 and 5) efforts have been concentrated at 
targeting spinal cord motor neurons via a direct stereotactic injection. Even 
though this technique does result in widespread neuronal transduction it is a 
relatively traumatic practice that may further exacerbate injury in the already 
compromised CNS. An alternative technique that would allow us to circumvent 
this problem would be to deliver potentially therapeutic molecules via peripheral 
nerve inoculation thus exploiting the innate ability of HSV1 to be retrogradely 
transported to neuronal cell somata. Such an approach has been previously 
attempted in our laboratory (Perez et al., 2004) when the minimally disabled 
vector 1764/pR20.9UL43 (HSVl.pR20.9/UL43) was compared to the highly 
disabled HSVl.pR19CMV vector. These experiments demonstrated that even 
though both vectors are capable of transducing DRGs and anterior horn motor 
neurons, transduction ceases relatively quickly (Palmer et al., 2000; Perez et al., 
2004).
One of the potentially contributing factors to the termination of transgene 
expression may be an immune response to the virally infected cells (Perez et al., 
2004; Simmons et al., 1992). This probability would explain the transgene 
expression patterns observed with either HSVl.pR20.9/UL43 or 
HSVl.pR19CMV vectors. HSV1 has innate machinery for evading the host 
immune responses and inhibiting apoptotic signals within the infected cell. 
However, the vectors used for delivery to the CNS are highly disabled and even 
though this may be beneficial in terms of reducing cytotoxicity, it also implies 
that its mechanisms for immune evasion are compromised. Even though these 
vectors can support transgene expression in the CNS for at least three weeks, 
possibly due to the more immunocompromised nature of the CNS milieu this is 
not the case when the same vectors are used to deliver transgenes to the PNS. 
Transgene delivery is not as extensive while expression is minimal after two 
weeks. The same pattern is noted when the less disabled vector 
HSVl.pR20.9/UL43 is used to transduce DRG and anterior horn motor neurons 
following a footpad inoculation. Again, transgene expression is notably strong at 
the 2-day time point but it is not sustained past the two-week time point. Given
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the fact that the immune response in the PNS is stronger than that observed in the 
CNS, it is possible that the HSVl.pR20.9/UL43 vector, even though capable of 
establishing latency in infected cells and initiating transgene expression, it is at 
the same time unable to evade the PNS immune response triggered by the 
infection itself. The observed lack of transgene expression could therefore be 
perceived as the result of losing the latently infected cells altogether or 
elimination of some of the inoculum as a consequence of an immune and 
inflammatory response.
7.1.1 HSV1 infection and the host immune response
The first line of defence following infection with HSV1 involves the activation of 
the innate immune response. This response involves the production IFN a  or p 
and subsequent recruitment of natural killer (NK) cells as well as other antigen 
presenting cells (APCs) such as dendritic cells (Biron, 1999). Initial recruitment 
of innate immune response participants as well as the nature and strength of the 
subsequent adaptive immune response is shaped through leukocyte secreted 
cytokines (Ramshaw et al., 1997). Additionally, a rough distinction must be made 
in the nature of the host immune response between the acute and latent stages of 
infection with HSV1. The mechanisms responsible for resolving HSV1 infections 
from the skin differ to those employed in clearance from the PNS. They involve 
different types of cells and the host-virus relationship is balanced by elaborate 
virus evasion strategies.
The host immune response during the brief, acute phase of HSV1 infection is 
primarily innate, involving CD4+ T cells and a Type IV hypersensitivity reaction 
(Nash et al., 1987). CD4+ T cells are the first to infiltrate the site of infection in 
response to Major Histocompatibility Complex (MHC) Class II protein-antigen 
complex recognition on APCs which in turn triggers their differentiation into 
cytokine secreting effector cells (Mikloska et a l , 1998). Activation of naive T- 
cells requires the simultaneous presence of MCH Class II-antigen complex and 
activation of co-stimulatory signals by APCs (Male et a l, 1996). Effector cells of 
the CD4+ class, can be further divided into two populations, either T-helper 1 
(Thl) or T-helper 2 (Th-2), depending on the profile of cytokine expression
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(Keane and Hickey, 1997). CD4+ Thl cells secrete IL2, IFNy and TNFa that 
activates CD8+ T cells, also known as cytotoxic T-lymphocytes (CTLs). CD8+ T 
cell receptor recognises and facilitates the lysis of cells that present MHC class I 
antigens leading to clearance of infection. They do so by triggering an 
autocatalytic suicidal cascade within the target cell, involving the Src-family of 
protein kinases. The resulting modification of cellular processes such as calcium 
mobilisation and the activation of the Ras pathway causes DNA fragmentation 
and an apoptosis-like death (Mullbacher and Ada, 1987).
HSV1 infection leads to a sharp increase in cytokine and chemokine levels, 
which are important for the recruitment of cells that initiate an effective immune 
response. Induction of RANTES expression, the main chemokine-induced by 
macrophages during a primary infection, is triggered by ICPO in vitro 
(Melchjorsen et a l , 2002). In addition, cellular IFN induces the double-stranded 
RNA-activated protein kinase R (PKR) (Melchjorsen et al., 2002). PKR is a 
central factor in the up regulation of TNFa, IL-6, and RANTES, since expression 
of a dominant-negative mutant form of PKR strongly inhibits production of these 
cytokines in HSV1 infected macrophages (Melchjorsen and Paludan, 2003; 
Paludan and Mogensen, 2001). T lymphocytes require the presence of two signals 
for proliferation, induction of effector functions and initiation of a maximal T-cell 
response (Male et al., 1996). The first signal depends on the binding of the CD8+ 
or CD4+ T cell receptor (TCR) to MHC class I or II respectively on APCs. The 
second signal is antigen independent and relies on the interaction between the B7- 
costimulatory molecules expressed on APCs and their ligands present on T cells 
(Singh et al., 2003). Even in the presence of the first signal, absence of co­
stimulation by B7 isomers, B7-1 (CD80) and B7-2 (CD86) results in T-cell 
antigen specific clonal anergy which renders T cells incapable of responding to 
antigen (Bretscher, 1992; Mueller et al., 1989). Unlike the humoral response, the 
T cell-mediated immuno-protection is mediated by cell disruption (Male et al., 
1996; Mullbacher and Ada, 1987). It is therefore not surprising that cytotoxic 
responses are tightly regulated in both PNS and CNS. The inflammatory infiltrate 
observed during the initial stages of infection is composed of monocytes, NK 
cells, Thl CD4+ and y/6 CD8+ T cells (Liu et al., 1996). NK cells and CD8+ T
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cells secrete IFN-y which can prevent host cell apoptosis by inhibiting HSV1 
replication (Halford et al., 1997). IFNy, also induces the extravasation of 
polymorphonuclear (PMN) leukocytes (Liu et al., 1996) and activation of NK 
cells and macrophages (Barcy and Corey, 2001) that phagocytose viral particles 
in a CTL-independent and non-specific manner, primarily through their C3 
receptors for complement formed via the alternative pathway (Keane and Hickey, 
1997; Male et al., 1996). IFNa results in production of defective virions (Munoz 
and Carrasco, 1984) and direct inhibition of viral replication due to a block in a  
and (3 viral gene transcription (Straub et a l, 1986). Cytokines also stimulate the 
clonal differentiation of B-cells. B-lymphocytes, activated by the CD4+ Thl 
effector cells, become plasma cells and secrete antibodies specific to viral 
antigens. These recognise epitopes on the virus required for infection and by 
binding to them via their Fab region, render them neutral. B-lymphocytes, can 
also recognise epitopes through their specific immunoglobulin (Ig) receptors 
present on their cell membrane. Once bound, the Ig-viral antigen complex is 
engulfed, partially digested and the antigenic portion is displayed on its cell 
membrane as a complex with the MHC Class II protein. IgG and IgM class 
antibodies are also crucial in complement fixation via the classical pathway 
(Male et al., 1996).
Effector Cytokine Effect
IFN-y
• Enhances MHC class I and II expression.
•  Increases macrophage phagocytic activity by inducing Nitric Oxide 
synthase.
Thl TNFa • Produced by B-cells/astrocytes in response to viral infections & IFNy
IL-2 • Influences growth of oligodendrocytes, macrophages and B-cells.• Initiates activated T-cell clonal expansion.
1L-13 •  Regulator of B-cell and monocyte activity.
IL10
• Inhibits cytokine synthesis by activated Thl and NK cells.
• Down regulates MHC class II expression on macrophages.
• Synergistically with TGF0 causes IgA production by B-cells.
Th2 IL-6
• Promotes growth and maturation of B-cells.
• Enhances the secretion of IgG by B-cells.
IL-5 • Induces the expression of IL-2 receptor on B-cells
• Enhances the production of IgA from B-cells.
IL-4
• Promotes class switching o f B-cells to IgE (contributes to inflammatory 
reactions) & augments IgG production.
• Enhances growth of T-cells & B-cells.
Table 7.1.1-a: Expression of cytokines by CD4+ effector cells and their effects.
Adopted from M ale et al. 1996.
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7.1.2 Latent stage of infection & the PNS immune response
The CNS and PNS are shielded by the blood-brain (BBB) and blood-nerve 
(BNB) anatomical barriers respectively. These barriers along with the lack of 
regular lymphatic drainage, the absence of intraneural lymphatic channels and the 
atypical expression of MHCs (Oldstone, 1991), afford an immune privileged 
environment (Theil et al., 2003). However, both BBB and BNB are permeable to 
activated T cells (Allt and Lawrenson, 2000; Hickey, 2001) which constitute the 
main immune surveillance mechanism for both the CNS and PNS . The ability of 
nervous tissue to tolerate an immune response is due to an active process that 
tightly controls its nature, quantity and quality with priority focused on 
preserving organ integrity. Unwillingly, this mechanism also provides a survival 
advantage to the virus present within neurons.
Latent infections in the PNS are associated not only with the expression of LATs 
but also with low level, constant expression of viral immediate-early (IE) genes 
such as ICP4 and thymidine kinase (TK) (Kramer and Coen, 1995). The 
establishment of a persistent, latent infection in sensory ganglia instigates an 
adaptive immune response (Simmons and Tscharke, 1992) involving primarily 
y/S TCR CD8+ T cells (Liu et al., 1996). This response, further enforces latency 
and controls infection via non-cytolytic mechanisms based on cytokine secretion 
(Guidotti and Chisari, 2001). It is these responses that cause latent HSV1 
infections to be coupled with a low grade, chronic inflammation. The persistent 
infiltration of y/8 TCR CD8+ T cells is accompanied by high levels of IFNy 
expression (Cantin et al., 1995; Liu et al., 1996), altered expression or 
distribution of GAP43 (Martin et al., 1996), upregulation of nitric oxide 
synthetase (Koprowski et al., 1993; Meyding-Lamade et a l, 1998) and 
upregulation of TNFa (Theil et a l, 2003) which synergises with IFNy to further 
block HSV1 replication (Feduchi et al., 1989; Paludan and Mogensen, 2001). In 
response to secreted chemokines, macrophages also infiltrate the infected area. 
Studies in the HSV1 latently infected human trigeminal ganglion neurons (Lodge 
and Sriram, 1996) demonstrated the presence of very high levels of RANTES in 
macrophages (Melchjorsen et al., 2002). RANTES is thought to play a crucial 
role in the recruitment of other immune cells to the site of infection.
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Persisting CD8+ T cells can interact with latently infected neurons or 
macrophages (Khanna et a l, 2003). Indeed, CD8+ T cells are found in high 
numbers around the cell bodies of latently infected neurons but they do not 
interact directly with them. They do however interact directly with satellite cells 
(SC) (Liu et a l, 1996) which have been shown to upregulate MHC Class I 
expression (Pereira et a l, 1994) in response to HSV1 infection. SCs are also 
thought to play a role in neuroprotection in response to HSV1 infections even 
though the exact mechanism by which they do is still unclear. SCs resemble 
schwann cells in their phagocytic capacity (Wilkinson et a l, 1999) and they are 
notoriously difficult to differentiate from other immune system infiltrating cells 
(Elson et al, 2003). SCs are found to contain empty or incomplete HSV1 virions, 
suggesting that they undergo an abortive infection (Dillard et a l, 1972). 
Interestingly, SCs proliferate in response to infection by HSV1 and almost double 
in numbers around the infected sensory ganglia. Several hypotheses have tried to 
address the reasons behind this response to neuronal infection. One hypothesis is 
that it is initiated in response to direct stimulation by viral factors (Elson et al, 
2003). The only evidence-supported explanation so far is that normally, SCs are 
kept under inhibitory control. Upon infection, neurons secrete mitogenic signals 
that stimulate SCs to proliferate vigorously (Wen et a l, 1994). However, the 
molecular mechanisms involved are not fully understood and it is thought that the 
benefits of SC proliferation are primarily in preventing trans-neuronal spread 
(Elson et a l, 2003).
PNS neurons can themselves prevent their own destruction due to certain 
physiological features they possess. Firstly, they are able to down-regulate the 
formation of MHC class I antigen and thus impede recognition by CD8+ T cells 
(Wong et a l, 1984). In normal conditions neurons do not express MHC class I 
(Oldstone, 1991). Secondly, due to their differentiation they may lack 
transcription factors required for efficient IE viral gene transcription (Valyi-Nagy 
et a l, 1991) or they possess repressors preventing it in the first place (Kemp et 
al, 1990).
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7.1.2.1 Immune evasion strategies by HSVI
Even though incapable of antigenic variation, HSVI has evolved mechanisms 
that allow evasion of detection from host immune surveillance. These 
mechanisms target both the ability of the host to initiate cytotoxic and 
antibody/complement mediated responses as part of the innate immune response 
as well as inhibition of mounting an adaptive immune response. HSVI can 
interfere with antigen presentation to CD4+/CD8+ T cells. It achieves this by 
preventing the expression of MHC class II protein, or by inhibiting the binding of 
antigen to MHC class I protein. Blocking of viral antigen presentation to MHC 
class I specific CD8+ CTLs is prominent during lytic infection and not in latency 
(Pereira et a l , 1994). Experimental evidence supports the fact that ICP47, even 
though not an essential protein (Mavromara-Nazos et a l , 1986), plays a crucial 
role in this mechanism (Goldsmith et a l , 1998). Normally, the viral antigen is 
loaded onto empty MHC class I proteins in the endoplasmic reticulum (ER). 
Transporter-associated with antigen processing (TAP) proteins (Bauer and 
Tampe, 2002), mediate transport of the viral antigen to the ER. It is thought that 
ICP47 binds to the cytosolic portion of the TAP transporter, thus preventing its 
translocation into the ER and the presentation of MHC class I - viral antigen 
complex to CD8+ T cells (Fruh et a l , 1995). MHC Class I molecules remain 
unloaded in the ER (Bauer and Tampe, 2002). Interestingly, ICP47 expressing 
cells show a similar MHC class I instability to that of TAP deficient in cells (Fruh 
et a l , 1995). In addition, TAP has been detected using ICP47 antibodies, further 
elucidating the direct interaction of the two proteins (Goldsmith et a l , 1998). It is 
worth noting that there is some evidence to suggest that the strength and nature of 
that interaction is species specific. HSVI ICP47 was found to inhibit human TAP 
but ICP47 concentrations of 50 to 100 times more were necessary to efficiently 
block the murine version of TAP (Tomazin et a l , 1998). HSVI has also been 
reported to interfere with the function and maturation of dendritic cells during the 
initial stages of infection (Sprecher and Becker, 1987). Infected dendritic cells, 
even though non-permissive to virus growth themselves, are prevented from 
undergoing maturation and they are therefore incapable of presenting viral 
antigens to either CD4+ or CD8+ T cells (Pollara et a l , 2003; Sprecher and 
Becker, 1987). This inefficiency allows HSVI more time to spread (Mikloska
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and Cunningham, 2001). A recent study suggests that this block of dendritic cell 
maturation is a consequence of the HSVI Vhs protein. In fact, deleting vhs 
allows the activation of dendritic cells and efficient presentation of antigens to T 
cells (Samady et al., 2003).
MHC class II processing pathway is also thought to be targeted by HSVI 
(Lewandowski et a l , 1993). As previously reported, generation of Thl/Th2 CD4+ 
effector cells and subsequent activation of plasma cells, requires interaction with 
viral peptides loaded onto MHCII ap heterodimers. Peptide loading of MHCII 
heterodimers takes place in endosomal vesicles. Normally, MHCII molecules are 
found associated with the invariant chain peptide (Castellino and Germain, 1995) 
that blocks the binding groove of MHCII to ensure correct loading of antigen 
while preventing random association with self peptides (Roche and Cresswell, 
1991). Later in the maturation process, human leukaemia antigens-DM (HLA- 
DM) heterodimers remove the invariant chain (Denzin and Cresswell, 1995) and 
further processes bound peptides for stronger structural binding to MHCII 
(Sanderson et al., 1994). Several HSVI antigens are thought to have a negative 
impact on the molecular processing of MHCII. Firstly, HSVI infection strongly 
down-regulates the expression of the invariant chain which in turn prevents the 
formation of DR-peptide complexes. Secondly, the viral envelope protein gB can 
bind to DR (Sievers et al., 2002) and prevent it from binding to the invariant 
chain. Thirdly, gB-associated DR and DM heterodimers are exported from the 
ER but are primarily localised in sub-cellular vesicles which are prevented from 
being expressed on the surface of the infected cell (Neumann et al., 2003).
Apart from interfering with MHCI/MHCII processing and antigen presentation, 
HSV1 is also capable of evading complement attack in vivo. It accomplishes this 
by two mechanisms, either by mimicking complement regulators or by 
preventing complement binding to antibody-antigen complexes (Favoreel et a l ,
2003). Viral glycoprotein gE synergises with gl (Dubin et a l, 1991; Johnson and 
Feenstra, 1987) and binds host IgG (Para et a l, 1982) via its immunonoglobulin 
binding domain which demonstrates a high similarity to mammalian Fc receptors 
(Dubin et a l, 1990; Dubin et a l, 1994). The gE-gl functions as an Fc receptor 
and allows the virus to avoid complement-mediated lysis via a process described
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as anibody biopolar bridging (Frank and Friedman, 1989). This consists of IgG 
binding with its hypervariable Fab region to a viral envelope or cell surface 
protein and with its Fc region to the HSV Fc receptor gE-gl which in turn 
interferes with Clq binding and antibody-dependent cytotoxicity (Dubin et a l , 
1991). This protects the virus from complement and antibody dependent 
neutralisation in vitro and in vivo (Frank and Friedman, 1989; Lubinski et a l , 
2002; Nagashunmugam et a l , 1998). Indeed, mutant strains of HSVI in which 
gE binding to IgG is defective, display a 40 to 100 fold increase in susceptibility 
to complement neutralisation (Nagashunmugam et a l, 1998).
Glycoprotein gC is a non-essential glycoprotein, present on the viral envelope 
and on the surface of infected cells, known to play a role in viral attachment, 
release and virulence (Herold et a l, 1991). gC can act as an immunoevasin by 
binding to complement components and its activation products C3, iC3b and C3c 
and it can accelerate the decay of the C3 convertase in the alternative pathway 
and in vivo. Viral gC also interferes with C5 and properdin from binding to C3b 
(Fries et a l, 1986; Kostavasili et a l, 1997). Properdin’s role is to increase the 
half-life of the alternative C3 convertase whereas C5 is an important complement 
component by participating in the formation of the terminal, membrane 
associated complex (MAC) (Favoreel et a l, 2003). Both proteins require binding 
to C3b in order to perform these functions. Inhibition of properdin is carried out 
by the transmembrane segment of gC while inhibition of C5 binding to C3b is the 
result of steric hindrance, preventing the C5 binding site from accessing the C3b 
binding site (Kostavasili et a l, 1997).
In addition, ICP34.5 has been associated with a mechanism that can counteract 
the virally induced pro-inflammatory interferon response (Samuel, 2001). HSVI 
can target both Type I (IFNa and IFNp) and Type II (IFNy) interferons which are 
involved in the primary or productive phases of viral infection (Male et al,
1996). Type I proteins IFNa and IFNP are secreted by all virally infected 
nucleated cells especially fibroblasts, macrophages and dendritic cells. On the 
other hand, IFNy is specific to cells of the immune system such as NK cells, 
CD4+ Thl and y/8 CD8+ T cells (Bach et a l, 1997). Even though the actions of 
Type I or II interferons are initiated via different receptors, they converge on the
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JAK/STAT signalling pathway ultimately resulting in the up-regulated expression 
of specific interferon-responsive genes. However, the expression of interferon- 
responsive genes can also be initiated by virus infection directly, and in cases 
such as that of paramyxovirus infections, the signalling mechanisms differ from 
those used by the cytokines themselves in that the JAK/STAT signalling pathway 
is bypassed (Guo et al., 2000; Marie et al., 1998; Wathelet et al., 1998).
The spectra of cellular genes induced by interferons and by viral infection are 
similar but not identical, with some genes responding to either or both inducers 
(Wathelet et a l , 1992). One such interferon-responsive gene is the PKR gene. 
PKR is ubiquitously expressed in mammalian tissues, is maintained in an inactive 
form and belongs to the eukaryotic initiation factor-2 subunit a (eIF-2a) family of 
protein kinases (Lu et a l , 1999). Upon a positive signal, induced by either IFN or 
the presence of double stranded RNA, PKR undergoes auto-phosphorylation and 
a conformational alteration that allows dimerisation into the now active PKR 
(Gale, Jr. and Katze, 1998). PKR then phosphorylates and inactivates eIF-2a 
which as a result leads to a total shut down of translation within the host cell, be it 
host or viral (Gale, Jr. and Katze, 1998). This ultimately leads to the death of the 
host cell by apoptosis (Kaufman, 1999). A study in which trigeminal ganglia 
cultures were transduced to express IFNp by means of an adenoviral vector, 
demonstrated that PKR is up regulated in response to a concomitant HSVI 
infection (Al khatib et a l , 2003; Carr et a l , 2003). HSVI has evolved a specific 
mechanism in order to avoid this response. The carboxy-terminal domain of the 
ICP34.5 binds to protein phosphatase 1-a (PPla) and directs PPla to reverse the 
phosphorylation of eIF-2a mediated by PKR (He et a l, 1997; He et a l, 1998; 
Pasieka et a l, 2006), thus allowing translation to resume. It must however be 
pointed out that this effect has only been demonstrated in vitro. Moreover, an 
ICP34.5 mutant is capable of exhibiting wild-type replication levels in mice 
lacking the PKR gene (Leib et a l, 2000). The authors of this study suggest that 
this restoration of virulence is specific to ICP34.5 since a virus deleted for viral 
thymidine kinase (TK) failed to reach wild type replication levels in the same 
paradigm. Recently, more HSVI proteins have been implicated with PKR 
control.
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Another viral protein US11, an RNA binding protein, can compensate for the 
absence of ICP34.5 and it was shown to directly associate with PKR early in 
infection thus decreasing its activation both in vitro (Cassady et al, 1998) and in 
vivo (Ward et al, 2003). Studies directed at evaluating the responsiveness of 
individual HSVI genes to interferons demonstrated that ICPO mutants are 
hypersensitive to IFNa in vitro compared to the less sensitive VP 16, UL13, vhs 
or ICP22 mutants (Mossman et a l, 2000). When ICPO mutants were grown on 
complementary cell lines they displayed normal sensitivity to IFNa. This might 
suggest that ICPO interferes with IFNa responses and may act as a regulator on 
sensitivity. Whether this response is separate or part of the ICP34.5 response is 
currently not clear (Mossman and Smiley, 2002). A recent report suggests that 
the ICPO functions as an antagonist to the functions of not only IFNa but also 
IFNp and IFNy which would explain why wild type HSVI is apparently highly 
resistant to the hostile state induced by the activation of the IFNa, IFNp and IFNy 
receptors (Harle et al, 2002). This is in sharp contrast to the ICPO' versions of the 
virus, that appear to be hypersensitive to the activation of these receptors in vitro 
(Mossman and Smiley, 2002) while being able to replicate with improved 
efficiency in knockout mice that lack ICPO and ICP34.5 (Leib et a l, 1999). IFNa, 
IFNp and IFNy receptors activate their effectors via the activation of the Stat-1 
transcription factor which ICPO appears to directly antagonise (Halford et al, 
2006). In the experiments by Halford and colleagues (2006) it was demonstrated 
that in mice lacking Stat-1, infection with an ICPO' mutant was lethal. The 
authors suggest that when ICPO is present, it is able to overcome the HSVI 
genome silencing that occurs in the presence of stat-1, which is in turn activated 
by all three INFs. These authors go on to suggest that ICPO is essentially a switch 
that decides whether the virus will enter replication, i.e. whether it is able to 
overcome the stat-1 induced silencing, or enter latency instead (Halford et a l, 
2006).
HSVI can also down-regulate the production of a group of pro-inflammatory 
cytokines, such as Interleukin 6 (IL6) (Mogensen et a l, 2004). This ability is 
attributed to the viral IE genes ICP4 and ICP27, which are expressed in a VP 16- 
dependent manner during primary HSV infection. Interestingly and from the
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same study it was elucidated that after infection with an VP16 inl814 mutant, IL6 
mRNA demonstrates a significantly longer half-life compared to that observed 
after infection with the wild type virus (Mogensen et a l , 2004). Based on these 
results, Mogensen and colleagues (2004) proposed that HSV is able to suppress 
expression of pro-inflammatory cytokines by decreasing the stability of mRNAs, 
thereby potentially impeding the antiviral host responses to infection. The HSVI 
vector used for the regenerative studies in the CNS described in this thesis, has 
both ICP34.5 and VP 16 disabled. As discussed in Chapter 3, it is possible that the 
lack of transgene expression in cortical neurons is likely to be due to the silencing 
of the exogenous promoter that does not appear to occur when these genes are 
present, as in the case of less disabled vectors. However, it is also likely that the 
long-term transgene expression in highly disabled constructs may be partly due to 
an inability to evade the host immune response.
7.1.2.2 HSVI Viral Vectors ~ Anti-Apoptotic Signals
Apart from immune detection, the virus can also suppress apoptotic signals 
within the infected cell. Two viral proteins have been suggested for their 
involvement in this mechanism: ICP4 and ICP34.5. 40-50% of Vero cells 
infected with ICP4' mutants show apoptotic signs, i.e. DNA fragmentation, 
obliteration of the nuclear membrane and vacuolisation of the cytoplasm 
(Leopardi and Roizman, 1996). On the contrary, cells infected with an ICP4+ 
virus that was unable to express any of the p  or y  genes, had the characteristics of 
an infected cell but no apoptotic signs. The mechanism of action of the proposed 
anti-apoptotic function of ICP4 remains largely unknown. In addition to ICP4, 
the ability of ICP34.5 to prevent apoptosis has also been examined. Initially it 
was noted that y34.5 deletion mutants induced apoptosis in human neuroblastoma 
cells, via the phosphorylation of the eukaryotic translation initiation factor eIF-2a 
(Chou and Roizman, 1992), hence leading to the premature shut-off of host 
protein synthesis. In another line of experimentation, the ability of an ICP34.5 
deleted HSVI viral vector to safely deliver transgenes to the brain was found to 
be limited (McMenamin et al., 1998). The animals, injected in the brain, suffered 
severe weight loss and experienced a powerful immune response. Furthermore, 
y34.5' mutants where compared to wild type HSVI for their ability to suppress
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DNA fragmentation in Hep-2 carcinoma cells (Koyama and Miwa, 1997). Hep-2 
cells were stimulated to undergo apoptosis by sorbitol treatment, prior to 
infection. Surprisingly, the deleted virus was as effective as wild type HSVI in 
suppressing DNA fragmentation. The authors of this study reasoned that more 
viral proteins are responsible for the inhibition of apoptosis in infected Hep-2 
cells.
Another theory concerning the anti-apoptotic abilities of HSVI regards the fact 
that the LAT transcript in itself has the ability to protect infected neurons from 
programmed cell death, as an innate mechanism to make latent infections more 
persistent (Pemg et al., 2000; Thompson and Sawtell, 2001). Replacing LAT 
with an antiapoptosis gene restores the wild-type reactivation phenotype in a 
LAT null mutant of HSVI (Pemg et al., 2002). In addition, a plasmid expressing 
a fragment of LAT between nucleotides 301-2659^ can efficiently block 
apoptosis in transient transfection assays, further demonstrating its powerful anti- 
apoptotic activity (Pemg et al., 2000).
7.1.3 Interleukin 10 & Immunosuppression
Interleukin 10 (IL10) has been identified as a natural anti-inflammatory cytokine, 
produced by CD4+ Th-2 cells, activated B cells and macrophages (Howard and 
O’Garra, 1992). It inhibits activation and proliferation of T-cells indirectly, by 
reducing the antigen-presentation capacity of monocytes. This inhibition is 
achieved by reducing the expression of co-stimulatory molecules, such as CD80 
or CD54 (Chang et al., 1994), and MHC class II presentation by monocytes 
(Chang et al., 1994). IL10, has also been shown to ameliorate the effects of septic 
shock that can be induced by TNFp (Griffith et al., 1995). In the absence of 
APCs, IL10 can suppress IL2 and TNF-a secretion by CD4+ Thl cells and can 
induce long lasting antigen specific anergy (Groux et al., 1996; Groux et al.,
1998). Interestingly, repetitive antigen activation of CD4+ cells in the presence of 
IL10 results in the differentiation of a new subset of regulatory cells termed T- 
regulatory cells-1 (Trl). These cells have a poor proliferative response, do not 
produce IL2 and advantageously, produce high levels of IL10 (Groux et al.,
1997).
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IL10 has been further shown to inhibit IFNa production by monocytes and 
natural IFNa producing cells (NIPCs) in response to viral infections (Cederblad 
and Aim, 1991). HSVI infection results in IFNa up-regulation by NIPCs, which 
in the CNS leads to an increase in expression of MHC class II by astrocytes 
(Payvandi et al., 1998). In addition, IL10 inhibits the production of nitric oxide 
and IL12 production by activated microglia, suggesting an important role for this 
cytokine as a negative regulator of a CNS immune response (Lodge and Sriram, 
1996). More evidence for the IL10 regulatory function in suppressing a CNS 
immune response comes from studies where BALB/c and SJL strains of mice 
were compared for their susceptibility to Sindbis virus infection (SV) (Rowell 
and Griffin, 1999). SV causes acute nonfatal encephalomyelitis in both strains of 
mice. SJL mice are susceptible to autoimmune inflammatory diseases of the 
CNS, while BALB/c mice are relatively resistant. Even though clearance of virus 
was similar in both strains, SJL mice developed a more intense inflammatory 
response in the brain and spinal cord than the BALB/c mice and inflammation 
persisted for several weeks. Analysis of lymphocytes present in brains isolated 
early after infection, showed an absence of activated NK cells in SJL mice. In 
contrast to its anti-inflammatory and immunosuppressive properties, IL10 can 
have immuno-stimulatory and anti-apoptotic effects in both B and T cells. In 
addition, it has been shown to augment the proliferation of spleenic activated B 
cells into antibody secreting cells. In a mouse transgenic model, IL10 enhances 
the accumulation of CD8+ cells in the pancreas, leading to diabetes (Groux et al.,
1999). Additionally, IL10 has been shown to rescue T-cells from apoptosis when 
IL2 is not present. Injection of high doses of IL10 in mice with graft vs. host 
disease, resulted in exacerbation of the disease (Krenger et al., 1994). The 
benefits of IL10 have been demonstrated in transplantation and various disease 
models. For example, local production of IL10, mediated by adenovirus vectors, 
by canine islets, improves early islet survival in rat recipients (Deng et al., 1997). 
In addition, adenoviral transfer of the Epstein-Barr derived homologue of the 
IL10 gene (the BCRF1 protein) to mouse paws, suppressed the development of 
collagen-induced arthritis (Whalen et al., 1999). It has been postulated that loss 
of vector-mediated transgene expression is the result of immune clearance of the 
infected cells rather than a cell specific down regulation of transgene expression
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(Palmer et al., 2000). The ability of IL10 to promote immuno-suppression 
establishes this interleukin as an attractive molecule that could potentially allow 
longer transgene expressions when co-expressed by the vector, allowing it to 
evade immune surveillance mechanisms.
7.1.4 Rationale
The experiments described in this study aimed to test the hypothesis that if 
immune system clearance is the cause of the short-lived HSVl.pR20.9/UL43- 
mediated transgene expression noted in DRG neurons, then suppressing the host's 
immune response may lead to transgene expression that can persist for longer 
time points in these neurons. This could be measured in terms of longer transgene 
expression in target cells.
To elucidate any potential immune system involvement, GFP/LacZ transgene 
expression was compared between BALB/c and the immunocompromised Severe 
Combined Immunodeficiency Disease (SCID) mice at different time points using 
the backbone vector HSVl.pR20.9/UL43. SCID mice suffer from an abnormality 
that selectively kills lymphocytes. As they have neither T nor B-lymphocytes 
they are unable to generate an immune response and can therefore provide 
important data regarding the involvement of the immune system in shutting down 
transgene expression. If there is no immune system involvement then there may 
be no differences between BALB/c mice and the immunocompromised SCID 
mice in terms of the longevity of transgene expression. In order to suppress the 
immune system response in host animals, a new vector was constructed (termed 
HSVl.pR20.9mIL10/UL43). This vector co-expresses the LacZ marker gene 
along with the potent anti-inflammatory cytokine IL10. In the experiments 
described here, transgene expression in the immune-competent BALB/c DRG 
neurons achieved with the IL10 expressing vector is evaluated at longer time 
points and compared to that achieved with vector HSVl.pR20.9/UL43.
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7.2 Methods
7.2.1 Construction and characterisation of HSVl.pR20.9mIL10/UL43
Vector HSVl.pR20.9/UL43 (1764/pR20.9UL43) has been well characterised for 
its ability to simultaneously deliver two transgenes (GFP and LacZ) into adult 
mice DRGs (Lilley et al., 2001b; Palmer et al., 2000) and presented the ideal 
candidate for the delivery of mouse IL10. This vector is based on the wild type 
HSVI strain 17+ (Brown et al., 1973), is deleted for both copies of the 
neurovirulence factor ICP34.5 (MacLean et a l, 1991) and is inactivated for VP 16 
via the ini814 mutation (Ace et al., 1989). The lack of ICP34.5 hinders the 
primary envelopment of the virus and thus prevents the virus from infecting other 
cells and cross trans-synaptically. (Bjerke et al., 2003). The bicistronic promoter 
construct pR20.9 is inserted into the UL43 gene at the unique Nsil site (nt
94,911). In order to create a vector based on this backbone, capable of delivering 
biologically active mILlO, it was first necessary to sub-clone the cDNA into the 
pR20.9UL43 expression cassette, substituting the GFP marker gene. As pR20.9 is 
a bicistronic cassette, it allows monitoring of how LacZ expression is affected 
when IL10 is co-expressed in adult BALB/c or SCID mouse DRGs.
7.2.1.1 Cloning of mILlO into pGEM2/pR20.9UL43
cDNA encoding for mILlO (Kim et al., 1992) (GeneBank accession number 
M84340) was a gift from Oxford University (Dept, of Anatomy). mILlO cDNA 
(~600bp) was removed by digesting first with Notl, blunted using T4 DNA 
Polymerase and finally digested with Hindlll. The fragment was then sub cloned 
into the pR20.9 shuttle plasmid flanked by UL43 sequences. The pR20.9 
expression cassette is flanked by homologous HSVI UL43 sequences that enable 
it to be inserted by homologous recombination into the UL43 region located in 
the unique long region of the viral genome (Palmer et al., 2000). The reporter 
gene GFP of the vector backbone pGEM2/pR20.9UL43, was removed by 
enzymatic digest using Xhol followed by blunt ending with T4 DNA polymerase 
and restriction digest with Hindlll. After ligation, mILlO containing clones were 
confirmed by screening multiple restriction digests for the correct restriction 
profile. The new plasmid generated was termed pGEM2/pR20.9mIL10/UL43.
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7.2.1.2 Production of HSV1 .pR20.9mIL 10/UL43 vector
Purified HSVl.pR20.9/UL43 (1764/pR20.9/UL43) viral DNA was co-transfected 
with pGEM2/pR20.9mIL10/UL43 plasmid DNA. Recombinant plaques were 
detected by their white phenotype (no GFP expression), indicative of a correct 
recombination event and insertion of the pGEM2/pR20.9mIL10/UL43 expression 
cassette into the UL43 gene of the 1764 backbone, at the unique Nsil site (nt
94,911) (Palmer et al., 2000). Plaque purification was carried out until all plaques 
had the recombinant, non-GFP expressing but LacZ expressing phenotype. The 
new vector was termed HSVl.pR20.9mIL10/UL43 (1764/pR20.9mIL10/UL43) 
(Figure 7.4.1-a). Correct insertion of the mILlO gene was confirmed by Southern 
blotting on all purified recombinant plaques, originating from separate 
recombination events. The recombinant vector was propagated by standard cell 
culture techniques on BHK cells and viral stocks were produced as outlined in 
Chapter 2.
7.2.1.3 Southern blotting on HSVl.pR20.9mIL10/UL43 plaques
Each purified recombinant HSVl.pR20.9mIL10/UL43 viral plaque was used to 
infect lx l06 BHK cells in a 36 mm well tissue culture plate. Viral DNA from 
each plaque was extracted as outlined in Chapter2, digested with Hindlll/Nsil and 
run on a 2% agarose gel. HSVl.pR20.9/UL43 viral DNA digested by 
Hindlll/Nsil (releasing a 600bp fragment corresponding to GFP) was used as a 
negative control while a Hindlll/Notl digested plasmid pXCXR-mlLlO was used 
as a positive control. To produce the mILlO specific probe, the pXCXR-mlLlO 
plasmid was digested with Hindlll/Notl and the mILlO 600bp fragment produced 
was purified and labelled with aP32-dCTP.
7.2.1.4 Isolation & concentration of secreted mILlO from cultured BHKs
lx l06 BHK cells in a 36 mm well were infected at an MOI of 1. Two days later 
the infected monolayer was washed twice with 0.1M PB, 500 pi of DMEM were 
aliquoted in each well and the cells were returned to a 37°C, 5% CO2 incubator. 
At 2, 4 and 8 hour time points, the DMEM was collected and centrifuged at 
3,000G for 5 minutes to remove any cells present. The supernatant was then
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transferred onto a 500 pi Microcon column with a lOkDa molecular weight cut­
off (G-10000, Green). The column was then spun at 11,500G for 25 minutes at 
4°C. The total volume of the concentrated sample was 20-25 pi, which represents 
the amount of mILlO secreted from lxlO6 BHK cells infected with 
HS V1 .pR20.9mIL 10/UL43.
7.2.1.5 Western blotting
Secreted mILlO from lxl 06 BHK cells previously infected with 
HSVl.pR20.9mIL10/UL43 at an MOI of 1 was obtained as outlined above. 
Expression was analysed at 2, 4 and 8-hour time points. An equal volume of 
protein sample buffer [50mM Tris-HCl pH 8.0, 2% (w/v) SDS, 6% (v/v) glycerol 
and 0.005% (w/v) bromophenol blue] was added to each sample. Samples were 
placed on ice immediately and then denatured by heating to 95°C for 4 minutes. 
They were then cooled on ice for 2 minutes and either loaded onto a 15% SDS- 
polyacrylamide gel or stored at -20°C. SDS-PAGE and Western blotting were 
performed as described in Chapter 2. All the gels run were normalised for total 
protein content and all nitrocellulose membranes were stained with 1% (w/v) 
Panceau stain to ensure equal loading.
7.2.2 Animal Surgery - Foot-pad inoculations in adult mice
Three-week-old female BALB/c or SCID mice were inoculated subcutaneously 
into the plantar surface of the right hind paw with either HSVI .pR20.9/UL43 or 
HSVl.pR20.9mIL10/UL43 vectors (~l-2xl06 pfu) at a volume of 20-25 pi. In 
the case of BALB/c mice it was possible for them to be sedated under brief 
volatile anaesthesia with (3% Isofluothane in oxygen) throughout the procedure. 
In the case of SCID mice this was not possible and injections had to be carried 
out in a sterile hood without anaesthesia. At the predetermined time points (2 
weeks and 2 months), mice were sacrificed and DRGs from the lumbar spine (LI 
to L6) and ipsilateral to the inoculated side were extracted, post-fixed for 1 hour 
in 4% (w/v) PFA and examined first for the expression of GFP and then 
processed with X-gal stain. None of the controlateral DRGs in any of the animals 
used in this experiment were found to be infected with the vector.
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7.3 Results
7.3.1 Characterisation of vector HSVl.pR20.9mIL10/UL43
The recombinant HSVl.pR20.9mIL10/UL43 vector was produced by the co­
transfection of plasmid pGEM2/pR20.9mIL10/UL43 with purified 
HSVl.pR20.9/UL43 viral DNA. As the UL43 gene exists in one copy, located in 
the unique long region of the HSVI genome, the viral plaques that displayed a 
GFP‘/LacZ+ phenotype were selected. Purification of the six 
HSVl.pR20.9mIL10/UL43 plaques initially selected was achieved in nine rounds 
of purification.
In order to confirm that the GFP'/LacZ+ phenotype observed was due to the 
correct recombination event and not due to a random mutation of the GFP gene, 
all purified plaques were subjected to Southern blot analysis. Each of the six 
different constructs purified was used to infect lx l0 6 BHK cells and the presence 
of the mILlO cDNA was confirmed using a mIL 10-specific aP -dCTP 
radiolabelled probe, originating from the pXCXR-mlLlO plasmid. As can be seen 
in Figure 7.3.1-b (panel A), out of the six different constructs purified, only two 
were found to be positive for the presence of mILlO cDNA. Even though a 
thorough investigation into the reasons for this was not thought necessary, two 
possibilities arise. Firstly, it is possible that a random mutation of the GFP gene 
prevented the phenotype from presenting while the recombination event was in 
itself unsuccessful. Secondly, it is possible that a recombination event between 
the LAP1 and LATP2 regions within the pR20.9 cassette and the endogenous 
LAT region resulted in the loss of either the GFP or mILlO genes. In both these 
cases, the resulting plaque phenotype would be white and blue, even though the 
recombination event was not due to the successful insertion of mILlO. The latter 
recombination event has been noted before in our laboratory when using this type 
of vector and it is more frequent when a viral stock has been extensively 
propagated.
Successful expression of mILlO was confirmed by Western blot analysis of 
supernatants obtained from HSVl.pR20.9mIL10/UL43 transduced, BHK cells.
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lx l06 cells were infected with an MOI of 1 and supernatants were collected after 
2, 4 and 8 hours. Supernatants were screened for the presence of mILlO using a 
Goat polyclonal anti-mouse IL10 antibody (Santa Cruz, SC-1718) and compared 
to supernatants obtained from HSVl.pR20.9/UL43 transduced cells or 
recombinant murine IL10. As it can be seen in Figure 7.3.1-b (panel B), vector 
encoded mILlO expression is significant at 2 hours, while the two later time 
points confirm that expression is continuous with increasing amounts of mILlO 
accumulating in the tissue culture supernatants.
Murine IL10 is composed of 174 amino acids (Kim et al., 1992; Moore et al., 
1990) which determine the purely a-helical, secondary structure of the protein. 
The mature protein has a molecular weight of approximately 18 kDa and when 
biologically active, it forms non-covalent 30 kDa homodimers. This tertiary form 
is possible due to two disulfide bonds (Windsor et al., 1993) forming between 
monomers. Whether the protein remains a monomer (18 kDa) or associates into a 
dimer (30 kDa) depends on the pH of the solution and the presence of a reducing 
agent such as mercaptoethanol. mILlO predominates as a homodimer at neutral 
pH, migrating as a single band to 30 kDa while at acidic pH only the 18 kDa 
monomer is present (Syto et al., 1998). Based on this observation and on the fact 
that, at least for the human analogue of the protein, it is the dimer that is 
biologically active (Syto et a l, 1998), it was decided to analyse the 
HSVl.pR20.9mIL10/UL43 delivered mILlO under non-reducing conditions (pH 
-5.2). As it is shown in Figure 7.3.1-b (panel B), it was possible to see both 
forms of the protein in the absence of a reducing agent. Even though the pH of 
the sample and that of the SDS-Page gel are alkaline thus favouring the dimeric 
structure, this association is disturbed by the length and temperature of incubation 
which in turn favours the monomer. This is not observed for the recombinant 
mouse IL10 (R&D Systems, 474-MR) as it is formulated with a cross-linking 
agent and is thus resistant to alterations of pH and temperature. In addition, there 
appears to be no cross reactivity of the antibody with any other viral or cell 
proteins.
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Figure 7.3.1-b: Characterisation of vector HSVl.pR20.9mIL10/UL43.
A. Southern blotting on six purified recom binant plaques o f  H SV l.pR20.9m IL10/UL43 
vector. pXCXR-mlLlO: positive control and H SV l.pR 20.9/U L43 used as a negative 
control. The only band recognised from the mILlO  probe corresponds to the mILlO gene 
(600bp).
B. W estern blot probed with G oat polyclonal anti-m ouse IL10 (Santa Cruz, S C -1783). 
Recombinant mouse IL10 (blocking peptide, Santa Cruz, SC-1783P) and loaded at 50 
pg/ml to act as a positive control. The supernatant obtained from BHK cells infected 
with H SV l.pR20.9/U L43 did not produce any bands that cross-reacted with the primary 
antibody used endorsing its specificity to m urine IL10.
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7.3.2 Involvement of the immune system on transgene expression
This experiment was designed in order to demonstrate whether the host’s immune 
response has an effect on the longevity of transgene expression. To test for this, a 
comparative study was initiated, assessing differences in transgene expression 
achieved via footpad inoculation of vector HSVl.pR20.9/UL43 between the 
immunologically-competent BALB/c mice and the immunocompromised strain 
SCID mice (Bosma et al., 1983; Bosma and Carroll, 1991). Transgene expression 
was evaluated at the 2-week and 2 month time points. As already discussed in the 
previous section, vector HSV1 .pR20.9/UL43 co-expresses two transgenes: LacZ 
and GFP under the control of LAP1 and MMLV promoters respectively. This 
vector had previously been shown in our laboratory to consistently have identical 
expression patterns for either of the two transgenes in DRG neurons following 
footpad inoculation (Palmer et a l , 2000). In other words, each of the transduced 
DRG neurons co-expresses LacZ and GFP for each of the time points tested. As it 
can be seen in Figure 7.3.2-a, transgene expression appears to be achieved with 
similar efficiency in both strains at the 2-week time point. However, transgene 
expression in the BALB/c mice is markedly reduced at the 2-month time point. 
Table 7.3.2-a summarises the average number of BALB/c or SCID DRG neurons 
found to be expressing GFP at the 2 weeks and 2 months time point.
Number of LacZ - expressing DRGs
Strain Tested (Mean ±SD)
2 weeks 2 months
SCID 205 ±81 (n=5) 118±43(n=5)
BALB/c 213 ± 60(n=5) 7±4(n=5)
Table 7.3.2-a: GFP expression in BALB/c & SCID mice via HSVl.pR20.9/UL43 vector.
The above results demonstrate a difference between BALB/c and SCID mice. It 
appears that at 2 months post injection expression of LacZ persists in 118±43 
DRG neurons of SCID mice and in 7±4 BALB/c mice. Even though at the 2- 
months time point transgene expression has deteriorated in both strains, there are 
still more transduced DRG neurons in SCID mice (Table 7.3.2-a). This points to a 
possible immune system involvement to the fading transgene expression via the 
HSVl.pR20.9/UL43 vector. Immunomodulation by means of mILlO should 
therefore be a suitable approach for extending the period of transgene expression.
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F igure 7.3.2-a: HSVl.pR20.9/lIL43 LacZ & GFP expression  in BA LB/c SC ID  mice.
GFP vector transduced DRG neurons (green) and LacZ vector transduced DRG neurons (blue) in 
wholemounts o f  DRG, 2 weeks (A) and 2 months (B) after injection into the footpad o f  BALB/c 
mice (left) and SCID mice (right). Note the larger num ber o f  transduced neurons in SCID 
compared to BALB/c mice at the two month tim e point. Scale bar: 150pm, applies to all figures.
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7.3.3 Effect of IL10 co-expression on BALB/c DRG transduction
This experiment was designed to test the hypothesis that by suppressing the host's 
immune response by means of co-expressing mILlO would allow transgene 
expression to proceed for at least as long as it did in the case of SCID mice. In 
order to test this ~2xl 06 pfu of either HSVl.pR20.9/UL43 or 
HSVl.pR20.9mIL10/UL43 vector were delivered via footpad inoculation to the 
DRGs of BALB/c mice (n=5, per vector per time point). The effect of mILlO co­
expression in the expression patterns of LacZ was examined at 2 weeks and 2 
months post injection by counting the LacZ positive DRG neurons. The numbers 
achieved with either HSVl.pR20.9/UL43 (control) or HSVl.pR20.9mIL10/UL43 
vectors are summarised in the table below.
BALB/c
ONLY
Number of LacZ - expressing DRGs
(M ean ±SEM )
2 weeks 2 weeks
H S V 1 .pR20.9/UL43 
HS V 1 .pR 20.9/U L43/m ILl 0
222 ±  97 (n=5) 
241 ± 8 3  (n=5)
11 ±  4 (n=5) 
154 ±  42 (n=5)
Table 7.3.3-a: HSVl.pR20.9mIL10/UL43 mediated LacZ expression in BALB/c DRGs.
As shown in Figure 7.3.3-a, the presence of mILlO is closely linked with the 
ability of the vector to support the long-term expression of the LacZ transgene. 
This effect becomes more pronounced in the 2-month time point when normally 
expression of the transgene would be confined to a handful of BALB/c DRGs. 
Table 7.3.3-a confirms this observation. Actual counts of the LacZ expressing 
DRGs demonstrate that in the case when LacZ is co-expressed with mILlO, the 
number of LacZ positive neurons at 2 months post injection is higher than the 
number noted in HSV1 .pR20.9/UL43 transduced DRGs. Table 7.3.3-a 
demonstrates that at the 2-month time point expression of LacZ persists in 
154±42 (n=5) DRG neurons in HSVl.pR20.9mIL10/UL43 treated animals. On 
the contrary only 11±4 (n=5) LacZ positive DRG neurons could be seen in 
HSVl.pR20.9/UL43 injected animals.
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Figure 7.3.3-a: HSVl.pR20.9mIL10/UL43 LacZ expression at 2wks & 2months in BALB/c.
DRG neurons expressing LacZ in wholemounts of BALB/c mice DRG, 2 weeks (A) and 2 
months (B) after vector injection into footpad. These figures together with Table 7.3.3-a show 
that the addition of mILlO to the vector clearly leads to increased numbers of transduced DRGs 
at 2 months post-injection.
Scale bars: Left column (HSV1 .pR20.9UL43 vector):
A: Top= 150pm and Bottom= 100pm 
B: Top & Bottom= 100pm;
Right column (HSV 1 .pR20.9 UL43mIL 10 vector): 9 
A: Top & Bottom= 150pm,
B: Top & Bottom=200pm.
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7.4 Discussion
Even though the HSVl.pR20.9/UL43 vector used in this study is disabled for 
ICP34.5 and VP 16 and can not cross trans-synaptically, it is still capable of some 
degree of replication. When the vector is delivered subcutaneously via foot-pad 
inoculation, it replicates locally and then it infects and establishes a latent and 
persistent infection within sensory ganglia (Palmer et a l , 2000). It is therefore 
plausible that HSVl.pR20.9/UL43 is capable of producing an immune response, 
especially prior to establishing latency. This is confirmed when inflammatory 
infiltrate was found surrounding motor neurons of the spinal cord following 
sciatic nerve inoculation with HSVl.pR20.9/UL43 (Perez et al., 2004). 
Unfortunately, this study did not include any immune specific markers and hence 
the nature of the infiltrate cannot be established with certainty. It is not therefore 
possible to draw any conclusions regarding how this vector actually affects 
specific subclasses of immune cells such as satellite cells and how these differ to 
the responses invoked by wild type strains. This study however does support the 
notion that by disabling ICP34.5 and VP 16, the stealth machinery of the vector is 
compromised as well. This would in theory accentuate the pro-inflammatory 
nature of the vector. Another argument supporting the potential involvement of 
an immune response in reducing transgene expression comes from a series of 
experiments where Vero cells were infected with a vector without any immediate 
early genes but with a GFP marker gene under the control of the human 
cytomegalovirus immediate early promoter (HCMVIEp). Even though this virus 
was not toxic to the host cells, expression of GFP faded gradually. Interestingly, 
GFP expression could be switched on by the re-infection of the same cells with a 
virus only deleted for ICP27. This is an indication that the genome remains 
functional in the infected cells long after transgene expression stops (Samaniego 
et a l , 1998). The fact that the viral genome remains active has been confirmed 
via super-infection experiments using an ICP4 and ICP27 disabled vector co­
expressing GFP and LacZ in vitro (Lilley et a l , 2001b) (discussed in Chapter 1).
The experiments described here show that co-expression of mILlO and LacZ 
from HSVl.pR20.9mIL10/UL43 appears to increase longevity of LacZ 
expression in transduced DRGs in comparison to the length of transduction
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achieved with vectors co-expressing LacZ & GFP (i.e. control vector 
HSVl.pR20.9/UL43). This further supports the importance of the host immune 
response in clearance of the virally infected cells. It appears plausible that even 
though HSVl.pR20.9/UL43 is a minimally disabled vector, its ability to 
efficiently evade the host immune response is impaired enough to lead to its 
clearance and premature cessation of transgene expression. Additional supporting 
evidence for this hypothesis came after the completion of this study by Mogensen 
and colleagues who demonstrated that impaired VP16 activity via an inl814 
mutation leads to a hyper activation of pro-inflammatory cytokine production 
during HSV1 infection both in vitro and in vivo (Mogensen et a l, 2004). Hence, 
the induction of a Th2 response by the vector-encoded mILlO appears to be able 
to compensate for the compromise in the stealth machinery of the virus caused by 
the inl814 and 1764 mutations by dampening the host immune response. Even 
though the experiments carried out in this study targeted the PNS system it would 
be interesting to assess whether the CNS immune response also plays a part in the 
cessation of transgene expression noted with vectors of more severe disablement. 
IL10 would present a suitable means of re-enforcing the ability of highly 
disabled, CNS targeting vectors to persist for longer in infected neurons.
Sum m ary
The experiments described in this study support the hypothesis that the host's 
immune system is involved in the reduced, HSVl.pR20.9/UL43-mediated 
transgene expression noted in BALB/c DRG neurons. Suppressing the host's 
immune response using the HSVl.pR20.9mIL10/UL43 vector allows for 
transgene expression to be sustained for 2 months following footpad inoculation. 
This is a significant increase when one considers that the DRG transgene 
expression noted with vector HSV1 .pR20.9/UL43 ceases at 2 weeks post 
inoculation in BALB/c mice. Overall the data presented here lead us to believe 
that Thl immune responses contribute to the diminishing nature of transgene 
expression achieved with this vector. Co-expressing an immunomodulatory gene 
such as IL10 it is possible to significantly enhance the longevity of transgene 
expression achieved with HSV viral vectors via the peripheral route of 
administration.
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8.1 Summary
The studies included in this thesis set out to examine the use of replication 
incompetent HSV1 vectors as tools for the delivery of potentially therapeutic 
genes to the injured spinal cord and optic nerve. The experiments described in the 
previous chapters of this thesis have been discussed individually. In this section, 
the experimental findings are briefly summarised and final conclusions are 
drawn.
Replication incompetent HSV1 based vectors present a suitable gene therapy tool 
for use in the injured CNS (Palmer et al., 2000; Lilley et al., 2001b). The 
backbones employed here are minimally cytotoxic thus allowing the endogenous 
production of foreign genes by injured CNS neurons themselves. In Chapter 3, 
the capabilities and limitations of two of these vectors to deliver and sustain 
marker gene expression in the injured spinal cord were established. Vector 
HSVl.pR19CMV was selected as the backbone for the production of 
neurotrophin expressing constructs. This vector, despite its disablement, was 
shown to exploit the innate neurotropism of HSV1. A single spinal cord 
inoculation leads to the transduction of somata of neurons that project to the 
injection site. Importantly, the experiments of Chapter 3 showed that transgene 
delivery is equally efficient in the acutely and chronically injured spinal cord. 
Other virally based vector systems such as lentivirus, AV and AAV vectors, have 
been shown to be capable of some, albeit limited, retrograde axonal transport 
(Ghadge et al., 1995; Kuo et al., 1995; Mazarakis et al., 2001; Kaspar et al., 
2002; Boulis et al., 2003; Wong et al., 2004).
The main limitation that came to light regarding the highly disabled 
HSVl.pR19CMV backbone was that it did not transduce corticospinal pyramidal 
neurons. This was probably due to the fact that these neurons are naturally 
refractory to HSV1 and are actively repressing expression from this vector. As 
discussed in Chapter 3, this feature is likely to be a reflection of the highly 
disabled nature of the vector and the fact that ICP0 levels are too low to 
overcome this repression. Further vector development in our laboratory has led to
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the production of a new generation of less disabled vectors that can successfully 
transduce cortical pyramidal neurons following either direct cortical inoculation 
or a single spinal cord inoculation. These less disabled vectors do not bear 
deletions in the ICP34.5 and ICP27 genes (described in Chapter 3). In addition, in 
the closing stages of this project, these less disabled vectors were combined with 
an expression cassette that utilises the WPRE element responsible for stabilising 
transgene mRNAs and therefore potentially prolonging their expression (Chapter 
6) (Patema et al., 2000; Klein et al., 2002; Glover et al., 2003; Hlavaty et al., 
2005).
The first growth factor expressing construct produced was the 
HSVl.pR19CMVrNT3 vector (Chapter 4). This vector was shown to be able to 
transduce non-complementing cells and thus enable them to secrete biologically 
active rNT3 protein. This was confirmed by the fact that the virally delivered 
rNT3 could promote the extension of a halo of neurites from E14 DRG explants. 
In the chronic injury model of CST lesion however, it was shown that the sole 
vector-mediated delivery of NT3 could enhance proximal sprouting but was not 
sufficient to promote regeneration of corticospinal axons. This finding is in line 
with previous reports showing that in order for any anatomically significant 
regeneration to occur via the delivery of a single neurotrophic factor, it may be 
necessary to deliver a biologically excessive amount of neurotrophin (Bradbury et 
al., 1999). When the vector was used in combination with an E l4 spinal cord 
segment transplanted within the lesion site, CST axons displayed enhanced 
sprouting proximally to the lesion and they were able to extend their axons -600 
pm within the lesion site. This response was not observed when E14 transplants 
were not accompanied by NT3 vector administration. This finding is again in 
agreement with reports that have used this combinatorial approach (Bregman et 
al., 1997; Bregman et a l, 1998). In the closing stages of this study a new vector 
became available. This vector employed the WPRE element and EFla, a new 
promoter driving transgene expression instead of CMV. Inoculating the spinal 
cord this vector it is possible to selectively transduce large numbers of 
corticospinal neurons in layer V of the adult rat motor cortex. Furthermore, the 
corticospinal neurons remain strongly transduced up to 1 month post-inoculation.
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This novel vector is therefore very promising for selective gene therapy of 
corticospinal neurons, which may be necessary to overcome their poor intrinsic 
regenerative capacity following spinal injury (manuscript submitted)
In Chapter 5, two new vectors were produced: HSVl.pR19CMVrBDNF and 
HSVl.pR19CMVmCNTF in order to examine their potential to induce a 
regenerative response in the injured rubrospinal tract. The combination of 
HSV 1 .pRl9CMVrBDNF and HSVl.pR19CMVmCNTF did lead to a moderate 
increase in rubrospinal axon sprouting proximally to the site of a chronic 
rubrospinal tract lesion. Unfortunately, there was a lack of regeneration in the 
chronically injured rubrospinal tract even through sprouting was accompanied by 
the upregulation of SCG10 in sprouting axons. In addition, 
HSVl.pR19CMVrBDNF transduction of chronically injured red nucleus neurons 
led to some modest reduction in the extent of red nucleus cell body atrophy. 
However, this result can only be considered, in the context of a preliminary 
finding that will need to be repeated using a larger experimental group.
In Chapter 6, a panel of different neurotrophin-expressing vectors were examined 
in different combinations for their ability to promote regeneration in the crushed 
optic nerve injury model. These experiments examined the effect of transducing 
RGCs with a cocktail of neurotrophic factors containing rBDNF, mCNTF, 
rbFGF, rGDNF, rNT3 and NTN prior to inflicting an optic nerve crush. Different 
combinations of these vectors were used (Table 6.3.2-a). All combinations 
displayed some degree of enhanced sprouting proximally to the lesion site 
compared to control animals. In addition, injured RGCs can be seen extending 
their axons into the lesion as early as 20 days following the injury. In some cases, 
axons could be seen crossing the lesion site and entering the distal stump. This 
response was accompanied by enhanced GAP43 immunoreactivity in 
regenerating axons. Admittedly, transducing RGCs prior to inflicting the lesion 
does not represent the best simulation of the ability of these vectors to induce 
regeneration in a clinically relevant setting. This would be better achieved if 
delivery of the vector occurred after the lesion was carried out. This would of
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course involve injecting the proximal stump of the optic nerve as the 
microtubules necessary for the neuronal trafficking mechanism are disrupted thus 
rendering viral retrograde transport impossible. This route of administration did 
not yield any RGC transduction with the fully disabled vectors. However, this 
route of delivery was found to be possible with the use of the new generation of 
less disabled, WPRE containing vectors (Figure 6.3.3-a & b). Widespread RGC 
transgene expression was seen following a single optic nerve injection. It will be 
interesting to explore the ability of these vectors to influence the regenerative 
response of axotomised RGCs. Neurotrophin expressing vectors based on this 
latest backbone have already been produced and characterised and are soon to be 
tested in such injury paradigms (not presented in this thesis).
The brief study outlined in Chapter 7 intended to explore whether counteracting 
the host’s immune response could prolong transgene expression in virally 
transduced mouse DRG neurons. The vectors employed in this study were 
minimally disabled (HSVl.pR20.9UL43). Comparing marker gene expression in 
BALB/c and SCID mice demonstrated that these vectors were somewhat 
immunogenic, since transgene expression was prolonged in SCID animals. When 
these vectors were modified to co-express IL10 (HSVT.pR20.9UL43/mIL10), 
transgene expression in BALB/c mice was significantly enhanced. At the two- 
month time point, the number of HSVl.pR20.9UL43/mIL10 transduced BALB/c 
DRGs were comparable to the numbers transduced when the HSVl.pR20.9UL43 
vector was used in SCID mice. The fact that it is possible to prolong transgene 
expression in DRG neurons with this approach is of importance in terms of future 
regeneration experiments. The fully disabled HSVl.pR19CMV backbone used in 
this thesis for direct CNS delivery is not able to sustain transgene expression in 
DRG neurons following peripheral inoculation (Perez et al., 2004). However, 
with the development of this IL10 expressing vector it would be possible to 
combine direct delivery into the CNS (via the HSVl.pR19CMV vector) with the 
simultaneous transduction of DRG neurons.
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8.2 Conclusion
Following trauma to the spinal cord a cascade of degenerative events is initiated. 
Although the events that follow are mechanically very destructive to CNS 
neurons there is considerable evidence to suggest that spinal cord neurons are 
capable of some limited axonal sprouting. However, this is rapidly aborted due to 
intrinsic and extrinsic inhibitory factors (reviewed in Chapter 1). For any 
regenerative approach to be successful it must therefore address both these 
parameters.
Despite their initial promise, the use of neurotrophic factors in regenerative 
studies has proved to be somewhat disappointing. Over the last decade, a number 
of reports have emerged that suggest that the sole administration of neurotrophins 
stimulated only minimal regeneration and in only a handful of axotomised spinal 
cord fibres (Ramer et a l , 2002; Zhou et a l , 2003; Lu et a l , 2004). In this thesis, 
the main approach used to induce regeneration in the injured corticospinal and 
rubrospinal tracts was based on the delivery of a single neurotrophic factor. 
Therefore, it is not surprising that the resulting regeneration was at best minimal. 
In the case of the crushed optic nerve however, where a cocktail of 
BDNF/CNTF/NTN or BDNF/CNTF/bFGF/GDNF was used, regeneration was 
notably enhanced. This combinatorial approach is in line with the findings of a 
recent study that demonstrated that a triple combination of neurotrophic factors 
(NT3, BDNF and bFGF) acts synergistically to enhance neuronal survival and 
axonal regeneration in axotomised RGCs (Logan et a l, 2006).
Over the last decade a wealth of accumulating evidence supports what is now 
considered a given by researchers: a multifaceted approach to regeneration is 
needed in order to maximise the limited potential of CNS neurons to regenerate 
(Thuret et a l, 2006). Based on this reasoning, it is very likely that the delivery of 
multiple neurotrophic factors (Lu et a l, 2004; Logan et a l, 2006) needs to be 
coupled with inactivation of a variety of growth inhibitory signals (Fawcett and 
Asher, 1999; Hunt et a l, 2002a; Sandvig et a l, 2004; Silver and Miller, 2004; 
Ahmed et a l, 2005a; Ahmed et a l, 2005b) in order for any functionally 
meaningful regeneration to be achieved. Indeed, experiments that have employed
413
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this approach have shown significant promise in CST regenerative studies (von 
Meyenburg et al., 1998; Logan et al., 2002; Lu et al., 2004; Fouad et al., 2005; 
Lu et al., 2007). The highly disabled HSVl.pR19CMV vectors used here, as well 
as the new generation of less disabled WPRE containing vectors, could 
potentially be used for delivering a combination of neurotrophins. In addition, 
these can be examined in a variety of combinations in order to identify the most 
regeneration-favourable mixtures. Their effects can be evaluated not only in vivo 
but also in vitro. This would allow for the identification and characterisation of 
specific molecular events governing their effects.
An alternative to transducing neurons to express neurotrophic factors would be to 
target molecules that inhibit regeneration. One such target would be the inhibition 
of small GTPases such as Rho. Many inhibitory factors signal through these 
pathways that ultimately affect the neuronal cytoskeleton. The vectors employed 
here could be used to knock down the expression of RhoA via constructing 
cassettes that produce a dominant negative version of this GTPase. Such a vector 
has already been produced and is currently under investigation. Another approach 
would be to use RNA silencing technology (Dykxhoom et al., 2006). RNA 
interference (RNAi) is an innate cellular process involved in post-transcriptional 
gene silencing. It involves a highly specific degradation of target mRNAs through 
the use of homologous, double stranded, 19-23;?/ RNA, termed small interfering 
RNA (siRNA). siRNAs essentially guide the intracellular RNA degradation 
machinery to target mRNAs in a highly specific manner (Shinagawa and Ishii, 
2003). It can be easily generated from a single stranded RNA precursor that folds 
into a hairpin loop structure that is subsequently cleaved by the ribonuclease 
Dicer to produce siRNAs (Meister and Tuschl, 2004). The use of siRNA is 
currently under investigation by a variety of research laboratories and some 
reports as to its use in the injured CNS are beginning to emerge (Raoul et al., 
2006; Dykxhoom et al., 2006).
Overall, the vectors described here are powerful and versatile gene therapy tools 
that can be applied in either in vivo or in vitro paradigms designed to elucidate 
the mechanisms involved in the refractory nature of the injured CNS milieu.
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